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Abstract
Background Unlike many other psychiatric conditions, individuals with drug
dependence pass through a number of intermediate stages before developing a
clinical condition. Studying variation in speeds of transitions between these stages
provides novel insights into Substance Use Disorder aetiology.
Aims To explore:
￿. Relationships between early cannabis transitions and later outcomes;
￿. Relationships between individual, childhood, mental health and drug use
factors and transitions;
￿. The extent to which speed of early cannabis transitions are in￿uenced by
genes and environment, and the genetic correlation with dependence;
￿. The relationship between early heroin transitions and later heroin outcomes,
and the effect of route of administration.
Design Three samples were analysed: ￿) ￿8￿￿ Australian twins and siblings; ￿)
￿￿ opiate substitution treatment clients; ￿) ￿￿8 heroin users.
Methods Cox PH Survival Analysis; Regression Analysis; Classic and Bivariate
Twin Modelling.
Findings Early onset of ￿rst opportunity to use (OTU) cannabis was associated
with increased risks of later cannabis use outcomes, with those who reported
￿rst OTU before age ￿￿ being twice as likely to report cannabis daily use,
abuse/dependence or treatment-seeking relative to those whose ￿rst OTU
occurred after age ￿8.
Faster progression to subsequent cannabis use was associated with increased
risks of later cannabis use outcomes, with those whose subsequent use was
within a week of initiation being twice as likely to report cannabis daily use, and
more likely to abuse/dependence, relative to those whose subsequent use was
more than year after initiation.
Conduct disorder, weekly tobacco use, male gender and parental drug problems
were associated with faster progression to both OTU cannabis, and from
opportunity to dependence. A genetic correlation of .￿￿ was observed between
iv
age of OTU cannabis and cannabis abuse/dependence.
Early OTU heroin was associated with three times likelihood of overdose and
neck/groin injecting. Injecting heroin was associated with faster progression to
daily use.
Conclusions Considering the stage-sequential nature of drug use has identi￿ed
factors associated with dependence that also in￿uence behaviour from the earliest
stage of drug involvement, and has revealed potential targets for intervention.
v
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￿.￿ What Are Substance Use Disorders?
Drug use is prevalent amongst adolescents; one Australian study has estimated
lifetime prevalence of adolescent cannabis use as high as 6￿% (Patton et al., ￿￿￿￿).
It is widely accepted that a large proportion of those using drugs in adolescencewill
do so infrequently, with a smaller proportion developing Substance Use Disorders
(SUDs) and related problems, as de￿ned by DSM-IV and DSM-￿ criteria (American
Psychiatric Association, ￿￿￿￿; American Psychiatric Association et al., ￿￿￿￿). SUDs
require those diagnosed to experience a number of negative effects of drug use,
including the neglect of personal relationships, employment and health; signi￿cant
time investment in obtaining and using the drug; control being lost as the drug
is used in greater quantitates, or more frequently, than an individual intends; and
unsuccessful attempts to cut down or stop using the drug of abuse. As tolerance
towards the drug increases, greater amounts are needed tomeet the psychological
or physical demands underlying use (American Psychiatric Association, ￿￿￿￿;
American Psychiatric Association et al., ￿￿￿￿).
SUDs are an area of global and national health concern (Degenhardt et al., ￿￿￿￿),
with prevalence estimated at ￿￿% in the US population (Kessler et al., ￿￿￿￿) and
￿.6% in the UK (Fuller et al., ￿￿￿￿). These disorders directly account for ￿￿.￿million
Disability Adjusted Life Years (DALYs), equating to ￿.8% of global DALYs from all
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causes (Degenhardt et al., ￿￿￿￿).
￿.￿.￿ Cannabis and Heroin Use
Prevalence of drug treatment seeking indicates that, of illicit drugs, cannabis and
opioids have some of the most negative impacts on the health of those using
them (UNODC, ￿￿￿￿). The focus of this thesis is cannabis use and disorders, with
some additional consideration of heroin use and outcomes. Cannabis is the most
commonly used illicit drug, with prevalence of lifetime use estimated at between
￿.￿% and ￿.￿% of the global population aged ￿￿-6￿ years (UNODC, ￿￿￿￿); although
as stated above, prevalence may be much higher amongst adolescent populations
(Patton et al., ￿￿￿￿). It is estimated that ￿￿ - ￿6% of cannabis users develop
dependence (Anthony, ￿￿￿6), and that globally ￿￿.￿million individuals meet criteria
for cannabis dependence, contributing ￿￿.￿% of the illicit drug use global burden of
disease (Degenhardt et al., ￿￿￿￿).
Conversely heroin use is less common, with global prevalence of use of heroin
and other opioids estimated at ￿.6% - ￿.8% (UNODC, ￿￿￿￿). However, despite
the low use prevalence, dependence on these drugs accounts for the highest
proportion (￿6%) of illicit drug contribution to DALYs (Degenhardt et al., ￿￿￿￿).
Heroin use is also associated with signi￿cant health risks beyond addiction, such
as overdose, which is the leading cause of mortality amongst users of this drug
(Degenhardt et al., ￿￿￿￿).
￿.￿ The Aetiology of Substance Use Disorders
It could be assumed that the effect of drug pharmacology on brain biology is the
main contributor to the development of SUDs. From a behavioural pharmacological
viewpoint, the development of dependence is relatively straightforward. The
drug creates a “reward” effect in the brain, most likely through activation of
the mesolimbic dopamine pathway, and each use of the drug strengthens this
association (West and Brown, ￿￿￿￿). After repeated use, physiology can adapt to
the drug, resulting in withdrawal when the drug is not used (West and Brown, ￿￿￿￿).
If the aetiology of drug dependence were purely pharmacological we could expect
all those who initiated use of the drug to follow the same course. However, as
￿
￿.￿. CONSIDERING THE MULTI-STAGE NATURE OF DRUG USE
stated above, only ￿￿-￿6% of those who use cannabis go on to develop dependence
(Anthony, ￿￿￿6). A complete understanding of the aetiology of this disorder
requires exploration of the cause of these individual differences.
Genetic variation may contribute to the aetiology of SUDs. Humans share
￿￿% of their genes, with the remaining ￿% underlying individual variation. Twin
methodologies are oneway that the extent towhich genetics in￿uence a trait can be
examined (Plomin et al., ￿￿￿￿). Agrawal and Lynskey (￿￿￿8) noted that estimates
of the heritability of drug dependence ranged from ￿.￿￿ to ￿.￿￿, and were broadly
equivalent across individual drugs. Genetic in￿uences that increase vulnerability
to drug use across drug classes have been identi￿ed (Mof￿tt et al., ￿￿￿￿; Tsuang
et al., ￿￿￿￿), although some evidence has been found for separate, albeit highly
correlated, licit and illicit drug genetic factors (Kendler et al., ￿￿￿￿).
However, given that not all of the variation in SUDs is attributable to genetic
in￿uences (Agrawal and Lynskey, ￿￿￿8), we can extrapolate that the environment
must also contribute to the variance. A highly cited review of risk for adolescent
SUDs identi￿ed a wide range of contributing factors, including drug availability,
economic deprivation, personality factors (such as sensation seeking and impulse
control), individual and family attitudes towards drug use, family con￿ict, childhood
antisocial behaviour, academic failure, peer drug use, and early initiation of drug use
(Hawkins et al., ￿￿￿￿). Consequently the study of the aetiology of SUDs is complex,
requiring understanding of the effect of a number of factors.
￿.￿ Considering the Multi-Stage Nature of Drug Use
The development of SUDs is a multi-stage process in which a number of speci￿c
transitions must occur. In this way, SUDs differ from many other psychiatric
conditions. The ￿rst stage of drug involvement is having the opportunity to use
(regardless of whether the individual uses the drug or not). Opportunity is required
for use to occur, and forms an individual’s earliest necessary condition from which
they are at risk of developing dependence (Wagner and Anthony, ￿￿￿￿). Following
this is initiation of use, progression to subsequent use, and using the drug regularly.
Regular use itself can be de￿ned as use within a time period, for example monthly,
weekly, or daily. By necessity, only individuals who pass through these stages can
progress to the development of SUDs. After the development of SUDs, further
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transitions may take place, such as those into treatment and recovery, and in some
instances back to drug use. An outline of the stages of drug use is provided in
Figure ￿.￿.











As stated above, not all individuals who initiate drug use – or who reach some
of the subsequent stages of drug use - progress to SUDs. Despite this, studies of
dependence commonly compare individualswho are drug dependent against those
who are not dependent. This fails to distinguish between non-cases whomay have
never used a drug and those who used the drug (potentially regularly) but did not
progress to disorder development. This con￿ation of stages leads to uncertainty
as to the points in the development of drug dependence at which speci￿c genetic
or environmental in￿uences are most prominent (Nelson et al., ￿￿￿￿).
Research that has considered themulti-stage nature of drug use has suggested
that the relative strength of genetic and environmental in￿uences varies by both
stage of drug use and by developmental age (Distel et al., ￿￿￿￿; Heath et al., ￿￿￿￿;
Kendler et al., ￿￿￿￿b; Lynskey et al., ￿￿￿￿; Sartor et al., ￿￿￿￿, ￿￿￿8). For example,
there is evidence from studies of tobacco and alcohol use that suggest that, in
their aggregate, genetic in￿uences are relatively weaker at earlier stages in the
development of drug dependence (e.g. initiation of use; see Lynskey et al. (￿￿￿￿)
for review). Although weak at these early stages, there is evidence that the genetic
factors that in￿uence initiation are at least partially shared with those that in￿uence
later problem use (Kendler et al., ￿￿￿￿a; Neale et al., ￿￿￿6b; Heath et al., ￿￿￿￿).
The extent to which the importance of measured genetic and environmental
in￿uences on drug dependence may vary across stages of drug involvement
deserves further exploration. Early stages of drug use, such as initiation, may
be genetically in￿uenced through personality traits such as novelty seeking
(Laucht et al., ￿￿￿￿). Drawing on existing research, we can speculate that at
subsequent stages, such as drug dependence and development of withdrawal,
genetic in￿uences on drug metabolism, or from genes that are associated with
use of speci￿c drugs may be more in￿uential (Dick et al., ￿￿￿￿). Similarly, there
may be distal (in￿uences which are removed from the onset of behaviour)and
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some proximal (in￿uences that may act directly on the onset of that behaviour)
environmental risk factors that are unique to speci￿c stages of drug involvement,
while others may act across multiple stages, or show correlation while not being
identical (Lynskey et al., ￿￿￿￿). Consequently, it is expected that utilising the multi-
stage approach will reveal that observed genetic and environmental associations
alter throughout the development of SUD.
Some recent research utilising the multi-stage approach to drug use has
demonstrated differences in association by stage of use. Sartor et al. (￿￿￿￿)
reported a number of factors that were unique to onset of alcohol use (e.g.
male gender, attention de￿cit hyperactivity disorder, parental divorce and maternal
alcohol dependence), while others were unique to the transition from alcohol use
to dependence (e.g. nicotine dependence, cannabis abuse, generalised anxiety
disorder). Differences have also been observed for genetic risk factors by stage
of drug use. Belsky et al. (￿￿￿￿) reported that a multi-locus genetic risk score,
derived from the results of meta-analyses for nicotine dependence, was unrelated
to initiation of tobacco use but was signi￿cantly associated with increased risks for
daily tobacco use, more rapid progression from initiation to heavy use, increased
risks for the development of nicotine dependence and reduced likelihood of
successful cessation.
There is someevidence that the effect of genes alters across drug use behaviour
trajectories. This has been observed in relation toGABRA￿ andOPRM￿, respectively
a gene associated with the inhibitory neurotransmitter GABA, and a gene that
encodes opioid receptors. Modelling development and changes in alcohol use
over time has found that GABRA￿ is associated with an increase in drunkenness
between ages ￿8–￿￿, suggested to be due to the enhanced independence related
to reaching adulthood (Dick et al., ￿￿￿￿). Similarly, OPRM￿ has been found to
differentiate those who were light drinkers from those who had progressed to
moderate drinking in participants followed up over 6 years (participants on average
aged ￿￿.￿ at start of study) (van der Zwaluw et al., ￿￿￿￿).
In summary, studies utilising the multi-stage approach are likely to reveal that
differential in￿uences, both internal and external, operate at each stage. However,
despite the utility of taking a multi-stage approach, this is rarely incorporated into
studies of drug use. In this thesis I apply the multi-stage approach to gain new
insights into the aetiology of SUDs.
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TRANSITIONS
￿.￿ Exploring SUD Aetiology Through Studying the
Speed of Drug Use Transitions
Variation in drug use progression can be used to explore the relationship between
the earlier stages of drug use and SUDs. Speed of transition is one point of variation
that can be utilised for this purpose. The majority of research utilising speed of
transitions in drug use comes from the literature on early initiation of use (with
younger age at initiation of use representing a faster transition to use). By taking a
selection of studies from this research area, focussed on initiation of cannabis or
heroin use, I will provide an overview of what current knowledge of speed of early
drug use transitions reveals about SUD aetiology.
A number of studies of early initiation of use have identi￿ed a relationship to later
drug use outcomes. In a cross-sectional US study of ￿￿,86￿ participants age ￿8 and
over, the prevalence of lifetime drug (including cannabis) abuse and dependence
declined as a function of increasing age at onset of drug(including cannabis) use
(Grant and Dawson, ￿￿￿8). Amongst ￿￿￿￿ individuals involved in a longitudinal
Australian cohort study, adolescents who experienced early initiation of cannabis
use (before age ￿6) had increased likelihood of experiencing cannabis dependence
by age ￿￿ (OR ￿.￿, ￿￿% CI ￿.￿-￿.8), compared to those who reported later initiation
of use (Swift et al., ￿￿￿8). In the same study, there was evidence of an effect of use
frequency. Amongst those in the sample who had initiated cannabis use by age
￿￿, the likelihood of cannabis dependence by age ￿￿ increased with frequency of
use at age ￿￿. Similarly, in a birth cohort of ￿￿6￿ New Zealand children followed-up
until ￿8 years of age, the prevalence of cannabis abuse/dependence at age ￿6-￿8
was twice as high amongst those who had used cannabis ￿￿+ times at age ￿￿-￿6,
compared to those who had used cannabis fewer than ￿￿ times (Fergusson and
Horwood, ￿￿￿￿). Amongst heroin users, younger age of heroin initiation has been
found to be associated with likelihood of overdose (Lynskey and Hall, ￿￿￿8). These
￿ndings indicate a consistent association between earlier age of initiation and later
abuse, dependence and other drug use outcomes.
Twin studies have provided evidence that genetic factors in￿uence the age of
cannabis initiation, and have provided further insight into the relationship between
this and later SUDs. A longitudinal study of ￿￿￿ African-American female twins
tested the genetic contribution to the age of cannabis initiation, and found that
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the majority of the variance in age of initiation (with early initiation de￿ned as ￿6
years old) was attributable to genetic effects (￿.￿￿, ￿￿% CI: ￿.￿￿–￿.￿￿) (Sartor et al.,
￿￿￿￿a).
Genetic effects have also been considered in discordant twin studies, which
(due to the genetic and environmental similarity of the twin pairs) allow for genetic
effects to be controlled for. In a sample of Dutch twins discordant for early onset of
use (￿8 years), likelihood of lifetime regular cannabis use was not increased in the
early-onset twin compared to the later onset twin (Lynskey et al., ￿￿￿6). A similar
study comparing ￿￿￿ co-twins discordant for early initiation of cannabis use from
anAustralian sample, whereby only one twin in each pair initiated cannabis use￿￿,
found that the twin who reported early initiation of cannabis use was at increased
likelihood of later cannabis dependence (OR ￿.￿6, ￿￿ CI ￿.￿￿-￿.￿￿) (Lynskey et al.,
￿￿￿￿); but this association disappearedwhen analyseswere restricted to twin pairs
who had both initiated cannabis use. Given that the association to problematic
use did not remain after controlling for genetic and environmental similarity, these
￿ndings suggest that the association between early onset and later problem use is
due to shared genetic and environmental factors.
A large number of individual and external factors that are associated with early
initiation of cannabis use have been identi￿ed in the literature. The studies of
adolescents discussed here have been selected due to their sample size (￿￿￿￿+
participants) and prospective design. Use of cannabis by age ￿￿-￿￿was associated
with having divorced/separated parents (OR ￿.￿, ￿￿% CI ￿.￿ – ￿.￿), peer cannabis
use (OR ￿￿.￿, ￿￿% CI 8.6–￿￿), daily smoking (OR ￿.￿, ￿￿% CI ￿.￿–6.￿), high dose
drinking (OR ￿.￿, ￿￿% CI ￿.￿–￿.￿), and anti-social behaviours (OR ￿.￿, ￿￿% CI
￿.8–￿.￿) (Coffey et al., ￿￿￿￿). Similarly, initiating cannabis use before age ￿￿ was
signi￿cantly (P=￿.￿￿￿) correlated with parental report of disruptive behaviour
(r=￿.￿￿), oppositional problems (r=￿.￿￿), attention de￿cit hyperactivity (r=￿.￿￿) and
conduct problems (r=￿.￿￿) (Creemers et al., ￿￿￿￿a). High childhood hyperactivity-
inattention symptoms and high Conduct Disorder (CD) symptoms have been
associated with speed of transition to initiation of cannabis use (males HR ￿.￿￿,
￿￿%CI ￿.￿￿-￿.6￿, femalesHR￿.￿￿, ￿￿%CI ￿.￿￿–￿.￿￿) (Galéra et al.,￿￿￿￿). Sensation
seeking personality traits were associated with early cannabis use, represented as
use before age ￿￿ (OR ￿.￿￿, ￿￿% CI ￿.￿￿–￿.￿￿) (Creemers et al., ￿￿￿￿b).
The literature on early initiation of cannabis and heroin use, a selection of which
￿
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TRANSITIONS
is considered above, highlights the range of factors that contribute to variation
in speed of transition and the potential for speed of transition to be indicative of
later drug use outcomes. However, there are issues with using this literature to
explore transition speed. Firstly, the majority of studies do not use a continuous
measure of time to initiation, resulting in wide heterogeneity in what is considered
“early” initiation (and, consequently, what is considered a fast transition). Within
the studies cited above, the cut-off point for early initiation ranges from ￿￿ – ￿￿
years of age. A large number of developmental changes can be expected to
occur between these time points, which limits the extent to which results can be
generalised. Consequently, in order to isolate speed of transition from individual
age, the study of transitions needs to focus on speed between stages. Opportunity
to use a drug has been recognised as the ￿rst stage of drug use, and consequently
studies of age of initiation (rather than time form opportunity to initiation) do not
strictly represent between-stage transitions. Secondly, there is wide variation in the
factors that have been considered in relation to the speed of transition. This makes
it dif￿cult to compare factors in￿uencing early initiation with factors in￿uencing
the development of SUDs, which may give an indication of what underlies the
association between early initiation and later drug use outcomes.
Therefore, whilst the research focussed on age of initiation of use can give some
insight into SUD aetiology, more meaningful and informative results will be gained
by considering literature on other multi-stage transitions, and studies that report
on transitions between stages. Considering multiple stages will allow identi￿cation
of how in￿uences of speci￿c risk factors may change between stages, providing a
clearer picture of what may in￿uence progression towards dependence.
The focus placed on cannabis and heroin in this thesis adds an additional
dimension to the issue of speed of transition. The majority of research examining
transitions in drug use has focussed on alcohol (Donovan and Molina, ￿￿￿￿; Wu
et al., ￿￿￿6; Pitkänen et al., ￿￿￿￿; Johnson et al., ￿￿￿￿; Hingson and Zha, ￿￿￿￿;
Hingson et al., ￿￿￿6, ￿￿￿8; Dube et al., ￿￿￿6; Grant et al., ￿￿￿6; Schulenberg and
Maggs, ￿￿￿￿) and tobacco (Maes et al., ￿￿￿￿a; Stallings et al., ￿￿￿￿; Jamal et al.,
￿￿￿￿; Kendler et al., ￿￿￿￿b); both licit and widely-available drugs in most countries.
It is of interest to observe whether similar patterns emerge for transitions in illicit
drug use. Cannabis and heroin are of interest as they are understudied in the
￿eld, and in addition differ from each other in terms of prevalence of use (see
8
￿.￿. LITERATURE REVIEW: OUTCOMES AND FACTORS ASSOCIATED WITH THE SPEED OF
SPECIFIC TRANSITIONS IN CANNABIS AND HEROIN USE
Section ￿.￿.￿, above). Additionally, those using heroin have a high proportion of
reported childhood abuse and neglect compared to populations using other drugs
(Darke, ￿￿￿￿). Consequently focussing on these drugs provides a test of whether
associations with transition speed apply to illicit drugs, to drugs with differing
prevalence of use, and to populations with different degrees of dysfunction.
￿.￿ Literature Review: Outcomes and Factors
Associated with the Speed of Speci￿c Transitions in
Cannabis and Heroin Use
￿.￿.￿ Search Strategy
Table ￿.￿: Literature Review Search Terms
Drug Stages Transition Speed
Cannabis Opportunity Fast
Marijuana Initiation Slow
Hashish First use Early
Opiate Onset Rapid








A systematic search was conducted to gain a comprehensive view of the existing
research exploring the speci￿c transitions represented in a multi-stage model of
drug use progression (see Figure ￿.￿), in populations of cannabis or heroin users.
The focus of the review was on factors in￿uencing transition speed, and the
relationship to drug use outcomes. Any research on speed of transition between
stages of drug use (or age at opportunity, given that there is no preceding stage of
drug involvement) was included. Search terms (abstract and keyword search) were
combined to identify the drugs of interest, stages of drug use, and transition speed
(see Table ￿.￿ for list of terms).
￿
￿.￿.￿ Critical Appraisal of Identi￿ed Studies
Only primary journal articles written in English and using human participants
were screened. See Figure ￿.￿ for the search numbers and screening criteria. A
total of ￿￿ articles were identi￿ed that focussed on speed of transition between the
stages of drug use. See Table ￿.￿ for search results grouped by drug and transition,
and a quality rating for each paper (see Appendix ￿ for Quality Rating Table).
Figure ￿.￿: Search Results and Exclusion Criteria
Articles from initial search
N = 4709









Articles that were/did not:
Primary research
Human subjects
Focus on cannabis or heroin use
Focus on drug use outcomes
Focus on speed of transition
Time between stages
N = 2192
The transitions that emerged from the literature review are presented in
Figure ￿.￿. The majority of research focuses on the transition from initiation
to problematic use, or abuse/dependence; these were studied in ￿ papers. As
Figure ￿.￿ demonstrates, transitions from initiation to problem use encompass a
number of other stages of drug use. Opportunity (represented as age of onset,
given that there are no preceding stages of drug use) was reported on in 8 papers,
and progression from initiation to regular use was studied in ￿ papers. The
majority of the research was taken from literature focused on cannabis use, which
was featured in ￿￿ identi￿ed papers; only ￿ papers explored transitions in heroin
use. This likely re￿ects the low prevalence of heroin use, and the relatively high
prevalence of cannabis use, in general populations. The ￿ndings of the review are
summarised below.
￿.￿.￿ Critical Appraisal of Identi￿ed Studies
Five papers that were identi￿ed in the literature had quality score lower than ￿￿. For
three of these papers (Reboussin et al., ￿￿￿￿; Best et al., ￿￿￿￿; Chamla et al., ￿￿￿6),
the focus of the researchwas not on transition speed. Consequently ￿ndings drawn
￿￿
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from these papers may be limited, and the approach to analysis of the variables is
unlikely to have been given careful consideration. In keeping with this, one of these
papers (Reboussin et al., ￿￿￿￿) applied an approach whereby opportunity by 8th
grade was compared against no opportunity by this stage. This does not allow
differentiation between those who had later opportunity and those who never had
opportunity, which may con￿ate estimates within the analysis.
Three papers had a sample size that under ￿￿￿ participants or a response
rate of fewer than 6￿% (Reboussin et al., ￿￿￿￿; Haas and Peters, ￿￿￿￿; Ridenour
et al., ￿￿￿6; Chamla et al., ￿￿￿6). These factors may lead to a sample that
is unrepresentative of the population of interest, and this should be considered
when attempting to extrapolate their ￿ndings to the wider population. Similar
consideration is required for the studies that utilised convenience sampling rather
than randomsampling of the population of interest (Best et al., ￿￿￿￿; Ridenour et al.,
￿￿￿6).
Two of the low quality studies utilised analyses methods that did not allow for
the adjustment of confounding variables (Haas and Peters, ￿￿￿￿; Ridenour et al.,
￿￿￿6). Consequently the ￿ndings presented from these studies may not provide
accurate estimates of observed associations. For the low quality studies that did
not make use of prospective data (Haas and Peters, ￿￿￿￿; Chamla et al., ￿￿￿6),
there is potential for recall bias to affect observations.
￿￿
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￿.￿.￿ Age of Opportunity
Cannabis Research
Opportunity to use is the stage transition with themost research, and the only stage
transition that has been considered in relation to later drug use outcomes. In a
sample of ￿￿￿8 ￿￿-￿6 year old school pupils, age at ￿rst opportunity to use cannabis
was not signi￿cantly associated with frequency of past-month cannabis use (Best
et al., ￿￿￿￿). However, there was a signi￿cant negative correlation between age of
￿rst opportunity to use cannabis and frequency of use (r=￿.￿￿, P￿.￿￿￿), before
regression adjustment for age at tobacco and alcohol opportunity and initiation,
and age at cannabis initiation. This association may have been over adjusted; the
stated covariates have potential for collinearity with age of opportunity, and it is
plausible that age of initiation may mediate rather than confound this association.
Exploring the relationship between opportunity and later outcomes was not a main
aim of this study. Analyses focused speci￿cally on age of opportunity to use and
the associationswith drug use outcomes, taking a careful approach to confounding
variables, may yield different results.
Onset of this stage tends to happen in adolescence, and consequently identi￿ed
associated factors focus on early life in￿uences. Results from a longitudinal
study following individuals from ￿rst grade of school to early adulthood (N=￿6￿￿)
identi￿ed that low parental involvement (RR ￿.￿, ￿￿% CI ￿.￿–￿.￿), but not low levels
￿￿
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of parental monitoring (RR ￿.￿, ￿￿% CI ￿.8–￿.￿) or coercive discipline (RR ￿.￿, ￿￿%
CI ￿.￿–￿.￿), was associated with having the opportunity to use cannabis before
age ￿￿-￿￿ (Chen et al., ￿￿￿￿b). Having opportunity to use cannabis by age ￿￿ has
been found to be associated with aggressive/disruptive behaviour, deviant peer
af￿liation, and childhood disadvantage (Reboussin et al., ￿￿￿￿), when compared
to individuals who had not had the opportunity to use cannabis by this age. A study
looking at similar factors, taking behavioural measures when participants were a
mean age of 6.￿ years old and measuring cannabis opportunity at a mean age of
￿￿, found gender differences in the factors in￿uencing earlier opportunity to use
cannabis (Storr et al., ￿￿￿￿). Earlier opportunity to use cannabis was associated
with higher childhood aggressive/disruptive behaviour in males but not females
(rank P=￿.￿￿; mean age ￿￿.￿ for males with higher levels of aggressive/disruptive
behaviour mean age of ￿￿.￿ for males with lower levels), higher reading scores in
females (P￿.￿￿; mean age ￿￿.￿ for those in quartile ￿, mean age of ￿￿.6 for females
in the lowest reading readiness quartile), and higher maths readiness in males
(mean age ￿￿.￿ for males in quartile ￿, mean age of ￿￿.￿ for those in quartiles ￿ or ￿;
P=￿.￿￿ and ￿.￿￿ respectively). It is important to note that no further behavioural or
contextual measures were assessed between ages 6.￿ and ￿￿. This is a long time
period in which a number of developmental and situational changes will occur for
individuals, and the result is that a number of potential in￿uencing variables were
unable to be considered.
Gender differences in age of opportunity to use cannabis have not been
identi￿ed. Research froma large (N = ￿￿￿￿￿6) representative cross-sectional survey
in the USA found mean age of ￿rst opportunity to use cannabis was the same for
males and females (￿6 years of age for bothmales and females, P=￿.86) (van Etten
and Anthony, ￿￿￿￿). With regard to other factors, the use of tobacco has been
studied in relation to age of opportunity to use cannabis. In a large, cross-sectional
Australian twin sample (N=￿￿￿￿), those who had lifetime history of regular tobacco
use (smoking ￿￿￿+ cigarettes) were found to have an earlier opportunity to use
cannabis (Agrawal et al., ￿￿￿￿). However, as the study considered lifetime tobacco
use, rather than tobacco use prior to opportunity to use cannabis, it is not possible
to assess the direction of the relationship between regular tobacco use and earlier
cannabis use opportunity.
Genetic in￿uences have been observed on age of opportunity to use cannabis.
￿￿
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In one Australian twin study, having early opportunity to use cannabis (￿￿ years)
had a heritability estimate of ￿.￿￿ (CI ￿.6￿–￿.8￿) and unique environment estimate
of ￿.￿8 (CI ￿.￿￿–￿.￿8) (Lynskey et al., ￿￿￿￿). This indicates that variation in the
speed of transition to cannabis use opportunity is predominately attributable to
additive genetic factors.
Heroin Research
The only research regarding heroin opportunity focuses on gender differences,
which were not identi￿ed. Research from a large (N = ￿￿￿￿￿6) representative cross-
sectional survey in the USA found that mean age differed for heroin opportunity,
but this difference was not statistically signi￿cant (￿8 years of age for males and
￿￿ years of age for females, P=￿.￿￿) (van Etten and Anthony, ￿￿￿￿).
￿.￿.￿ Opportunity to Initiation
Cannabis Research
Very little research has focussed on the transition from opportunity to initiation of
drug use. The review identi￿ed three papers that had explored this transition, based
on the same study that utilised data from a large representative cross-sectional
survey in the USA conducted every three years from ￿￿￿￿ - ￿￿￿￿ (total N = ￿￿￿￿￿6).
A rapid transition from opportunity to initiation of use was observed in 66% of those
who initiated cannabis use (van Etten and Anthony, ￿￿￿￿).
One paper, again based on the same sample, reported basic proportions and
identi￿ed that those who had younger age of opportunity to use cannabis had a
slower transition to initiation of use. Of participants who reported opportunity to
use cannabis at age ￿￿, ￿￿% reported initiating cannabis use within a year, whereas
this proportion rose to ￿￿% for those reporting opportunity at age ￿￿ (van Etten
et al., ￿￿￿￿). Further statistical tests had not been conducted on these ￿gures so
signi￿cance of this difference cannot be determined.
Cohort differences were not identi￿ed in speed of this transition. The proportion
progressing to initiation within a year of their ￿rst opportunity increased slightly
between ￿￿8￿ – ￿￿￿￿ for cannabis use, but remained relatively stable (van Etten
and Anthony, ￿￿￿￿; van Etten et al., ￿￿￿￿). Again, further statistical tests were not
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conducted on these ￿gures so signi￿cance cannot be determined. No signi￿cant
gender differences in the proportion of participants making a “rapid” transition
(within the same year) from opportunity to initiation of cannabis use at any survey
year (van Etten et al., ￿￿￿￿).
Heroin Research
A study that utilised data from a large representative cross-sectional survey in the
USA conducted every three years between ￿￿￿￿ - ￿￿￿￿ (total N = ￿￿￿￿￿6) identi￿ed
a rapid transition from opportunity to initiation of use was observed in 8￿% of those
who initiated heroin use (van Etten and Anthony, ￿￿￿￿). Consequently, it is likely that
de￿ning transition from opportunity to initiation within a year as a “rapid” transition
is not accurate. Rather, it re￿ects the majority of individual transitions. Exploring
this transition in terms of weeks/months may be more appropriate.
Cohort differences were not identi￿ed in speed of this transition. The proportion
progressing to initiation within a year of their ￿rst opportunity increased slightly
between ￿￿￿￿ – ￿￿￿￿ for heroin use, but remained relatively stable (van Etten and
Anthony, ￿￿￿￿; van Etten et al., ￿￿￿￿). Gender differences in transitions speed were
observed for heroin in ￿￿￿￿ and ￿￿￿￿ (a higher proportion of males making a fast
transition) (van Etten et al., ￿￿￿￿).
￿.￿.￿ Initiation to Regular Use
Cannabis Research
A study of ￿￿￿ participants, recruited in childhood to represent groups at different
levels of risk for substance involvement, found no signi￿cant differences between
males and females in speed of transition from initiation of cannabis to monthly
cannabis use (Ridenour et al., ￿￿￿6).
Heroin Research
Themajority of identi￿ed heroin research is focused on the transition from initiation
to “regular” use. Two of these studies have focussed on age as a factor in the speed
of this transition. One study of 6￿￿Australian heroin users found that those aged ￿8-
￿￿ at time of interview had experienced amore rapid transition fromheroin initiation
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to using at least once a month compared to those aged over ￿￿ in the sample (￿.￿
vs. ￿.￿ years, P￿.￿￿￿) (Mills et al., ￿￿￿￿). The study authors suggest this may
re￿ect an increase in drug availability, and changes in societal attitudes towards
drug use. However, given that this is a population of “young” heroin users it is
possible that this group re￿ects a distinct population amongst those in treatment.
Considering the characteristics of the complete sample, the mean age at ￿rst
seeking treatment was ￿￿ (Ross et al., ￿￿￿￿). The majority (8￿%) of the ￿8-￿￿
heroin users were in treatment, and whilst information on the proportion seeking
treatment before age ￿￿ is not provided it is likely that many of this ￿8-￿￿ sample
sought treatment earlier than the base population mean. Additionally, compared to
the base population the ￿8-￿￿ year olds had a lower mean age of heroin initiation
(￿8-￿￿ = ￿6.8, s.d. ￿.￿, whole sample =￿￿.￿, s.d. ￿.￿) and initiation of injecting (￿8-￿￿
= ￿￿.8 s.d. ￿.￿, whole sample = ￿￿.￿, s.d. ￿.￿). It is possible that these differences,
or factors relating to them, have also contributed to the more rapid transition to
monthly use amongst ￿8-￿￿ year olds in the sample. Supporting these ￿ndings, a
separate study of ￿6￿ out-of-treatment USA heroin users found that younger age at
initiation of heroin use was associated with more rapid progression from initiation
to using heroin at least three times per week (Woodcock et al., ￿￿￿￿).
The review has also identi￿ed that the very use of heroin, as opposed to other
drugs, may lead to comparatively faster transition to regular use. Amongst a
sample of 6￿￿ injecting drug users, recruited through street outreach and snowball
sampling in Melbourne, those injecting heroin had a more rapid transition from
￿rst injecting heroin to injecting once a month (￿.￿8, ￿￿% CI ￿.￿￿–￿.￿￿) compared
to those injecting any other drugs (O’Keefe et al., ￿￿￿6). The study authors
identify that heroin is associated with greater severity of dependence compared to
methamphetamine (the other predominantly used drug in the sample), and these
results indicate that speed of transitions in drug use can be in￿uenced by drug
pharmacology.
Finally, a demographic effect on speed of this transition has been identi￿ed. A
study of ￿￿￿ out-of-treatment USA heroin users found that Caucasian Americans
had a faster progression than African Americans from initiation of heroin use to
using more than three times per week (interaction signi￿cant at P￿.￿￿ for both
males and females) (Stoltman et al., ￿￿￿￿). This study did not ￿nd a signi￿cant
effect of gender on speed of progression to regular heroin use.
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Heroin Research
One study has considered the heroin-speci￿c transition of progression from non-
injecting to injecting route of administration (ROA) using a sample of ￿66 Chinese
heroin-using participants recruited from detoxi￿cation treatment. The majority of
participants had begun using heroin through nasal ROA, and time from initiation of
use to injecting heroin was associated with age (HR ￿.￿￿, ￿￿% CI ￿.8￿–￿.￿￿) and
duration of heroin use (HR ￿.￿￿, ￿￿% CI ￿.￿￿–￿.￿￿) (Chamla et al., ￿￿￿6). This may
re￿ect cohort effects on speed of transition.
￿.￿.￿ Initiation to Problem Use
Cannabis Research
The research on the transition from initiation to problem drug use provides
further evidence of genetic effects on transition speed. In a sample of ￿￿￿￿
female participants (comprised of a mix of twins and sibling pairs), a sibling
experiencing cannabis use disorder symptoms was associated with increased
hazard of progression to cannabis use disorder at any age in African-American
participants (HR ￿.￿￿, CI ￿.￿￿-￿.￿￿). Analyses were strati￿ed by onset age for
European Americans, and sibling experience of cannabis use disorder symptoms
was associated with participant cannabis use disorder symptom onset at age ￿8-
￿￿ (HR ￿.￿￿, CI ￿.8￿-￿.￿￿) and at age ￿￿+ (HR ￿.￿￿, CI ￿.￿￿-￿.￿￿) (Sartor et al., ￿￿￿￿).
Although the study design does not allow these ￿ndings to be disentangled from the
environmental in￿uences shared by siblings, they hint at a shared genetic in￿uence
between cannabis use disorder symptoms and increased rate of progression
between initiation and problematic use.
A number of proximal and distal factors have been found to be associated with
the speed of this transition. Childhood Sexual Abuse (CSA) has been associated
with rate of progression from cannabis use initiation to problematic use. In
a sample of ￿￿￿￿ twin and sibling pairs, CSA was associated with increased
hazard of progression to cannabis use disorder after ￿￿ years of age in African
American participants (HR ￿.￿￿, CI ￿.￿￿-￿.￿￿), and at any age in European-American
participants (HR ￿.￿￿, CI ￿.￿￿-￿.88) (Sartor et al., ￿￿￿￿). In a sample of twins
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and family members at risk of drug use (N=￿￿￿￿) the rate of progression to ￿rst
symptomof cannabis use disorder was increased amongst thosewho experienced
CSA (HR ￿.￿￿, CI ￿.￿￿–￿.￿￿) (Sartor et al., ￿￿￿￿a).
Speed of transition to problematic cannabis use has also been associated with
mental health factors. Using a sample of ￿￿￿￿ female twin and sibling pairs, rate of
progression from initiation of cannabis use to problem use was increased amongst
those who experienced Conduct Disorder (CD) (HR ￿.8￿, CI ￿.￿￿–￿.￿￿) and Major
Depressive Disorder (MDD) (HR ￿.￿￿, CI ￿.￿￿–￿.6￿) (Sartor et al., ￿￿￿￿a). Due to the
methodology used, the measure of MDD was only included in the analysis if onset
was reported before the development of problematic use, indicating that this factor
may have a causal relationship with speed of transition.
In the same sample, those who were regularly smoking tobacco at least once a
week for ￿months prior to problematic cannabis use (and had smoked greater than
￿￿ cigarettes in their lifetime) were found to have faster progression from initiation
to their ￿rst symptom of problematic use (HR ￿.￿￿, ￿￿% CI ￿.￿8 - ￿.6￿) (Sartor et al.,
￿￿￿￿a). Those who had lifetime alcohol use had increased rate of progression to
their ￿rst symptom of problematic cannabis use (HR ￿.￿￿, CI ￿.￿￿–￿.￿￿).
The research on this transition has not identi￿ed any effect of gender on the
speed of progression. No signi￿cant differenceswere observed betweenmales and
females for latency from initiation to problematic marijuana use in a sample of ￿6￿
poly-substance using individuals (Haas and Peters, ￿￿￿￿). Similarly, no signi￿cant
differences between males and females were observed in speed of transition from
cannabis initiation to ￿rst problem in a sample of ￿￿￿ participants recruited in
childhood to represent groups at different levels of risk for substance involvement
(Ridenour et al., ￿￿￿6).
￿.￿.8 Initiation to Abuse/Dependence
Cannabis Research
Analysis of this transition has focussed on the factors that are associated with
faster progression to abuse or dependence. No signi￿cant differences between
males and females have been observed in speed of transition to dependence
(Ridenour et al., ￿￿￿6). Amongst ￿￿￿￿ participants who reported cannabis use
for the ￿rst time within the ￿￿ months prior to assessment, drawn from a
￿￿
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large US survey on drug abuse (residents aged ￿￿ and over, total N = ￿￿￿￿￿￿),
those who reported using three or more drugs (from a choice of tobacco,
alcohol, cocaine/crack, heroin, hallucinogens, inhalants, pain relievers, anxiolytic
tranquilizers, stimulants other than cocaine, and sedative-hypnotics) were found
to have a fast progression from cannabis initiation to dependence (RR ￿.￿, ￿￿% CI
￿.￿–￿.￿) (Chen et al., ￿￿￿￿a). In this study, a progression was considered fast if the
individual had developed dependence within ￿￿ months of initiation. In the same
study, age of ￿rst cannabis use was associated with fast onset of dependence for
the following initiation age groups:￿6–￿￿ (RR ￿.￿, CI ￿.￿–￿￿.￿); ￿￿–￿￿ (RR ￿￿.￿, CI
￿.￿–￿￿.￿); ￿￿–￿￿ (RR ￿￿.6, CI ￿.￿–￿￿.￿). This is in contrast to a longitudinal study
of German youths (N = ￿￿￿￿), which found that those with later onset cannabis
use had faster progression to cannabis abuse, but slower progression to cannabis
dependence (Behrendt et al., ￿￿￿￿). However, the approach to analysis may have
affected these German results. By stratifying the analysis by age of initiation, some
younger age groups had lower power (N = ￿￿￿). Applying age of onset data as
a continuous, non-strati￿ed variable may have provided a more comprehensive
picture of the progression to abuse and dependence.
￿.￿.￿ Abuse to Dependence
Cannabis Research
One study has considered the speed of transition from the development of
drug abuse to dependence. Using a sample of ￿￿￿6 participants recruited from
clinical and community groups for the DSM-IV ￿eld trials, the study identi￿ed no
signi￿cant differences in length of time from meeting cannabis abuse criteria to
meeting cannabis dependence criteria between early cannabis initiators (the ￿￿%
of the study population who reported youngest ages of cannabis use) and later
initiators, betweenmen and women, or between African-Americans and Caucasian
Americans (Ridenour et al., ￿￿￿￿). However, there are issues surrounding the study
of this transition. In this study, it was observed that a proportion of the sample
(￿6% of males and ￿8% of females) met criteria for cannabis dependence before
meeting criteria for abuse; as such, there could not be a length of progression from
abuse to dependence. Abuse and dependence have been found to have a single
underlying continuum of severity (Lynskey and Agrawal, ￿￿￿￿), and this is re￿ected
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in the DSM-￿ (released since the publication of the Ridenour et al. (￿￿￿￿) study)
whereby drug abuse and dependence have been combined into a measure of SUD
(American Psychiatric Association et al., ￿￿￿￿). The “￿ipped” order of progression
seen in the described study highlights that the onset of these symptoms will not
necessarily be sequential, and demonstrates the importance of careful, sequential
application of the multi-stage approach to drug use.
￿.￿.￿￿ Initiation to Treatment
Heroin Research
The only research relating to time to treatment seeking was conducted in a heroin-
using population. One study of 6￿￿ Australian heroin users found that those aged
￿8-￿￿ at time of interview had experienced a more rapid transition from heroin
initiation to treatment for their heroin use (￿.￿ vs. ￿.￿ years for those aged ￿￿+ at
interview, P￿.￿￿￿) (Mills et al., ￿￿￿￿). As discussed above, compared to the base
population the ￿8-￿￿ year olds had a lower mean age of heroin initiation (￿8-￿￿ =
￿6.8, s.d. ￿.￿, whole sample =￿￿.￿, s.d. ￿.￿) and injecting (￿8-￿￿ = ￿￿.8 s.d. ￿.￿, whole
sample = ￿￿.￿, s.d. ￿.￿), which could have contributed to the more rapid transition
to treatment seeking in this sample. Additionally, being female was independently
associated with an increased speed of progression from initial heroin use to ￿rst
treatment for heroin use (HR= ￿.￿￿, ￿￿%CI ￿.￿￿–￿.￿￿).
￿.￿.￿￿ Literature Review Conclusions
A number of proximal and distal factors have emerged from the literature as
associated with speed of transition through one or more of the stages of drug
use. For cannabis transitions these include childhood disruptive behaviour, strict
parenting, CSA, MDD, CD, and pre-existing tobacco or other drug use. One factor
that emerged as consistently not associated with transitions in cannabis use was
gender. Fewer factors have been explored in relation to heroin, but for this drug
gender and ethnicity were found to have some in￿uence. Additionally for heroin
there were indications of cohort effects on use patterns, although the underlying
reasons for these were not explored.
￿￿
￿.￿.￿￿ Identi￿ed Gaps in the Literature
Some evidence for genetic effects on speed of transition emerged from this
review. A high heritability estimate was observed for age of opportunity to use
cannabis (Lynskey et al., ￿￿￿￿), and other genetically informative designs indicate
there are genetic effects on speed of progression to problematic use. Heritability
estimates for speed of transition are high even at the early stages of drug use, given
that studies of the stages of drug use (but not focussed on the speed of transitions)
typically identify lower heritability estimates at earlier stages (Lynskey et al., ￿￿￿￿).
Finally, the review has highlighted that there may be transitions speci￿c to use
of individual drugs. Research into heroin use has considered transitions in ROA,
which is signi￿cant for this drug given the increased health risks associated with
moving from non-injecting ROA to injecting (Strang et al., ￿￿￿8). This demonstrates
the importance of considering the idiosyncrasies of different drugs when exploring
transitions.
￿.￿.￿￿ Identi￿ed Gaps in the Literature
One of the most striking ￿ndings is the dearth of literature focussing on the
relationship between speed of transition and later drug use outcomes in either
cannabis or heroin use. Only one identi￿ed study explored this topic (Best et al.,
￿￿￿￿). This is especially surprising given the research linking early initiation of
cannabis use with later problem use outcomes. The time between drug use
initiation and the development of SUDs has been found to be short, leaving only a
small window for targeted intervention (Wittchen et al., ￿￿￿8). Therefore, exploring
whether early transitions in drug use are related to later problems is an avenue that
has scope for improving prevention methods.
The majority of the transitions that were identi￿ed were those from initiation of
drug use to varying degrees of problematic use. Given the importance of identifying
early markers of SUDs (Wittchen et al., ￿￿￿8), there is utility in exploring more
transitions from the early stages of drug use. Considering drug use from a multi-
stage approach identi￿es that there are transitions that have not yet been explored.
One is the transition from initiation to subsequent use (see Figure ￿.￿). Exploring a
novel transition such as this will further break down the progression towards drug
dependence, and has the potential to develop new understanding of the processes
underlying the development of dependence.
￿￿
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DRUG USE
Existing ￿ndings indicate that individual, childhood, and mental health factors
play a role in speed of transition. However, currently the factors studied have
only been sparsely investigated across the different stages of drug use. Testing
the association between a consistent selection of factors and different stage
transitions would provide greater understanding of how in￿uences alter as an
individual progresses towards drug dependence.
Research has indicated that genetic factors play a role in speed of transition,
but as this has only been explored in relation to a small number of transitions
a large amount still remains unknown about the genetic contribution to variation
in speed. It is currently unknown whether genetic in￿uences on transition speed
have a consistent contribution, or if this differs across transitions. Additionally,
research has failed to explore whether the genetic factors contributing to speed of
transitions in drug use overlap with those contributing to the development of SUDs.
Further exploration of this area may have implications for our understanding of the
aetiology of drug dependence.
The literature search focussed on cannabis and heroin use, but very little
research was found relating to heroin use transitions. Additionally, the research
identi￿ed that users of heroin may experience faster transitions in drug use than
those using other drugs. Consequently it is possible that associations between
transition speed and heroin use will differ from those seen in cannabis using
populations. There is scope to explore the association between transition speeds
and outcomes in heroin use, and to take into account the idiosyncrasies of this drug,
such as the importance of ROA and the risk of overdose, when doing so.
￿.6 Key Methodologies for Studying Transitions
Through the Stages of Drug Use
Studying the genetic, proximal and distal factors that in￿uence speed of transitions
in drug use requires the use of methodologies that are ￿) appropriate for analysing
temporal (time-to-event) data and ￿) are able to account for the multi-stage nature
of drug use, whereby progression to a stage is contingent on an individual having




For the study of factors in￿uencing speed of transition, Cox’s Proportional Hazards
Survival Analysis is an appropriate methodology. Using time-to-event data to
explore the effect of factors on an individual’s outcome, it has previously been
applied in the drug and alcohol research ￿eld to study the speed with which an
individual develops an outcome such as opportunity to use, initiation of use and
development of use disorders (Agrawal et al., ￿￿￿6; Behrendt et al., ￿￿￿￿; Sartor
et al., ￿￿￿￿b; Storr et al., ￿￿￿￿; Waldron et al., ￿￿￿￿), and was used in ￿ of the papers
identi￿ed in the literature review (Agrawal et al., ￿￿￿￿; Chen et al., ￿￿￿￿b; Storr et al.,
￿￿￿￿; Lynskey et al., ￿￿￿￿; O’Keefe et al., ￿￿￿6; Sartor et al., ￿￿￿￿, ￿￿￿￿a; Behrendt
et al., ￿￿￿￿; Chamla et al., ￿￿￿6). The methodology can incorporate time-varying
effects, whereby the status of certain factors can bemodelled to alter over time. For
example, if an individual develops an additional health problem during the period of
time that is being analysed, this can be modelled so that the effect of this is not
incorporated into the analysis until the time at which the problem occurred. This
methodology allows for both the multi-stage nature of drug use, as the starting
and ending time points can be set, and is designed to analyse and account for the
complexities of time data.
Table ￿.￿: Results from Studies Utilising Two-Stage Twin Modelling in Drug Use
Paper Drug Stages of Use Genetic correlation
Males Females Overall
Broms et al. ￿￿￿6 Tobacco Initiation and Amount smoked .￿￿ .￿￿ -
Initiation and Cessation .￿￿ - -
Grant et al. ￿￿￿￿ Alcohol Heaviness of Use - - .￿￿
and Abuse/Dependence
Morley et al. ￿￿￿￿ Tobacco Age Tobacco Onset and .8￿ .￿￿ -
Cigarette Consumption
Cigarette Consumption and .88 .￿￿ -
Smoking Persistence
Age Onset and .￿￿ .￿￿ -
Smoking Persistence
Pagan et al. ￿￿￿6 Alcohol Initiation and Frequency of use - - .￿￿
Initiation and Problem Use .￿￿ .￿￿ -
Frequency of Use and Problem Use .6￿ .￿8 -
McCutcheon et al. ￿￿￿￿ Alcohol Alcohol Use Disorder (AUD) ￿+ symptoms - -.￿￿ -
and Remission
Alcohol Use Disorder (AUD) ￿+ Symptoms - .￿￿ -
and Remission
Sartor et al. ￿￿￿￿ Cannabis Number of Times of Use - - .￿8
and Number Dependence Symptoms
Alcohol Heaviness of Use and - - .￿￿
Number of Dependence Symptoms
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￿.6.￿ Genetically Informative Methods
Given consistent evidence that there are genetic in￿uences acting on speed of
transitions (Lynskey et al., ￿￿￿￿; Sartor et al., ￿￿￿￿a; Lynskey et al., ￿￿￿6, ￿￿￿￿),
there is value is utilising genetically informative methods in this thesis. Classical
twin modelling can be used, as in previous studies providing estimates of the
heritability of SUDs, age of opportunity and age of initiation of use. However, in order
to determine whether the genetic factors affecting speed of transition overlap with
those affecting SUDs a more nuanced analytic approach is required. Two-stage
multivariate twin modelling allows estimation of the correlation between genetic
in￿uences on two behaviours in situations where an earlier behaviour, such as
opportunity to use a drug, is necessary for the expression of later behaviours, such
as the development of dependence (Heath et al., ￿￿￿￿). This issue applies in many
studies of alcohol, tobacco and drug use (Neale et al., ￿￿￿6a), and consequently
this approach has been applied previously in research into tobacco, alcohol and
cannabis (Broms et al., ￿￿￿6; Grant et al., ￿￿￿￿; McCutcheon et al., ￿￿￿￿; Morley
et al., ￿￿￿￿; Pagan et al., ￿￿￿6; Sartor et al., ￿￿￿￿). A summary of the drugs
previously studied using thismethod, and the ￿ndings regarding genetic correlation,
are presented in Table ￿.￿. These studies have consistently demonstrated a genetic
correlation between the earlier and later stages of drug use, although themagnitude
of the effect differs. Thismethodology allows for themulti-stage nature of drug use,
and for the study of the consistency of in￿uences across drug use stages.
￿.￿ Thesis Aims
Based on the results of the literature review, and drawing on the identi￿ed gaps in
the literature, the following aims will be addressed in this thesis.
Aim ￿
Using a general population sample, explore the relationship between the speed
of transitions to cannabis opportunity and initiation to subsequent use, and later




Individuals who have faster transitions in early cannabis use will have an increased
likelihood of later cannabis daily use, abuse and/or dependence, and treatment-
seeking.
Hypothesis ￿
Associations between speed of transitions in cannabis and increased likelihood
of later cannabis daily use, abuse and/or dependence, and treatment-seeking will
persist after control for identi￿ed individual, childhood,mental health and other drug
use confounding variables.
Aim ￿
Using a general population sample, explore the extent to which the speed
of transition to cannabis opportunity and from opportunity to dependence are
in￿uenced by individual, childhood, mental health and other drug use factors.
Hypothesis ￿
There will be individual variation in the speed of the transitions studied.
Hypothesis ￿
The associations between speed of transition in cannabis use and individual,
childhood, mental health and other drug use factors will differ between the stages
of cannabis use.
Aim ￿
Examine the extent to which the speed of early stage transitions in trajectories
of cannabis use are in￿uenced by additive genetic, shared and non-shared
environmental in￿uences; explore the extent to which genetic in￿uences on these
transitions are unique to the phenotype, and the extent to which they are correlated
with cannabis dependence.
Hypothesis ￿
Opportunity to use cannabis and time from initiation to subsequent use will be
in￿uenced by additive genetic factors.
Hypothesis ￿
Heritable in￿uences on speed of early transitions will be highly correlated with
heritable in￿uences on the liability to cannabis dependence
Aim ￿
In a clinical sample, explore the relationship between the speed of early heroin
transitions and later heroin dependence severity, overdose, injecting behaviours and
￿￿
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heavy heroin use, and the effect of route of administration on speed of transition.
Hypothesis ￿
Individuals who have faster early transitions in heroin use will have increased
dependence severity at treatment seeking, time to treatment seeking, overdose,
and injecting behaviour.
Hypothesis ￿
Associations between speed of speci￿c early transitions in heroin use and
increased dependence severity at treatment seeking, time to treatment seeking,
overdose, and injecting behaviour will persist after control for demographic factors.
Hypothesis ￿
Injecting route of administration will be associated with faster speed of transition





The literature review (see Chapter ￿) identi￿ed a number of gaps in the literature.
The relationship between early transitions in drug use and important clinical
outcomes has not been systematically studied, it is unknown whether factors
in￿uencing progression in drug use are consistent across stages of drug use, and
there are novel transitions that have not been explored. By utilising variation in the
speed of transitions in drug use and using a combination of epidemiological and
genetically informative study designs, I address the aims of this thesis (see Chapter
￿). An outline of the structure of the thesis is presented in Figure ￿.￿.
￿.￿ Sample ￿: Australian Twin Study Of Cannabis And
Other Illicit Drug Misuse
Chapters ￿, ￿ and ￿ are based on secondary analysis of existing data from
a cross-sectional survey of Australian born twins interviewed ￿￿￿￿-￿￿￿￿. The
Australian Twin Study Of Cannabis And Other Illicit Drug Misuse (Lynskey et al.,
￿￿￿￿) was established to collect detailed phenotypic information on patterns of
cannabis use and cannabis-related symptomatology, associated use, abuse, and
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dependence on both licit and illicit drugs; psychiatric comorbidity including conduct
disorder, major depressive disorder, social phobia, and panic disorder; child and
family circumstances including opportunity to use drugs, exposure to inter-parental
con￿ict, parenting practices, and peer af￿liations. Using these data, I explore the
relationship between speed of early transitions in cannabis use and later cannabis
daily use, abuse/dependence and treatment-seeking, and to identify in￿uences on
the speed of transitions in cannabis use.
￿.￿.￿ Procedure
The Australian Twin Registry
The participants included in this study were recruited via the Australian Twin
Registry (ATR). Full details on the structure and processes of the ATR can be
found in Hopper et al. (￿￿￿￿) and Hopper (￿￿￿￿). Established in ￿￿8￿, the
ATR is administered through the University of Melbourne and recruits twins
from across Australia. At the time of data collection on the present study, an
executive committee consisting of researchers with expertise in twin research,
a gynaecologist specialising in multiple births, a representative of the Australian
Multiple Births Association, and a twin representative, oversaw the ATR. A selection
of this committee approved the Australian Twin Study Of Cannabis And Other Illicit
Drug Misuse. In order to reduce attrition and ensure data quality, the ATR has
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staff who manage on-going recruitment, participant information and contact with
members of the registry. Each year these staff update the records of more than
￿￿￿￿ pairs (roughly a quarter of the members of the registry), keeping records of
active members accurate.
The ATR is a voluntary registry. Twins are recruited through their own volition in
adolescence or adulthood, and the ATR advertises through Association of Multiple
Births clubs, word of mouth, schools, medical centres, posters, and electronic and
print media. At the end of ￿￿￿￿, nearly ￿￿￿￿￿ pairs were registered with the ATR. Of
thosewho had registered, ￿￿%were “active” pairs, meaning that bothmemberswere
alive, willing to participate and able to be traced by the ATR. When joining the ATR,
participants complete baseline questionnaires on basic demographics, lifestyle and
general health.
At most recent estimate, ￿￿% of the ATR were monozygotic females, ￿6%
monozygoticmales, ￿￿%dizygotic females, ￿￿%dizygoticmales, and ￿￿%dizygotic
opposite-sex pairs. There were also ￿% same-sex twin pairs of unknown zygosity.
The average age of members was ￿￿ years (age range from ￿month to ￿￿ years),
with ￿￿% under the age of ￿8 years (Hopper et al., ￿￿￿￿).
Recruitment and Data Collection
ATR pairs born ￿￿￿￿ - ￿￿￿￿ were reached through a two-tiered process, required by
the ATR ethics committee. Twins initially received a letter from the ATR outlining
the study and the review process that it underwent, and this was followed by
telephone contact. Once twins had been provided with details of the study purpose,
procedures involved, associated risks, feedback that would be provided, and who
to contact for further information by the ATR, they were asked if they were willing to
have their name and contact details forwarded to the team leading the study, who
were based at Queensland Institute of Medical Research (QIMR).
Those researchers then contacted the twins who had agreed to provide their
details, in order to explain the study purposes and enrol those who wanted to
participate. Factors that may have affected recruitment in this study included
the burden of time (which this study sought to compensate through ￿nancial
reimbursement of a $￿￿ (Australian Dollars) gift card on completion of the study),
and concerns about privacy and con￿dentiality (Singer and Presser, ￿￿￿￿). Due
to low response to ATR contact, the recruitment sample was extended to include
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siblings of twins who had taken part to increase the power for the genetic design.
A total of ￿8￿￿ individuals participated in the interview, forming the complete
sample for the analyses in this thesis (Lynskey et al., ￿￿￿￿). Figure ￿.￿ summarises
the recruitment process and provides response rates at each stage of the data
collection. The composition of the twin sample is provided in Table ￿.￿.
Figure ￿.￿: Outline of Recruitment to the Australian Twin Study Of Cannabis And Other Illicit
Drug Misuse
Twins contacted by ATR 
N= 7850
Declined N = 1971
Passive refusal N = 2093
Twins consented to 





Siblings consented to 
participete in study
N = 849








Lost to attrition 
N = 438
Lost to attrition 
N = 373
Data were collected through Computer Assisted Telephone Interview (CATI)
with a trained researcher. These researchers were lay interviewers who had
received two weeks of structured interview training, and all interviews were
recorded by audiotape (if permission was granted by the interviewee) in order to
ensure data quality. Different interviewers conducted the interviews for each family
member, in order to avoid any bias that could be introduced through the interviewer
possessing prior knowledge of the twin or their family members. CATI methods
allow for more complex questionnaires than those conducted using pen and paper,
as computer scripts can provide tailored questions, and allow the interview to be
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routed to ensure all relevant questions are asked (Hansen, ￿￿￿￿).
Table ￿.￿: Composition of the ATR Sample
Zygosity Total N N Pairs N Unpaired twins
Monozygotic females ￿￿6 ￿￿8 ￿8￿
Monozygotic males ￿￿￿ ￿￿￿ ￿￿￿
Dizygotic females ￿￿￿ ￿￿￿ ￿￿￿
Dizygotic males ￿￿￿ ￿￿8 ￿￿￿
Dizygotic opposite sex ￿￿6 ￿￿￿ ￿8￿
Unknown zygosity female ￿￿ - -
Unknown zygosity male ￿ - -
Siblings female ￿6￿ - -
Siblings male ￿￿￿ - -
Funding and Ethical Approval
This research was funded by National Institute on Drug Abuse (NIDA) grant:
DA￿8￿6￿ and facilitated through review by the Australian Twin Registry (as
described above), a national resource supported by an Enabling Grant (ID 6￿8￿￿￿)
from the National Health & Medical Research Council (Lynskey et al., ￿￿￿￿). Ethical
approval for data collection was obtained from QIMR Berghofer Medical Research
Institute and the Washington University School of Medicine. King’s College London
Research Ethics Subcommittee approved access and storage of the data.
The Semi-Structured Assessment for the Genetics of Alcoholism
The Semi-Structured Assessment for the Genetics of Alcoholism (SSAGA-II), a
semi-structured measure of mental health, formed the basis of the CATI. This
was developed for genetic studies of alcoholism, and was created to explore
polydiagnosis, co-morbidity, and how phenotypes are expressed (Bucholz et al.,
￿￿￿￿). The measure incorporates DSM-III, DSM-IV and ICD￿￿ diagnostic criteria to
allow comparison to other research, and non-clinical researchers who are trained
for a week in advance can administer the measure.
The SSAGA-II has good reliability and validity. Interrater reliability for cannabis
use disorders in cross-centre tests of all subjects had kappas of ￿.￿￿ for
cannabis dependence, ￿.6￿ for cannabis abuse and ￿.8￿ for cannabis abuse or
dependence. Within-centre tests showed similar results, with kappas of ￿.￿6 for
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cannabis dependence, ￿.￿￿ for cannabis abuse and ￿.8￿ for cannabis abuse or
dependence (Bucholz et al., ￿￿￿￿). To measure validity the SSAGA has been
compared to the Schedule for Clinical Assessment in Neuropsychiatry (SCAN).
For cannabis dependence sensitivity (proportion of true cases correctly identi￿ed)
was ￿￿.￿%, and speci￿city (proportion of non-cases correctly identi￿ed) was 86.￿%
(Hesselbrock et al., ￿￿￿￿; Prince, ￿￿￿￿). The kappa for the cannabis dependence
diagnosed on the SSAGA compared to the positive symptoms identi￿ed by the
SCAN was ￿.￿￿. The version of the SSAGA used in the present study was the
SSAGA-OZ, a version modi￿ed for telephone interview in an Australian population.
Modi￿cation of telephone interview did not affect the test-retest reliability and
accuracy of self-report (compared to family report) on this measure (Heath et al.,
￿￿￿￿).
￿.￿.￿ Measures
The CATI collected data on a number of drug use behaviours, and analyses
presented in this thesis focus on cannabis use. A detailed description of items
used and variables derived is provided below.
Cannabis Variables
Age of First Opportunity to Use Cannabis
To measure opportunity to use cannabis participants were asked “have you ever
been offered, or had the opportunity to use marijuana/hash, even if you didn’t use
them at the time?". Those reporting a lifetime opportunity to use cannabis were
then asked: “How old were you the ￿rst time?”.
Table ￿.￿: Percentile groups for calculating analysis groups for speed of transition to
opportunity to use cannabis
Percentile Maximum age Age range Analysis group N(%)
￿￿th ￿￿ ￿-￿￿ ￿88 (￿￿.￿)
￿￿th ￿6 ￿￿-￿6 ￿86 (￿￿.￿)
￿￿th ￿￿ ￿￿ ￿88 (￿6.￿)
Reference category ￿8 ￿8-￿8 ￿￿6￿ (￿￿.￿)
￿￿
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Out of a total of ￿8￿￿ interviewed participants, data were available for ￿￿￿8
participants. Of these, 8￿.￿% (N=￿￿￿￿) reported having a lifetime opportunity to
use cannabis.
For categorical analyses on speed of transition to cannabis use opportunity the
￿￿th, ￿￿th, ￿￿th percentiles of the age of onset distribution were used to determine
transition speed groups (see Table ￿.￿). This formed a four level categorical
variable with the groups’ opportunity age ￿￿ and under, opportunity age ￿￿-￿6,
opportunity age ￿￿, and opportunity age ￿8 and over, which was used for all
analyses in Chapter￿. See Figure ￿.￿ for distribution, and age categories used in
analysis.
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Cannabis Use To measure lifetime cannabis use participants were asked “have
you ever used either of [marijuana or hashish]?". Those reporting lifetime cannabis
use were then asked: “How old were you the ￿rst time you used [marijuana or
hashish]?”. Out of a total of ￿8￿￿ interviewed participants, data were available
for ￿￿￿￿ participants. Of these, 68.￿% (N=￿6￿￿) reported lifetime cannabis use.
Reporting on opportunity to use cannabiswas not required for participants to report
lifetime cannabis use.
There is no consensus in the literature as to what constitutes early onset, which
has been categorized as anywhere between ￿￿ – ￿8 years, but in line with a number
of existing publications (Agrawal et al., ￿￿￿6; Michael T. Lynskey et al., ￿￿￿￿; Sartor
et al., ￿￿￿￿) the selected cut-off for early onset was those who were aged ￿6 and
￿￿
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under when cannabis was ￿rst used. Early onset of cannabis use was reported by
￿6.￿￿% (N=￿￿￿￿) of participants.
Time to Subsequent Use of Cannabis
Those who reported using cannabis more than once were asked: “how soon after
you ￿rst tried marijuana did you try it again?” Responses to this question were
collected using the following response options:
• The same day
• The next day
• Within a week
• Within a month
• Within ￿months
• Within 6 months
• Within a year
• More than a year
Progression to subsequent cannabis use was reported by ￿￿% (N=￿￿￿￿) of
participants, and 86% of those who reported ever using cannabis.
Daily Cannabis Use
Participants who reported using cannabis more than ￿￿ times were asked if they
had used cannabis at least once a day during their period of heaviest cannabis use.
Lifetime daily cannabis use was reported by ￿.￿￿% (N=￿￿￿) of participants, and
￿6.￿% of those who reported ever using cannabis.
Cannabis Abuse
Participants were classi￿ed as meeting DSM-IV criteria (American Psychiatric
Association, ￿￿￿￿) for lifetime cannabis abuse if they reported one or more of the
following within a ￿￿month period:
• Often using cannabis in a situation where they might get hurt
• Arrestedmore than twicewithin a ￿￿month period as a result of their cannabis
use
• Cannabis use having caused dif￿culty with work, study or household
responsibilities
• Cannabis having caused social and interpersonal problems
Lifetime cannabis abuse was reported by ￿￿.￿% (N=￿8￿) of the whole sample, and




Participants were classi￿ed as meeting lifetime criteria for DSM-IV (American
Psychiatric Association, ￿￿￿￿) cannabis dependence if they reported ￿ or more of
the following symptoms occurring within the same ￿￿month period:
• Using cannabis a greater number of times/greater amount thanwas intended
• Tolerance
• Wanting to cut down/stop use
• Spending so much time obtaining/using/recovering from the effects of
cannabis that the participant had little time for anything else
• Reducing important activities as a result of cannabis use
• Continuing use despite it worsening health/emotional problems
Withdrawal was not included as it was not part of DSM-IV criteria for cannabis
dependence.
The mean age of dependence onset was ￿￿.￿ (s.d. ￿.￿, range ￿￿-￿8). Lifetime
cannabis dependence was reported by ￿.￿￿% (N=￿￿￿) of participants, and ￿￿.￿%
of those who had ever reported using cannabis.
Age of onset of cannabis dependence was ascertained by asking participants how
old they were the ￿rst time they experienced three or more of these symptoms
within the same ￿￿month period. See Figure ￿.￿ for distribution.
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Lifetime Cannabis Abuse and Dependence
For analyses examining associations between early transitions and later cannabis
￿￿
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outcomes, meeting cannabis abuse criteria and meeting cannabis dependence
criteria (outlined above) were combined into a composite measure of abuse and/or
dependence. Lifetime cannabis abuse and/or dependence was reported by ￿6.￿￿%
(N=6￿￿) of participants, and ￿￿.￿% of those who reported ever using cannabis.
Treatment-Seeking for Cannabis Use
Participants self-reported seeking treatment for cannabis problems from a
professional and were asked to describe who they had sought treatment
from: Psychiatrist (N=￿￿), General Practitioner or other medical doctor (N=8￿),
Psychologist (N=￿￿), another mental health professional (N=6￿), member of the
clergy (N=￿) or another source (N= ￿). Seeking treatment for cannabis use was




Sex/gender was determined through self-report. 6￿.￿% of the sample was female.
Education
Participants were asked to report their highest level of education from the options
primary incomplete, primary complete, year 8 completed, year ￿ completed, year ￿￿
completed, year ￿￿ completed, year ￿￿ completed, Technical and Further Education
college, undergraduate degree, or post-graduate degree. For analysis, respondents
were classi￿ed by whether or not their highest level of education was post-
secondary/higher education. Completing post-secondary/higher education was
reported by ￿￿.6% (N=￿￿￿) of participants.
Childhood Environment Age 6-￿￿
Single Parent Family
Interviewers recorded whether participants lived with both their mother/mother
￿gure and their father/father ￿gure for at least ￿ full years between ages 6-￿￿.
Growing up in a single parent family was reported by ￿.￿￿% (N=￿￿￿) of participants.
Parental Con￿ict
Respondents were asked “How often did your parents ￿ght or argue in front of you”
and “Howmuch con￿ict and tension was there between your parents”. Participants
￿8
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who reported parents ‘sometimes’ or ‘always’ fought or argued, or reported ‘a lot’
or ‘some’ con￿ict/tension were coded as experiencing high parental con￿ict. High
parental con￿ict was reported by ￿6.8￿% (N=￿￿￿￿) of participants.
Strict Parenting
Respondent were asked “In your opinion, when you were 6 to ￿￿, was your
mother/mother ￿gure more strict than most mothers?” and “ In your opinion, when
you were 6 to ￿￿, was your father/father ￿gure more strict than most fathers?”.
Responses were either yes or no. Those who endorsed either of these items were
classi￿ed as having experienced strict parenting (N=￿86￿, ￿8.￿%).
Childhood religious attendance
Childhood religious service attendance was determined through participant self-
report to the question “how often did you attend religious services between the
ages of 6 and ￿￿?”. Participants selected from the options more than once a week,
once a week, once or twice a month, every couple of months, once or twice a year,
rarely, or never. Participants were coded as regularly attending religious services
if they reported attendance more than once a week, once a week, once or twice a
month or every couple of months. Regular religious attendance was reported by
6￿.￿￿% (N=￿￿￿￿) of participants.
Childhood Adversity
Childhood sexual abuse (CSA)
Individuals were asked "before age ￿8, were you ever forced into sexual intercourse
or any other sexual activity?" Those who reported that they had were classi￿ed as
having experienced CSA. Participants were then asked for the age at which they
were ￿rst forced into sexual activity. Individuals who had reported an age of ￿8 or
over for being forced into sexual activity (N=8) were recoded tomissing, to account
for the inconsistency in their response to the two questions. Childhood sexual
abuse was reported by 8.￿% (N=￿￿￿) of participants. Mean age of onset of sexual
abuse was age ￿￿.￿ (s.d. ￿.6, range ￿-￿￿).
Parent Covariates
Parental alcohol problems
Participants were asked “Did drinking ever cause [your biological father/mother]
￿￿
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to have problems with health, family, job or police, or other problems?” and “Did
you ever feel that [your biological father/mother] were excessive drinkers?” These
measures were derived from the Family History Assessment Module (FHAM),
which has been shown to have good accuracy at identifying alcohol dependence
from family interviews (￿￿.￿%of caseswere identi￿ed by at least one positive report,
and 8￿% of non-cases had no positive reports; Rice et al. (￿￿￿￿)). Individuals who
responded ’yes’ to either of these questions were coded as experiencing parental
alcohol problems (￿￿.￿￿% (N=￿￿￿) of participants).
Parental drug problems
Participants were asked “Did using drugs ever cause [your biological father/mother]
to have problems with health, family, job or police, or other problems?” and “Did
you ever feel that [your biological father/mother] had a problem with drugs?” As
with parental alcohol problems, thesemeasures were derived from the FHAM (Rice
et al., ￿￿￿￿). Individuals who responded ’yes’ to either of these questions, were
classi￿ed as having a parental history of drug problems. Parental drug problems
were reported by ￿.￿￿% (N=￿￿￿) of participants.
Peer Cannabis Use
High-School Peer Cannabis Use
The extent of cannabis use amongst high school peers wasmeasured through self-
report questions askingwhether ‘hardly any’, ‘some’, ‘half’, ‘three quarters’ or ‘almost
all’ the students who were in their grade in high-school used cannabis. Participants
were categorised as being exposed to high levels of illicit drug use during high
school if they reported that at least three quarters of their peers used cannabis.




Participants were coded as meeting criteria for CD if they reported at least ￿ of the
￿￿ DSM-IV criteria (American Psychiatric Association, ￿￿￿￿) occurring within the
same ￿￿-month period, and speci￿ed to refer to the time period before age ￿8:
• Aggression to people and animals
￿￿
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￿. often bullies, threatens, or intimidates others
￿. often initiates physical ￿ghts
￿. has used a weapon that can cause serious physical harm to others (e.g.,
a bat, brick, broken bottle, knife, gun)
￿. has been physically cruel to people
￿. has been physically cruel to animals
6. has stolen while confronting a victim (e.g., mugging, purse snatching,
extortion, armed robbery)
￿. has forced someone into sexual activity
• Destruction of property
￿. has deliberately engaged in ￿re setting with the intention of causing
serious damage
￿. has deliberately destroyed others’ property (other than by ￿re setting)
• Deceitfulness or theft
￿. has broken into someone else’s house, building, or car
￿. often lies to obtain goods or favours or to avoid obligations (i.e., "cons"
others)
￿. has stolen items of nontrivial value without confronting a victim (e.g.,
shoplifting, but without breaking and entering; forgery)
• Serious violations of rules
￿. often stays out at night despite parental prohibitions, beginning before
age ￿￿ years
￿. has run away from home overnight at least twice while living in parental
or parental surrogate home (or once without returning for a lengthy
period)
￿. is often truant from school, beginning before age ￿￿ years
Those who reported symptom onset after age ￿8 (N=￿) were coded as missing,
to account for the inconsistency in their response to the two questions. Conduct
disorder criteria were met by 8.￿% (N=￿￿￿) of participants, and the mean age of
￿￿
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reported onset was ￿￿.￿ (s.d. ￿.￿, range ￿-￿￿).
Non-Clinical Depressive Episodes
A non-clinical depressive episode was recorded if participants reported a two week
period during which they were more irritable than usual (if under age ￿8 at the
time, in line with American Psychiatric Association (￿￿￿￿) DSM-IV guidance), felt
depressed/down/sad/blue/discouraged, or had a lot less interest in things. Non-
clinical depressive episodes were reported by ￿￿.6￿% (N=￿8￿￿) of participants.
Alcohol, Tobacco and Other Drug Use
Monthly Alcohol Use
Monthly alcohol use was measured through the interview item “At what age did
you start to drink regularly - that is, drinking at least once a month for 6 months
or more?” Lifetime regular alcohol use was reported by ￿￿.￿￿% (N=￿￿6￿) of
participants. Themean age of monthly alcohol use onset was ￿8.￿ (s.d. ￿.￿￿, range
￿-￿￿).
Alcohol dependence
Participants were classi￿ed as experiencing lifetime alcohol dependence
(American Psychiatric Association, ￿￿￿￿) if they reported ￿ or more of the
following DSM-IV criteria occurring within a ￿￿month period:
• Increased tolerance to alcohol use
• Drinking on occasions when did not intend to, or for a longer time than
intended, or a greater amount than intended
• Wanted to or tried to cut down/quit, but found they could not
• Had a period of several days when drinking or recovering from the effects of
alcohol meant there was little time for anything else
• Gave up or reduced important activities to drink
• Continued to drink alcohol despite causing/worsening health problems,
having a negative effect on mental health, or experiencing blackouts
• Experienced withdrawal from alcohol
Lifetime alcohol dependence was reported by ￿￿.8￿% (N=￿￿￿) of participants. The
mean age of alcohol dependence onset was ￿￿.￿ (s.d. ￿.￿, range ￿￿ - ￿￿).
Weekly Tobacco Use
Weekly tobacco use was measured through the interview item “Was there ever a
￿￿
￿.￿.￿Measures
time in your life when you smoked cigarettes at least once a week for at least two
months in a row?” Lifetime weekly tobacco use was reported by ￿￿.￿% (N=￿￿￿￿) of
participants. The mean age of weekly tobacco use onset was ￿￿.￿ (s.d. ￿.￿, range
￿ – ￿￿).
Tobacco Dependence
Those sample members who reported smoking ￿￿￿+ cigarettes in their lifetime
were asked a series of further questions about their experiences of nicotine
dependence symptomatology. Participants were classi￿ed as experiencing lifetime
tobacco dependence (American Psychiatric Association, ￿￿￿￿) if they reported ￿ or
more of the following DSM-IV criteria occurring within a ￿￿month period:
• Smoking more than ￿￿ cigarettes a day, or smoking more/using a stronger
type of tobacco than when started smoking
• Often chain smoked cigarettes
• Gave up important activities/missed socialising due to being unable to smoke
cigarettes
• Smoked more cigarettes than intended, or broke own rules on smoking
• Wanted to or tried to cut down/quit, but found they could not
• Experienced withdrawal from cigarettes
• Continued to smoke cigarettes despite causing/worsening health problems
and anxieties
Lifetime tobacco dependencewas reported by ￿￿.￿￿% (N=￿￿6) of participants. The
mean age of tobacco dependence onset was ￿￿.￿ (s.d. ￿.￿, range ￿￿ – ￿￿).
Other Drug Use
Other drug use was recorded if participants reported lifetime non-prescribed use of
any of the following:
• cocaine (all forms)
• stimulants
• opiates and major painkillers
• sedatives
• hallucinogens




Lifetime illicit drug use was reported by ￿￿.￿￿% (N=￿6￿￿) of participants. Themean
age of other illicit drug use onset was ￿￿.￿ (s.d. ￿.￿, range ￿ – ￿￿).
Other Drug Dependence
Participants were classi￿ed as meeting criteria for lifetime other drug dependence
(American Psychiatric Association, ￿￿￿￿) if they reported ￿ or more DSM-IV criteria
for dependence occurring within the same ￿￿month period for any one of the drugs
listed above:
• Using the drug a greater number of times/greater amount than was intended
• Tolerance
• Wanting to cut down/stop use but being unable to
• Spending so much time obtaining/using/recovering from the effects of the
drug that the participant had little time for anything else
• Reducing important activities as a result of drug use
• Continuing use despite it worsening health/emotional problems
• Experiencing withdrawal
All symptoms had to occur in relation to the same drug for dependence to be
recorded. Lifetime other illicit drug dependence was reported by ￿.68% (N=￿￿￿)
of participants. The mean age of onset was ￿￿.￿ (s.d ￿.￿, range ￿￿ – ￿￿).
Prevalence of dependence on individual drugs was:
• cocaine (all forms): ￿.￿%
• stimulants: ￿.￿%
• opiates and major painkillers: ￿.￿%
• sedatives: ￿.￿%
• hallucinogens: ￿.￿%
• solvents and inhalants: ￿%
• dissociative drugs: ￿.￿%
Equality of Environment
The following self-reported items were asked only to twin pairs, to assess twin
similarity: “When you were 6 to ￿￿, how often did you share the same friends?”,
“How often did you dress alike?”, "In primary school, how often were you in the
same classes?”, “In high school howoftenwere you in the same classes?”, “Between
￿￿
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the ages of 6 and ￿￿, how often did your mother/ father/teachers/strangers have
trouble telling you and your twin apart?”, and “Without using a list, when you and your
twin were children, were you as alike as ’two peas in a pod’, or only of normal family
physical likeness?”. Concordance on these items was used to test the equality of
the twin childhood environment.
￿.￿.￿ Missing Data
Non-random patterns of missing data can bias results. As cannabis use and
outcome phenotypes are the independent and dependent variables in the analyses
on these data, analyses of patterns of missing data have been conducted on these
variables.
Due to the CATI method of data collection, there is very little missing data in
this dataset. A full outline of the missing data for analysis variables can be found
in Figure ￿.￿. This ￿gure summarises the structure of the interview and provides
details of both the number of respondents reporting a speci￿c behaviour and the
number of participants for whom there was missing data. A full list of the missing
data for each covariate used in the analyses, and missing data on ages of onset
where relevant to the analyses, can be found in Appendix ￿.
For the majority of independent and dependent variables used within the analyses,
the numbers of missing participants are so low (N￿) that they did not introduce
risk of bias. For opportunity to use cannabis and lifetime use of cannabis, missing
and non-missing participants were compared on the demographic characteristics
of gender and education using 2, and age at interview using anova tests. Statistical
signi￿cance was determined at the P￿.￿￿ level.
Missing on Opportunity to Use Cannabis
Compared to those who responded to the item on opportunity to use cannabis
(N=￿￿￿8), those who were missing (N=￿6) were signi￿cantly different on both
gender (￿6.￿% of non-missing participants were male, compared to 6￿.￿% of
missing participants, P=￿.￿￿￿, OR ￿.￿￿, ￿￿% CI ￿.￿￿ - ￿.￿￿) and education (￿￿.￿%
of non-missing participants had completed further/higher education, compared to
￿6.￿% of missing participants, P￿.￿￿￿, OR ￿.￿, ￿￿% CI ￿.￿6 -￿.￿￿). Mean age
at interview was ￿￿.￿ for non-missing participants (S.D ￿.￿) and ￿￿.￿ for missing
￿￿
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Figure ￿.￿: Group Numbers and Missing Data Numbers for Cannabis Variables
Never Used 
cannabis 
N = 1196 
Reported lifetime cannabis *
use
N = 2601
Missing N = 27
Used cannabis once
N = 359
Used cannabis twice or 
more
N = 2239
Missing N = 3
Used cannabis fewer 
than 11 times
N = 703 




Case N = 581
Cannabis dependence 
Case N = 372
Cannabis daily use
Case N = 373
Missing N = 2
Cannabis treatment seeking
Case N = 133
Missing N = 2
Lifetime Opportunity to Use Cannabis
N = 3399
Missing N = 26 
*Group numbers differ from opportunity as reporting opportunity 
was not criteria for reporting lifetime cannabis use
participants (S.D ￿.￿) (F=￿.￿8, df = ￿, P=￿.6￿). To account for the signi￿cant
differences between missing and non-missing groups, analyses were adjusted for
gender and education.
Missing on Lifetime Cannabis Use
Compared to those who responded to the item on lifetime cannabis use (N=￿￿￿￿),
those who were missing (N=￿￿) were signi￿cantly different on both gender
(￿6.￿% of non-missing participants were male, compared to 6￿.￿% of missing
participants, P=￿.￿￿￿, OR ￿.￿￿, ￿￿% CI ￿.￿￿ - ￿.￿￿) and education (￿￿.￿% of non-
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missing participants had completed further/higher education, compared to ￿￿.￿%
ofmissing participants, P=￿.￿￿￿, OR ￿.6￿, ￿￿%CI ￿.￿￿ - ￿.￿￿). Mean age at interview
was ￿￿.￿ for non-missing participants (S.D ￿.￿) and ￿￿.￿ for missing participants
(S.D ￿.￿) (F=￿.￿￿, df = ￿, P=￿.￿￿). To account for the signi￿cant differences between
missing and non-missing groups, analyseswere adjusted for gender and education.
￿.￿ Sample ￿: South London and Maudsley NHS Trust
(SLAM) Opiate Substitution Treatment Sample
This exploratory study was conducted in order to test hypotheses relating to speed
of early heroin transitions and later outcomes, and to establish whether ￿ndings
relating to speed of transition for cannabis use would also be found for a different
drug class. Given the low prevalence of heroin use in the general population (see
Chapter ￿), a clinical population was required to study heroin use. Data collection
took place in two Drug and Alcohol Treatment services within the South London
and Maudsley NHS Trust (SLAM). The data from this study are used in Chapter 6.
￿.￿.￿ Procedure
Service User Involvement
Participants in the Service User’s Research Group at the Aurora Project, Lambeth,
were invited to a focus group to discuss the study purpose and design. A number of
individuals in recovery from drug and alcohol abuse attended the session, read and
discussed the interview items and patient information, and provided feedback. As
a result of this session, the following suggestions were incorporated into the study
design:
• The interview was administered by a researcher as opposed to being
produced as a questionnaire for participants to complete themselves, in order
to avoid literacy issues.
• Following concerns raised by focus group participants that the proposed
measures of severity of dependence (Severity of Dependence Scale) would
not have much variation in the sample, additional items were included to
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represent severity in the sample, including injecting behaviours and amount
of heroin used.
• It had been proposed to use daily heroin use as a marker of having developed
problem heroin use. Feedback strongly indicated that judgement of the onset
of problem heroin use should not rely solely on the measure of daily heroin
use, but should also incorporate measures such as effect on relationships
and employment. There were concerns that daily heroin use may not be the
￿rst experienced sign of problems.
Recruitment and Data Collection
In total ￿￿ participants were recruited into the study and ￿￿ approached participants
declined to participate, providing a participant response rate of 8￿%. Potential
participants attending for opiate substitution treatment, who had capacity to
take part, were identi￿ed and informed of the study by clinic staff. Interested
participants contacted the PhD researcher located in the clinic waiting area,
and clinic staff provided the researcher with refusal ￿gures. The researcher
accompanied the participant to a private room within the clinic, then outlined
the study using the participant information sheet (see Appendix ￿), and obtained
informed consent from the participant (see Appendix ￿). Any participants who
were intoxicated, assessed by the researcher asking a screening question on
intoxication, were asked to participate in the study at a later date.
Participants provided responses to a short structured quantitative interview
administered by the researcher. This included demographic information, age of
onset for a number of drug behaviours, and the Severity of Dependence Scale (see
measure outline below; see Appendix ￿ for full interview schedule). Participants
were reimbursed £￿￿ upon completion of the interview.
Sample Size and Power Calculation
The pre-planned primary analysis for this study was a regression model testing for
an association between speed of early transition in heroin use and dependence
severity. Assuming a positive linear relationship between speed of transitions
in heroin use and dependence severity, power analysis was based on whether
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the standardized regression co-ef￿cient or slope differed from ￿. Power was
calculated in G-Power ￿.￿ (Faul et al., ￿￿￿￿) using a linear bivariate model. With
￿￿ participants and assuming an alpha level of ￿.￿￿ the study has ￿￿% power to
detect a standardized regression slope of ￿.￿.
Data security
Participants were assigned an anonymous study identi￿cation number, including
a clinic location identi￿er. Completed interviews were kept separate from consent
forms at all times. Completed interviewswere kept in a locked bagwhen in the clinic
and when transporting to the Institute of Psychiatry, Psychology and Neuroscience
(IoPPN). On arrival at the IoPPN, records of completed interviews were stored in a
secured cabinet. Completed consent forms were stored in a separate but equally
secure locked cabinet on a different ￿oor. When responses were entered onto the
computer for analysis, the data were stored on a secure IoPPN server that was only
accessible to the research team.
Data entry
Data were double-entered using a custom designed spreadsheet in Microsoft Excel
in preparation for data analysis. In order to minimise entry inaccuracies self-
validating drop-downboxes containing the interview response optionswere created
for each categorical item. Any inconsistent entries were checked against the
original interviews and corrected. The double entered and checked data was then
transferred into a Stata ￿le (StataCorp, ￿￿￿￿) for analysis.
Ethical approval
Ethical approval was granted by the NHS Research Ethics Committee (￿￿/LO/￿￿￿￿)
and SLAM Research and Development Department.
￿.￿.￿ Measures
The following analysis itemswere derived from the interview data. The full interview
can be found in Appendix ￿.
￿￿
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Speed of Transition Variables
Early Opportunity to Use Heroin
Participants self-reported their age at ￿rst opportunity to use heroin. To aid recall
and improve understanding, participants were given the following prompt: “By an
opportunity I mean someone either offered you heroin, or you were present when
others were using and you could have used if you wanted to” (de￿nition from Storr
et al. (￿￿￿￿)).
As there is no known precedent in the literature for what is considered early
opportunity to use heroin, the continuous age measure of this item was
transformed into tertiles. Participants were in the lowest tertile for reported age
of opportunity if they had opportunity to use heroin at age ￿￿ or under. A binary
variable of early/later opportunity was created using this data. In the sample ￿￿.6%
(N=￿￿) reported early opportunity to use heroin. See Figure ￿.6 for distribution.
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Age Distribution of Opportunity to use Heroin
Time From Opportunity to Use Heroin to Initiation of Use
Participants self-reported the time between their ￿rst opportunity to use heroin and
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initiation of heroin use. Participants provided responses in days, weeks, months or
years. These responses were coded to a dichotomous variable of “within a week
of opportunity” and “more than one week after opportunity”. In the sample 6￿.￿%
(N=￿￿) reported progressing to initiation of use within a week of opportunity to use
heroin.
Time From Initiation to Subsequent Heroin Use
Participants self-reported the time between their initiation of heroin use to their
subsequent use of heroin (clari￿ed in the interviewer as “the second time in your
life that you used heroin”). Participants provided responses in days, weeks, months
or years. These responses were coded to a dichotomous variable of “within a week
of initiation” and “more than one week after initiation”. In the sample ￿￿.￿% (N=￿￿)
reported using heroin for a second time within a week of initiating use.
Outcome Variables

















Distribution of Time to Treatment Seeking
Time From Problem Use Onset to First Seeking Treatment
Participants’ self-report of age at onset of problem heroin use, ascertained through
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one or more of daily heroin use, using heroin alone, experiencing withdrawal
symptoms, experiencing relationship problems as a result of heroin use, and
experiencing employment/studying problems as a result of heroin use was utilised
to create this variable. Mean age of ￿rst reported problemwas￿￿ (s.d. ￿.￿, range 8–
￿￿). The earliest reported age of any of these was taken as the age of ￿rst reported
problem with heroin use. Mean age at ￿rst treatment-seeking was ￿￿.￿ (s.d. 8.￿,
range ￿￿ - ￿￿). The time from the onset of problem use to treatment-seeking was
calculated by selecting the age of ￿rst problemonset, and calculating the difference
between this and the age at treatment-seeking. Any negative values (indicating
that treatment-seeking was initiated before onset of any of these problems) were
recoded to missing (N=￿). The mean time from ￿rst problem to ￿rst seeking
treatment was ￿.￿ years (s.d. 6.￿, range ￿ - ￿￿ years). See Figure ￿.￿ for distribution.
Severity of Dependence at Time of Treatment-Seeking
The Severity of Dependence Scale (SDS) was administered as part of the interview.
The SDS is a validated unidimensional measure (González-Saiz et al., ￿￿￿8; Gossop
et al., ￿￿￿￿) that consists of ￿ve items investigating drug taking behaviours that are
related to dependence severity (Gossop et al., ￿￿￿￿) and measures the degree to
which users are experiencing psychological dependence through a scoring system,
with a score of ￿ indicating dependence and higher scores indicating greater
degrees of dependence severity (Ding et al., ￿￿￿￿; González-Sáiz et al., ￿￿￿￿).
The SDS has previously been tested for validity in London heroin using
populations, and has positive correlations with heroin dose (r=￿.￿￿, P￿.￿￿￿),
duration of heroin use (r=￿.￿￿, P￿.￿￿￿) and frequency of use in days per week
(r=￿.￿￿, P￿.￿￿￿), and participants who were using heroin daily, spending the
majority of time with other users and being in contact with treatment services
had signi￿cantly higher SDS scores (Gossop et al., ￿￿￿￿). Amongst an Australian
methadone treatment sample SDS scores were positively correlated with current
use (r=￿.￿￿, P￿.￿￿￿), frequency of use of heroin (r=￿.￿￿; P￿.￿￿￿, respectively)
and duration of heroin use (r=￿.￿￿, P￿.￿￿￿), and negatively correlated with time in
methadone treatment (r=-￿.￿￿, P￿.￿￿￿) and methadone dose (r=-￿.￿￿, P￿.￿￿)
(Gossop et al., ￿￿￿￿). Principal components analysis has demonstrated that the
items within the SDS load onto a single factor, with good internal consistency




The SDS is the only measure of dependence severity to include items focussing
on compulsive drug taking and seeking (Conway et al., ￿￿￿￿), and has previously
been shown to be appropriate for determining variation in dependence in opiate
treatment populations (Gossop et al., ￿￿￿￿; Miller et al., ￿￿￿￿). The SDS items
are scored never/almost never, sometimes, often or nearly always/always for the
items:
• Do you think your use of opiates is out of control?
• Does the prospect of missing a ￿x (or dose) or not chasing make you anxious
or worried?
• Do you worry about your use of opiates?
• Do you wish you could stop using opiates?
and scored not dif￿cult, quite dif￿cult, very dif￿cult and impossible for the item:
• How dif￿cult do you ￿nd it to stop or go without opiates?
Severity of opiate dependence at time of initial treatment-seeking was assessed
through retrospective participant SDS self-report. Total scores were used for the
analysis, with higher scores indicating increased dependence severity. The mean
score at treatment-seeking was ￿￿.￿, s.d. ￿.￿, range ￿ – ￿￿. See ￿gure ￿.8 for
distribution.
Injecting into the Groin or Neck
Participants self-reported whether they had ever engaged in femoral (groin vein)
injecting or neck injecting as a result of their heroin use. These two individual items
were combined into one measure of lifetime groin or neck injecting. In the sample,
￿￿.￿% (N=￿￿) reported injecting into the groin or neck.
Overdose
Participants self-reported whether they had ever experienced overdose as a result
of their heroin use. In the sample, ￿￿.8% (N=￿￿) reported experiencing overdose.
Heavy Use of Heroin
Information on the amount of heroin used was collected through the item “At
your period of heaviest use, what amount of heroin/opiates were you using on a
typical day?”. Participants were permitted to respond with an amount in grams
and/or in pounds sterling (£). The continuous measures of these responses were
transformed into tertiles. Participants who reported being in the highest tertile for
￿￿
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Distribution of SDS Score
reported amount in grams or in £ were classi￿ed as heavy users of heroin. In the
sample, ￿6.￿% (N=￿￿) reported heavy heroin use.
Demographic Covariates
Gender
Gender was self-reported by participants: ￿￿% (N=6￿) were male.
Ethnicity
Participants were asked to classify their ethnicity from the options: White British,
White Irish, Other White, White and Black Caribbean, White and Black African, White
and Asian, Other Mixed, Indian, Pakistani, Bangladeshi, Other Asian, Caribbean,
African, Other Black, Chinese, Other. The variable was collapsed into the categories





Participants self reported their age at the time of the interview. The mean age was
￿￿.￿ (s.d. ￿.￿, range ￿￿ – 6￿).
￿.￿.￿ Missing Data
The only speed of transition variables missing data were ’age of opportunity to use
heroin’ (missing N=￿) and ’time from opportunity to use heroin to initiation of use’
(missing N=￿). The outcomes with missing data were ’heavy opiate use’ (missing
N=￿), and ’age at treatment-seeking for opiate use’ (missing N=￿), which would
contribute to the variable of ’time from problem use to treatment-seeking’. These
numbers were considered low enough for missing data to present no concerns.
Information onmissing data for all independent variables, dependent variables and
covariates is available in Appendix ￿.
￿.￿ Sample ￿: The ￿￿￿￿s Drug Transitions Study
Chapter 6 includes analysis of data from a study conducted in the early ￿￿￿￿s in
London (Grif￿ths et al., ￿￿￿￿). This study aimed to explore the nature and extent
of transitions in route of heroin administration, using a sample that consisted of
heroin users both in and out of treatment who had a variety of heroin administration
routes. Prior to ￿￿8￿, the predominant route of administration among London-
based heroin users was injecting, but after ￿￿8￿ chasing (inhaling heroin vapour)
became more prevalent as a route of administration (Strang et al., ￿￿￿￿). Thus, at
the time the study was conducted, the population contained individuals who had
initiated heroin use by both routes. Utilising a population with variation in the route
of heroin administration allows for speci￿c testing of the relationship between Initial
Heroin Administration Route (IAR) and transition speed.
￿.￿.￿ Procedure
Recruitment and Data Collection
The sample consisted of ￿￿8 heroin users who were recruited in the London area
during ￿￿￿￿. All participants had used heroin in the month prior to interview. The
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sample was structured to include ￿￿￿ subjects in contact with treatment agencies
and ￿￿￿ subjects who were not in treatment. Participants were de￿ned as in
treatment if they were attending a drug dependence unit, attending voluntary or
statutory street agencies, in contact with a general practitioner speci￿cally for a
drugs problem, or in contact with any other organization speci￿cally for a drugs
problem.
Recruitment and interviewingwere conducted byPrivilegedAccess Interviewers
(PAIs) (Grif￿ths et al., ￿￿￿￿). This method utilises individuals who have attributes
that make them non-threatening to members of the population under study, and
who have access to populations that traditional researchers would ￿nd dif￿cult to
reach. Current drug use was neither an inclusionary nor exclusionary criterion for
the PAIs, who were selected based on:
• Having existing contacts (or the ability to easily develop contacts) within the
population of interest
• Having personal attributes and life experiences that made them non-
threatening to the population
• Being socially and educationally equipped to conduct the interview schedule,
and having a relatively stable lifestyle that allowed employment
• conducting the interview andmaking contacts not being damaging to the PAI.
The mean number of interviews conducted by each interviewer was ￿￿.
Methodologies such as PAI can have a number of limitations, including being
labour intensive, the risk of the researchers only reaching small and idiosyncratic
networks, the likelihood of thosewhoare socially isolated being excluded, and those
who are more vocal or prominent in the community being over-represented, and
the potential for ￿ndings to be strongly affected by the quality of the researcher
(Grif￿ths et al., ￿￿￿￿). The Drug Transitions study sought to overcome these issues
by recruiting PAIs from a range of backgrounds, all of who would have access to a
wide selection of networks, and by developing a structured questionnaire to guide
the interview.
The questionnaire collected basic demographic data, current patterns of drug
use, history of drug-using behaviour, transitions in route of administration, social
factors associated with transitions or non-transitions in route of administration,
injection and sharing practice, details on living situation, and current andpast sexual
behaviour. PAIs were trained in the use of the interview schedule and, to ensure
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data quality, all interviews were recorded and checked by the research team (with
the caveat that recorders could be turned off during the interview if participants
requested).
Ethics
Ethical approval was gained from the Joint Ethics Committee of the Institute of
Psychiatry (prior to it becoming part of King’s College London) and the Bethlem &
Maudsley NHS Trust (the former name of SLAM).
￿.￿.￿ Measures
Initial Route of Heroin Administration (IAR)
Participants were asked “Thinking back to the ￿rst time you used heroin:
• did you inject it?
• did you chase it?
• other
Of the ￿￿8 participants, ￿￿￿ reported chasing as their IAR and ￿￿6 reported
injecting. ‘Other’ was reported by 6￿ participants, of whom ￿8 reported snorting
heroin, ￿ reported smoking heroin and ￿ reported oral administration. The IARs of
injecting, chasing and snorting were included in the analyses, with smoking and
oral excluded due to very low group numbers.
Speed of Transition Variable
Speed of Transition to Daily Use
Participants were asked “how long was it from your ￿rst use of heroin until it
became something you used every day or most days?” Responses were provided
in days, months or years, and were then recoded into the categories ￿ to ￿ weeks
(i.e. up to one month), ￿ month to ￿￿ months, ￿ to ￿ years and ￿ or more years.
Individualswho had reported not progressing to daily heroin use at time of interview





Data on gender were obtained through interviewer report. The sample was
predominately male (6￿.￿%, N=￿￿6).
Ethnicity
Participants reported being White, African/Caribbean, Asian, or Mixed. Due to low
numbers of Black and Minority Ethnic participants this was coded as a binary
White/Non-White variable. The sample was predominately white (￿￿.￿%, N=￿￿￿).
Daily Other Drug Use Prior to Heroin Initiation
Data were obtained through self-report to the item “when you used heroin for the
￿rst time, were you using any other drugs regularly (that is every day ormost days)?”
The majority of the sample reported regular use of other drugs at heroin initiation
(68.￿%, N=￿￿￿). Reported drugs included amphetamine (N=8￿), cannabis (N = ￿￿￿),
cocaine (N = ￿￿) and ecstasy (N = ￿).
Year of Initiation of Heroin Use
This was calculated from recorded year of interview, participant age at interview
and age at initiation of heroin use. Year of initiation ranged from ￿￿￿￿ – ￿￿￿￿ (mean
= ￿￿8￿, s.d. 6.￿).
Current Treatment
Data were obtained through self-report of attending a drug clinic, a street agency, a
needle exchange, or receiving treatment for a drug problem somewhere else at the
time of interview. As a result of the sampling method (i.e. by design) just over half
the sample (￿8.￿%, N = ￿￿￿) was receiving treatment at time of interview.
￿.￿.￿ Missing Data
There were ￿￿ participants with missing data on daily heroin use status. These
participants were not signi￿cantly different to those who had reported their time to
daily heroin use on gender (P=￿.￿￿, OR ￿.￿6, ￿￿% CI ￿.￿￿ - ￿.￿￿), ethnicity (P=￿.￿￿,
OR not possible due to ￿ cell counts), year of heroin onset (F=￿.￿￿, d.f=￿, P=￿.￿￿),
or IAR (chasing P = ￿.8￿, OR = ￿.￿￿, ￿￿% CI ￿.￿6 - ￿.￿￿; snorting P = ￿.￿￿, OR = ￿6,
￿￿% CI = ￿.￿￿ - ￿.￿6). No participants were missing data on their IAR. Information
on missing data for all independent and dependent variables and covariates is
available in Appendix ￿.
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￿.￿ Analysis of Data
This section provides an overview of how analyses will address the aims of the
thesis. See Figure ￿.￿ for an outline of analyses by aims addressed.
The results chapters (Chapter ￿, ￿, ￿ and 6) will contain individual analysis plans
outlining the speci￿c aims of the analyses in relation to that chapter, howmeasures
are used within each analysis, identi￿ed confounding variables, and any further
speci￿c details of the analysis.
The following statistical methods are employed throughout the thesis. The
aim that the method is addressing in each chapter will be outlined, followed by an
overview of the methodology, a description of the assumptions, and exposition of
the complexities of the analysis as applied in this thesis.




















Aim 2 Aim 3 Aim 4
￿.￿.￿ Data Preparation
Due to the size of the dataset, ATR data were initially cleaned and coded into the
required variables using SAS software (SAS Institute Inc, ￿￿￿￿). Epidemiological
analyses were conducted in Stata (StataCorp, ￿￿￿￿) and genetically informative
analyses were conducted in R (R Core Team, ￿￿￿￿) using the package OpenMx
(Boker et al., ￿￿￿￿). For the SLAM Opiate Treatment Sample and ￿￿￿￿s Drug
Transitions Study data, all variables were coded and analysed using Stata
(StataCorp, ￿￿￿￿).
￿￿
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￿.￿.￿ Regression Models for Categorical Data
Aims Addressed
Regression analyses were used
￿. in Chapter ￿ to explore the association between early opportunity to use
cannabis and the later outcomes of daily cannabis use, abuse/dependence
and treatment-seeking;
￿. in Chapter ￿ to explore the extent to which the speed of transition to cannabis
opportunity and from opportunity to dependence are in￿uenced by individual,
childhood, mental health and other drug use factors;
￿. in Chapter ￿ to explore the association between speed of transition from ￿rst
to second use of cannabis and the later outcomes of daily cannabis use,
abuse/dependence and treatment-seeking;
￿. in Chapter 6 to explore the association between early transitions in heroin use
and the later heroin use outcomes of heroin dependence severity, overdose,
injecting behaviours and heavy heroin use, and the relationship between IAR
and speed of transition.
Regression Outline
Regression analysis is used to determine the association between one or more
factors and a single outcome (Vittinghoff et al., ￿￿￿￿), and can be used to establish
the change in an outcome, or Dependent Variable (DV) for every one unit increase
in a predictor, or Independent Variable (IV) (Vogt and Johnson, ￿￿￿6). The size of
this change is represented through the regression coef￿cient, which in analysis of
dichotomous data can be calculated as an Odds Ratio (OR) through exponentiation
of the regression coef￿cient. An OR of ￿.￿ indicates no relationship between the
variables, and the difference from ￿.￿ in either direction provides an estimate of
whether the relationship is positive or negative, and what the size of the effect is
(Vogt and Johnson, ￿￿￿6). Precision of the estimate can be assessed through ￿￿%
con￿dence intervals (￿￿% CI).
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Forms of Regression Used in the Thesis
Binary Logistic Regression
Logistic regression is appropriate for use when the DV is dichotomous, such as
being a case or a non-case for cannabis dependence. The IV can be either binary or
have three or more categories, and provides regression coef￿cients that compare
each level of the independent variable against a set reference category. In this
thesis, this reference category is the group with the least risk under the study
hypothesis. When the IV has ￿+ levels, differences between levels can be assessed
through the use of post-hoc tests, such as Wald  2.
Ordered Logistic and Generalised Ordered Logistic Regression
When the DV has three or more levels and is an ordered variable, an ordered logistic
model is appropriate (Williams, ￿￿￿6). Under the proportional odds assumption
the relationship with the IV must be the same for each level of the DV. This can
be tested using likelihood ratio tests and the Brant test, with a signi￿cant result
(P￿.￿￿) indicating assumptions are violated (Williams, ￿￿￿6).
When the assumption is violated a generalised ordered logistic model can
be used (Williams, ￿￿￿6; Miller et al., ￿￿￿￿), which allows a different relationship
between theDVand each level of the IV. This analysis producesmultiple coef￿cients
as the levels (J) of the DV are analysed equivalent to a series of binary logistic
regressions where the categories (M) of the DV are combined. For example when
M = ￿, for J = ￿ category ￿ is contrasted with categories ￿, ￿, and ￿; for J = ￿ the
contrast is between categories ￿ and ￿ versus ￿ and ￿; and for J = ￿, it is categories
￿, ￿, and ￿ versus category ￿ (Williams, ￿￿￿6).
￿.￿.￿ Survival Analysis and Cox’s Proportional Hazards Model
In order to identify factors that in￿uence the speed of transition in stages of
cannabis use, survival analysis was utilised for variables where continuous time
data were available. Survival analysis uses regression analysis for time-to-event
data to determine how many individuals in a sample will "survive" (not develop the
outcome) past a certain time point (t), and allows for the inclusion of covariates to
6￿
￿.￿.￿ Survival Analysis and Cox’s Proportional Hazards Model
explore how other factors affect the probability of "survival" (Fisher and Lin, ￿￿￿￿;
Kleinbaum and Klein, ￿￿￿￿). This is represented through the hazard function (h(t)),
which is the potential per time unit for an event to occur, given that the individual
has survived up until t. Survival analysis uses time data h(t) as a rate rather than
a probability or likelihood (Kleinbaum and Klein, ￿￿￿￿). The regression coef￿cient
for survival analysis is the hazard ratio, which compares the hazard function for
unexposed and exposed individuals in order to provide an estimate of the hazard
for each group (Kirkwood and Sterne, ￿￿￿￿). This hazard represents an individual’s
increased rate of progression to the outcome.
The Proportional Hazards Assumption
A key assumption underlying survival analysis is the proportional hazards
assumption: the hazard ratio does not vary with time. If this assumption is
breached by covariates in the model, the relative risks of covariates will be
incorrectly estimated, with increasing hazard ratios over time resulting in over-
estimation and converging hazards resulting in an underestimation (Schemper,
￿￿￿￿).
There are a number of equally suitable options for assessment of the
proportionality of the assumption (Bellera et al., ￿￿￿￿), and in this thesis, as in
previous research (Waldron et al., ￿￿￿￿), analysis of Schoenfeld residuals has been
selected. The residuals quantify the differences between what has been observed
in the data and what would be expected under the model assumptions, and are
calculated for every failure time (Bellera et al., ￿￿￿￿). A signi￿cant Pearsons
Rho (P￿.￿￿) indicates breach of the proportional hazards assumption. When
covariates do breach the assumption, the interaction with time has been included
in the model in order to adjust for the breach of assumptions (Bellera et al., ￿￿￿￿;
Schemper, ￿￿￿￿; Waldron et al., ￿￿￿￿). This results in an “extended” cox model.
Censored Data
One key feature of survival analysis is the use of censored data, whereby data
that are missing after a certain time point are analysed without introducing bias
through lost information (Kleinbaum and Klein, ￿￿￿￿). Censoring most commonly
occurs when a subject does not experience the event before t, when a subject
is lost to follow-up, or when a subject withdraws from the study. Given that the
analyses in this thesis are retrospective, data are right censored: the outcome of
interest has not occurred by t (time at interview). As there is still potential for the
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outcome to occur after this time point, data are censored for analysis rather than
being analysed as if the individual would never experience the outcome.
Person-Year data
Person-year data sets were constructed for the analyses, providing a separate row
of participant data for each year so that there are as many data rows as there
are time intervals at risk of the event occurring for each person (Jenkins, ￿￿￿8).
In order to create person-year data in Stata, the stsplit command was used once
survival data had been created. This created a separate row of data for each year
in which the participant was included within the analysis. In order to account for
multiple participants experiencing failures events in the same year and having
identical failure times, the Efron adjustment for survival ties was applied (Efron,
￿￿￿￿).
Time-Varying Covariates (TVC)
Where temporal data were available Time Varying Covariates (TVC) were created.
In this thesis, TVC have been used to create a “step function” (Fisher and Lin, ￿￿￿￿);
the hazard associated with the covariate will alter in the analysis at the point of
covariate onset. If visualised, the hazard would "step" up or down (depending
on the association with the outcome) at the point of onset. To achieve this, the
Stata stsplit command was used once survival data had been created. This allows
for individuals to be coded as ￿ at the time-points before the reported onset of
the behaviour of interest, and ￿ at and forwards from the reported onset of the
behaviour, and thus provides a more accurate representation of the individual
hazards over time.
￿.￿.￿ Additional Regression Considerations
Huber-White Adjustment for Clustered Data
The non-independence of observations from members of a twin pair or from
participants recruited from within the same treatment clinic, can violate the
assumptions of regression analyses. Therefore, the Huber-White analysis for
clustered data was implemented in all regression and Cox PH analyses for data
from the ATR (clustering by family) and the SLAM Opiate Treatment Sample
(clustering by clinic). Clustering data were not available for the ￿￿￿￿s Drug
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Transition Study. This method ensures robust standard errors (Maas and Hox,
￿￿￿￿).
Selection of Potential Confounding Covariates
The regression equation allows for multivariate modelling, whereby additional
covariates are added to the regressionmodel to allow the effect of the independent
variable on the dependent variable to be assessed after accounting for the in￿uence
of these covariates. Doing so statistically adjusts the variables in the model for
their differences in distribution and their relationship to the other variables in the
model, providing estimates that are adjusted for the other variables (Hosmer et al.,
￿￿￿￿). This method allows the model to account for confounding variables. These
are covariates which are associated with both the independent and dependent
variables, can therefore account for part of the association between the variables of
interest, and may lead to incorrect estimation of the true association if not handled
correctly (Hennekens and Buring, ￿￿8￿).
For the logistic and generalised ordered logistic regression analyses of the ATR
data (Chapter ￿ and ￿) potential covariates (described above in ATR measures,
section ￿.￿.￿) were selected based upon the literature (see Chapter ￿) and their
availability within the data set. In order to determine appropriate adjustment for
each analysismodel, all study covariates were entered intomultivariable regression
models with the variables age of opportunity to use cannabis, speed of transition
from initiation to subsequent cannabis use, daily cannabis use, cannabis abuse
and/or dependence, and cannabis treatment-seeking. This method is preferable to
bivariable analysis (testing associations between covariates and IV/DV singularly),
through which signi￿cant associations can be masked (Sun et al., ￿￿￿6). Using
multivariable regression allows associations to be adjusted for the effect of the
other covariates, and the results were used to select confounding variables for
analysis. Covariates that were identi￿ed as signi￿cantly associated with the model
IV and DV were included to adjust for the potential confounding variable. The
associations between the model IV and the covariates are reported in the relevant
chapter (Chapters ￿ and ￿), and the associations between DV and the covariates
are reported in Appendix ￿. No ATR data analyseswere adjusted for age at interview




For the data from the SLAM Opiate Treatment Sample and the ￿￿￿￿s Drug
Transitions Sample, a much smaller range of covariates was available. Analyses
were adjusted for demographic factors, year of heroin onset to account for any
cohort effects, and where possible, treatment status and regular other drug use
preceding heroin initiation.
￿.￿.￿ Twin Modelling
Twin modelling was used in Chapters ￿ and ￿ to address the aim of
￿. examining the extent to which the speed of early stage transitions in
trajectories of cannabis use were in￿uenced by additive genetic, shared and
non-shared environmental in￿uences
￿. exploring the extent to which genetic in￿uences transitions are unique to
the phenotype, and the extent to which they are correlated with cannabis
dependence.
The Underlying Theory Of Twin Modelling
Underlying twin modelling is the concept of heredity – traits from parents are
passed down to offspring through genes. Between any two individuals ￿ in ￿￿￿￿
genes will have a polymorphism that differs, and these alternative forms of genes
are referred to as alleles (Neale and Cardon, ￿￿￿￿). One allele can be dominant over
another, which can determine which traits are expressed. Differences in genetic
variants result in variation in physical traits such as eye colour, disease propensity,
and individual behaviour. A person’s complete collection of genes is referred to as
the genotype, and observable characteristic or behaviour is termed the phenotype
(Neale and Cardon, ￿￿￿￿).
Research has indicated that there are not singles genes that in￿uence mental
health and behavioural phenotypes. Rather, in￿uences from a number of genes
combine to produce outcomes such as drug dependence (Plomin et al., ￿￿￿￿).
Consequently it is important to consider the combined effect of genes on a
phenotype. This can be achieved by looking at the “variance” of a phenotype:
the measure of individual differences in the population (Plomin et al., ￿￿￿￿).
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The proportion of the phenotypic variance that can be accounted for by genetic
differences amongst individuals is known as heritability (Plomin et al., ￿￿￿￿).
Not all variance in a population is attributable to genetic effects. There is a
strong role played by the environment in mental health and behavioural outcomes.
For example, it is impossible for genes to contribute to the development of
dependence if an individual does not have access to the drug. This drug access can
only come from the environment (and is only one example of many environmental
in￿uences). Environmental variance is partitioned into genetic and environmental
sources through twin modelling.
The Role of Monozygotic (MZ) and Dizygotic (DZ) Twin Pairs
If phenotypic variance can result from both genetic and environmental differences,
how can these be disentangled? Approaches using twins reared together can be
used to determine the heritability of, and environmental contribution to, a phenotype
or trait. Identical – or monozygotic (MZ) – twins pairs share ￿￿￿% of their genetic
material. Conversely fraternal – or dizygotic (DZ) – twin pairs share only ￿￿% of
the same genetic material. This means that they are no more alike, genetically,
than full siblings. However, unlike siblings, DZ twins will grow up in the same
environment. Using this knowledge we can calculate the extent to which the
variance in a phenotype is due to genetic effects, and the extent to which it is
due to environmental effects (Plomin et al., ￿￿￿￿). An MZ twin concordance that
is greater than DZ concordance indicates that there is evidence for heritability,
whereasMZ twin concordance that is less than ￿ provides evidence for the effect of
the environment on the trait. The different components of this variance, and further
details on twin concordance, are outlined below.
Variance Components
Genetic Effects (A or D)
Genetic in￿uences are indicated when within-pair concordance is greater in MZ
twin pairs than in DZ twin pairs. Twin modelling can estimate the additive genetic
effect (A), which is the sum of the effects of multiple genes on the phenotype.
Increased within-pair similarity in MZ twins relative to DZ twin pairs is assumed
to indicate that a greater proportion of the variability in the trait can be attributed
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to genetic effects, and if the MZ correlation is twice the DZ correlation then all
twin-pair similarity can be attributed to A (Verweij et al., ￿￿￿￿).
It is also possible to estimate the effect of interactions between alleles within
genes (dominant genetic effects, D) (Neale and Cardon, ￿￿￿￿). If theMZ correlation
is more than twice the DZ correlation, non-additive genetic factorsmay be involved.
This component can also include epistatic variance – the effect of interactions
between genes (Verweij et al., ￿￿￿￿). In studies of twins reared together it is not
possible to estimate shared environmental in￿uences (see below) at the same
time as D, as the two variance components are confounded.
Shared Environment Effects (C)
The shared environment (C) refers to the non-genetic in￿uences that lead
to similarity amongst twin pairs (Plomin et al., ￿￿￿￿). These can include
characteristics of parents such as socioeconomic status, and the neighbourhood
a child is brought up in. If the MZ correlation is greater than the DZ correlation, but
not twice the DZ correlation, there is evidence of some effect of C on the variance.
Unique Environment Effects (E)
The unique environment (E) refers to non-genetic effects that are independent
amongst twin pairs (Plomin et al., ￿￿￿￿). This can include friendship groups, and
differences in treatment by family members. The extent to which the MZ twin
correlation is less than ￿.￿ indicates the magnitude of non-shared environmental
in￿uences. As MZ twins share the same A and C effects, differences within these
pairs (and also measurement error) are attributed to E (Plomin et al., ￿￿￿￿).
Obtaining Variance Estimates Through Twin Modelling
Structural equation modelling of twin data is used to obtain precise estimates
of A, D, C and E and allows for the inclusion of effects such as sex and age,
the comparison of models, and the generation of con￿dence intervals around
estimates (Verweij et al., ￿￿￿￿). Using the R analysis package OpenMx (Boker
et al., ￿￿￿￿) allows the parameters of the variance components to be estimated
by use of matrix algebra. Matrices are created containing the expected variance
(the differences in the phenotype within the whole population) and the expected
covariance (the relationship between two characteristics studied; in twinmodelling,
the covariance of the observations within twin pairs) (Plomin et al., ￿￿￿￿). The
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expected covariance is set to ￿.￿ for MZ twins and ￿.￿ for DZ twins, representing
the known genetic correlation within these pairs. An outline of this, showing the
variance components utilised in thesis analyses, can be seen in Figure ￿.￿￿. These
expected variance-covariance matrices are compared to the observed variance
and covariance. Maximum likelihood estimation, based on the assumption that
observed variables have a multinormal distribution (Neale and Cardon, ￿￿￿￿),
maximises the extent to which the model ￿ts the data available by testing multiple
possible model solutions. The model solution that provides the optimum ￿t to the
data is selected (Verweij et al., ￿￿￿￿).
Figure ￿.￿￿: Path Diagram of Classic Twin Model, Indicating the Covariance of A and C
Between MZ and DZ Twin Pairs
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Tests of Model Fit
The methods used to assess model ￿t in this thesis are the Akaike Information
Criterion (AIC) and the -￿ log-likelihood ratio (-￿LL). The AIC is a measure of the
￿t of a model that can be used to aid model selection, and utilises assessment
of goodness of ￿t whilst also applying penalties for the number of parameters
in a model. As such, this measure favours the most parsimonious models. The
distribution of -￿LL approximates a  2 distribution with degrees of freedom equal
to model parameters. When assessing a model, a lower -￿LL indicates a better




In order to identify the most parsimonious model, models can be "nested". Once a
model has been speci￿ed, nested models with different restrictions (but the same
underlying speci￿cation) are compared against it. The -￿LL of a model is especially
useful when assessing nested models as it can be used to test differences in
the ￿t of more parsimonious models compared to the saturated or ACE model
(P￿.￿￿ indicating that there are signi￿cant differences in the ￿t of the twomodels).
An increase in -￿LL and the accompanying degrees of freedom between nested
models would suggest that model ￿t had degraded rather than improved. In this
thesis the -￿LL is used to assess the difference in model ￿t between a saturated
model and amodel with equated parameters or thresholds, between an ACEmodel
in which all the parameters are freely estimated and a more parsimonious version
of the same model with certain parameters equated or ￿xed to a certain value, and
between a model with different parameter estimates for males and females and
one in which these parameters are equated across sexes.
The Liability Threshold Model For Ordinal Twin Data Analysis
Ordinal data analysis is required when the data used are not continuous, as is
the case for the analyses in this thesis. In this circumstance a liability threshold
model is used. The threshold model for ordinal data assumes that the liability to an
outcome has an underlying normal distribution , but that the outcome is considered
to occur once a certain point is reached (Plomin et al., ￿￿￿￿).
The thresholds in the model are determined through the use of z-values, which
ensure that the area under the standard normal distribution curve between two
thresholds re￿ects the prevalence of that categorywithin the population (Posthuma
et al., ￿￿￿￿). The proportion in each sample is calculated cumulatively: the N in
the ￿rst category is estimated as a percentage (e.g. ￿￿% of sample), setting the
￿rst threshold. The next threshold will be the proportion in that group added to the
proportion of the ￿rst. Z scores are calculated from these proportions and used to
set the thresholds for analysis.
These thresholds are then used for the expected variance-covariance matrices
in the twin model. Correlations between ordinal variables, or between one
ordinal and one continuous variable, are calculated as tetrachoric (￿ variables) or
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polychoric (￿+ variables) correlations (Neale and Cardon, ￿￿￿￿). The expected and
actual variance-covariancematrices are then compared and parameters estimated,
as outlined above. One implication for the interpretation of threshold model results
is that power is reduced when compared to the analysis of continuous data (Neale
et al., ￿￿￿￿). Nonetheless, this methodology is a viable and commonly used
approach for categorical phenotypes.
Multivariate Twin Modelling
Multivariate analysis extends twin modelling to allow the study of multiple traits,
and to identify whether the traits share the same underlying causes (Plomin et al.,
￿￿￿￿). By including two or more traits, the covariance across traits and between
twins can be studied. For example, hypotheses can be tested relating to the
correlation between drug use in one twin and problematic drug use in their co-twin.
The correlation between the traits can be partitioned into the same A, C and E
variance components as in univariate analysis. The multivariate analyses utilised
in this thesis are outlined below.
Causal Contingent Common Pathway Model
Twin modelling can be used to test whether the in￿uences underlying two related
phenotypes are correlated. When an outcome cannot occur unless an earlier
stage has been reached – for example, an individual cannot report cannabis
dependence if they have not had the opportunity to use cannabis – a Causal
Common Contingent Pathway (CCC) extension to classic twin modelling can be
applied. See Figure ￿.￿￿ for an outline of the model. This model tests whether
liabilities to the study outcomes are consistent with a single liability distribution (all
the same underlying factors), or a multiple liability distribution (underlying factors
independent or correlated) (Maes et al., ￿￿￿￿b). Conceptualising the phenotypes
as related through a process of stages (Neale et al., ￿￿￿6b), an estimation of the
magnitude of the relationship between the two phenotypes studied is provided
through a beta pathway (Fowler et al., ￿￿￿￿). If the beta estimate is ￿ this suggests
that the two phenotypes completely overlap – a single liability distribution (Do
et al., ￿￿￿￿; Fowler et al., ￿￿￿￿). However, whilst this model can identify whether
liabilities are correlated, it cannot determine the extent to which this correlation is
attributable to genetic or environmental in￿uences.
￿￿
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Figure ￿.￿￿: Causal Contingent Common Pathway Model Path Diagram
Two-Stage Bivariate Twin Model
Twin models can be extended to include more than one phenotype, and determine
not only the variance components for those two or more phenotypes, but also
the extent to which genetic and environmental in￿uences on the phenotypes
are correlated (Neale and Cardon, ￿￿￿￿). However, there are issues with this
methodology for phenotypes that require an environmental exposure for them to
occur; phenotypes such as drug dependence. Structural missing data (for example,
individuals who have not had an opportunity to use cannabis are unknown/missing
on liability to dependence) would preclude standard bivariate analysis of the
relationship between two traits. It is not feasible to simply remove those who
are not exposed from the analysis, as genetic and environmental factors that
determine variation in dependence may also determine risk of exposure, and
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excluding those unexposed from the analysis will discard genetic information
and result in bias. Alternately, if genetic and environmental in￿uences on risk of
exposure are uncorrelated with in￿uences on dependence, including non-users as
non-dependent individuals would confound two traits that have different modes of
inheritance (Heath et al., ￿￿￿￿).













Two-stage twinmodelling has been developed to overcome this issue. Aswith a
CCCmodel, the two-stage twinmodel conceptualises the phenotypes of interest as
staged, but the analyses in thismodel allow estimation of the overlap in genetic and
environmental in￿uences between two phenotypes that have correlated liabilities.
Developed by Heath et al. (￿￿￿￿), this model is used to estimate the correlation
between A, C and E in situations where early-stage phenotypes, such as cannabis
use opportunity, are necessary for the expression of later behaviours, such as
the development of dependence. Operationalising the ￿rst stage phenotype as a
multiple category trait with several ordered categories, rather than a binary trait,
overcomes this issue. By including those who did not reach the ￿rst stage of the
process (for example, those who never had the opportunity to use cannabis) the
model maximises the genetically informative information available and avoids bias
that can result from inappropriate classi￿cation on non-exposed individuals.
￿￿
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Once the data are coded as a multiple category trait, a standard Constrained
Correlations model can be applied to the data. By utilising the cross-covariance
within twin pairs the A, C and E parameters for each phenotype are estimated,
and the phenotypic correlation partitioned into the genetic and environmental
contributions to the correlation. See Figure ￿.￿￿ for outline of model.
Modelling Potential Sex Differences
Twin models can be modi￿ed to test for differences in the magnitude of genetic
and environmental effects between sexes (scalar sex differences), and differences
in the genetic and environmental factors in￿uencing the phenotype between sexes
(non-scalar sex differences) in the genetic and environmental parameters and
correlations for two phenotypes (Neale et al., ￿￿￿6c). Scalar sex differences are
tested by examining whether constraining the estimates of A, C and E to be equal
in males and females leads to a signi￿cant deterioration in model ￿t. Non-scalar
sex differences are tested by constraining the A correlation to be ￿.￿ and the C
correlation to be ￿ in opposite sex DZ twin pairs. Given the genetic relatedness of
DZ twin pairs the expectation is that the correlation between pairs will be ￿.￿. If the
opposite sex twin pair correlation is below this it suggests that different genetic
factors are involved for each sex. Similarly, the shared environmental correlation
between DZ twins is expected to be ￿.￿, so a correlation below this for opposite
sex twin pairs indicates that the shared environmental factors in￿uencing the
phenotype are not the same across sexes.
The Equal Environments Assumption (EEA)
The Equal Environments Assumption (EEA) is one of the key debates in twin
research, and is commonly levelled as a critique of the methodology. The
assumption states that, despite differences in genetic similarity, environmental
in￿uences will be equally correlated in both monozygotic and dizygotic twins. This
is important as estimates of heritability will be in￿ated if there is greater similarity
in MZ environments, as the heritability estimate is based on the principle that a
greater correlation with an outcome in MZ twins compared to DZ twins results will
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be due to the increased genetic similarity of MZ twins (Kendler et al., ￿￿￿￿).
A number of different methods have been used to test the EEA, including testing
if physical similarity correlates with trait similarity (on the basis that similarity
of treatment stems from physical similarity) (Plomin et al., ￿￿￿6), observing in
childhood whether the behaviour of others towards a twin is self-initiated or
occurs in response to the twin’s behaviour (Lytton, ￿￿￿￿), exploring correlations
of childhood environment similarity and later adult behaviour and personality
similarity (Heath et al., ￿￿8￿), and studying twins who were misinformed of their
zygosity to determine the in￿uence of social expectations of similarity (Kendler
et al., ￿￿￿￿). These studies suggest that twin resemblance is not in￿uenced by
physical similarity, excess resemblance in parental behaviour towards MZ than DZ
twins stems from the behaviour of the twin rather than being initiated by the parent,
consistent relationships have not been observed between childhood environment
similarity and later patterns of personality and behaviour, and perceived zygosity
does not in￿uence twin resemblance for psychiatric disorders (Kendler et al., ￿￿￿￿).
The critique of twin modelling is that differences in environmental similarity
between MZ and DZ twins will in￿ate estimates of heritability. In order to address
this, research has investigated the relationship between environmental similarity
and a number of psychiatric traits (Kendler and Gardner, ￿￿￿8). In a cohort of
female twins,measures of similaritywere assessed through questionnaire and then
grouped based on factor loadings into “childhood treatment”, “co-socialization” and
“similitude” (the degree to which twins viewed themselves to be alike). The study
found that MZ twins scored signi￿cantly higher for co-socialization and similitude
than DZ twins, but did not observe differences in childhood treatment. The study
went on to explore the effect of this ￿nding on correlations for a range of psychiatric
outcomes (including alcohol and tobacco dependence). Associations between
similarity of environmental experiences and later psychiatric outcomes were not
found, with the exception of associations between co-socialization and smoking
initiation, and co-socialization and broadly de￿ned bulimia. This indicates that,
even in situations where there is inequality in environmental similarity, this does
not impact on association with later psychiatric outcomes.
Testing the EEA
As the analyses in this thesis are based on retrospective self-report, many of the
methods mentioned above to test the EEA are not feasible. However, questions
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were available on the perceived similarity of childhood environments (see Section
￿.￿.￿). It was therefore possible to compute heritability estimates for twins
reporting similar or dissimilar childhood environments. The twin sample was split
into two, based on whether or not twins were concordant on reported childhood
environment similarity, and ACE models were run on these two separate data
groups. If violations of the EEA in￿ate estimates of heritability, it would be
hypothesised that heritability estimates would be higher for those raised in similar
environments. The method used to test the EEA in this thesis was based on that
used to test the assumption in a similar sample of Australian twins (Lynskey et al.,
￿￿￿￿).
Testing the EEA for the outcome of cannabis abuse and/or dependence, it
was found that estimates were similar across twins with equal and unequal
environments. Amongst those reporting equal environments parameter estimates
were A = ￿.6￿ (￿￿%CI ￿.￿￿– ￿.8￿), C = ￿.￿6 (￿￿%CI ￿.￿– ￿.￿￿) and E = ￿.￿￿ (￿￿%CI
￿.￿￿ – ￿.￿￿). For those reporting unequal environments parameter estimates were
A =￿.￿6 (￿￿% CI ￿.￿￿ – ￿.￿￿), C = ￿.￿ (￿￿% CI ￿.￿ – ￿.￿8) and E = ￿.￿￿ (￿￿% CI ￿.￿￿
– ￿.￿￿). All parameter estimates fall within the ￿￿% CI for either group, indicating
that equality of environment does not affect estimates for cannabis abuse and/or
dependence in this sample.
Model Adjustment for Covariates
Twin modelling analyses can be adjusted for variables such as sex, in order to
prevent overestimation of the intraclass twin correlation. In order to do so in
OpenMX, a separate matrix is created for the sex de￿nition variables, and the
estimated parameters are obtained by regressing the twin data on the sex variables
(McGue and Bouchard, ￿￿8￿).
￿￿
CHAPTER ￿
Begin at the Beginning: Age of
Opportunity to Use Cannabis and Later
Cannabis Use, Abuse and Dependence
￿.￿ Introduction
Opportunity to use a drug is the ￿rst stage of drug involvement, and a necessary
￿rst stage for the development of SUDs. Importantly, while opportunity is necessary
for use to occur, use of the drug is not necessary for a valid opportunity to have
happened. Opportunity has been de￿ned in the literature as being offered the drug,
or being present at a time when others were using and it would have been possible
for the individual to use the drug if they had wanted to (Storr et al., ￿￿￿￿).
A limited number of factors have been studied in relation to the speed
of transition to cannabis use opportunity (with earlier age at ￿rst opportunity
representing a faster transition, given that there are no preceding stages of drug
involvement). To date, few factors have been explored in relation to this. Disruptive
behaviour early in school in males and better reading scores in females was
found to be associated with younger age of opportunity to use cannabis (Storr
et al., ￿￿￿￿). The ￿ndings on early disruptive behaviour are consistent with large
body of literature, but the association with better reading scores may appear
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counterintuitive. Nonetheless, it is consistent with recent research demonstrating
that adolescents with higher academic ability at age ￿￿ are more likely to use
cannabis in high school (Williams and Hagger-Johnson, ￿￿￿￿). However, the Storr
et al. (￿￿￿￿) study was limited by the lack of information on later childhood and
adolescent factors. Lifetime regular tobacco use (Agrawal et al., ￿￿￿￿) has been
found to be associated with earlier cannabis use opportunity. There is scope to
understand this transition better by testing associations with a wider range of
factors. Doing so will also allow comparison with factors that are associated with
progression to dependence, and the identi￿cation of whether factors associated
with problematic use begin to exert an in￿uence on drug use behaviour at even this
early stage.
Additionally, the relationship between age of opportunity to use cannabis and
later cannabis use outcomeshas not been explored in detail, whereas early initiation
of cannabis use has been shown to be related to later cannabis abuse/dependence
(Swift et al., ￿￿￿8; Grant and Dawson, ￿￿￿8; Fergusson and Horwood, ￿￿￿￿).
Consequently little can currently be said about the relationship between age of
opportunity to use cannabis and the relationship to cannabis abuse or dependence.
In this chapter I will identify factors associated with faster transition to
opportunity to use cannabis, and whether these factors overlap with those that are
associated with progression to cannabis dependence. I will also explore whether
there is an association between age of opportunity to use cannabis and later
cannabis use outcomes.
￿.￿ Aims and Hypotheses
Aim ￿
Determine socio-demographic, childhood, mental health, peer and drug use factors
that are associated with faster transitions to cannabis use opportunity, and from
cannabis use opportunity to cannabis dependence.
Hypothesis ￿
Multiple socio-demographic, childhood, mental health, peer and licit drug factors
will be associated with more rapid transition from cannabis use opportunity, and




Establish whether there is consistency in the socio-demographic, childhood,
mental health, peer and drug use factors that are associated with faster transition
to opportunity to use cannabis and those associated with more rapid progression
from opportunity to dependence.
Hypothesis ￿
The associated socio-demographic, childhood, mental health, peer and drug use
factors will differ across the stages of cannabis use transitions.
Aim ￿
Explore the relationship between age of opportunity to use cannabis and later
cannabis daily use, abuse and/or dependence, and treatment seeking when
accounting for the in￿uence of individual, childhood, mental health, peer and licit
drug factors that may confound the association
Hypothesis ￿
Individuals who have faster transition to opportunity to use cannabis, represented
through earlier age of opportunity, will have an increased likelihood of cannabis
daily use, abuse and/or dependence, and treatment seeking later in life.
Hypothesis ￿
Associations between speed of transitions from birth to opportunity to use
cannabis and lifetime risks of cannabis daily use, abuse and/or dependence, and
treatment seeking will persist after controlling for identi￿ed individual, childhood,
mental health, peer and drug use factors identi￿ed as exerting a potentially
confounding in￿uence on the association.
See Figure ￿.￿ for an outline of how the hypotheses of this chapter are addressed
through two different analyses.
￿.￿ Sample
The sample for all analyses in this chapter was drawn from the Australian Twin
Registry (ATR). The ￿￿￿8 participants who provided information on whether or not
they had ever had the opportunity to use cannabis form the analysis sample in this
chapter (see Figure ￿.￿).
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Figure ￿.￿: Deriving the analysis sample from the complete twin cohort
No reported lifetime 
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N = 399
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￿.￿ Factors Associated With Faster Transitions To
Cannabis Use Opportunity, And From Cannabis Use
Opportunity To Cannabis Dependence
The following methods were applied in order to study the factors associated with
faster transitions to cannabis use opportunity and, in order to allow for study of
the consistency of these in￿uences across transitions, from opportunity to use




Exposure and Failure Variables
Age of opportunity to use cannabis
A continuous variable of age of opportunitywas used in the analysis. The underlying
timescale was in years, and data were normally distributed (see Chapter ￿ for
histogram).
Cannabis Dependence
A continuous measure of age at onset of cannabis dependence was used in
the analyses. The underlying timescale was in years, and data were normally
distributed (see Chapter ￿ for histogram).
Analysis Plan
Survival analysis was used to identify factors that were associated with transition
from ￿) birth to opportunity to use cannabis ￿) opportunity to use cannabis to
cannabis dependence. A separate Cox Proportional Hazards (Cox PH) model was
￿tted to the data for each transition. See Figure ￿.￿ for an outline of the models.
Analyses were conducted in Stata statistical software version ￿￿ (StataCorp, ￿￿￿￿).
This method uses regression analysis for time-to-event data to determine how
many in a sample will ‘survive’ past a certain time point, and allows for the inclusion
of covariates to explore how other factors affect the probability of survival (Fisher
and Lin, ￿￿￿￿; Kleinbaumand Klein, ￿￿￿￿) Speed of transitionwas assessed as time
in years, providing a continuous time-to-event variable suitable for this analysis.
The regression coef￿cient for survival analysis is the hazard ratio, which compares
the hazard function for unexposed and exposed individuals in order to provide
an estimate of the increase or decrease in speed of transition to outcome for
each group (Kirkwood and Sterne, ￿￿￿￿). To correct for the non-independence of
observations (due to family clustering), Huber-White adjustment for clustered data
was implemented to provide robust standard errors.
Data Preparation and Assumption Testing for Cox PH Models
Person-year datasets were constructed to provide a separate row of participant
data for each year from birth for model ￿, and for each year from age of opportunity
for model ￿. In order to account for participants experiencing onset of events in the
same year, the Efron adjustment for survival ties was applied (Efron, ￿￿￿￿). The
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Figure ￿.￿: Cox PH models for factors affecting speed of transition from ￿) birth to
opportunity to use cannabis and ￿) opportunity to use cannabis to cannabis dependence
assumption of proportional hazards was assessed through tests of Schoenfeld
residuals and modelling of the interaction of covariates with time in the analysis
(P￿.￿￿).
Censoring of Data
Participantswere right-censored at age of interview. Mean age of ￿rst cannabis use
opportunity was ￿￿.6 years (s.d. ￿.￿) and the mean age of cannabis dependence
￿￿.￿ years (s.d. ￿.￿). The mean survival time for the participants in the cannabis
use opportunity model was ￿￿.￿ years (s.d. ￿.￿) (age at opportunity, or for those
who did not report opportunity, age at interview). This ￿gure is higher than themean
opportunity age as a result of right censoring; individuals who have not experienced
opportunity by the point of interview are also included in the survival model, with
their age at time of interview in place of age of opportunity. The mean survival time
for participants in the cannabis dependence model was ￿￿.￿ years (s.d. ￿.￿) (time
fromopportunity to dependence, or for thosewhodid not develop dependence, time
from opportunity to age at interview). This ￿gure is higher than may be expected
from the mean dependence age, again as a result of right censoring; individuals
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who have not developed dependence by the point of interview are also included in
the survival time, with their time from opportunity to age at interview in place of
time to dependence.
Cox PH model ￿ - Identifying factors associated with speed of transition
to opportunity to use cannabis
This model identi￿es factors associated with hazard of the opportunity to use
cannabis. Survival data (time in years, starting from birth) were used for analysis
of ￿￿￿8 participants who had provided information on whether or not they had
experienced opportunity to use cannabis. Failure event was opportunity to use
cannabis, and ￿￿￿8 failure events were observed. Due to missing covariate data,
￿￿6￿ participants were included in the ￿nal model (￿￿6￿ failure events).
Cox PH model ￿ - Identify factors associated with speed of transition from
opportunity to use cannabis to cannabis dependence
This model identi￿es factors associated with hazard of the development of
dependence following the opportunity to use cannabis. Survival data (time in years,
starting from age of ￿rst opportunity to use cannabis) were used for analysis of
￿￿￿￿ participants who had reported their age of opportunity to use cannabis and
who had also reported lifetime cannabis use. The failure event was cannabis
dependence, and ￿￿￿ failures were observed. Due to missing covariate data, ￿￿6￿
participants were included in the ￿nal model (￿6￿ failure events).
Fixed and time-varying covariates
From the full list of potential covariates selected from the literature (see Chapter
￿, Section ￿.￿.￿) Time Varying Covariates (TVC) were produced for those for which
age of onset data were available. These were CD, depressive episode, CSA,monthly
alcohol use, alcohol dependence, weekly tobacco use, tobacco dependence, other
drug use, and other drug dependence. These variables were coded as present for
each year after their respective age of onset, and were only included in the model if
onset had occurred prior to the age of cannabis use opportunity for model one, or
prior to the age of dependence formodel two. For example, if a participant reported
￿rst opportunity to use cannabis at age ￿￿, and reported tobacco onset at age ￿￿,
they would be coded as a non-case for tobacco use in model ￿ as the TVC onset
was later than the failure event.
Fixed covariates included in the model were gender, education, strict parenting,
parental alcohol problems, parental drug problems, childhood religious attendance,
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high parental con￿ict, and single parent family.
Level of completed education and school peer cannabis use were not included
in the analyses as the temporality of these variables could not be determined (they
may have reverse causality in the analysis). See Figure ￿.￿ for model outline,
including ￿xed and TVC.
Observations removed from analysis
To minimise the likelihood that the effect of childhood covariates where the
speci￿ed time periods were ages 6 – ￿￿ (parental con￿ict, single parent family,
strict parenting, frequent childhood religious attendance) may have occurred after
the point of cannabis use opportunity, any individuals who reported use opportunity
before the age of 6were removed frommodel one. This resulted in the observations
of one participant being removed from the model.
Those who had not reported lifetime cannabis use were removed from model
￿ in order to avoid the inverse association that would exist between never-use of
cannabis and cannabis dependence. Additionally, one participantwas omitted from
model ￿ as their recorded age of dependence was earlier than recorded age of
opportunity.
￿.￿.￿ Results
Testing the Proportional Hazards Assumption
All covariates were tested for breach of the proportional hazards assumption, as
outlined in the methods section (see Table ￿.￿). The following did not satisfy the
proportional hazards assumption for the opportunity to use model and therefore
the interaction term between the covariate and analysis time was modelled in
the cannabis use opportunity analysis (Bellera et al., ￿￿￿￿): CD, parental drug
problems, weekly tobacco use and monthly alcohol use. Similarly, for the cannabis
dependence analysis the following variables had the interaction with analysis time
modelled in the analysis: parental drug problems and alcohol dependence.
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Table ￿.￿: Results of Proportional Hazards Assumption tests for all covariates, determined
through tests of Schoenfeld Residuals and through modelling of the interaction with time
in the analysis ((in the ATR sample, N=￿￿￿8)
Covariates Test of Schoenfeld Residuals Test of Interaction With Time
Pearsons rho HR (￿￿% CI)
Birth to Opportunity Model
Gender ￿ ￿.￿￿ (￿.￿8 – ￿.￿￿)
Conduct Disorder -￿.￿￿* ￿.￿￿* (￿.8￿ – ￿.￿￿)
Depressive Episode ￿ ￿.￿￿ (￿.￿6 – ￿.￿￿)
High Parental Con￿ict -￿.￿￿ ￿.￿￿ (￿.￿￿ – ￿.￿￿)
Parental Alcohol Problems ￿.￿￿ ￿.￿￿ (￿.￿￿ – ￿.￿￿)
Parental Drug Problems ￿.￿￿* ￿.￿￿* (￿.8￿ – ￿.￿￿)
Single Parent Family ￿.￿￿ ￿.￿￿ (￿.￿￿ – ￿.￿￿)
Strict Parenting ￿.￿￿ ￿.￿￿ (￿.￿￿ – ￿.￿￿)
Infrequent Childhood ￿.￿￿ ￿.￿8 (￿.￿6 – ￿.￿￿)
Religious Attendance
Childhood Sexual Abuse ￿ ￿.￿￿ (￿.￿￿ – ￿.￿￿)
Weekly Tobacco Use -￿.￿6*** ￿.￿￿*** (￿.8￿ – ￿.￿6)
Tobacco Dependence ￿ ￿.￿6 (￿.￿￿ – ￿.￿￿)
Monthly Alcohol Use ￿.￿￿* ￿.￿￿* (￿.￿￿ – ￿.￿￿)
Alcohol Dependence ￿.￿￿ ￿.￿￿ (￿.￿￿ – ￿.￿6)
Other Drug Use ￿.￿￿ ￿.￿￿ (￿.￿6 – ￿.￿￿)
Opportunity to Dependence Model
Gender -￿.￿￿ ￿.￿￿ (￿.￿6 – ￿.￿￿)
Conduct Disorder -￿.￿￿ ￿.￿￿ (￿.￿￿ – ￿.￿6)
Depressive Episode -￿.￿￿ ￿.￿8 (￿.￿￿ – ￿.￿￿)
High Parental Con￿ict ￿ ￿.￿￿ (￿.￿￿ – ￿.￿6)
Parental Alcohol Problems ￿.￿￿ ￿.￿￿ (￿.￿6 – ￿.￿￿)
Parental Drug Problems -￿.￿￿* ￿.8￿* (￿.8￿ – ￿.￿￿)
Single Parent Family ￿.￿￿ ￿.￿￿ (￿.￿￿ – ￿.￿￿)
Strict Parenting -￿.￿￿ ￿.￿￿ (￿.￿￿ – ￿.￿6)
Infrequent Childhood -￿.￿￿ ￿.￿￿ (￿.￿￿ – ￿.￿￿)
Religious Attendance
Childhood Sexual Abuse ￿.￿￿ ￿.￿￿ (￿.￿8 – ￿.￿6)
Weekly Tobacco Use -￿.￿￿ ￿.￿8 (￿.￿￿ – ￿.￿￿)
Tobacco Dependence -￿.￿￿ ￿.￿￿ (￿.￿￿ – ￿.￿6)
Monthly Alcohol Use -￿.￿8 ￿.￿￿ (￿.8￿ – ￿.￿￿)
Alcohol Dependence -￿.￿6*** ￿.8￿*** (￿.8￿ - .￿￿￿)
Other Drug Use ￿.￿￿ ￿.￿￿ (￿.￿￿ – ￿.￿￿)
Other Drug Dependence -￿.￿6 ￿.￿￿ (￿.8￿ – ￿.￿6)
*P ￿.￿￿ **P￿.￿￿ ***P ￿.￿￿￿.
Factors Uniquely Associated with Opportunity to Use Cannabis
Results from the Cox proportional hazards model for transition to opportunity to
use cannabis are presented in Table ￿.￿. High parental con￿ict (HR ￿.￿￿, ￿￿% CI
￿.￿￿ - ￿.￿8), parental alcohol problems (HR ￿.￿￿, ￿￿% CI ￿.￿8 - ￿.￿￿), CSA (HR ￿.￿￿,
￿￿% CI ￿.￿￿ - ￿.￿￿) and infrequent childhood religious attendance (HR ￿.￿￿, ￿￿%
CI ￿.￿6-￿.￿￿) were associated with increased hazard of earlier opportunity to use
cannabis.
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Factors Uniquely Associated with Progression to Cannabis Dependence
Results from the Cox proportional hazards model for transition from opportunity
to use cannabis to dependence are presented in Table ￿.￿. Non-clinical depressive
episode (HR ￿.￿￿, ￿￿% CI ￿.￿￿ - ￿.8￿), tobacco dependence (HR ￿.￿6, ￿￿% CI ￿.￿￿ -
￿.￿8), alcohol dependence (HR ￿.6￿, ￿￿% CI ￿.￿￿ - ￿.￿8), other drug use (HR ￿.￿￿,
￿￿% CI ￿.6￿ - ￿.6￿) and other drug dependence (HR ￿.￿￿, ￿￿% CI ￿.￿￿ - ￿.￿￿) were
associated with increased hazard of faster transition cannabis dependence.
Factors Consistently Associated Across Transitions
Factors associated with increased hazard of both earlier cannabis use opportunity
and faster progression to cannabis dependencewere CD (opportunity HR ￿.￿￿, ￿￿%
CI ￿.￿￿-￿￿.￿￿; dependence HR ￿.￿￿, ￿￿% CI ￿.￿￿ - ￿.￿￿), parental drug problems
(opportunity HR ￿.￿￿, ￿￿% CI ￿.￿￿ - ￿￿.6￿; dependence HR ￿.￿￿, ￿￿% CI ￿.6￿ - 6.6￿),
male gender (opportunity HR ￿.￿￿, ￿￿% CI ￿.￿￿-￿.￿￿; dependence HR ￿.￿￿, ￿￿%
CI ￿.8￿ - ￿.￿6) and weekly tobacco use (opportunity HR 8.￿￿, ￿￿% CI ￿.￿￿ - ￿8.68;
dependence HR ￿.￿6, ￿￿% CI ￿.￿￿ - ￿.6￿) (see Table ￿.￿).
Results Summary ￿
The analyses have identi￿ed a number of factors uniquely associated with
progression to cannabis use opportunity and dependence, predominately
representing proximal in￿uences acting at the time of drug use. However, a
number of consistent in￿uences acting across stages have also been identi￿ed.
These are predominately distal in￿uences.
￿.￿ The Relationship between Age Of Opportunity To
Use Cannabis And Later Cannabis Daily Use, Abuse
and/or Dependence, And Treatment Seeking
The second part of this chapter focuses on identifying whether there is an
association between age of opportunity to use cannabis and later cannabis abuse
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Table ￿.￿: Hazard ratios (￿￿%CI) fromATRCox RegressionModels: Factor Associated with
Earlier Opportunity to Use Cannabis (N=￿￿￿8), and for Progression fromOpportunity to Use
Cannabis to Cannabis Dependence (N=￿￿￿￿)
Covariate Transition to Cannabis Transition to Cannabis
Use Opportunity Dependence
N = ￿￿6￿ N = ￿￿6￿
Unadjusted HR Adjusted HR Unadjusted HR Adjusted HR
(￿￿% CI) (￿￿% CI) (￿￿% CI) (￿￿% CI)
Male gender ￿.￿￿*** ￿.￿￿*** ￿.￿￿*** ￿.￿￿***
(￿.￿￿ - ￿.￿6) (￿.￿￿ - ￿.￿￿) (￿.6￿ - ￿.￿8) (￿.8￿ - ￿.￿6)
Conduct disorder1 2￿.￿￿*** 2￿.￿￿** ￿.￿￿*** ￿.￿￿***
(￿.￿￿ – ￿￿.￿6) (￿.￿￿-￿￿.￿￿) (￿.6￿ – ￿.￿￿) (￿.￿￿-￿.￿￿)
Depressive episode1 ￿.￿￿ ￿.￿8 ￿.￿￿*** ￿.￿￿***
(￿.￿￿ - ￿.￿￿) (￿.8￿-￿.￿￿) (￿.￿￿ - ￿.￿￿) (￿.￿￿-￿.8￿)
High parental ￿.￿￿* ￿.￿￿* ￿.￿6 ￿.￿￿
con￿ict (￿.￿￿ – ￿.￿8) (￿.￿￿-￿.￿8) (￿.￿￿ – ￿.￿￿) (￿.￿￿-￿.￿￿)
Parental alcohol problems ￿.￿￿*** ￿.￿￿*** ￿.￿￿** ￿.￿￿
paroblems (￿.￿6 – ￿.￿8) (￿.￿8-￿.￿￿) (￿.￿￿ – ￿.6￿) (￿.86-￿.￿￿)
Parental drug problems 28.￿6** 2￿.￿￿** 2￿.￿￿*** 2￿.￿￿***
problems (￿.￿￿ – ￿￿.￿￿) (￿.￿￿-￿￿.6￿) (￿.￿￿ – 8.￿￿) (￿.6￿-6.6￿)
Single parent family ￿.￿￿** ￿.￿￿ ￿.6￿* ￿.￿￿
family (￿.￿￿ – ￿.￿￿) (￿.￿￿-￿.￿￿) (￿.￿￿ - ￿.￿￿) (￿.￿8-￿.8￿)
Strict parenting ￿.￿￿ ￿.￿￿ ￿.￿￿** ￿.￿￿
(￿.￿6 - ￿.￿￿) (￿.￿￿-￿.￿￿) (￿.￿￿ – ￿.6￿) (￿.88-￿.￿￿)
Infequent childhood ￿.￿￿*** ￿.￿￿*** ￿.￿6 ￿.￿8
religious attendance (￿.￿￿ - ￿.￿6) (￿.￿6 - ￿.￿￿) (￿.￿￿ - ￿.￿￿) (￿.￿￿-￿.￿8)
Childhood sexual ￿.￿￿** ￿.￿￿* ￿.￿8*** ￿.￿￿
abuse1 (￿.￿8 – ￿.￿￿) (￿.￿￿-￿.￿￿) (￿.￿￿ – ￿.6￿) (￿.￿￿-￿.￿￿)
Weekly tobacco 2￿￿.￿￿*** 28.￿￿*** ￿.￿8*** ￿.￿6***
use1 (￿.￿￿ – ￿￿.￿￿) (￿.￿￿-￿8.68) (￿.￿￿ – ￿.￿￿) (￿.￿￿-￿.6￿)
Tobacco ￿.8￿* ￿.8￿ ￿.￿￿*** ￿.￿6*
dependence1 (￿.￿￿ – ￿.￿6) (￿.6￿-￿.￿￿) (￿.￿8 – ￿.￿￿) (￿.￿￿-￿.￿8)
Monthly alcohol ￿.6￿ ￿.￿￿ ￿.￿￿ ￿.￿￿
use1 (￿.￿8 – ￿.￿￿) (￿.￿￿-￿.6￿) (￿.￿￿ – ￿.￿￿) (￿.6￿-￿.￿￿)
Alcohol ￿.￿￿*** ￿.￿6 ￿￿.￿￿*** ￿.6￿***
dependence1 (￿.￿￿ – ￿.￿8) (￿.8￿-￿.￿8) (￿.6￿ – ￿.￿￿) (￿.￿￿-￿.￿8)
Other drug ￿.￿￿** ￿.￿￿ ￿.￿6*** ￿.￿￿***
use1 (￿.￿￿ – ￿.6￿) (￿.￿￿-￿.￿￿) (￿.￿￿ – ￿.￿￿) (￿.6￿-￿.6￿)
Other drug - - ￿.￿￿*** ￿.￿￿***
dependence1 (￿.￿￿ – ￿￿.￿￿) (￿.￿￿-￿.￿￿)
*P￿.￿￿ **P￿.￿￿ ***P ￿.￿￿￿.
1Time Varying Covariate
2Interaction with analysis time included in the model
All models have applied the Huber-White adjustment for family clustering
and/or dependence. An association has previously been observed between age of
initiation and later SUDs, but it is not known if this will extend to the stage before




Independent and Dependent Variables
Age of Opportunity to Use Cannabis
Age of opportunity to use cannabis was coded into a categorical or dichotomous
variable to provide meaningful estimates of effect size. The ￿￿th, ￿￿th, ￿￿th
percentiles of the distribution of the variable were used to determine transition
speed groups (see Chapter ￿ for distribution). This formed a four level categorical
variable with the groups opportunity age ￿￿ and under, opportunity age ￿￿-￿6,
opportunity age ￿￿, and opportunity age ￿8 and over, whichwas used for all analyses
in this chapter.
Cannabis Outcome Variables
The outcomes of daily cannabis use, cannabis abuse and/or dependence and
cannabis treatment seeking were used in the logistic regression analyses (see
Chapter ￿ for derivation of these variables).
Analysis Plan
Logistic regression analysis was used to determine the association between the
speed of transition to cannabis use opportunity and the following outcomes:
(a) daily cannabis use; (b) cannabis abuse/dependence; (c) treatment-seeking
for cannabis use problems. The reference category was the lowest-risk group,
opportunity age ￿8 and over, based on the hypothesis that earlier opportunity
to use is associated with greater likelihood of problematic cannabis outcomes.
Figure ￿.￿ provides an outline of the analysis. To correct for the non-independence
of observations Huber-White adjustment for clustered data was implemented to
provide robust standard errors. Post hoc comparisons across the varying speeds
of transitionwere conducted usingWald 2 tests. Analyseswere conducted in Stata
statistical software version ￿￿ (StataCorp, ￿￿￿￿).
Identi￿cation of Covariates
From the full list of potential covariates selected from the literature (see Chapter
￿), those that may confound the association between age of opportunity to
use cannabis and later outcomes were identi￿ed through multivariate logistic
regression. Covariates were included in the logistic models if signi￿cantly
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Figure ￿.￿: Logistic regression analyses for age of cannabis opportunity and later cannabis
use outcomes of daily use, abuse and/or dependence, and treatment seeking. Covariates
identi￿ed for adjusted analyses listed in boxes above and below the independent variable
associated with both age of opportunity (see Table ￿.￿) and the dependent variable
(see Appendix ￿).
￿.￿.￿ Results
Analysis of the Relationship between Age of Opportunity to Use Cannabis and
Cannabis Outcomes of Daily Use, Abuse and/or Dependence, and Treatment
Seeking
Signi￿cant differences were observed between the age of opportunity groups for
the prevalence of daily cannabis use, cannabis abuse and/or dependence and
cannabis related treatment seeking (see Table ￿.￿). Amongst those who reported
opportunity to use cannabis at age ￿￿, daily cannabis use (￿8.￿%), cannabis
abuse and/or dependence (￿8.￿%), and treatment seeking (￿￿.￿%). Figure ￿.￿
demonstrates that the proportion of those reporting these outcomes decreased
as age of opportunity to use cannabis increased, and indicates a linear relationship
between transition speed and all later outcomes.
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Table ￿.￿: Association between age of ￿rst opportunity to use cannabis and daily cannabis
use, cannabis abuse and/or dependence, and cannabis related treatment seeking in the
ATR sample (N=￿￿￿￿)
Variable Under ￿￿ ￿￿-￿6 ￿￿ ￿8 and over Phi coef￿cient  2 P value
N = ￿88 N = ￿86 N = ￿￿8 N = ￿￿6￿
N (%) N (%) N (%) N (%)
Daily cannabis use ￿￿￿ (￿8.￿) ￿￿￿ (￿￿.￿) ￿￿ (￿.￿) 6￿ (￿.￿) ￿.￿￿ ￿.￿￿￿
N=￿￿￿
Cannabis abuse and/or dependence ￿￿￿ (￿8.￿) ￿￿￿ (￿6.￿) ￿6 (￿￿.￿) ￿￿￿ (8.￿￿) ￿.￿￿ ￿.￿￿￿
N=6￿￿
Treatment seeking ￿￿ (￿￿.￿) ￿￿ (￿.￿) ￿￿ (￿.8) ￿￿ (￿.￿) ￿.￿8 ￿.￿￿￿
N=￿￿￿
Figure ￿.￿: Diagram visualising the prevalence of cannabis outcomes by age of opportunity
to use cannabis
























































Association Between Age of Opportunity to Use Cannabis and Potential Model
Covariates
After adjustment for other variables within the model, a number of factors were
identi￿ed as signi￿cantly associated with age of opportunity to use cannabis
analysis groups (see Table ￿.￿). Gender, education, CD, depressive episode,
parent drug problems, strict parenting, high levels of school peer cannabis use,
infrequent childhood religious attendance, lifetime monthly alcohol use, lifetime
weekly tobacco use, lifetime other drug use, lifetime alcohol dependence and




Table ￿.￿: Association between age of ￿rst opportunity to use cannabis and socio-
demographic, childhood, mental health, peer and drug use factors in the ATR sample
(N=￿￿￿￿)
Variable Age at ￿rst cannabis use opportunity (years)
Under ￿￿ ￿￿-￿6 ￿￿ ￿8+
N = ￿88 N = ￿86 N = ￿￿8 N = ￿￿6￿
N (%) N (%) N (%) N (%)
OR (￿￿% CI) OR (￿￿% CI) OR (￿￿% CI) OR (￿￿% CI)
Male gender ￿66 (￿￿.8) ￿￿8 (￿￿.￿) ￿￿￿ (￿￿.8) ￿8￿ (￿￿.￿)
￿.￿￿ (￿.￿￿-￿.6￿) ￿.￿6* (￿.￿￿-￿.￿￿) ￿.￿￿ (￿.￿￿-￿.￿￿) ￿.￿
Lower level of ￿￿￿ (￿￿.￿) ￿8￿ (￿8.￿) ￿￿￿ (￿6.￿) ￿￿￿ (￿￿.8)
completed education ￿.￿6 (￿.￿￿-￿.6￿) ￿.￿￿** (￿.￿6-￿.6￿) ￿.￿￿* (￿.￿￿-￿.6￿) ￿.￿
Conduct disorder ￿￿￿ (￿6.￿) ￿￿￿ (￿￿.8) ￿￿ (6.￿) ￿8 (￿.6)
6.￿￿*** (￿.￿8-￿.￿￿) ￿.￿￿*** (￿.￿￿-￿.￿￿) ￿.￿￿* (￿.￿￿-￿.8￿) ￿.￿
Non-clinical depressive ￿￿￿ (￿￿.￿) ￿￿8 (￿￿.￿) ￿￿￿ (￿6.￿) ￿￿￿ (￿8.￿)
episode ￿.8￿ (￿.66-￿.￿￿) ￿.￿￿** (￿.6￿-￿.￿￿) ￿.88 (￿.￿￿-￿.￿8) ￿.￿
Parental alcohol problems ￿￿￿ (￿￿.￿) ￿￿￿ (￿￿.￿) ￿￿￿ (￿￿.￿) ￿￿￿ (￿￿.￿)
￿.￿￿ (￿.8￿-￿.￿￿) ￿.￿6 (￿.8￿-￿.￿￿) ￿.￿6 (￿.￿￿-￿.￿￿) ￿.￿
Parental drug problems ￿6 (￿.￿) ￿￿ (￿.￿) ￿￿ (￿.￿) ￿￿ (￿.￿)
￿.￿￿** (￿.￿8-￿.6￿) ￿.￿￿ (￿.￿￿-￿.￿￿) ￿.￿￿ (￿.6￿-￿.￿￿) ￿.￿
Single parent family ￿￿ (￿￿.￿) ￿￿ (￿.6) ￿￿ (6.6) ￿￿ (￿.￿)
￿.￿￿ (￿.8￿-￿.6￿) ￿.￿￿ (￿.6￿-￿.￿￿) ￿.￿￿ (￿.8￿-￿.￿￿) ￿.￿
High parental con￿ict ￿￿￿ (￿￿.￿) ￿68 (￿8.￿) ￿￿￿ (￿6.￿) ￿￿6 (￿￿.￿)
￿.￿8 (￿.88-￿.￿￿) ￿.￿￿ (￿.8￿-￿.￿￿) ￿.￿￿ (￿.￿￿-￿.￿￿) ￿.￿
Strict parenting ￿￿￿ (￿￿.￿) ￿￿￿ (￿￿.8) ￿￿￿ (￿￿.￿) ￿￿￿ (￿￿.6)
￿.8￿ (￿.6￿-￿.￿￿) ￿.8￿* (￿.68-￿.￿8) ￿.￿8* (￿.6￿-￿.￿6) ￿.￿
High levels of peer ￿￿ (￿￿.￿) ￿￿ (￿￿.￿) ￿￿ (￿.6) ￿6 (￿.￿)
cannabis use 6.￿8*** (￿.￿￿-￿￿.￿￿) ￿.￿￿*** (￿.￿￿-￿.8￿) ￿.￿￿*** (￿.￿8-￿.6￿) ￿.￿
Childhood sexual abuse 6￿ (￿6.￿) 8￿ (8.￿) ￿￿ (￿.￿) ￿￿￿ (￿.￿)
￿.￿8 (￿.￿￿-￿.￿6) ￿.￿￿ (￿.￿￿-￿.￿￿) ￿.￿￿ (￿.￿￿-￿.￿￿) ￿.￿
Infrequent childhood ￿￿￿ (￿￿.￿) ￿6￿ (￿￿.￿) ￿￿8 (￿￿.￿) ￿￿￿ (￿￿.￿)
religious attendance ￿.8￿*** (￿.￿8-￿.￿￿) ￿.66*** (￿.￿8-￿.￿￿) ￿.￿6*** (￿.￿￿-￿.6￿) ￿.￿
Lifetime monthly alcohol ￿66 (￿￿.￿) ￿￿￿ (￿￿.8) ￿￿6 (￿￿.￿) ￿￿66 (￿￿.￿)
use ￿.66 (￿.￿8-￿.￿￿) ￿.￿￿* (￿.￿￿-￿.￿￿) ￿.￿￿ (￿.6￿-￿.￿6) ￿.￿
Lifetime weekly tobacco ￿￿￿ (66.￿) ￿￿6 (￿￿.￿) ￿￿￿ (￿￿.8) ￿6￿ (￿￿.￿)
use ￿.￿￿*** (￿.￿6-￿.￿￿) ￿.86*** (￿.￿￿-￿.￿6) ￿.￿￿*** (￿.￿6-￿.￿￿) ￿.￿
Lifetime other drug ￿8￿ (￿￿.￿) ￿￿￿ (￿￿.￿) ￿￿￿ (￿6.￿) ￿￿￿ (￿6.￿)
use ￿.￿6*** (￿.￿￿-￿.￿￿) ￿.￿￿*** (￿.￿￿-￿.8￿) ￿.￿￿ (￿.￿￿-￿.￿￿) ￿.￿
Lifetime alcohol ￿6￿ (￿￿.￿) ￿￿￿ (￿￿.￿) ￿6￿ (￿8.￿) ￿6￿ (￿8.￿)
dependence ￿.￿8*** (￿.￿￿-￿.￿8) ￿.8￿*** (￿.￿6-￿.￿￿) ￿.6￿*** (￿.￿6-￿.￿￿) ￿.￿
Lifetime tobacco ￿8￿ (￿￿.￿) ￿￿￿ (￿￿.￿) ￿￿￿ (￿￿.6) ￿6￿ (￿8.￿)
dependence ￿.￿￿ (￿.8￿-￿.￿￿) ￿.￿￿ (￿.8￿-￿.￿￿) ￿.￿6 (￿.￿￿-￿.￿6) ￿.￿
Lifetime other drug 6￿ (￿￿.￿) 6￿ (6.￿) ￿￿ (￿.￿) ￿￿ (￿.￿)
dependence ￿.￿￿** (￿.￿￿-￿.￿￿) ￿.￿￿ (￿.￿8-￿.￿￿) ￿.￿￿ (￿.6￿-￿.￿￿) ￿.￿
*P ￿.￿￿ **P￿.￿￿ ***P ￿.￿￿￿.
Adjusted Analysis of the Relationship Between age of Opportunity and Later
Cannabis Outcomes
The results of the logistic regression model (see Table ￿.￿) show that progression
to daily cannabis use is more than twice as likely amongst those who have the
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earliest opportunity to use cannabis (OR ￿.￿6, ￿￿% CI ￿.￿6-￿.￿￿), and more likely
amongst those who were age ￿￿-￿6 (OR ￿.6￿, ￿￿% CI ￿.￿8-￿.￿￿) when they had
their ￿rst opportunity to use cannabis, compared to those who were ￿8 and over.
Reporting cannabis abuse and/or dependence was more likely amongst who were
under ￿￿ (OR ￿.￿￿, ￿￿% CI ￿.￿￿-￿.￿￿) or ￿￿-￿6 (OR ￿.86, ￿￿% CI ￿.￿￿-￿.￿8), and aged
￿￿ (OR ￿.￿￿, ￿￿%CI ￿.￿8-￿.￿￿). Signi￿cant associations with treatment seeking were
only observed for those who had their ￿rst opportunity to use cannabis before
the age of ￿￿. This group were more than twice as likely to progress to seeking
treatment for cannabis use (OR ￿.6￿, ￿￿% CI ￿.￿￿-￿.6￿). Post hoc tests revealed
differences between levels were not signi￿cant.
Table ￿.￿: Odds ratios (￿￿% Con￿dence intervals) for association between age of
opportunity to use cannabis, covariates and later cannabis outcomes from logistic
regression analysis of the ATR sample (N=￿￿￿￿)
Age at Opportunity Daily Use Abuse and/or Dependence Treatment Seeking
to Use Cannabis N = ￿￿￿ N = 6￿￿ N=￿￿￿
Odds Ratio Odds Ratio Odds Ratio
(￿￿% Con￿dence) (￿￿% Con￿dence) (￿￿% Con￿dence)
(Interval) (Interval) (Interval)
Univariate Adjusted Univariate Adjusted Univariate Adjusted
model model model model model model
Under ￿￿ ￿.￿6*** ￿.￿6*** ￿.￿￿*** ￿.￿￿*** ￿.￿￿*** ￿.6￿***
N=￿88 (6.￿6 - ￿￿.￿￿) (￿.￿6-￿.￿￿) (￿.￿￿ - ￿.6￿) (￿.￿￿-￿.￿￿) (￿.￿6 - ￿6.￿￿) (￿.￿￿-￿.6￿)
￿￿–￿6 ￿.￿￿*** ￿.6￿*** ￿.￿￿*** ￿.86*** ￿.￿￿*** ￿.￿￿
N=￿86 (￿.￿￿ - ￿.￿￿) (￿.￿8-￿.￿￿) (￿.￿6 - ￿.￿￿) (￿.￿￿-￿.￿8) (￿.￿￿ - ￿.6￿) (￿.6￿-￿.￿￿)
￿￿ ￿.￿￿*** ￿.￿￿ ￿.￿￿*** ￿.￿￿* ￿.￿￿** ￿.￿￿
N=￿￿8 (￿.￿￿ - ￿.￿￿) (￿.￿￿-￿.￿￿) (￿.￿￿ - ￿.￿6) (￿.￿8-￿.￿￿) (￿.￿￿ - ￿.8￿) (￿.8￿-￿.￿￿)
￿8 and over ￿ ￿ ￿ ￿ ￿ ￿
N=￿￿6￿
Covariate
Male gender ￿.￿￿*** (￿.￿8-￿.￿￿) ￿.8￿*** (￿.￿￿-￿.￿6) ￿.￿8 (￿.￿￿-￿.￿￿)
Lower level of ￿.6￿*** (￿.￿￿-￿.￿8) ￿.￿8** (￿.￿￿-￿.￿￿) ￿.￿￿ (￿.￿￿-￿.￿￿)
completed education
Conduct disorder ￿.￿￿*** (￿.￿8-￿.￿￿) ￿.￿￿*** (￿.6￿-￿.￿￿) -
Lifetime weekly ￿.6￿*** (￿.￿￿-6.￿￿) ￿.￿￿*** (￿.￿￿-￿.8￿) ￿.￿6*** (￿.86-6.￿￿)
tobacco use
Lifetime other 6.￿￿*** (￿.￿￿ - ￿.￿￿) ￿.￿￿*** (￿.￿8-￿.6￿) ￿.￿￿*** (￿.￿￿-￿.6￿)
drug use
Lifetime other ￿.￿￿*** (￿.8￿-￿.￿￿) ￿.￿8 (￿.￿8-￿.6￿) ￿.￿￿*** (￿.￿8-6.￿6)
drug dependence
*P ￿.￿￿ **P￿.￿￿ ***P ￿.￿￿￿.




Age of opportunity to use cannabis under age ￿8 was associated with lifetime daily
cannabis use and cannabis abuse/or dependence, with effect sizes indicating a




A number of factors were uniquely associated with the transition to cannabis use
opportunity, and with the transition from opportunity to cannabis dependence, but
several factors were found that increase hazards of both these transitions. Parental
con￿ict, parental alcohol problems, infrequent childhood religious attendance and
CSA were uniquely associated with faster transition to opportunity. Depressive
episode, tobacco dependence, alcohol dependence, other drug use and other drug
dependence were uniquely associated with faster progression from opportunity to
dependence. CD, parental drug problems, male gender and weekly tobacco use
were associated with faster progression to both opportunity and from opportunity
and dependence. See Figure ￿.6 for an overview of these ￿ndings.
Given the overlapping in￿uences, it is perhaps unsurprising that the age of
opportunity to use cannabis was found to be signi￿cantly associated with later
cannabis use outcomes. Those whose ￿rst opportunity to use cannabis occurred
before the age of ￿￿weremore than twice as likely to experience daily cannabis use
and cannabis related treatment seeking, and almost twice as likely to experience
cannabis abuse and/or dependence, compared to those reporting cannabis
opportunity after age ￿8. Those who reported cannabis use opportunity age ￿￿-￿6
were almost twice as likely to report daily cannabis use and cannabis abuse
and/or dependence, and those who were age ￿￿ at opportunity to use cannabis
age ￿￿ were almost twice as likely to report cannabis abuse and/or dependence,
compared to those reporting cannabis use opportunity after age ￿8.
￿￿
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Figure￿.6: Unique and consistent associations across the transitions ￿) birth to opportunity















￿.6.￿ Factors Associated With Multi-Stage Transitions
Survival analysis identi￿ed a number of factors associated with both transitions.
Male gender was associated with faster progression to both opportunity and
dependence. In contrast to previous research, gender differences held across
both transitions. Previous research has found males more likely to have lifetime
opportunity to use cannabis, but that these gender differences do not extend
to the transition into drug use once opportunity has occurred (van Etten et al.,
￿￿￿￿). Similarly, weekly tobacco use was associated with increased hazard of both
cannabis use opportunity and progression to cannabis dependence, consistent
with existing ￿ndings relating to use (Wagner and Anthony, ￿￿￿￿). CD was
associated with faster progression to both opportunity and dependence, echoing
previous research showing disruptive or aggressive behaviour in both males and
females is associated with earlier opportunity to use cannabis (Storr et al., ￿￿￿￿),
and that CD increases risks of the development of cannabis dependence (Agosti
et al., ￿￿￿￿; Elkins et al., ￿￿￿￿).
Parental drug problems were signi￿cantly associated with a more rapid
transition to both opportunity and dependence, in line with existing research
demonstrating increased cannabis use opportunity amongst those with parental
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drug problems (Benjet et al., ￿￿￿￿). Given the especially strong association with
opportunity to use cannabis it is plausible that parental drug problems facilitate an
environment in which drug access is increased, whether this is indirectly or directly
through parents.
The identi￿cation of tobacco, alcohol and other drug involvement as factors
associated with progression to dependence suggests that a pattern of poly-use
emerges. Although alcohol use has previously been found to be associated
with early onset of cannabis use (Coffey et al., ￿￿￿￿) it was not associated with
opportunity to use cannabis in the present analyses. The comparatively rarer
outcomes of tobacco dependence, other drug use and other drug dependence
were found to be associated with increased speed of progression to cannabis
dependence. The co-occurrence of tobacco and cannabis use has been frequently
observed (Agrawal et al., ￿￿￿￿; Hindocha et al., ￿￿￿￿, ￿￿￿6), and regular cigarette
smokers are more likely to report earlier cannabis use opportunity (Agrawal et al.,
￿￿￿￿). Present results strongly supported this ￿nding, and extend it to show
weekly tobacco use and dependence were signi￿cantly associated with speed
of progression to cannabis dependence. The observed association between
cannabis dependence and tobacco may be due to a number of factors including
shared genetic and environmental in￿uences, the co-administration of tobacco and
cannabis, and smoking habituation (Agrawal et al., ￿￿￿￿).
￿.6.￿ Age Of Opportunity To Use Cannabis And Later Outcomes
The results demonstrate a linear relationship between speed of transition to
opportunity to use cannabis (represented through earlier age at ￿rst opportunity)
and the outcomes of daily use and abuse and/or dependence. This is a novel
￿nding as the relationship between age of opportunity and later outcomes has
not been previously explored in the literature (see Chapter ￿). The ￿ndings
are interesting given that opportunity to use cannabis does not incorporate
psychopharmacological elements of cannabis use on the developing brain, which
could be theorised to explain the association between early initiation and later
dependence. Although the mechanisms of this have not been explored in relation
to later cannabis use outcomes, those who initiate cannabis use earlier have been
found to experience attentional and working memory dysfunctions, demonstrated
￿￿
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through cortical activation compared to alter onset users and non-users (Becker
et al., ￿￿￿￿; Kempel et al., ￿￿￿￿; Skosnik et al., ￿￿￿6). The present results suggest
that the association between early initiation and later dependencemay be separate
from psychopharmacology.
Given the associations between early initiation of cannabis and later
problematic cannabis use (Swift et al., ￿￿￿8; Grant and Dawson, ￿￿￿8; Fergusson
and Horwood, ￿￿￿￿), this may suggest that age of opportunity to use cannabis is a
proxy for age of cannabis initiation, and an earlier point on the same liability axis.
Within the sample the majority of participants within each age group progressed to
initiation of cannabis use in less than a year after having had the opportunity to use
cannabis (analyses not included in thesis due to homogenous speed of transition;
mean = ￿.￿￿ years, s.d. = ￿.￿￿, range = ￿ - ￿￿). This is slightly faster than published
estimates of the median delay between opportunity and use of a drug, which was
estimated at ￿ year (Swendsen et al., ￿￿￿8). The effect sizes obtained for the
relationship between age of opportunity and cannabis abuse and/or dependence
in the present analysis broadly map onto the effect sizes obtained in a study of
the relationship between age of cannabis initiation and DSM-III marijuana disorder
(DeWit et al., ￿￿￿￿), which found that in comparison to those who initiated age ￿￿
and over likelihood of dependence symptoms was increased in those who initiated
use age ￿￿ (OR ￿.￿8, CI ￿.￿￿ – ￿.￿￿, compared to present ￿nding of OR ￿.￿￿ ￿￿% CI
￿.￿￿-￿.￿￿ for opportunity age ￿￿ and under), ￿6 (OR ￿.￿￿, CI ￿.￿￿ – ￿.￿￿, compared
to present ￿nding of OR ￿.86 ￿￿% CI ￿.￿￿ – ￿.￿8 for opportunity age ￿￿-￿6), and ￿￿
(OR ￿.￿8, CI ￿.￿6 – ￿.￿￿, compared to present ￿nding of OR ￿.￿￿, ￿￿% CI ￿.￿8 – ￿.￿￿
for opportunity age ￿￿).
The associations between earlier age of opportunity to use cannabis and later
cannabis-related outcomes remained (albeit with a large decrease in effect size)
after controlling for the identi￿ed potentially confounding variables. This suggests
that other factorsmay be underlying this association. It is plausible that someof the
same genetic factors are underlying both opportunity to use cannabis and cannabis




There are certain considerations required in interpretation of this work. Firstly,
analyses were conducted on retrospective self-report data, introducing the
possibility of recall bias. This is a viable method of data collection (Darke, ￿￿￿8),
and indeed recall of early experience with cannabis has been found to be especially
reliable (Johnson and Mott, ￿￿￿￿), but as the analyses rely on accurate recall of
age of onset of a number of behaviours the work would bene￿t from replication
in longitudinal cohorts. Secondly, analyses of the progression from opportunity to
cannabis use initiationwere not possible, as timing of transitionswas only available
as time in years, and there was not enough variation in the speed of this transition
to allow for analysis (the majority of participants progressed to use within ￿ year
after having the opportunity to use, data available on request). Thirdly, selected
covariates measured occurrence within an age range (6-￿￿), and consequently
may have occurred prior to the age of opportunity to use cannabis for a small
number of individuals. Fourthly, while the prevalence of lifetime cannabis use in
this sample was relatively high at 68.￿% it is important to note this estimate is
consistent with previous estimates from the Australian young adult population
(of Health and Welfare, ￿￿￿￿). Finally, interpretation of these analyses should be
in light of the twin and sibling sample used, as there is some residual uncertainty
about whether inferences from twin data have external validity with respect to what
might be found in general population samples (Vitaro et al., ￿￿￿￿). Analyses were
adjusted for clustering effects using theHuber-White estimator, whichwas selected
over other potential analyses that can be conducted to explore within twin/sibling
frailties as the most parsimonious method.
￿.6.￿ Implcaitions
Consideration of multiple stages of drug use from non-use to dependence allows
identi￿cation of factors uniquely associated with speci￿c transitions. The current
results demonstrate that different factors are in￿uential at different stages of
the development of cannabis dependence. Additionally, the differences and
consistencies in factors across the stages of drug use provide an insight into
which similarities and differences we may expect to see occurring through the
transitions towards dependence. The ￿ndings have implications for substance use
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prevention efforts, as both the targeting of interventions aswell as the interventions
themselves may bene￿t from being tailored to stages of drug use. Speculatively,
adolescents may feel more comfortable reporting having had the opportunity to
use cannabis then initaition of cannabis, as opportunit does not involve reporting
illegal activity. It may therefore prove a useful tool for targeting interventions.
￿￿
CHAPTER ￿
Go on Until you Reach the End: Genetic
Correlation Between Cannabis
Opportunity and Abuse and/or
Dependence
￿.￿ Introduction
In the previous chapter an association was observed between age of opportunity to
use cannabis and the development of abuse and/or dependence. This association
remained after adjusting for the effect of factors that were associated with
progression to both stages. It is possible that shared genetic factors may
underlie part of the association between these two variables. Cannabis use
disorders have a strong genetic component, with a review of 6 studies in the area
concluding heritability estimates range from ￿￿% – ￿8% (Agrawal and Lynskey,
￿￿￿6). Opportunity to use a drugmay be a putatively environmental factor, but such
factors have been shown to have heritable in￿uences (Kendler and Baker, ￿￿￿￿).
Heritable in￿uences on early stages of cannabis use, such as the opportunity to use
cannabis, may include personality factors and behaviours which have been shown
to be associated with earlier exposure (such as disruptive childhood behaviour
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(Storr et al., ￿￿￿￿)) and are in￿uenced by additive genetic in￿uences (Hudziak et al.,
￿￿￿￿). In contrast, genetic in￿uences on abuse or dependence can be hypothesised
to include factors associated with drug metabolism.
Heritable and environmental in￿uences on progression through stages of drug
use may vary (see Chapter ￿), and some risk factors may be unique to speci￿c
stages of substance involvement, while others may act, or be correlated, across
multiple stages (Kendler et al., ￿￿￿￿a). No research to date has explored whether
there is overlap between factors associated with earlier opportunity and those
associated with lifetime cannabis abuse and/or dependence.
Twin studies estimate additive genetic effects, common environment effects
and unique environment effects on a phenotype (Neale and Cardon, ￿￿￿￿). Two-
stage bivariate twin modelling (Heath et al., ￿￿￿￿) is an extension of bivariate
twin modelling. This model is used to estimate the correlation between additive
genetic (A), shared environment (C) and unique environment (E) in situations where
early-stage phenotypes, such as opportunity to use a drug, are necessary for the
expression of later behaviours, such as abuse and/or dependence. In order to
overcome the issue that those who have not had the opportunity to use cannabis
will have structural missing data for the outcome of dependence, the initial variable
of opportunity is coded to have at least three categories, two of which include
individuals who can be assessed on the second outcome.
The present study aims to apply bivariate models to twin data on cannabis
opportunity and abuse and/or dependence to determine the extent towhich genetic
in￿uences on the development of cannabis abuse/dependence are unique to the
phenotype, and the extent to which they are correlated with genetic in￿uences on
opportunity to use cannabis.
Aim
Establish the extent to which age of opportunity to use cannabis is in￿uenced by
additive genetic, shared environmental and unique environmental factors, and the
extent to which these in￿uences correlate with those in￿uencing the development
of abuse and/or dependence.
Hypothesis ￿
There will be genetic in￿uences on age of opportunity to use cannabis, and on




Genetic in￿uences on age of opportunity to use cannabis will be moderately




The sample was drawn from the Australian Twin Registry (ATR). The ￿￿￿￿ twins
who provided information on whether or not they had ever had the opportunity
to use cannabis, and who had complete zygosity information, form the analysis
sample in this chapter (see Figure ￿.￿).
Figure ￿.￿: ATR sample for analyses in this chapter
￿.￿.￿ Measures
For these analyses age of opportunity was coded into three levels. These were
having never had the opportunity to use cannabis (N = ￿￿6), having had later
￿￿￿
￿.￿. ANALYTIC STRATEGY
opportunity to use cannabis (￿rst opportunity reported as happening at age ￿6 and
over, N = ￿￿6￿), or having had early opportunity to use cannabis (￿rst opportunity
reported as happening at age ￿￿ or earlier, N = 68￿). The variable levels were coded
in this order to represent the increasing liability to the outcome associated with
each level. Sensitivity testing of the cut-off of ￿￿ and under for early cannabis use
opportunity is available in Appendix ￿. The correlations obtained by different cut-off
points indicated that results were not affected by the choice of ￿￿ as age cut-off for
early opportunity (see Appendix ￿).
Cannabis abuse and/or dependence was derived from participants meeting the
DSM-IV criteria for either of these disorders (American Psychiatric Association,
￿￿￿￿) (derivation outlined in Chapter ￿ Section￿.￿.￿). Within the twin only
subsample that had provided data on opportunity to use cannabis, ￿6.￿% (N = ￿￿￿)
participants reported meeting criteria for cannabis abuse and/or dependence.
￿.￿ Analytic Strategy
￿.￿.￿ Testing the Assumptions of Common Liabilities
In order to establish if there were shared liabilities between lifetime opportunity to
use cannabis (coded yes/no for this part of the analysis) and abuse/dependence
a Causal Common Contingent model was used. This provides a beta pathway
between the two phenotypes, which suggests correlated liabilities if signi￿cant
(Do et al., ￿￿￿￿), and if the beta pathway is greater than ￿ (independent liability
distribution) but less than ￿ (single liability distribution) (Maes et al., ￿￿￿￿b).
A signi￿cant beta test indicating moderate to high multiple liabilities (common
causes underlying both phenotypes) demonstrates that there are shared in￿uences
acting on both phenotypes, and further bivariate twin modelling is necessary to
determine the sources of these common causes.
￿.￿.￿ Equating Thresholds and Correlations
In order to test whether thresholds and correlations could be equated between MZ
and DZ males and females, a series of nested models were compared against
a complete saturated model (see Chapter ￿, Section ￿.￿.￿ for full explanation of
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nested modelling). If the nested model was not signi￿cantly different (P￿.￿￿) to
the saturated model then the parameters tested were equated, in order to develop
the most parsimonious model.
￿.￿.￿ Two-Stage Bivariate Twin Model
A two-stage twin model was ￿tted to assess contributions of additive genetic (A),
shared environmental (C), and unique environmental (E) factors to the variance
in age of opportunity to use cannabis and on lifetime cannabis abuse and/or
dependence, and to estimate the extent to which in￿uence of A, C and E on the
two phenotypes were correlated (Heath et al., ￿￿￿￿). This model is a variation
of the classic bivariate models that is appropriate for analysis of variables with
data missing at random (data that are missing as a result of observations on a
previous variable, as opposed to data that are missing completely at random (Little
and Rubin, ￿￿￿￿)). In the present analysis twins who had no opportunity to use
cannabis have a ￿￿￿% a priori probability of having a value of zero for the outcome
cannabis abuse/dependence, resulting in structuralmissing data. Themodel coded
opportunity as a three level variable (never opportunity/later opportunity/early
opportunity, as described in the measures section above), two levels of which
have non-missing data on abuse/dependence. A constrained correlations model
is applied, which utilises the cross-covariance within twin pairs, which refers to the
correlation between trait X in twin ￿ and trait Y in twin ￿ (Plomin et al., ￿￿￿￿).
￿.￿.￿ Sex-Limitation Bivariate Modelling
Sex limitation techniques can be applied to multivariate modelling to determine
whether the effects of genetic (or environmental) factors differ between males
and females. Sex differences can be scalar, in which the same factors affect
the phenotype in both sexes but the magnitude of the effect differs, or non-
scalar, in which one or more factors affect a phenotype in one sex but not the
other (Neale et al., ￿￿￿6c). Scalar sex differences can be assessed through the
covariance between same-sex MZ and DZ twins, whereas assessment of non-
scalar sex differences require the inclusion of opposite-sex DZ twins to assess
whether correlation within these pairs is reduced compared to same-sex DZ twin
pairs.
￿￿￿
￿.￿.￿ Selection of Correlation Model over Cholesky Decomposition
Caution needs to be taken when applying sex limitation modelling in a
multivariate twin analysis context. In an in-depth exploration of the issue, Neale
et al. (￿￿￿6c) tested the optimumway to approach the analysis, outlining a number
of requirements for the generation of covariance matrices within this analysis.
These include:
￿. The processes causing individual differencesmust cause positive variance in
the phenotypes;
￿. Correlation matrices must remain consistent with each other (e.g. if the
correlation between X and Y is ￿.￿, the correlation between X and Zmust equal
the correlation between Y and Z);
￿. The predicted phenotypic covariance must be positive de￿nite (each of the
values contributing to the equation must be positive).
￿.￿.￿ Selection of Correlation Model over Cholesky Decomposition
Bivariate twin modelling commonly utilises a Cholesky Decomposition analysis,
whereby variance in the ￿rst variable in the model is assumed to be caused be a
latent factor that can explain the variance in the second variable. The variance in the
second variable in the analysis is assumed to be caused by a second latent variable,
which does not explain the variance in the ￿rst variable. Consequently all variables
load on to the ￿rst latent factor, but only the second variable in the analysis will load
on to the second latent factor (Gillespie and Martin, ￿￿￿￿). This allows estimation
of the extent to which two variables share latent factors.
For scalar sex limitation, an additional requirement is that the factors must
covary to the same extent in males and females, resulting in a common factor
correlation structure with different factor loadings for males and females. As a
result, the use of Cholesky Decomposition analysis has been found to be unsuitable
for sex limitation models, as it does not retain the required constraint for scalar
sex limitation that the factors correlate equally in males and females(Neale et al.,
￿￿￿6c).
A correlation approach to the multivariate sex-limitation model has been found
to be more suitable. The correlation model can be speci￿ed in terms of factors for
males and females, and can estimate covariance within male and female factors
separately. These factors are constrained to have the same covariance matrix in
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males and females. The factors then in￿uence the phenotype via path coef￿cients
that are not constrained to be equal across sexes. Thus the model speci￿es
that the same factors in￿uence males and females but that they may do so to
different degrees. Path analysis can then be conducted on the correlated model
to determine the variance unique to each factor, and the variance shared between
factors, providing the same estimates that are achieved with a Cholesky model.
￿.￿.6 Analysis Summary
First, the assumption of correlated liabilities underlying both phenotypes was
tested using a CCC model to estimate the beta pathway. A liability threshold
model estimating co-twin correlations was ￿tted to the data set and used to test
assumptions regarding the equality of thresholds between sexes, and MZ and DZ
correlations. Next, a constrained correlation bivariate model was ￿tted, partitioning
the variance attributable to A C and E for both phenotypes, and the A C and E
correlations between these variance components. A freely estimated model was
￿tted for both sexes, and then separate nested models ￿tted to test whether
parameters and correlations could be equated across sexes. Difference in model
￿t was assessed via the likelihood-ratio  2 test and examination of the Akaike
Information Criterion (AIC) (a description of these tests of model ￿t is provided in
Chapter ￿, Section ￿.￿.￿).
￿.￿ Results
￿.￿.￿ Prevalence of, and Correlations between, Opportunity to use
Cannabis and Abuse and/or Dependence
Of those who reported opportunity to use cannabis by age ￿￿, ￿￿.￿% (N = ￿￿￿)
reported cannabis abuse and/or dependence. Of those who reported cannabis use
opportunity at age ￿6 or older, ￿￿.￿% (N = ￿6￿) reported cannabis abuse and/or
dependence. A saturated model was used to estimate tetrachoric correlations for
the traits of age of opportunity and lifetime cannabis abuse and/or dependence (see
table ￿). The phenotypic correlation was ￿.￿￿ in males and ￿.￿￿ in females. The
across twin/across trait correlation between age of opportunity to use cannabis
￿￿￿
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and cannabis abuse and/or dependence (see Table ￿.￿) was similar in MZ and
DZ males but almost twice as high in MZ female pairs compared to DZ female
pairs, indicating there may be stronger in￿uence of additive genetic effects on the
correlation in females.
Table ￿.￿: Phenotype correlations for ATR MZ and DZ male, female and opposite sex twin
pairs (N=￿￿￿￿)
Opportunity/Abuse and/or Age of opportunity Abuse and/or dependence
dependence twin ￿/twin ￿ twin ￿/twin ￿ twin ￿/twin ￿
Correlation ￿￿% CI Correlation ￿￿% CI Correlation ￿￿% CI
MZ males ￿.￿￿ (￿.￿6 – ￿.￿￿) ￿.￿￿ (￿.￿￿ – ￿.8￿) ￿.￿￿ (￿.￿￿ – ￿.8￿)
N=￿8￿
DZ males ￿.￿￿ (￿.￿6 – ￿.6￿) ￿.￿8 (￿.￿￿ – ￿.68) ￿.￿6 (￿.￿6 – ￿.6￿)
N=￿￿￿
MZ females ￿.￿￿ (￿.￿￿ – ￿.￿￿) ￿.6￿ (￿.￿￿ – ￿.￿￿) ￿.8￿ (￿.￿￿ – ￿.8￿)
N=￿￿￿
DZ females ￿.￿￿ (￿.￿￿ – ￿.￿￿) ￿.￿￿ (￿.￿8 – ￿.￿￿) ￿.￿8 (￿.￿￿ – ￿.6￿)
N=￿￿￿
DZ opposite sex ￿.￿￿ (￿.￿6 – ￿.￿￿) ￿.￿6 (￿.￿￿ – ￿.￿￿) ￿.￿￿ (￿.￿￿ – ￿.￿￿)
N=￿￿￿
￿.￿.￿ Assumption Testing
Results of CCC modelling indicated signi￿cant correlated liabilities between
cannabis opportunity and the development of cannabis dependence, with the beta
estimated at ￿.￿￿ (￿￿% CI ￿.￿￿ – ￿.￿￿). This indicates that there is correlation in the
factors underlying expression of the two traits.
Thresholds for age of opportunity to use cannabis and for cannabis abuse
and/or dependence could not be equated (for both models tested against the
saturated model, P=￿.￿￿￿). Within trait and within twin correlations could be
equated for MZ male and female twins, DZ male and female twins, and DZ M/F
twins and OS twin pairs with no signi￿cant loss of model ￿t (compared to saturated
model  -￿LL=￿￿.￿,  DF= ￿, P value = ￿.￿8). This precluded the necessity to test




Table ￿.￿: Testing whether thresholds and correlations can be equated between male and
female twins (N=￿￿￿￿)
Model Model Comparison -￿LL DF AIC  -￿LL  DF P value
number name model
￿ Saturated model - ￿68￿.￿ 6￿8￿ -￿￿￿8 - - -
￿ Equating m/f opportunity thresholds ￿ ￿￿6￿.￿ 6￿8￿ -￿￿￿￿ ￿￿.￿ ￿ ￿.￿￿￿
￿ Equating m/f abuse and/or dependence ￿ ￿￿￿￿.￿ 6￿8￿ -￿￿86.6 ￿￿.6 ￿ ￿.￿￿￿
thresholds
￿ Equating MZ m/f within trait and ￿ ￿688.￿ 6￿8￿ -￿￿8￿.6 ￿.￿ ￿ ￿.￿￿
and within twin correlations
￿ Equating DZ male/female within trait and ￿ ￿6￿￿.￿ 6￿88 -￿￿8￿.￿ 6.￿ ￿ ￿.￿￿
within twin correlations
(MZ MF correlations equated)
6 Equating DZ male/female and ￿ ￿6￿8.6 6￿￿￿ -￿￿8￿.￿ ￿.￿ ￿ ￿.￿6
OS twin within trait
and within twin correlations
(DZ MF and MZ MF correlations equated)
￿ Correlations equated for all MZ ￿ ￿6￿8.6 6￿￿￿ -￿￿8￿.￿ ￿￿.￿ ￿ ￿.￿8
and DZ twin pairs;
m/f thresholds freely estimated
The correlations for a model where male and female correlations were equated
for MZ pairs were:
• Opportunity/Abuse and/or dependence twin ￿/twin ￿: ￿.￿￿ (￿￿% CI ￿.￿8 -
￿.￿￿)
• Opportunity twin ￿/twin ￿: ￿.6￿ (￿￿% CI ￿.￿8 - ￿.￿￿)
• Abuse and/or dependence twin ￿/twin ￿: ￿.￿￿ (￿￿% CI ￿.￿￿ - ￿.￿8)
The correlations for amodelwheremale, female and opposite sex correlationswere
equated for DZ pairs were:
• Opportunity/Abuse and/or dependence twin ￿/twin ￿: ￿.￿6 (￿￿%CI￿.￿6 -￿.￿￿)
• Opportunity twin ￿/twin ￿: ￿.￿￿ (￿￿% CI ￿.￿￿ - ￿.￿6)
• Abuse and/or dependence twin ￿/twin ￿: ￿.￿￿ (￿￿% CI ￿.￿6 - ￿.￿￿)
As converting continuous variables to categorical can be a source of bias
in analyses (Altman, ￿￿￿￿), sensitivity analyses were conducted for the early
opportunity to use cannabis cut-off age. The analysis indicated that correlations
obtained did not differ by choice of the age cut-off (see Appendix ￿).
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￿.￿.￿ Constrained Correlations Bivariate Sex Limitation Model
Fitting
The results of the full freely-estimated correlation model, with separate parameter
and correlation estimates for males and females, are provided in Figure ￿.￿ and
￿￿￿
￿.￿.￿ Nesting Models to Develop Parsimonious Model Fit
Figure ￿.￿. The ￿t statistics for this model were -￿LL=￿6￿￿.6, DF=6￿8￿, AIC=-
￿￿￿￿.￿.
￿.￿.￿ Nesting Models to Develop Parsimonious Model Fit
In order to achieve the most parsimonious model ￿t, nested models were ￿tted
equating the A, C and E variance components and correlations for males and
females. It was possible to equate the estimates for A (-￿LL=￿6￿￿.￿, DF=6￿88,
AIC=-￿￿8￿.￿, compared to freely estimated model  -￿LL= ￿.￿,  DF= ￿, P value =
￿.￿￿), C (-￿LL=￿6￿6.￿, DF=6￿88, AIC=-￿￿8￿.￿, compared to freely estimated model
 -￿LL=￿.￿,  DF= ￿, P value = ￿.￿￿), and E (-￿LL=￿6￿￿.￿, DF=6￿88, AIC=-￿￿8￿.￿,
compared to freely estimated model -￿LL= ￿.￿, DF= ￿, P value = ￿.￿￿). A model
equating ACE simultaneously across males and females was not a signi￿cantly
worse model ￿t compared to the freely estimated model (-￿LL=￿6￿8.￿, DF=6￿￿￿,
AIC=-￿￿8￿.￿, compared to freely estimated model  -￿LL=8.￿,  DF= ￿, P value =
￿.￿￿). The contribution of C to this fully equated model was found to be small (￿.￿8
for age of opportunity, ￿.￿￿ for abuse and/or dependence). Consequently, the ￿t
of a model where C was dropped was tested against the ￿t of the freely estimated
model. The AE model did not have signi￿cantly worse ￿t than the freely estimated
model (-￿LL=￿￿￿￿.￿, DF=6￿￿￿, AIC=-￿￿￿￿.8, compared to freely estimated model
 -￿LL=￿￿.6, DF= ￿￿, P value = ￿.￿8).
￿.￿.￿ Final Model: An AE Sex-Equated Model
As the AE model equated across males and females provided the most
parsimonious model without signi￿cant deterioration of ￿t to the data, this was
selected as the ￿nal model. Parameter estimates for age of opportunity to use
cannabis were:
• A=￿.66 (￿￿% CI ￿.￿￿ – ￿.￿￿)
• E=￿.￿￿ (￿￿% CI ￿.￿8-￿.￿￿)
Parameter estimates for cannabis abuse and/or dependence were:
• A=￿.￿8 (￿￿% CI ￿.68-￿.86)
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• E=￿.￿￿ (￿￿% CI ￿.￿￿-￿.￿￿)
Correlations between the two phenotypes were estimated at:
• A = ￿.￿￿ (￿￿% CI ￿.￿8 – ￿.￿￿)
• E = -￿.￿￿ (￿￿% CI -￿.￿￿ – ￿.￿￿)
Using path analysis, from these results it can be calculated that, of the variance
in age of opportunity to use cannabis and cannabis abuse and/or dependence
attributable to genetics, ￿￿% is shared between these phenotypes (
p
0.66 ⇥ p0.78
⇥ ￿.￿￿). From this, it can be estimated that ￿.￿6 (￿.￿8 - ￿.￿￿) (￿6%; ￿.￿6÷￿.￿8) of
the additive genetic contribution to variance in cannabis abuse and/or dependence
is unique to that phenotype.
￿.￿ Discussion
Additive genetic in￿uences determine the majority of variance in both age of
opportunity to use cannabis (￿.66, ￿￿% CI ￿.￿￿ – ￿.￿￿) and cannabis abuse
and/or dependence (￿.￿8, ￿￿% CI ￿.68-￿.86). Of the additive genetic in￿uences on
cannabis abuse and/or dependence, ￿￿%were commonwith genetic in￿uences on
opportunity, whilst ￿6% was speci￿c to abuse and/or dependence. No effect of the
shared environment on either age of opportunity to use cannabis or cannabis abuse
and/or dependence was observed, but there were unique environmental in￿uences
on both phenotypes. Given that parameter estimates and correlations could be
equated for males and females, there was no indication of scalar sex differences
acting on these phenotypes.
Previous research has not explored the correlation between in￿uences on
cannabis use opportunity and cannabis abuse or dependence, but existing studies
focussing on cannabis initiation have observed overlapping liabilities (￿.88) to
cannabis initiation and progression to heavy use (Fowler et al., ￿￿￿￿), and extremely
high genetic correlation (r=.￿8) between frequency of cannabis use and cannabis
dependence (Sartor et al., ￿￿￿￿). As such the present ￿ndings are in line with
existing research showing genetic correlation between the early stages of cannabis
use and later SUDs.
￿￿￿
￿.￿. DISCUSSION
Opportunity to use cannabis is the necessary ￿rst step in progression towards
problematic use, and is a phenotype that could be thought to be subject to
external in￿uence only,. However, there were moderate genetic in￿uences on age
of opportunity of cannabis use (￿.66). Environmental measures can be heritable if
an individual’s behaviour impacts on the environmental exposures, and if aspects
of that behaviour are subject to genetic in￿uences (Kendler and Baker, ￿￿￿￿).
A review of this area identi￿ed that positive and negative life events, divorce
and social support all have heritable in￿uences (Kendler and Baker, ￿￿￿￿). The
previous chapter (Chapter ￿) identi￿ed that CD in￿uences transitions to cannabis
use opportunity, and from opportunity to dependence. This is in line with existing
research demonstrating the consistent in￿uence of CD on drug use (Lynskey et al.,
￿￿￿￿; Reboussin et al., ￿￿￿￿; Storr et al., ￿￿￿￿), and genes relating to CD and
antisocial behaviour are plausible candidates that may contribute to the shared
genetic liability between age of opportunity and the development of cannabis abuse
and/or dependence.
Both cannabis opportunity and abuse and/or dependence show a moderate
effect of the unique environment (￿.￿￿ and ￿.￿￿, respectively), but there is
low negative correlation between the unique environmental in￿uences on these
phenotypes (r-￿.￿￿). This supports existing research demonstrating that the
pattern of environmental factors associated with progression between speci￿c
stages of drug use differs between transitions (Belsky et al., ￿￿￿￿; Sartor et al.,
￿￿￿￿); indeed, this was observed in the previous chapter (Chapter ￿).
In the present analysis it was possible to drop C from the model without
signi￿cant deterioration inmodel ￿t, indicating that none of the observed variance in
opportunity to use cannabis or abuse and/or dependence inmales was attributable
to the shared environment in this sample. The shared environment is usually found
to bemore implicated at earlier stages than later (Fowler et al.,￿￿￿￿), These ￿ndings
are contradictory to ￿ndings of a high C correlation between cannabis availability
and cannabis abuse (Gillespie et al., ￿￿￿￿). The samples differ, with the Gillespie
et al. (￿￿￿￿) ￿ndings based on an all-male population, but the ￿ndings may indicate




Certain limitationsmust be taken into account when interpreting these results. The
data are based on retrospective self-report. Retrospective recall of age onset of
drug use behaviours has been shown to be reliable (Ensminger et al., ￿￿￿￿)), but
the analyses would bene￿t from replication in longitudinal cohorts. Self-report
has been shown to be a valid measure of data collection relating to drug use
(Darke, ￿￿￿8), and has been described as the gold standard for collecting data on
phenotypes such as initiation and opportunity (Wagner and Anthony, ￿￿￿￿). Given
that use of cannabis is illegal (at time of data collection), some participants in the
ATR studymay have incorrectly reported on their drug use. However, given the high
prevalence of self-reported lifetime cannabis use, it seems unlikely that this was a
problem.
The results are based on a twin population. Research has demonstrated twin
and non-twin populations do not differ in incidence of psychiatric illness (Kendler
et al., ￿￿￿6) and that no association has been found between twin environmental
similarity and mental health outcomes (Kendler et al., ￿￿￿￿).
￿.￿.￿ Implications
The ￿ndings of this paper have important implications for future studies of gene
variants and heritability of problematic cannabis use, and in the choice of controls
in case-control studies. These results indicate that only a moderate proportion of
genetic in￿uences on cannabis abuse and/or dependence are unique from those
acting on age of opportunity to use cannabis. Such arguments have previously been
made regarding the importance of considering drug use opportunity when looking
at the genetics of opiate use. By comparing participants in treatment for opiate
dependence with controls sourced from the ATR (individuals not dependent on
alcohol or illicit drugs, with signi￿cantly lower illicit drug exposure), and separately
with nondependent neighbourhood controls (high exposure to illicit drugs, either
via use or from residing in environments with widespread drug availability),
differences were found in the SNPs associated with heroin dependence (Nelson
et al., ￿￿￿￿). Until now the importance for genetic studies of considering cannabis
use opportunity has not been explored and no genetic studies of problematic
cannabis use have considered cannabis use opportunity amongst the control
￿￿￿
￿.￿.￿ Implications
group. The present ￿ndings indicate that by not taking this into consideration, and
by ignoring the stage-speci￿c nature of drug use, there is a risk of con￿ation of
genetic in￿uences.
Consequently, a key implication of the current ￿ndings is the necessity of taking
into consideration the stage of drug use reached amongst the controls. Existing
research has utilised information on the extent of cannabis use in controls (e.g.
excluding those who had used cannabis fewer than 6 times) (Hartman et al., ￿￿￿￿),
but such issues are not always being taken into consideration (Benyamina et al.,
￿￿￿￿). Depending on the research question, and on the development of research
identifying genetic overlap between progression to other stages of cannabis use
and problematic cannabis use, screening controls not only for opportunity or
initiation of cannabis use, but also for frequency of usemay have utility in improving
cannabis dependence SNP identi￿cation in the future.
These ￿ndings may have further implications for of the overlap of genetic
in￿uences across drug classes. Existing research has suggested that a proportion
of the genetic factors underlying SUDs are not speci￿c to individual drugs, and that
it is environmental in￿uences that determine the drug of dependence (Kendler et al.,
￿￿￿￿) However, previous research in this area has not incorporated consideration
of the stage sequential nature of drug dependence into their analyses. Much of the
non-speci￿city of genetic in￿uences on SUDsmay result from shared in￿uences on
the earlier stages of drug use, with more speci￿c in￿uences (such as those related
to drug metabolism, for example) associated with later stages of use.
￿￿￿
CHAPTER ￿
A Curious Transition: Examination of
Time from Initiation to Subsequent Use
of Cannabis
￿.￿ Introduction
So far, the research in this thesis has focussed on the transition to opportunity to
use cannabis. In this chapter I consider the transition from initiation to subsequent
use of cannabis. This is a novel transition, previously unexplored in research (see
Chapter ￿), the speed of which is de￿ned by the time between two stages. Studying
transition speed that is de￿ned by time between stages, rather than age of onset,
removes the potential for the correlates of early initiation tomask associations that
are speci￿c to speed of transition. In turn, this will improve understanding of the
relationship between transition speed and later outcomes and the stages of drug
use.
Additionally, if a relationship is observed between this speci￿c transition and
later cannabis use outcomes this may provide a new marker for those who would
bene￿t from intervention, regardless of whether or not they experience early onset
of cannabis use. Cannabis initiation does not occur solely during adolescence,
and research into US college students found that ￿￿% of those sampled initiated
￿￿￿
￿.￿. AIMS AND HYPOTHESES
cannabis use after starting college, having not used it previously (Pinchevsky et al.,
￿￿￿￿). If speed of the speci￿c transition studied within this chapter is associated
with later cannabis outcomes, after controlling for the effect of early initiation
of cannabis use, it may prove useful as an early marker for intervention that is
applicable to a wider population of cannabis users.
In this chapter I explore the relationship between the speed of this speci￿c
transition and later cannabis use, abuse and dependence outcomes, and identify
the extent to which variance in the speed of transition to subsequent use of
cannabis is attributable to genetic and environmental factors.
￿.￿ Aims and Hypotheses
Aim ￿
Test whether speed of transition from initiation to subsequent use of cannabis
is associated with increased likelihood of later daily cannabis use, abuse and/or
dependence, and cannabis related treatment seeking when accounting for the
in￿uence of socio-demographic, childhood, mental health, peer and drug use
factors that may confound the association
Hypothesis ￿
Individuals who have faster transition from initiation to subsequent use of cannabis
will have an increased likelihood of daily cannabis use, abuse and/or dependence
and cannabis related treatment seeking later in life.
Hypothesis ￿
Associations between speed of transition from initiation to subsequent use of
cannabis and lifetime risks of daily cannabis use, abuse and/or dependence
and cannabis related treatment seeking will persist after control for socio-
demographic, childhood, mental health, peer and drug use factors identi￿ed as
potentially confounding variables.
Hypothesis ￿
Speed of transition from ￿rst to subsequent use of cannabis will be associated
with later cannabis outcomes after controlling for early cannabis initiation.
Aim ￿
Examine the extent to which the speed of the transition is attributable to additive
genetic, shared environmental or non-shared environmental effects.
￿￿￿
￿.￿. THE RELATIONSHIP BETWEEN SPEED OF TRANSITION FROM INITIATION TO
SUBSEQUENT CANNABIS AND LATER CANNABIS OUTCOMES
Hypothesis ￿
The speed of transition will be in￿uenced by both additive genetic and
environmental factors.
See Figure ￿.￿ for an outline of how the hypotheses of this chapter are addressed
through two different analyses.







Hypothesis 2 Hypothesis 3 Hypothesis 4
Classic Twin
Model
￿.￿ The Relationship Between Speed of Transition
from Initiation to Subsequent Cannabis And Later
Cannabis Outcomes
￿.￿.￿ Methods
The ￿rst analyses in this chapter focus on the relationship between the speed of
transition to subsequent use and later cannabis outcomes.
Sample
The sample for this portion of the chapter analyses was ATR participants who had
progressed to subsequent cannabis use (used cannabis more than twice in their
lives, see Figure ￿.￿).
￿￿￿
￿.￿.￿Methods
Figure ￿.￿: Deriving the sample for the subsequent use analysis from the complete twin
cohort
Independent and Dependent Variables
Speed of Transition to Subsequent Cannabis Use
Those who had reported using cannabis at least once in their lives were asked how
long after their ￿rst use did their second use of cannabis occur. The categories in
this analysis represent the underlying continuous construct of time to subsequent
use, but continuous data were not available. These raw data were coded into ￿
different categories, de￿ned in terms of days, weeks, months or years. These
original categories were collapsed into ￿ discrete groups to overcome sparse cells:
within ￿ week (￿￿.8%), within ￿ months (but not including those who transitioned
within ￿ week) (￿￿.￿%), between ￿ months – ￿￿ months (￿￿.￿%), more than ￿ year
later (￿￿.8%) (with those who had reported not trying cannabis for a second time




The outcomes of daily cannabis use, abuse and/or dependence, and treatment
seeking were used in the analyses (see Chapter ￿ for variable derivation).
Analysis Plan
Analyses were conducted in Stata Statistical Software Version ￿￿ (StataCorp,
￿￿￿￿).  2 tests and phi coef￿cients were used to assess the association
between the speed of transition from initiation to subsequent use of cannabis
and lifetime cannabis daily use, abuse and/or dependence and treatment seeking.
Associations were deemed signi￿cant at the P ￿.￿￿ level. Logistic regression
analysis was used to explore the association between the speed of transition
from initiation to subsequent use of cannabis and the outcomes daily cannabis
use, abuse/dependence, and treatment-seeking for cannabis use problems after
adjustment for sociodemographic, childhood, mental health, peer and licit drug
factors. An outline of the analysis is presented in Figure ￿.￿. To correct for the
non-independence of observations (due to family clustering), Huber-White analysis
for clustered data was implemented to provide robust standard errors. Post hoc
comparisons across the varying speeds of transition were conducted using Wald
 2 tests.
Identi￿cation of Covariates
From the full list of potential covariates selected from the literature (see Chapter
￿), those that may confound the association between speed of transition to
subsequent cannabis use and later outcomes were identi￿ed through multivariate
logistic regression. Covariates were included in the logistic models if signi￿cantly
associated with both speed of transition (see Table ￿.￿) and the dependent variable
(see Appendix ￿).
￿.￿.￿ Results
Analysis of the Relationship between Transition Speed and Cannabis Outcomes of
Daily Use, Abuse and/or Dependence, and Treatment Seeking
In this sample ￿6.6% self-reported using cannabis daily during their period
of heaviest use, ￿￿.￿% reported cannabis abuse and/or dependence, and 6%
￿￿￿
￿.￿.￿ Results
Figure ￿.￿: Logistic regression model for the association between speed of transition to
subsequent use and cannabis daily use, abuse and/or dependence, and treatment seeking
self-reported having discussed cannabis related problems with a professional.
Proportions of each of the three cannabis use outcomeswere signi￿cantly different
between the transition speed groups (P ￿.￿￿￿ for all outcomes, see Table ￿.￿).
For all outcomes the proportion that would go on to develop problems decreased
approximately linearly across the groups (see Figure ￿.￿). Those whose second
use of cannabis was within one week of initiation had the highest proportion of
daily cannabis use (￿8.￿%), abuse and/or dependence (￿6.￿%), or cannabis-related
treatment seeking (￿￿.6%) (see Table ￿.￿).
Table ￿.￿: Association between speed of transition to subsequent cannabis use and daily
cannabis use, cannabis abuse and/or dependence, and cannabis related treatment seeking
in the ATR sample (N=￿￿￿￿)
Variable Within a week ￿ week - ￿months - More than Phi coef￿cient  2 P value
￿months ￿ year ￿ year
N = ￿￿￿ N = 8￿￿ N = ￿8￿ N = ￿6￿
N (%) N (%) N (%) N (%)
Daily cannabis use ￿￿6 (￿8.￿) ￿￿￿ (￿￿.￿) 6￿ (￿￿.8) ￿￿ (￿.￿) ￿.￿￿ ￿.￿￿￿
N=￿￿￿
Cannabis abuse ￿￿￿ (￿6.￿) ￿￿8 (￿8.￿) ￿￿￿ (￿￿.￿) 8￿ (￿￿.6) ￿.￿￿ ￿.￿￿￿
N=6￿￿
and/or dependence




Figure ￿.￿: Diagramvisualising the prevalence of cannabis outcomes by speed of transition
to subsequent use







































































Association Between Speed of Transition to Subsequent Cannabis Use and
Potential Model Covariates
After adjustment for other variables within the model, few factors were identi￿ed
as signi￿cantly associated with the speed of transition to subsequent cannabis
use analysis groups (see Table ￿.￿). These were level of completed education,
CD, single parent family, lifetime weekly tobacco use and lifetime other drug
dependence.
Adjusted Analysis of the Relationship Between Transition Speed and Later
Cannabis Outcomes
After controlling for identi￿ed potentially confounding variables, those whose
second use of cannabis was within a week were at increased odds of reporting
daily use (OR ￿.￿8, ￿￿%CI ￿.￿￿-￿.￿￿) andmeeting criteria for abuse/dependence (OR
￿.￿￿, ￿￿%CI ￿.￿￿-￿.￿￿) (see Table ￿.￿). Those whose subsequent use of cannabis
was within ￿months of initiation were at increased likelihood of reporting cannabis
abuse and/or dependence (OR ￿.￿￿, ￿￿%CI ￿.￿￿-￿.￿￿) (see Table ￿.￿). Post-hoc tests
￿￿￿
￿.￿.￿ Results
identi￿ed that only the level ’within a week’ was signi￿cantly different from both
other levels, for the outcomes of cannabis daily use and abuse and/or dependence.
Speed of this transition was not signi￿cantly associated with cannabis
treatment seeking; this association was non-signi￿cant regardless of whether early
initiation of cannabis use was included in the model.
Table ￿.￿: Association between speed of transition to subsequent cannabis use and socio-
demographic, childhood, mental health, peer and drug use factors in the ATR sample
(N=￿￿￿￿)
Variable Speed of transition to subsequent use
Within a week ￿ week - ￿months ￿months - ￿ year More than ￿ year
N = ￿￿￿ N = 8￿￿ N = ￿8￿ N = ￿6￿
N (%) N (%) N (%) N (%)
OR (￿￿% CI) OR (￿￿% CI) OR (￿￿% CI) OR (￿￿% CI)
Male gender ￿￿￿ (￿6.￿) ￿￿￿ (￿￿.￿) ￿￿8 (￿￿.￿) ￿68 (￿6.￿)
￿.￿￿ (￿.￿6-￿.￿￿) ￿.￿￿ (￿.88-￿.￿￿) ￿.￿8 (￿.8￿-￿.￿￿) ￿.￿
Lower level of ￿￿￿ (￿￿.￿) ￿￿￿ (￿￿.￿) ￿￿￿ (￿6.￿) ￿8 (￿￿.￿)
completed education ￿.￿8*** (￿.￿￿-￿.￿￿) ￿.￿￿ (￿.86-￿.￿￿) ￿.￿6 (￿.￿￿-￿.8￿) ￿.￿
Conduct disorder ￿8 (￿￿.￿) ￿￿￿ (￿￿.￿) ￿￿ (￿.￿) ￿￿ (￿.￿)
￿.￿￿*** (￿.￿￿-￿.6￿) ￿.￿8 (￿.￿￿-￿.￿￿) ￿.￿￿ (￿.8￿-￿.￿￿) ￿.￿
Non-clinical depressive ￿￿￿￿ (￿￿.￿) ￿￿￿ (￿￿.8) ￿￿￿ (￿8.￿) ￿￿8 (￿￿.￿)
episode ￿.8￿ (￿.6￿-￿.￿￿) ￿.88 (￿.6￿-￿.￿￿) ￿.￿￿ (￿.￿￿-￿.￿￿) ￿.￿
Parental alcohol problems ￿￿￿ (￿￿.￿) ￿￿￿ (￿￿.￿) ￿￿8 (￿￿.6) ￿￿￿ (￿￿.￿)
￿.￿￿ (￿.8￿-￿.￿￿) ￿.8￿ (￿.66-￿.￿￿) ￿.￿￿ (￿.￿8-￿.￿￿) ￿.￿
Parental drug problems ￿￿ (6.￿) ￿6 (￿.￿) ￿￿ (￿.￿) ￿￿ (￿.￿)
￿.￿￿ (￿.66-￿.￿￿) ￿.￿￿ (￿.￿￿-￿.￿￿) ￿.￿￿ (￿.6￿-￿.￿￿) ￿.￿
Single parent family ￿8 (6.￿) 6￿ (￿.￿) ￿￿ (￿.￿) ￿ (￿.￿)
￿.￿￿ (￿.￿￿-￿.88) ￿.￿￿* (￿.￿￿-￿.￿￿) ￿.￿￿ (￿.6￿-￿.6￿) ￿.￿
High parental con￿ict ￿8￿ (￿￿.6) ￿￿￿ (￿￿.￿) ￿￿6 (￿8.￿) ￿￿￿ (￿￿.￿)
￿.￿￿ (￿.￿￿-￿.￿8) ￿.￿￿ (￿.￿￿-￿.￿￿) ￿.8￿ (￿.6￿-￿.￿￿) ￿.￿
Strict parenting ￿￿8 (￿￿.￿) ￿￿￿ (￿8.￿) ￿￿￿ (￿￿.￿) ￿￿8 (￿￿.￿)
￿.￿￿ (￿.￿￿-￿.￿￿) ￿.8￿ (￿.6￿-￿.￿￿) ￿.￿￿ (￿.6￿-￿.￿￿) ￿.￿
High levels of peer ￿6 (￿￿.6) 8￿ (￿￿.￿) ￿8 (￿.￿) ￿8 (8.￿)
cannabis use ￿.￿8 (￿.86-￿.￿￿) ￿.￿￿ (￿.8￿-￿.8￿) ￿.￿￿ (￿.￿￿-￿.￿￿) ￿.￿
Childhood sexual abuse ￿6 (￿￿.8) ￿8 (￿.￿) ￿8 (￿.￿) ￿￿ (￿￿.￿)
￿.￿￿ (￿.66-￿.6￿) ￿.8￿ (￿.￿￿-￿.￿￿) ￿.￿￿ (￿.￿8-￿.￿￿) ￿.￿
Infrequent childhood ￿￿￿ (￿￿.￿) ￿￿6 (￿￿.6) ￿￿8 (￿￿.8) ￿￿￿ (￿￿.￿)
religious attendance ￿.￿￿ (￿.68-￿.￿￿) ￿.￿￿ (￿.￿￿-￿.￿8) ￿.￿6 (￿.8￿-￿.￿￿) ￿.￿
Lifetime monthly alcohol use ￿￿￿ (￿￿.￿) 8￿￿ (￿8.￿) ￿￿￿ (￿6.￿) ￿￿￿ (￿6.8)
￿.￿￿ (￿.￿￿-￿.8￿) ￿.6￿ (￿.8￿-￿.￿￿) ￿.￿￿ (￿.￿￿-￿.￿￿) ￿.￿
Lifetime weekly tobacco use ￿￿￿ (6￿.￿) ￿￿￿ (￿8.￿) ￿6￿ (￿￿.￿) ￿￿￿ (￿￿.￿)
￿.￿￿*** (￿.￿￿-￿.￿￿) ￿.￿8* (￿.￿￿-￿.8￿) ￿.￿￿ (￿.8￿-￿.￿￿) ￿.￿
Lifetime other drug use ￿￿6 (￿￿.￿) ￿￿￿ (6￿.￿) ￿￿￿ (￿￿.￿) ￿￿￿ (￿￿.6)
￿.￿6 (￿.￿￿-￿.￿￿) ￿.￿￿ (￿.￿￿-￿.￿￿) ￿.6￿ (￿.￿￿-￿.￿￿) ￿.￿
Lifetime alcohol ￿8￿ (￿￿.￿) ￿￿￿ (￿￿.￿) ￿￿￿ (￿￿.8) ￿￿8 (￿￿.8)
dependence ￿.￿￿ (￿.8￿-￿.￿￿) ￿.￿8 (￿.￿6-￿.￿￿) ￿.￿￿ (￿.￿￿-￿.￿￿) ￿.￿
Lifetime tobacco ￿￿￿ (￿￿.￿) ￿6￿ (￿￿.￿) ￿￿￿ (￿￿.6) ￿￿8 (￿￿.8)
dependence ￿.￿￿ (￿.6￿-￿.￿￿) ￿.￿￿ (￿.6￿-￿.￿￿) ￿.￿￿ (￿.68-￿.￿8) ￿.￿
Lifetime other drug 6￿ (￿￿.￿) 6￿ (￿.￿) ￿￿ (￿.￿) ￿￿ (￿.￿)
dependence ￿.6￿*** (￿.￿￿-￿.￿￿) ￿.6￿ (￿.￿￿-￿.￿￿) ￿.￿￿** (￿.￿￿-￿.￿￿) ￿.￿
Early initiation ￿.8￿ (￿.6￿-￿.￿￿) ￿.￿￿ (￿.8￿-￿.￿￿) ￿.8￿ (￿.6￿-￿.￿￿) ￿.￿
of cannabis (￿6)




The analyses identi￿ed a signi￿cant association between speed of transition
to subsequent use of cannabis and the outcomes daily cannabis use and
cannabis abuse and/or dependence, which remained after controlling for identi￿ed
confounding variables and for the effect of early initiation of cannabis use.
Table ￿.￿: Odds ratios (￿￿% Con￿dence intervals) for association between speed of
transition to subsequent cannabis use, covariates and later cannabis outcomes from
logistic regression analysis of the ATR sample (N=￿￿￿￿)
Speed of Transition Daily Use Abuse and/or Dependence Treatment Seeking
to Subsequent Use N = ￿￿￿ N = 6￿￿ N=￿￿￿
Odds Ratio Odds Ratio Odds Ratio
(￿￿% Con￿dence Interval) (￿￿% Con￿dence Interval) (￿￿% Con￿dence Interval)
Univariate Adjusted Univariate Adjusted Univariate Adjusted
model model model model model model
Within a week ￿.￿￿*** ￿.￿6***￿ ￿.￿￿*** ￿.8￿***￿ ￿.￿￿*** ￿.6￿
N = ￿￿￿ (￿.￿￿ - ￿.￿8) (￿.￿￿-￿.￿￿) (￿.￿￿ - ￿.￿￿) (￿.￿￿-￿.￿￿) (￿.6￿ - ￿.8￿) (￿.￿￿-￿.￿￿)
Within ￿months ￿.￿6*** ￿.￿￿ ￿.8￿*** ￿.￿￿** ￿.￿￿ ￿.￿8
N = 8￿￿ (￿.￿￿ - ￿.￿￿) (￿.8￿-￿.￿￿) (￿.￿￿ - ￿.￿6) (￿.￿8-￿.￿8) (￿.￿￿ - ￿.￿8) (￿.￿￿-￿.￿￿)
￿months - ￿.￿￿* ￿.￿￿ ￿.￿￿ ￿.￿8 ￿.￿6 ￿.￿￿
￿ year (￿.￿￿ - ￿.￿￿) (￿.￿6-￿.￿￿) (￿.8￿ - ￿.6￿) (￿.8￿-￿.￿￿) (￿.￿8 - ￿.￿￿) (￿.￿￿-￿.￿￿)
N = ￿8￿




Male gender ￿.￿￿*** (￿.￿￿-￿.￿6) ￿.￿￿*** (￿.￿￿-￿.￿￿) ￿.￿￿ (￿.￿￿-￿.￿￿)
Lower completed ￿.￿￿*** (￿.￿￿-￿.￿8) ￿.￿8* (￿.￿￿-￿.6￿) -
education level
Conduct disorder ￿.￿8*** (￿.￿￿-￿.8￿) ￿.￿￿*** (￿.￿￿-￿.6￿) -
Lifetime weekly ￿.￿￿*** (￿.￿￿-6.￿6) ￿.86*** (￿.￿￿-￿.6￿) ￿.￿6*** (￿.8￿-6.￿￿)
tobacco use
Lifetime other 6.￿￿*** (￿.￿￿-￿.￿￿) ￿.￿￿*** (￿.￿6-￿.￿￿) ￿.￿￿*** (￿.￿￿-￿.￿￿)
drug use
Lifetime other ￿.￿￿*** (￿.￿6-￿.6￿) ￿.￿￿*** (￿.￿￿-￿.￿￿) ￿.￿￿*** (￿.￿￿-6.￿6)
drug dependence
Early initiation ￿.6￿*** (￿.￿6-￿.￿￿) ￿.￿￿*** (￿.￿￿-￿.￿￿) ￿.6￿* (￿.￿￿-￿.￿￿)
of cannabis (￿6)
*P￿.￿￿ **P￿.￿￿ ***P￿.￿￿￿
￿Identi￿ed as signi￿cantly different to other levels in post-hoc tests
All models have applied the Huber-White adjustment for family clustering
￿￿￿
￿.￿. THE EXTENT TO WHICH THE SPEED OF TRANSITION IS ATTRIBUTABLE TO
ADDITIVE GENETIC, SHARED ENVIRONMENTAL AND NON-SHARED ENVIRONMENTAL
EFFECTS
￿.￿ The Extent to Which the Speed of Transition
is Attributable to Additive Genetic, Shared
Environmental and Non-Shared Environmental
Effects
The next section of this chapter determines the extent to which the variance in




The sample for this analysis is formed of the twins (siblings in sample excluded)
who provided information on their progression to subsequent cannabis use (see
Figure ￿.￿). The complete sample for the twin analysis included 8￿￿ MZ and ￿￿￿￿
DZ twins.




Independent and Dependent Variables
Speed of Transition to Subsequent Cannabis Use
As outlined above, those who had reported using cannabis at least once in their
lives were asked how long after their ￿rst use did their second use of cannabis
occur, and continuous datawere not available. The variablewas coded as ￿ discrete
groups, and the twin-only group numbers were: within ￿ week N = ￿￿￿ (￿￿.￿%),
within ￿ months (but not including those who transitioned within ￿ week) N = ￿￿6
(￿￿.￿%), between ￿months – ￿￿months N = ￿￿￿ (￿￿.￿%), more than ￿ year later N
= ￿￿￿ (￿￿.￿%) (with those who had reported not trying cannabis for a second time
excluded from the analysis, N = ￿￿￿). These ￿gures are comparable to the group
numbers for the complete sample (see outline above, Section ￿.￿.￿).
Analysis Plan
Twin modelling was used to assess the extent to which variation in the speed of
transition was attributable to additive genetic and environmental factors. Analyses
were conducted using OpenMX (Boker et al., ￿￿￿￿) for the statistical software R (R
Core Team, ￿￿￿￿). A full description of twin modelling methodology is provided in
Chapter ￿, section ￿.￿.￿.
As there were low numbers of concordant twins, univariate analyses used raw
ordinal data and full-information maximum-likelihood (FIML) estimation, which
utilises data from twin pairs where data from a co-twin is unavailable. Model ￿tting
was conducted using a step-wise approach. A liability threshold model estimating
co-twin correlations was ￿tted to the data set and used to test assumptions
regarding the equality of thresholds within and between MZ and DZ twin groups.
Next, a univariate variance components model including adjustment for sex
was ￿tted, partitioning the variance attributable to additive genetic (A), shared
environmental (C), and unique environmental (E) factors (Figure ￿.6). Difference in
model ￿t was assessed via the likelihood-ratio 2 test and examination of the Akaike
Information Criterion (AIC) (a description of these tests of model ￿t is provided in
Chapter ￿, Section ￿.￿.￿).
￿￿￿
￿.￿.￿ Results
Figure ￿.6: Classic twin model to examine the extent to which speed of transition to
subsequent use is attributable to additive genetic and environmental factors
￿.￿.￿ Results
Additive Genetic and Environmental Factors Contributing to the Variance in Speed
of Transition to Subsequent Cannabis Use
In order to ￿nd the most parsimonious twin model, birth order and zygosity were
equated across groups, and the model ￿t compared against a saturated model
whereby all parameters were freely estimated.
There was a ￿￿.86 increase in -￿LL from the saturated model to the model
with equated parameters. This difference in ￿t was not found to be statistically
signi￿cant (P = ￿.￿￿), and the model with equated parameters was accepted
as the most parsimonious (see Table ￿.￿). For the model with equated
thresholds, tetrachoric correlations were very similar between MZ and DZ twin
pairs. Correlation was ￿.￿￿ for MZ twins, and ￿.￿￿ for DZ twins.
The estimate for additive genetic in￿uences for the full model was small (￿.￿￿￿,
￿￿%CI 5.80 ⇥ 10 8 – ￿.￿￿), and could be dropped from the model without a
signi￿cant loss of ￿t (P = ￿) (see Table ￿.￿). A model specifying only environmental
in￿uences (C and E) provided the best ￿t, with moderate shared environmental
in￿uences (￿.￿￿, ￿￿%CI ￿.￿￿ – ￿.￿￿) and large unique environmental in￿uences
(￿.￿￿, ￿￿%CI ￿.66 – ￿.8￿) on the variation in speed of this transition (see Table ￿.￿).
￿￿￿
￿.￿. DISCUSSION
Table ￿.￿: Fit Indices and Tetrachoric Correlations for the Saturated Model and Equated
Threshold Models of ATR Twins who Progressed to Subsequent Cannabis Use (N=￿￿6￿)
Parameters Correlations -￿LL DF AIC   -￿LL   DF P value
MZ DZ
Saturated model ￿￿ ￿.￿￿ ￿.￿￿ ￿￿6￿.￿￿ ￿￿￿￿ ￿￿￿￿.￿￿ - - -
Equate twin ￿/twin ￿ ￿￿ ￿.￿6 ￿.￿￿ ￿￿66.￿￿ ￿￿￿8 ￿￿￿￿.￿￿ ￿.￿￿ ￿ ￿.￿￿
thresholds within MZ group
Equate twin ￿/twin ￿ ￿￿ ￿.￿￿ ￿.￿￿ ￿￿6￿.￿6 ￿￿￿8 ￿￿￿￿.￿6 ￿.￿￿ ￿ ￿.￿￿
thresholds within DZ group
Equate thresholds across ￿ ￿.￿￿ ￿.￿￿ ￿￿￿6.￿8 ￿￿6￿ ￿￿￿8.￿8 ￿￿.86 ￿ ￿.￿￿
MZ and DZ groups
DF = degrees of freedom; AIC = Akaike Information Criterion; -￿LL = -￿ log-likelihood.
Table ￿.￿: ACE Model Fitting Results And Variance Components Point Estimates With
￿￿% Con￿dence Intervals For Speed Of Transition From Initiation To Subsequent Use Of
Cannabis in ATR Twins (N=￿￿6￿)
Model Proportion of Variance Model Fit Statistics
A C E -￿LL DF AIC   -￿LL   DF P value
(￿￿% CI) (￿￿% CI) (￿￿% CI)
ACE Model ￿.￿￿￿￿ ￿.￿￿ ￿.￿￿ ￿￿68.￿6 ￿￿6￿ ￿￿￿￿.￿6 - - -
(5.80⇥ 10 8 – (2.77⇥ 10 10 – (￿.6￿ – ￿.8￿)
￿.￿￿) ￿.￿￿)
CE Model - ￿.￿￿ ￿.￿￿ ￿￿68.￿6 ￿￿6￿ ￿￿￿￿.￿6 ￿ ￿ ￿
- (￿.￿￿ – ￿.￿￿) (￿.66 – ￿.8￿)
DF = degrees of freedom; AIC = Akaike Information Criterion; -￿LL = -￿ log-likelihood.
Model adjusted for sex
Results ￿ Summary
No additive genetic effect was observed to contribute to the variance in the speed




A signi￿cant association was observed between speed of transition from initiation
to subsequent use of cannabis and later likelihood of daily cannabis use and
cannabis abuse and/or dependence. This association remained after controlling
for potential confounders, and for early initiation of cannabis use. Those who
experienced the fastest transition to subsequent use of cannabis were more than
￿￿￿
￿.￿.￿ Relationship to Cannabis Outcomes
twice as likely to progress to daily cannabis use and cannabis abuse and/or
dependence.
The unique environment accounted for most (￿.￿￿) of the variance in the speed
of transition from initiation of cannabis to subsequent use, and additive genetic
effects could be dropped from the model without signi￿cantly affecting model ￿t.
Given the absence of prior research on this transition these ￿ndings provide an
original and intriguing contribution to the literature.
￿.￿.￿ Relationship to Cannabis Outcomes
Previous research has found earlier initiation of cannabis use is associated with
later problematic drug use/dependence (see Chapter ￿), and by studying the novel
transition from initiation to subsequent use this chapter has established that the
association between speed of transition and later outcomes remains regardless of
whether cannabis was initiated￿6 years. This indicates that this transitionmay be
useful to focus on for targeting intervention against problematic cannabis use, with
the possibility of identifying a wider range of at-risk individuals than interventions
focussing on early cannabis initiators.
￿.￿.￿ Additive Genetic Contribution to Speed of Transition
Additive genetic effects had little observed in￿uence on variation in the speed of
this transition, which is in contrast to ￿ndings of moderate heritability for other
transitions (Kendler et al., ￿￿￿￿a; Lynskey et al., ￿￿￿￿; Sartor et al., ￿￿￿￿a; Verweij
et al., ￿￿￿￿). Speed of other speci￿c transitions has been found to be moderately
heritable, with ￿￿% (￿￿% CI ￿.￿￿–￿.￿6) of the rate of transition from non-use to
initiation attributed to additive genetic effects and similar ￿ndings observed for
the rate of transition from initiation to ￿rst dependence symptom (￿6%, ￿￿% CI
￿.￿￿–￿.￿￿) and ￿rst dependence symptom to the development of dependence
(￿￿%, ￿￿% CI ￿.￿￿–￿.￿8) (Sartor et al., ￿￿￿8). In contrast, the present ￿ndings
suggest the speed of transition from initiation to subsequent use of cannabis is
predominately in￿uenced by unique environmental factors.
The absence of observed variation attributable to additive genetic factors will
require replication in future studies with a genetically informative design, as there
￿￿6
￿.￿.￿ Limitations
is potential for it to result from low power within the sample. Alternatively, the E
parameter in twinmodelling can represent measurement error (Plomin et al., ￿￿￿￿).
As stated this is a novel transitionmeasured through retrospective report, and other
methods of measuring this transition would need to be applied in order to fully
remove error as an explanation. However, a cautious interpretation of these results
is that the speed of this transition acts as a proxy for an individual being within an
environment in which drug access is easy (not measured within these data), and
which facilitates progression to problematic cannabis use.
￿.￿.￿ Limitations
Firstly, these data were based on retrospective self-report, which introduces
the possibility of recall bias. Secondly, the measure of transition speed was
comprised of relatively wide categories. Thirdly, there were a low number of
twin pairs concordant for speed of transition from initiation to subsequent use,
which was overcome through the use of raw data for the twin modelling. Ordinal
analysis can result in lower power, and may result in an underestimate of the
true liability correlation (Neale and Cardon, ￿￿￿￿). Fourthly, the study lacked
temporal information on a number of covariates within the analysis, and including
these variables in the analysis represents a cautious approach to adjustment
for confounding variables, which may lead to under-estimation of the effect of
this transition. Fifthly, whilst likely representative of base population (of Health
and Welfare, ￿￿￿￿) the prevalence of lifetime cannabis use in this sample is
relatively high which may limit generalizability.
￿.￿.￿ Implications
The faster transition from initiation to subsequent use is unlikely to have a
traditional causal relationship with cannabis dependence. The association likely
re￿ects a combination of individual and contextual factors, such as availability, that
surround the rapid escalation. If replicated in prospective research, these ￿ndings
may have practical utility for clinical practice, with the prospect of translation into
a clinically useful marker with which to identify individuals likely to bene￿t from
intervention. These ￿ndings have also highlighted the utility of studying different
￿￿￿
￿.￿.￿ Implications




Through the Looking Glass: Exploring
Transitions in Heroin Use
6.￿ Introduction
Throughout this thesis, analyses have focussed on transitions in cannabis use.
What is unknown is the extent to which these ￿ndings will also apply to other drugs.
Exploring similar hypotheses in a different drug class provides a test of whether
the relationship between early transitions and later drug use outcomesmay extend
beyond cannabis use.
Heroin has been found to contribute the highest proportion of the illicit drug
contribution to Disability Adjusted Life Years (DALYs) (Degenhardt et al., ￿￿￿￿),
and consequently is a drug of global health concern. However, the base rate of
heroin dependence in the general population is low, and in the twin sample only one
participant reported opiate dependence. Consequently general population samples
are not suitable for exploring this outcome, necessitating the use of samples
selected for their heroin use.
Data from a purposively selected community sample and a treatment-seeking
sample are analysed in this chapter. Given that those in treatment seeking
populations will predominately be already experiencing dependence, the sample
will lack variation in dependence status which precludes this outcome from
￿￿￿
6.￿. INTRODUCTION
analysis. Therefore, outcomes explored in relation to heroin use will be dependence
severity at treatment seeking, time to treatment seeking, overdose, heavy heroin
use, and injecting behaviour.
In addition to testing for ￿ndings similar to those observed for cannabis use,
a unique feature of heroin use within the UK is that it allows for exploration of an
additional hypothesis: does route of administration in￿uence speed of transitions
between stages of drug use? Heroin can be delivered through multiple routes of
administration, broadly split into injecting or non-injecting (Bridge, ￿￿￿￿). Injection
introduces heroin straight into the bloodstream, provides a near instant effect
and high bioavailability (Tas and Day, ￿￿￿6) which makes it the most ef￿cient
route of drug administration. In contrast, chasing (inhaling vapour from heated
heroin) and snorting (nasal administration) heroin produce slower absorption,
have lower bioavailability and a decreased onset of effect (Tas and Day, ￿￿￿6).
Injecting increases the individual’s risk of blood borne viruses (Lawrinson et al.,
￿￿￿8), dependence (Strang et al., ￿￿￿8), and unintentional overdose (Martins et al.,
￿￿￿￿). Indeed, overdose is the leading cause of mortality amongst heroin users
(Degenhardt et al., ￿￿￿￿). Additionally, amongst those who have been injecting
heroin for a long time there is the risk of injecting into the groin (found by Darke
et al. (￿￿￿￿) to be implemented after 6-￿￿ years of injecting heroin use), which is an
injecting site associated with physical harms (Hillstrom et al., ￿￿￿￿; Maliphant and
Scott, ￿￿￿￿).
This chapter utilizes two different data sets to study the effect of initial
heroin administration routes of ￿) injecting, ￿) chasing and ￿) snorting on speed
of transition to daily heroin use, and the relationship between early transitions
and the outcomes of dependence severity, time to treatment seeking, overdose,
groin/neck injecting, and heavy heroin use. Prior to ￿￿8￿, the predominant route
of administration among London based heroin users was injecting, but after ￿￿8￿
chasing becamemore prevalent as amethod of administration (Strang et al., ￿￿￿￿).
Thus at the time of the study the population sampled contained individuals who
had initiated their heroin use by both major routes. By utilising a population with
variation in the route of heroin administration, and a population who have entered
treatment for heroin dependence, speci￿c testing of the relationship between Initial
Heroin Administration Route (IAR) and transition speed, and transition speed and
later outcomes, is feasible.
￿￿￿
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6.￿ Aims and Hypotheses
Aim ￿
Examine whether there is a relationship between the speed of early transitions
in heroin use and time to treatment seeking, dependence severity at treatment
seeking, overdose, groin/neck injecting, and heavy heroin use.
Hypothesis ￿
Those who experience faster transitions in their early use of heroin will have shorter
time to treatment seeking, greater dependence severity at treatment seeking,
increased likelihood of overdose, more likely to be groin/neck injecting and have
experienced heavier heroin use than those who experience slower early transitions.
Hypothesis ￿
The association between faster transitions in their early use of heroin and time to
treatment seeking, dependence severity at treatment seeking, overdose, groin/neck
injecting, and heavy heroin use will remain after adjustment for demographic
variables.
Aim ￿
Examine whether route of heroin administration is associated with speed of
transition to daily heroin use.
Hypothesis ￿
Those who initiate heroin use through injection will have a more rapid progression
to daily heroin use.
Hypothesis ￿
The association between injection of heroin and faster progression to daily heroin
use will remain after adjustment for demographic variables.
See Figure 6.￿ for an outline of how the hypotheses of this chapter are addressed
through two different data sets.
6.￿ Is Speed of Early Transitions in Heroin Use
Associated with Later Heroin Use Outcomes
The ￿rst part of this chapter explores the association between speed of early
transitions in heroin use and later outcomes associated with heroin use. Given
￿￿￿
6.￿.￿Methods
Figure 6.￿: Dataset and analyses used to address the aims of this chapter (SLAM: South













that these analyses are conducted in a treatment-seeking sample, the outcomes
(dependence severity at treatment seeking, time to treatment seeking, overdose,




This sample includes ￿￿ participants who were in Opiate Substitution Treatment
(OST) at the time of interview, recruited from South London and Maudsley
Centres for Drug and Alcohol Treatment (see Chapter ￿ Section ￿.￿ for full study
description).
Independent and Dependent Variables
See Chapter ￿, Section ￿.￿ for variable derivation. The transition speed variables
included in the analysis were:
￿. early opportunity to use heroin (early=￿￿);
￿. time from opportunity to initiation of use;
￿. time from initiation to second use of heroin.
￿￿￿
6.￿.￿ Results
See Chapter ￿ Section ￿.￿ for full details of variable derivation.
The outcomes in the analysis were:
￿. time to treatment seeking;
￿. dependence severity at treatment entry (measured through the SDS);
￿. overdose;
￿. injecting into the groin/neck;
￿. heavy heroin use.
As the outcomes of SDS score at treatment seeking and time from problem use
to treatment seeking were not normally distributed (See Chapter ￿ for measure
de￿nition and histogram), and would thus breach the assumptions of linear
regression analyses, these potentially continuous outcomeswere coded into binary
variables and analysed accordingly.
To do so, (approximate) tertiles of the continuous variables were created. For
SDS this provided a cut-off of a score of ￿￿ and over for high SDS score (￿￿.￿%,
N=￿￿), and for time to treatment seeking those who sought treatment ￿ or more
years after the onset of their ￿rst problem were coded as having slow time to
treatment seeking (￿￿.8%, N = ￿8).
Analysis plan
Logistic Regression
Logistic regression was used to test whether transition speed was signi￿cantly
associated with the later drug use outcomes. Univariate associations that were
identi￿ed as signi￿cant (P￿.￿￿) were then entered into a multivariate logistic
model.
Covariates in Regression Model
The regression model was adjusted for gender, age and ethnicity. See Chapter
￿ Section ￿.￿ for a full outline of these covariates.
6.￿.￿ Results
Demographic Characteristics of the Sample
Most of the sample weremale (￿￿%), White British (￿6%), and reported both opiates
and crack as their primary drug(s) used (￿￿%) (see Table 6.￿ for full characteristics).
￿￿￿
6.￿.￿ Results
Data on IAR was not collected in this sample.
Table 6.￿: Characteristics of the SLAM sample (N=￿￿)
Characteristic N (%)
Gender Male 6￿ (￿￿)
Female ￿￿ (￿￿)
Age ￿￿ - ￿￿ ￿
￿￿-￿￿ ￿ (￿.￿)
￿￿ - ￿￿ ￿￿ (￿￿.￿)
￿￿-￿￿ ￿￿ (￿￿.8)
￿￿ - ￿￿ ￿￿ (￿￿.￿)
6￿+ ￿ (￿.￿)
Ethnicity White British ￿￿ (￿6)
Non-British White ￿￿ (￿￿)
BME ￿￿ (￿￿)
Primary drug used Opiates only ￿￿ (￿￿)
Opiates and ￿￿ (￿￿)
Crack Cocaine
Other ￿ (￿￿)
Association between Speed of Early Transitions in Heroin Use and Later Time to
Treatment-Seeking, Dependence Severity and Heroin Use Outcomes
Those who experienced early opportunity to use heroin (age ￿￿ or under) were
more than three times as likely to report overdose (OR ￿.￿￿, ￿￿% CI ￿.￿￿ - 8.8￿)
and injecting into the groin/neck (OR ￿.8￿, ￿￿% CI ￿.￿￿ - ￿.￿￿).
Signi￿cant associations were not observed between speed of transition from
opportunity to initiation, or from initiation to subsequent use, and later heroin use
outcomes. However, there was a moderately large association between speed of
transition to subsequent heroin use and overdose (OR ￿.￿￿, ￿￿% CI ￿.￿￿ - ￿.8￿) and
groin/neck injecting (OR ￿.￿￿, ￿￿% CI ￿.￿￿ - ￿.￿￿). The lower con￿dence intervals
on these results include ￿.￿, but only by a small amount. This may indicate that the
current sample did not have suf￿cient statistical power to detect these effects (see
Table 6.￿). Power for this sample was calculated to detect an effect size of ￿ or
more (see Chapter ￿ Section ￿.￿), and the effect size observed for the association






























































































































































































































































































































































































































































































Multivariate Analysis of the Association between the Predictors Early Opportunity
to Use Heroin and Early Initiation of Heroin Use and the Outcomes of Experiencing
Overdose and Injecting into the Groin/Neck
Analyses were adjusted for the demographic variables of gender, age and ethnicity.
After adjustment, those who reported early opportunity to use heroin were more
than three times as likely to have experienced overdose (OR ￿.￿8 ￿￿%CI ￿.￿￿ - ￿.￿￿)
and injecting into the groin/neck (OR ￿.8￿ ￿￿% CI ￿.￿￿ - ￿￿.￿8) (see Table 6.￿.￿).
Table 6.￿: Odds ratios (￿￿% Con￿dence intervals) for multivariate analyses of relationship
between early opportunity to use heroin and later overdose and groin/neck injecting in the
SLAM sample (N=￿￿)
Outcomes
Age of Opportunity Overdose Groin/Neck Injecting
to use Heroin N=￿￿ N=￿￿
Odds Ratio Odds Ratio
(￿￿% Con￿dence Interval) (￿￿% Con￿dence Interval)
Adjusted model Adjusted model
Early opportunity ￿.￿8*** ￿.8￿*
N=￿￿ (￿.￿￿ - ￿.￿￿) (￿.￿￿ - ￿￿.￿8)
Later opportunity ￿.￿ ￿.￿
Model covariates
Male gender ￿.￿￿*** ￿.￿￿***
(￿.￿￿ - ￿.￿￿) (￿.￿￿ - ￿.￿￿)
Ethnicity
White British ￿.￿ ￿.￿
Other White ￿.8￿ ￿.￿￿
(￿.6￿ - ￿.￿￿) (￿.￿￿ - ￿.￿￿)
BME ￿.￿￿ ￿.66
(￿.￿￿ - ￿.￿￿) (￿.￿￿ - ￿.￿￿)
Age at interview ￿.￿￿ ￿.￿￿
(￿.￿6 - ￿.￿￿) (￿.86 - ￿.￿￿)
*P ￿.￿￿ **P￿.￿￿ ***P ￿.￿￿￿.
All models have applied the Huber-White adjustment for clinic clustering
As converting continuous variables to categorical can be a source of bias in
analyses (Altman, ￿￿￿￿), sensitivity analyses were conducted for early opportunity
to use heroin, speed of transition from opportunity to initiation, and speed of
transition to subsequent use of heroin. The analyses of different cut-off points
indicated that results were not affected by the choice of age cut-off for transition
speed variables (see Appendix ￿).
￿￿6
6.￿. THE RELATIONSHIP BETWEEN ROUTE OF ADMINISTRATION AND SPEED OF
TRANSITION
Results Summary ￿
Those who experience faster transition to heroin use opportunity are at increased
likelihood of experiencing later overdose and groin/neck injecting than those who
have later opportunity to use heroin. This association remained after adjustment
for demographic variables. There was no association between speed of early
transition and SDS score at treatment entry, time to treatment seeking, or heavy
heroin use. There were no associations between the speed of transition from
opportunity to initiation, or from initiation to subsequent use of heroin, and later
heroin use outcomes; however, the results indicate this may result from a lack of
power.
6.￿ The Relationship Between Route of Administration
and Speed of Transition
Route of heroin administration has been identi￿ed as a consideration in heroin
transitions (Chapter ￿). The analyses in this section of the chapter aim to examine
the association between route of administration and speed of transition.
6.￿.￿ Methods
Sample
This sample was included ￿￿8 participants who had used heroin in the month prior
to interview. Participants were recruited in the London area in ￿￿￿￿ (see Chapter ￿
Section ￿.￿ for full study description).
Independent and Dependent Variables
The independent variable in these analyseswas IAR. Dummyvariableswere created
to for IAR, and these were used to test differences between IAR injecting and the
other IARs, and between IAR chasing and the other IARs. The dependent variable
was a categorical measure of time from initiation to daily heroin use. See Chapter




Initial tests of the association between IAR and speed of transition to daily heroin
use were conducted using  2.
Testing the Suitability of an Ordered Logistic Model
The dependent variable of time to daily heroin use was a four level ordinal variable
(￿-￿ weeks, ￿month – ￿￿months, ￿-￿ years, and ￿+ years), which necessitated the
use of an ordered logisticmodel. However, under the proportional odds assumption
the relationshipwith the independent variablemust be the same for each level of the
dependent. This can be tested using likelihood ratio tests and the Brant test, with a
signi￿cant result (P￿.￿￿) indicating assumptions are violated (Williams, ￿￿￿6). In
the present data, proportionality of odds assumption was violated for the dummy
variable of IAR injecting (Likelihood ratio test P=￿.￿￿, Brant test P=￿.￿￿), the dummy
variable of IAR chasing (Likelihood ratio test P=￿.￿￿, Brant test P=￿.￿￿), and year
of heroin onset (Likelihood ratio test P=￿.￿￿, Brant test P=￿.￿￿￿).
The Generalised Ordered Logistic Model - An Alternative to the Ordered
Logistic Model
When the proportional odds assumption is violated, a generalised ordered logistic
model can be used (Williams, ￿￿￿6). This allows variation in the relationship
between the dependent variable and each level of the independent variable. This
analysis producesmultiple coef￿cients. The levels (L) of the dependent variable are
analysed equivalent to a series of binary logistic regressions where the categories
(C) of the dependent variable are combined. When C = ￿ (as in the present analysis),
for L = ￿ category ￿ is contrasted with categories ￿, ￿, and ￿; for L = ￿ the contrast is
between categories ￿ and ￿ versus ￿ and ￿; and for L = ￿, it is categories ￿, ￿, and ￿
versus category ￿. The levels of the dependent variable were ￿ to ￿weeks, ￿month
to within a year, ￿ year, and more than ￿ years. Coef￿cients represent the likelihood
of those who inject heroin being in a more rapid transition group. Signi￿cance was
determined at a level of P￿.￿￿.
Covariates in Regression Model
The regression model was adjusted for year of initiation (to account for cohort
effects ￿rst reported by Strang et al. (￿￿￿￿), resulting from a rise in smoking of
heroin in the UK around ￿￿8￿), gender, ethnicity, regular drug use prior to heroin
initiation, and current treatment status (to account for sampling effects). See




Demographic Characteristics of the Sample
The majority of the sample were male (6￿.￿%), white ethnicity (￿￿.￿%) and initiated
their use of heroin through chasing (￿8.￿%) (see Table 6.￿). There were signi￿cant
differences between IAR groups for year of initiation of heroin use (P￿.￿￿￿), with
the majority of the sample who initiated heroin use after ￿￿8￿ using chasing for
their IAR (￿￿.￿% after ￿￿8￿ compared to ￿￿.￿% of those initiating use before ￿￿8￿).
Prior to ￿￿8￿, a greater proportion of the sample’s IAR was through injecting (￿￿.￿%
after ￿￿8￿ compared to ￿￿.￿%of those initiating use before ￿￿8￿) or snorting (￿￿.￿%
after ￿￿8￿ compared to ￿￿.8% of those initiating use before ￿￿8￿).
Table 6.￿: Characteristics of the ￿￿￿￿s Drug Transitions Study sample (N=￿￿8)
Characteristic N (%)
Gender Male ￿￿6 (6￿.￿)
Female ￿￿￿ (￿8.￿)




Initial route of Chasing ￿￿￿ (￿8.￿)
Heroin administration Injecting ￿￿6 (￿6.8)
(IAR) Snorting ￿8 (￿￿.￿)
Time from initiation ￿ to ￿ weeks 6￿ (￿8.￿)
to daily heroin use ￿month to ￿￿months ￿￿￿ (￿￿.￿)
￿ -￿ years 6￿ (￿￿.￿)
￿ or more years ￿￿ (￿￿.￿)
Year of initiation ￿￿￿￿ or earlier ￿￿￿ (￿￿.￿)
￿￿8￿ or later ￿￿8 (6￿.￿)
Association Between IAR and Speed of Transitions to Daily Use
There were signi￿cant differences between the IAR groups in the number of
participants who did not progress to daily use (see Table 6.￿): while only ￿ individual
(￿.￿%)who initiated injecting did not progress to daily heroin use, 8.6% of those who
initiated through snorting and ￿￿.￿% of those who initiated through chasing did not
progress to daily heroin use. Of those who did progress to daily use, differences in
speed of transition to daily use between IAR injecting and the other two IAR groups
are shown in Figure 6.￿.
￿￿￿
6.￿.￿ Results
Figure 6.￿: Speed of Transition Amongst Those in the ￿￿￿￿s Drug Transition Study who
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Table 6.￿ demonstrates these differences were signi￿cant. Transition to daily
use within ￿weeks of initiation was reported by ￿￿.￿% of those who initiated heroin
use via injection, compared with only ￿￿.8% of those who initiated via chasing and
￿.￿% of those who initiated via snorting.
Testing for proportionality of odds demonstrated that the assumption was
violated for IAR and for year of heroin onset. The proportional odds assumption
was relaxed for these variables using a generalised ordered logistic model.
￿￿￿
6.￿.￿ Results
Table 6.￿: Association between route of initial administration and speed of transition to
daily heroin use in the ￿￿￿￿s Drug Transition Study (N=￿￿8)
Progression to Initial Route of Heroin Administration (IAR)
Daily Heroin Use IAR injecting IAR chasing IAR snorting
N = ￿￿6 N = ￿￿￿ N = ￿8
N (%) N (%) N(%) P value ( 2)
Time to daily heroin use
￿ to ￿ weeks ￿￿ (￿￿.￿) ￿￿ (￿￿.8) ￿ (￿.￿) ￿.￿￿￿
N=6￿
￿month to ￿￿months ￿￿ (￿￿.6) ￿￿ (￿￿.￿) ￿￿ (￿￿.￿)
N=￿￿￿
￿ -￿ years (￿.￿) ￿￿ ￿￿ (￿￿.￿) ￿￿ (￿￿.￿)
N=6￿
￿ or more years ￿￿ (￿￿.8) ￿￿ (￿8.￿) ￿￿ (￿8.￿)
N=￿￿
Did not progress to ￿ (￿.￿) ￿8 (￿￿.￿) ￿ (8.6) ￿.￿￿￿
daily heroin use
Multivariate Analysis of the Association between IAR and Speed of Transitions to
Weekly and Daily Use
After adjustment, participants whose IAR was injecting were found to bemore than
four times as likely (OR ￿.￿￿, ￿￿% CI ￿.￿￿ – ￿6.￿) to progress to daily use within
￿-￿ weeks of initiation compared to other IARs (see Table 6.￿.￿). There were no
signi￿cant differences in transition speed between the non-injecting IARs. None









































































































































































































































































































































































































































































































































Initiation of heroin use through injection was associated with a more rapid
progression to daily heroin use; an association that remained after adjustment for
demographic variables.
6.￿ Discussion
These analyses con￿rmed that, to some extent, the relationship between speed of
transition and later drug use outcomes that was observed for cannabis also applies
for heroin. Thosewho reported early opportunity to use heroinweremore than three
times as likely to experience overdose and to report injecting into the groin/neck.
Additionally, analyses in this chapter have identi￿ed that IAR is associated with
speed of transition in heroin use. Participants whose IAR was through injection
(compared to those who initiated through chasing or snorting) weremore than four
times as likely to use daily within a month of initiation.
6.￿.￿ Speed of Early Transitions in Heroin Use and Later Heroin Use
Outcomes
Contrary to hypotheses, there was no association between early transitions in
heroin use and dependence severity, time to treatment seeking, or heavy heroin
use. Findings amongst alcohol dependent populations have previously identi￿ed
associations between younger age of dependence onset and increased severity of
alcohol problems (measured in number of symptoms, and length of dependence
episodes), as well as longer time to treatment (Hingson et al., ￿￿￿6). The null
￿ndings in the present thesis have plausible explanations. For dependence severity,
there may be issues with the measure used. The SDS has not been validated as a
retrospective measure, but was applied retrospectively in the thesis data collection
in order to assess dependence severity at treatment entry. The ￿ndings may
also result from low variation in speed of early transitions amongst the treatment
population. For the measure of speed of transition to subsequent use, over ￿￿%
of the population reported a very rapid transition of within a week. This is in
contrast to the observations for cannabis use in the general population ATR sample,
￿￿￿
6.￿.￿ The Relationship Between Route of Administration and Speed of Transition
whereby only ￿￿.8% reported such a rapid transition (see Chapter ￿, Section ￿.￿).
The reduced variation in speed of early transitions in this sample may re￿ect
previous ￿ndings that transitions are faster in heroin use compared to other drugs
(O’Keefe et al., ￿￿￿6), or may result from the use of a population solely comprised
of participants who have experienced problem use. Alternatively, it may be that
severity of dependence is simply not associated with early transitions, and is a
function of factors such as duration of heroin use (Barrio et al., ￿￿￿￿).
Earlier opportunity to use heroin was associated with increased likelihood of
both overdose and injecting into the groin/neck. This is similar to ￿ndings in the
literature that younger age of heroin initiation is associated with overdose (Lynskey
and Hall, ￿￿￿8); an association that remained after controlling for duration of heroin
use, whichwas not possible in the present analyses (despite participants beingOST
it is not certain whether or not they were using heroin at the time of interview). The
relationship between early opportunity to use heroin and increased likelihood of
groin/neck injecting has not previously been observed.
Given the cross-sectional nature of the data no conclusions about causality can
be drawn. However, it is plausible that those who have earlier opportunity to use
heroin are exposed to environmental risk factors that increase their likelihood of
later experiencing overdose. The heroin using population is one that is already at
risk of a range of harms, with overdose the leading cause of mortality (Degenhardt
et al., ￿￿￿￿). These ￿ndings relating to age of opportunity have potential clinical
relevance for identifying, and providing harm reduction interventions to, groupswho
may be at especially high risk of overdose and chronic heroin use.
6.￿.￿ The Relationship Between Route of Administration and Speed
of Transition
Participants who initiated their heroin use through injecting progressedmuchmore
quickly to daily heroin use than those using other methods. Injection of similar
doses produces a high concentration of the drug in the bloodstream (Rang and
Dale, ￿￿￿6), and has higher bioavailability than smoking administration (Tas and
Day, ￿￿￿6). Injection is already known to be associated with greater likelihood of
progressing to dependence as a result of the increased ef￿ciency of drug delivery
(Strang et al., ￿￿￿8), and it is plausible that a similar mechanism is underlying the
￿￿￿
6.￿.￿ Limitations
faster transition to daily use amongst participants whose IAR is through injection.
Non-injecting administration has previously been shown to minimise harms,
reducing likelihood of developing dependence (Strang et al., ￿￿￿8), overdosing
(Tas and Day, ￿￿￿6) and contracting blood-borne viruses (Strang et al., ￿￿￿8).
The increased latency to daily use amongst participants whose IAR is chasing or
snorting ￿ndings support the harm-reduction case for encouraging non-injecting
routes of administration (Bridge, ￿￿￿￿; Hunt et al., ￿￿￿8; Pizzey and Hunt, ￿￿￿8;
Strang, ￿￿88).
6.￿.￿ Limitations
There are limitations of this study that must be considered when interpreting the
results. Data were collected on only a small number of potential covariates, and
consequently detailed analysis of what may underlie the relationship between age
of opportunity to use heroin and overdose cannot be conducted. The data were
collected through self-report, which is unlikely to bias results in samples of injecting
drug users (Darke, ￿￿￿8). However, the use of retrospective self-report introduces
the potential for recall bias to affect the results. The present ￿ndings would need
to be replicated in prospective research. Additionally, these ￿ndings would bene￿t
from replication within a new cohort to ensure that the results are not an artefact
of the drug market at the time of data collection (Horyniak et al., ￿￿￿￿).
6.￿.￿ Implications
The ￿ndings support the case for encouraging non-injection as a route of
administration (Bridge, ￿￿￿￿; Wodak and McLeod, ￿￿￿8) as it was associated with
slower progression to daily injecting. Further, the faster transition to daily use
through injection has implications for drug treatment provision. The need for drug
services to attract those whose treatment needs are less immediate, in order to
encourage those already injecting to switch to non-injecting, has previously been
suggested in the literature (Strang, ￿￿88). Focus may bene￿t from shifting to target
thosewho have recently begun injecting, to provide encouragement to non-injecting
administration (or indeed, heroin abstinence) (Pizzey and Hunt, ￿￿￿8). However,
intervening at the treatment service level could never be expected to reach the
￿￿￿
6.￿.￿ Implications
complete population of individuals who have recently initiated heroin use; this
requires changes at the policy level. One idea that has previously been suggested
is that of altering policing to penalise the supply of injectable heroin whilst being
more tolerant of the supply of heroin that could only be smoked (Strang and King,
￿￿￿￿). The ￿ndings of this study suggest that doing so has the potential to limit the
harms of heroin use and reduce the prevalence of dependence by not only reducing
the number of people who use heroin who progress to daily use, but also to allow
a greater window for treatment services to reach people who use heroin before a




￿.￿ Summary of Findings
The analyses presented in this thesis have demonstrated that addiction is a multi-
stage process, and that studying transitions in drug use contributes novel insights
into the aetiology and developmental course of SUDs. Consistency has been
identi￿ed in not only the individual and external factors associated with multiple
stages of drug use, but also the additive genetic in￿uences acting on stage
progression. Additionally, speed of early transitions has emerged as a potential
marker of later problematic drug use. Taken together, these results provide answers
to a number of important questions relating to the course of SUDs.
￿.￿.￿ Is Transition Speed Associated with Later Likelihood of SUDs?
I explored the relationship between the speed of early cannabis transitions and
later cannabis daily use, abuse and/or dependence, and treatment using a general
population sample. Age of onset of opportunity to use cannabis at age ￿￿
(relative to those who had opportunity age ￿8 or over) was associated with more
than twice the likelihood of cannabis daily use, abuse and/or dependence, and
treatment seeking. Age of onset of opportunity to use cannabis at age ￿￿-￿6
(relative to those who had opportunity age ￿8 or over) was associated with almost
￿￿￿
￿.￿.￿What is the Pro￿le of Individual, Childhood, Mental Health And Other Drug Use Factors
Associated with Speed of Transition to Opportunity to Use and Dependence?
twice the likelihood of daily cannabis use, and twice the likelihood of cannabis
abuse and/or dependence. Age of opportunity age ￿￿ (relative to those who had
opportunity age ￿8 or over) was associated with increased likelihood of cannabis
abuse and/or dependence. Transition to subsequent use within a week of cannabis
initiation (relative to those whose transition was more than a year after initiation)
was associated with twice the likelihood of cannabis daily use and abuse and/or
dependence. Transition to subsequent use within three months of cannabis
initiation (relative to those whose transition was more than a year after initiation)
was associated with increased likelihood of cannabis abuse and/or dependence.
￿.￿.￿ What is the Pro￿le of Individual, Childhood, Mental Health And
Other Drug Use Factors Associated with Speed of Transition
to Opportunity to Use and Dependence?
I investigated factors that in￿uence the speed of early transitions, and whether
the in￿uence of these factors is consistent across transition stages. Again, these
analyses used a general population sample for which data on individual, childhood,
mental health and other drug use factors were available. I found that although
some factors were consistently associated with the speed of transition through
different stages of drug use, others displayed unique associations with speci￿c
transitions. Conduct Disorder (CD), parental drug problems, weekly tobacco
use (preceding onset of stage) and male gender were consistently associated
with faster progression to opportunity to use cannabis, and from opportunity to
dependence. The results demonstrated that the unique in￿uences on speed of
transitions are proximal factors, such as
￿. parental con￿ict, childhood religious attendance, Childhood Sexual Abuse
(CSA) and parental alcohol problems increasing the rate of progression to
opportunity;
￿. other drug and depressive disorders increasing rate of progression to
cannabis dependence.
￿￿8
￿.￿.￿ Are Genetic In￿uences on Speed of Early Transitions Correlated with Genetic
In￿uences on Dependence?
￿.￿.￿ Are Genetic In￿uences on Speed of Early Transitions
Correlated with Genetic In￿uences on Dependence?
Leveraging the genetically-informative nature of the general population sample
used in previous analyses, I conducted a classical twin study in order to examine the
extent to which the speed of early stage transitions in cannabis use are in￿uenced
by additive genetic and shared environmental in￿uences. This also allowed me
to explore the extent to which genetic and environmental in￿uences on these
transitions are unique or are correlated with those in￿uencing liability to cannabis
dependence. The study identi￿ed that additive genetic effects accounted for the
majority of the variance in the age of opportunity to use cannabis (66%) and
cannabis abuse and/or dependence (￿8%), and that these overlapped with the
genetic effects acting on the development of cannabis abuse and/or dependence
(￿￿%). However, there was no evidence that genetic factors in￿uenced liability to
the novel speci￿c transition from initiation to subsequent cannabis use.
￿.￿.￿ Is Speed of Transitions in Heroin Use Associated with
Outcomes Beyond Dependence, and Route of Administration?
In the ￿nal component of this thesis, I investigated drug transitions in a clinical,
rather than general population, sample. I explored the relationship between the
speed of early heroin transitions and later heroin dependence severity, overdose,
injecting behaviours and heavy heroin use. Given that injecting administration of
heroin is associated with worse health outcomes than non-injecting administration
(Strang et al., ￿￿￿8), the effect of Initial Heroin Administration Route (IAR) on speed
of transition was hypothesised to have a differential effect on speed of transition to
daily heroin use. I established that those who reported an earlier opportunity to use
heroinweremore than three times as likely to experience overdose and groin and/or
neck injecting, and that those who initiated their heroin use through injecting, rather
than snorting or chasing heroin, had a four-fold increase in speed of progression to
daily heroin use.
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￿.￿ The Value of Considering the Multi-Stage Nature of
Drug Use
As outlined in Chapter ￿, the development of SUDs is a multi-stage process in
which speci￿c transitions must occur. In this thesis I focussed on the early drug
use stages of opportunity to use and progression from initiation to subsequent
use in cannabis and heroin use. This included the transition from opportunity to
dependence for cannabis only, and the transition from initiation to daily use for
heroin only.
Studies of dependence commonly compare individualswho are drug dependent
against those who are not dependent, which leads to uncertainty about the stages
in the development of drug dependence at which speci￿c genetic or environmental
in￿uences are most prominent (Nelson et al., ￿￿￿￿). By applying a multi-stage
approach in this thesis, estimates of in￿uences on progression through the stages
of drug use were not con￿ated. Consequently, there were a number of unique
￿ndings that contribute to our understanding of SUDs and their aetiology.
Evidence from studies of tobacco and alcohol use has previously suggested
that, in their aggregate, genetic in￿uences are relatively weaker at earlier stages in
the development of drug dependence (see Lynskey et al. (￿￿￿￿) for review). In the
analyses presented in this thesis, the estimated heritability of age of opportunity
to use cannabis was ￿.66, and the estimated heritability of cannabis abuse and/or
dependence was ￿.￿8. This represents a strong contribution from additive genetic
effects to the variance in both opportunity to use and abuse and/or dependence,
and whilst the estimate for opportunity is smaller, the difference is not large.
However, my analyses of subsequent use of cannabis did not provide any evidence
for an additive genetic contribution to the variance of speed of this transition. The
results of this thesis have demonstrated variation in the extent to which genetic
effects in￿uence the early stages of drug use.
Considering opportunity to use cannabis and the development of cannabis
abuse and/or dependence as distinct stages of drug use allowed exploration of
the extent to which they were in￿uenced by shared genetic effects. Of these
genetic effects, ￿￿% were shared, and ￿6% of genetic effects on cannabis abuse
and/or dependence are unique from those acting on opportunity. These (potentially
surprising) ￿ndings will be discussed in greater detail later in this chapter. It
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has been speculated that early stages of drug use may be genetically in￿uenced
through personality traits such as novelty seeking (Laucht et al., ￿￿￿￿), which is
an example one of the many factors that may account for the overlap in genetic
in￿uences. With regards to the factors uniquely associated with dependence,
genetic in￿uences on drug metabolism may be more likely to exert in￿uence
at this stage (Dick et al., ￿￿￿￿). Similar ￿ndings from tobacco research, using
genetic risk scores created usingmultiple single-nucleotide polymorphisms (SNPs)
identi￿ed as associated with number of cigarettes smoked per day, has identi￿ed
that this risk was unrelated to initiation of tobacco use but that higher genetic
risk score was signi￿cantly associated with increased risks for the development of
nicotine dependence (amongst other progression outcomes) (Belsky et al., ￿￿￿￿).
Consequently the present ￿ndings support research indicating that at least some
of the genetic in￿uences on drug use differ at different stages, and suggest that
research identifying the unique gene associations is warranted.
I identi￿ed distal and proximal risk factors that were unique to speci￿c stages
of drug involvement, while others acted across multiple stages. CD, weekly
tobacco use, parental drug problems and gender were found to in￿uence the
speed of studied transitions in cannabis use. However, a number of unique factor
associations were observed for each transition; these were predominately proximal
in￿uences. Previous research into stages of alcohol use has demonstrated
differences in association by stage of use for environmental factors (Sartor et al.,
￿￿￿￿). Interestingly, a number of the factors identi￿ed as unique to alcohol
dependence (nicotine dependence, cannabis abuse, generalised anxiety disorder)
broadly re￿ect those found to be speci￿c to progression to dependence in the
present analyses.
￿.￿ What Factors Act Across Stages of Drug Use?
One advantage of the approach taken in this thesis is that a consistent selection
of factors was tested for their relationship to progression through different stages
of drug use. Figure ￿.￿ provides a visualisation of these results for clarity of
understanding. The following factors were identi￿ed as being associated with
transition across drug use stages; these are predominately distal factors; in￿uences
that are further removed from the onset of behaviour, as opposed to proximal
￿￿￿
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Figure ￿.￿: Factors associated with progression through the stages of drug use



















(all before stage onset)
factors which act directly on the onset of that behaviour.
￿.￿.￿ Conduct Disorder
CD was associated with faster progression to cannabis use opportunity, and from
opportunity to dependence. This ￿nding is in linewith existing research linking CD in
adolescence to both cannabis use and problematic cannabis use (Fergusson et al.,
￿￿￿￿; Heron et al., ￿￿￿￿; Pedersen et al., ￿￿￿￿; Zohsel et al., ￿￿￿6). Additionally, CD
has been linked to speed of transition to cannabis initiation (Galéra et al., ￿￿￿￿) and
from initiation to problem use (Sartor et al., ￿￿￿￿a), with childhood aggressive or
disruptive behaviour associated with earlier opportunity to use cannabis in males’
(Storr et al.,￿￿￿￿). The analyses in this thesis add to this literature, identifying further
transitions that CD is associated with.
The effect sizes for the association with CD differed for each transition, with
an estimated adjusted HR of ￿.￿￿ (￿￿% CI ￿.￿￿-￿￿.￿￿) for age of opportunity and
HR ￿.￿￿ (￿￿% CI ￿.￿￿-￿.￿￿) for transition from opportunity to dependence. It is
important to note that the con￿dence intervals indicate that effect sizes may
overlap. However, the difference in effect sizes across transitions does mirror
the trajectories of conduct problems. Conduct problems have been shown to
split into four classes: those limited to childhood, those that have early onset
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and persist into adolescence, those that have adolescent onset, and no problems
(Barker and Maughan, ￿￿￿￿; Mof￿tt, ￿￿￿￿). These trajectories have been shown
to be differentially associated with cannabis use and problem use, with those
in the adolescent onset class at increased likelihood of cannabis use (OR ￿.8￿,
￿￿% CI ￿.￿￿ - ￿.88) and those in the early-onset persistent class at increased
likelihood of problem cannabis use (OR ￿.￿￿, ￿￿% CI ￿.￿￿ - 8.￿￿) compared to a low
problem group (Heron et al., ￿￿￿￿). Similarly, research splitting CD into different
dimensions and exploring trajectories within those identi￿ed classes has identi￿ed
associations with substance use (Reef et al., ￿￿￿￿). Within the CD dimension of
Status Violations, which includes drug and alcohol use, a group was identi￿ed who
exhibited increased engagement in these behaviours between the ages ￿-￿8. This
group was at increased likelihood of substance abuse/dependence compared to
thosewhohad lowengagement in the behaviours (OR ￿￿.￿, ￿￿%CI￿.￿–￿￿.￿). Those
who only had a medium increase in these behaviours between the ages ￿-￿8 also
had an increase in likelihood of substance abuse/dependence, but to a lesser extent
than those with high increase (￿.￿, ￿￿%CI ￿.￿–￿.8). It is likely that differences in the
class of CD will be related to speed of transition in cannabis use, and may underlie
the changes in effect size over time.
The association between speed of transition in cannabis use and CD may have
a genetic basis. The genetic in￿uences associated with CD have been found to
correlate with the genes associated with cannabis use (r=￿.￿8 in males, r=￿.￿￿
in females) (Verweij et al., ￿￿￿6). In a separate study, the genetic correlation
between CD and cannabis abuse/dependencewas estimated at r=￿.￿￿ (Grant et al.,
￿￿￿￿). Additionally, the genetic overlap between alcohol, tobacco and cannabis use
disorders was attributable to genes shared with CD. In the present study, age of
opportunity to use cannabis and cannabis abuse and/or dependence were found
to have correlated genetic in￿uences (￿￿%). It is plausible that at least some of
these shared genetic in￿uences may overlap with those acting on CD.
￿.￿.￿ Weekly Tobacco Use
Weekly tobacco use (preceding cannabis use stage onset) was associated
with faster progression to cannabis use opportunity, and from opportunity to
dependence. This is in line with existing research that identi￿ed that those who
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reported lifetime use of at least ￿￿￿ cigarettes had an earlier opportunity to use
cannabis (Agrawal et al., ￿￿￿￿), and that thosewhowere regularly smoking tobacco
at least once a week for ￿ months prior to problematic cannabis use (and had
smoked greater than ￿￿ cigarettes in their lifetime) had faster progression from
initiation to their ￿rst symptom of problematic use (Sartor et al., ￿￿￿￿a).
This ￿nding is likely partially attributable to the shared typical route of tobacco
and cannabis administration (smoking). It may be expected that individuals who
are regularly smoking tobacco may have faster transitions in cannabis use as
a result of familiarity with the administration method. Additionally, tobacco and
cannabis are often administered simultaneously (Agrawal et al., ￿￿￿￿), which may
contribute to a relationship between tobacco use and speed of cannabis transitions.
Recent research has found that, globally, it ismore common to administer cannabis
with tobacco than without, and in Australia (where the analysis sample was drawn
from) ￿￿.6% of those surveyed were likely to use cannabis concurrent with tobacco
(Hindocha et al., ￿￿￿6). Additionally, research suggests that common genetic
in￿uences act on initiation of tobacco use and the initiation of illicit drugs, including
cannabis (Huizink et al., ￿￿￿￿). Thus shared administration route, concurrent use,
and shared genetic factors may, in combination, explain the ￿nding that regular
tobacco use is linked to transitions across the stages of cannabis use.
￿.￿.￿ Parental Drug Problems
Participant report of one or both parents experiencing problems with any drug
was associated with younger age of opportunity to use cannabis, and with
faster progression from opportunity to the development of cannabis dependence.
These ￿ndings are in line with existing research suggesting that parent substance
problems increase likelihood of drug use opportunity, but this existing research
did not ￿nd association between parent substance problems and SUD (Benjet
et al., ￿￿￿￿); this may result from a lower prevalence of SUDs in the population
in which this previous research was based. Associations have also previously
been found between parent illicit drug use (not necessarily problematic) and higher
frequency of offspring cannabis use at age ￿￿-￿6 (Fergusson and Horwood, ￿￿￿￿)
or vulnerability to substance use (Lynskey et al., ￿￿￿8), and familial transmission
has been identi￿ed for SUDs in studies of the families of those in treatment for
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SUDs (Merikangas KR et al., ￿￿￿8; Miles et al., ￿￿￿8). That these factors are also
associated with speed of progression to SUDs is a novel ￿nding.
There are a number of potential mechanisms through which parent drug
problems could in￿uence progression through the stages of drug use. One is
genetics, which will be discussed in detail later in this chapter (Section ￿.￿). A
second is family attitudes towards drug use, which have been highlighted in a
comprehensive review of the literature as a risk factor for SUDs (Hawkins et al.,
￿￿￿￿). However, regardless of attitudes towards their child’s drug use, parent
engagement in behaviour alone may have an effect. In studies of alcohol use,
parent alcohol use has been found to increase likelihood of adolescent alcohol
use even when the parent is opposed to adolescent drinking (Hung et al., ￿￿￿￿).
Although more dif￿cult to test in drug use due to the reduced prevalence of the
behaviour compared to alcohol, the relationship between parental drug problems,
family attitudes towards drug use, and the progression through the drug use stages
may prove to be a fruitful avenue for further exploration.
Another mechanism through which parental drug problems may lead to
earlier opportunities to use cannabis, and faster progression to development of
dependence, is the effect of parent drug use on a child’s drug access. It has
previously been found that cannabis availability accounted for almost all (￿￿%)
of the shared environmental (childhood and family environment) effects acting
on cannabis initiation and developing symptoms of cannabis abuse (Gillespie
et al., ￿￿￿￿). This may re￿ect direct availability, or parenting practices that are
conducive to drug exposure. Applied to the results of this thesis, it is plausible
that one mechanism through which progression to opportunity and dependence is
increased is through individualswhose parents experienced drug problemsgrowing
up in environments that increased cannabis availability.
￿.￿.￿ Gender
In the analyses presented in this thesis, gender was associated with earlier
age of opportunity to use cannabis and faster progression from opportunity to
dependence, with males at increased likelihood of making faster transitions. This
￿nding is in contrast to themajority of the existing research in this area. Differences
have not previously been found between males and females for age of opportunity
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to use cannabis (van Etten and Anthony, ￿￿￿￿), for progression from initiation
within a year of opportunity to use cannabis (van Etten et al., ￿￿￿￿), or for speed
of transition from initiation of cannabis to problem use (Haas and Peters, ￿￿￿￿;
Ridenour et al., ￿￿￿6). Gender differences in drug use and the development of SUDs
have previously been observed (Young et al., ￿￿￿￿), although there is a suggestion
that these differences are less pronounced in those aged ￿8-￿￿ compared to those
in older cohorts (Degenhardt et al., ￿￿￿8), which may indicate that drug use is
becoming more equal in younger generations.
Sex differences in lifetime drug use opportunity (not studied in the present
thesis) have previously been found. It has been observed that males are more likely
to have the opportunity to use drugs (Caris et al., ￿￿￿￿; van Etten et al., ￿￿￿￿), but
are no more likely than females to use that drug once the opportunity has occurred
(van Etten et al., ￿￿￿￿). It has been speculated that these differences may result
from males being involved in activities associated with higher drug exposure risk,
or that they may receive lower parental monitoring (van Etten and Anthony, ￿￿￿￿).
These may contribute to gender differences in speed of transition to opportunity
and dependence.
￿.￿ Which Factors Drive Progression to Individual
Stages of Drug Use?
The factors identi￿ed as uniquely associated with progression through speci￿c
stages of cannabis use can be described as proximal factors. An overview of the
factors associated with progression to speci￿c stages of drug use is provided in
Figure ￿.￿.
Factors uniquely associated with earlier age of opportunity to use cannabis
were infrequent childhood religious attendance, high parental con￿ict, parental
alcohol problems, and CSA. None of these factors have previously been found to be
associatedwith younger age of opportunity to use cannabis, but childhood religious
practices are associated with decreased likelihood of cannabis use opportunity
(Chen et al., ￿￿￿￿), as are the parenting factors of lower parental involvement and
higher levels of coercive discipline (Chen et al., ￿￿￿￿b). It is perhaps surprising that
CSA is uniquely associated with this stage given that the literature review (Chapter
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￿, Section ￿.￿) identi￿ed this factor was associated with speed of progression to
cannabis use disorder (Sartor et al., ￿￿￿￿a, ￿￿￿￿).
The factors uniquely associated with speed of transition from opportunity to
use cannabis to dependence indicate that a pattern of co-occurring substance use
and dependencies develops between the onsets of these stages. One explanation
for the development of co-occurring dependencies is that the same factors are
underlying dependence on different substances (Agrawal et al., ￿￿￿￿; Morral
et al., ￿￿￿￿). Research using twin populations has found that the genetic and
shared environmental factors underlying use and abuse/dependence for cannabis,
cocaine, hallucinogens, sedatives, stimulants, opiates, inhalants, and prescription
drugs were not drug-speci￿c (Kendler et al., ￿￿￿￿; Tsuang et al., ￿￿￿8), although
other research has found more evidence for drug-speci￿c genetic factors acting
on the development of dependence (Palmer et al., ￿￿￿￿; Sartor et al., ￿￿￿￿). The
￿nding that preceding dependence on other substances is associated with faster
progression to cannabis dependence supports the literature suggesting some
factors increase liability to multiple dependencies.
Non-clinical depressive episode onset (preceding the development of cannabis
dependence) was associated with faster progression to cannabis dependence.
Research into the relationship between cannabis dependence and depression has
not established a consistent causal role for cannabis use in the development of
major depressive disorder (Danielsson et al., ￿￿￿6; Feingold et al., ￿￿￿￿; Gage et al.,
￿￿￿￿). Research on the association in the other direction, as tested in this thesis,
has found association between major depressive disorder and incident cannabis
abuse, but not dependence (Pacek et al., ￿￿￿￿). The self-medication hypothesis
is a plausible explanation for the association observed within this thesis. Those
in treatment for drug abuse have been found to report using drugs to relieve
symptoms of depression (Weiss et al., ￿￿￿￿), but this has not been consistently
observed as a motivation amongst cannabis-dependence participants. (Arendt
et al., ￿￿￿￿). Alternatively, cannabis use and abuse and major depressive disorder
may have common liabilities (e.g. Ottena et al., ￿￿￿￿; Sherva et al., ￿￿￿6), whichmay
provide an explanation for their observed co-occurrence in the results of this thesis.
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￿.￿ HowDoGenetic In￿uences Contribute to Transitions
in Cannabis Use?
The use of a twin sample to study the genetic contribution to transitions in drug use
was one of the strengths of this research. Doing so demonstrated that heritability
estimateswere similar for age at ￿rst opportunity to use cannabis and development
of lifetime abuse and/or dependence. This is in contrast to existing research
suggesting that heritability increases as drug use progresses (Lynskey et al., ￿￿￿￿).
Heritability of age of opportunity to use cannabis has rarely been studied previously,
and the majority of this previous research focuses on cannabis initiation. This may
explain the inconsistency with previous ￿ndings.
Additive genetic effects were estimated to account for 66% of the variance in
age of opportunity to use cannabis. It has previously been shown that genetic
effects in￿uence putatively environmental factors (Kendler and Baker, ￿￿￿￿), of
which opportunity to use cannabis is one. Given that genetic effects acting on age
of opportunity to use cannabis cannot be drug related, as use has not been initiated
at this stage, the overlap in effects must arise from in￿uences that are unrelated to
drug metabolism.
A substantial correlation (￿.￿￿) was observed between additive genetic
in￿uences on age of opportunity to use cannabis and those on cannabis abuse
and/or dependence. Many studies have reported a genetic correlation between
different stages of drug use. In tobacco research genetic correlation has been
identi￿ed between i) initiation and amount smoked/cessation (Broms et al., ￿￿￿6),
ii) age of onset and cigarette consumption/smoking persistence (Morley et al.,
￿￿￿￿), and iii) cigarette consumption and smoking persistence (Morley et al., ￿￿￿￿).
In alcohol research genetic correlations have been identi￿ed between: (i) age of
initiation and frequency of use/problem use (Pagan et al., ￿￿￿6); (ii) age of ￿rst
alcohol use and alcohol dependence (Sartor et al., ￿￿￿￿b); (iii) frequency of use
and problem use (Pagan et al., ￿￿￿6); (iv) heaviness of alcohol use and alcohol
abuse/dependence (Grant et al., ￿￿￿￿); and (v) alcohol use disorder and remission
(McCutcheon et al., ￿￿￿￿). For cannabis, a genetic correlation has only been
identi￿ed between number of times of lifetime cannabis use and dependence
(Sartor et al., ￿￿￿￿). The analyses in this thesis are the ￿rst study to identify a
genetic correlation between opportunity to use and later SUD.
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The genetic correlation observed between age of opportunity and cannabis
abuse and/or dependence was high (r=.￿￿) compared to the majority of existing
research. No previous studies have considered age of opportunity, but there has
been focus on age of initiation. For alcohol, the genetic correlation between age
at initiation and problem use has been estimated as low as .￿￿ and .￿￿ for males
and females respectively (Pagan et al., ￿￿￿6), and as high as .￿￿ for the association
between age of ￿rst alcohol use and alcohol dependence (Sartor et al., ￿￿￿￿b). The
differences in these estimates may re￿ect differences in the de￿nition of problem
use, with only the higher correlation observed using the DSM-IV de￿nition of alcohol
dependence. An extremely high genetic correlation of ￿.￿8 has been observed
between number of instances of lifetime cannabis use and cannabis dependence
(Sartor et al., ￿￿￿￿). The correlation found in this thesis is concordant with the
higher estimates previously observed in the literature, but previous ￿ndings suggest
there is potential for the correlation to be lower should a different measure of
problem use be utilised.
The best ￿tting bivariate twinmodelwas onewhich equated additive genetic and
unique environmental parameters and correlations between age of opportunity and
abuse and/or dependence formales and females, which suggests there are not sex
differences in the genetic factors acting on these phenotypes, or in the magnitude
of the additive genetic effect. This is in contrast to much of the existing literature,
which has commonly observed sex differences in genetic correlation between
stages of drug use when these were tested for. Correlations in previous studies
were observed to be higher in males than for females in all cases (Broms et al.,
￿￿￿6; Morley et al., ￿￿￿￿; Pagan et al., ￿￿￿6; McCutcheon et al., ￿￿￿￿). However,
the present ￿ndings are in accordance with the only other study to look at genetic
correlations in cannabis use (Sartor et al., ￿￿￿￿).
Existing research has suggested that a proportion of the genetic factors
underlying SUDs are not speci￿c to individual drugs (Kendler et al., ￿￿￿￿; Sartor
et al., ￿￿￿￿), and the genetic overlap observed within this thesis may represent
factors that provide a general liability to drug use and SUDs. Much of the non-
speci￿city of genetic in￿uences on SUDs may result from shared in￿uences on the
earlier stages of drug use, with more speci￿c in￿uences (such as those related to
metabolism, for example) associated with the later, problematic stages of use.
The results also indicated that genetic effects do not consistently in￿uence
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the speed of transition. The inclusion of the novel transition from initiation to
subsequent use of cannabis identi￿ed a transition that had no observed variance
attributable to additive genetic effects. Themajority of the variance in this transition
was attributable to unique environmental effects. It is important to note that, within
twin modelling, estimates of the unique environment also include measurement
error (Plomin et al., ￿￿￿￿). The study of the transition to subsequent cannabis
use is a novel contribution to the literature, and consequently there is no existing
research against which to compare these results. As the subsequent use measure
is novel the reliability and validity of it is unknown, and these ￿ndings therefore
require replication to determine the reliability and validity of the measure. If the
measure of subsequent use has high unreliability, additive genetic in￿uences may
be masked.
If not due to measurement error, determining what the unique environmental
effects could be comprised instance requires speculation. Potential sources of
variation include parenting, which can contribute to non-shared environmental
sources of variation if twins are treated or perceive themselves to have been treated
differently (Plomin et al., ￿￿￿￿). One study of the effect of non-shared environment
on delinquent behaviour identi￿ed maternal disengagement as a source of such
variation (Beaver, ￿￿￿8), which could plausibly in￿uence this early stage of drug
use. The ￿ndings highlight the complexity of in￿uences on progression in drug use,
and the utility of genetically informative designs to provide important information
on the effect of the environment as well as genetics.
￿.6 What is the Relationship Between Speed of Early
Transitions in Cannabis Use and Later SUDs?
Both earlier opportunity to use cannabis and faster transition from initiation to
subsequent use of cannabis were associated with increased likelihood of cannabis
daily use, and likelihood of abuse and/or dependence. Age of opportunity alonewas
associatedwith likelihood of cannabis related treatment-seeking. An approximately
linear relationship was observed between age of cannabis use opportunity and
likelihood of progressing to daily cannabis use (OR ￿.￿6 ￿￿% CI ￿.￿6-￿.￿￿ and ￿.6￿
￿￿% CI ￿.￿8-￿.￿￿ for under ￿￿ and ￿￿-￿6 respectively) or cannabis abuse and/or
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dependence (OR ￿.￿￿ ￿￿% CI ￿.￿￿-￿.￿￿, ￿.86 ￿￿% CI ￿.￿￿-￿.￿8 and ￿.￿￿ ￿￿% CI ￿.￿8-
￿.￿￿ for under ￿￿, ￿￿-￿6 and ￿￿ and over respectively). Only those aged ￿￿ and
under at ￿rst opportunity to use cannabis were at increased likelihood of treatment
seeking (OR ￿.6￿, ￿￿% CI ￿.￿￿-￿.6￿). For speed of transition from initiation to
subsequent use, only the fastest transition speed was associated with progressing
to daily cannabis use (OR ￿.￿8, ￿￿%CI ￿.￿￿-￿.￿￿), but a linear relationshipwith speed
was indicated for progression to cannabis abuse and/or dependence (OR ￿.￿￿ ￿￿%
CI ￿.￿￿-￿.￿￿ and ￿.￿￿ ￿￿% CI ￿.￿￿-￿.￿￿ for transition within a week and within three
months respectively). There were no associations with treatment seeking. These
￿ndings broadly re￿ect previous research identifying an association between faster
transition to initiation of cannabis use and later cannabis dependence (Swift et al.,
￿￿￿8; Grant and Dawson, ￿￿￿8; Fergusson and Horwood, ￿￿￿￿). Additionally, these
results indicate that those who go on to develop SUDs are at heightened risk for
problematic outcomes from the earliest stages of cannabis involvement.
The key implication of this ￿nding is that individuals making faster early
transitions in drug use may already be exposed to in￿uences that will increase
their likelihood of later negative drug use outcomes. This suggests that some
of the contribution to SUD risk liability is in evidence at the very earliest stage of
drug use, and cannot be attributed to the pharmacological effects of the drug.
The association between age of opportunity to use cannabis and later SUDs may
re￿ect the genetic correlation between these two phenotypes. For the progression
to subsequent use, for which no additive genetic effect was observed, genetics are
unlikely to provide an explanation.
The association to later SUDs likely re￿ects a combination of individual and
contextual factors that surround the rapid escalation. One of these factors may
be availability. Although unmeasured in the present study, drug availability has
previously been proposed as an explanation for changes in the speed of transitions
in drug use (Mills et al., ￿￿￿￿). For cannabis, factors in the environment linked to
the availability of the drug have been found to account for part of the association
between cannabis initiation and the development of cannabis abuse (Gillespie
et al., ￿￿￿￿). Research has not yet explored which factors are associated with
higher cannabis availability in adolescence, but speed of transition to subsequent
cannabis use may act as a proxy measure of this and a combination of other
unmeasured factors that increase liability to SUDs.
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￿.￿ Consistency Across Drug Classes? Testing Speed of
Transition in Heroin Use
Including heroin-using populations in the study provided a test of whether speed
of transition is a relevant phenotype in drugs other than cannabis. This extended
the scienti￿c scope of my studies. As stated previously, heroin use is much less
prevalent in the general population than cannabis use (UNODC, ￿￿￿￿), but has
associated health and dependence risks that are more severe, especially when
administration of the drug is through injecting (Strang et al., ￿￿￿8). Very little
existing research has explored speed of transitions in heroin use but the available
literature highlights the importance of considering route of administration (see
Chapter ￿, Section ￿.￿).
One reason that it was interesting to test the association between transition
speed and later outcomes in heroin use was due to the nature of the drug itself.
It has previously been observed that, compared to individuals who inject other
drugs (e.g., methamphetamine), those injecting heroin have a faster progression
from initiation of use (through injecting) to regular use, and a greater severity of
dependence (O’Keefe et al., ￿￿￿6). Additionally, populations of heroin users often
have high levels of childhood abuse and neglect (Darke, ￿￿￿￿). Consequently it was
possible that ￿ndings relating to transition speed from populations using cannabis
may differ in heroin using populations. In the sample in which the relationship
between speed of early heroin use transitions and later outcomes was tested, only
age of opportunity to use heroin was associated with later outcomes. It may be
that heroin pharmacology, or the effect of other unmeasured life course factors,
mitigate the relationship between speed of transition and later outcomes.
Overdose was included as an outcome as it is the main cause of mortality
amongst opiate users (Degenhardt et al., ￿￿￿￿), and even non-fatal overdose has
associated health effects that may have a long-term in￿uence (Warner-Smith et al.,
￿￿￿￿). Suicidality and unsafe injecting practices (Bogdanowicz et al., ￿￿￿6), and
lower socioeconomic status and being on the edge of the workforce (Amundsen,
￿￿￿￿), have been found to be associated with overdose mortality. Additionally,
non-fatal overdose has been found to be associated with higher levels of use of
heroin and other drugs (Darke et al., ￿￿￿￿). However, the association in the present
study with earlier opportunity to use indicates that factors contributing to earlier
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opportunity may also contribute to overdose risk. Identifying what these factors
are, and how they increase the liability to overdose, will help to explain variation in
overdose risk and outcome amongst heroin users and may be useful for improving
interventions.
The literature review (Chapter ￿, Section ￿.￿) identi￿ed that, when exploring
heroin transitions, there is value in taking into account drug administration factors.
Consequently the analyses in this thesis considered the relationship between of
IAR and speed of transitions in heroin use. Injection of heroin was associated
with a four-fold increase in progression to daily heroin use, compared to smoking
and snorting administration. This is a novel ￿nding, and highlights the importance
of considering drug speci￿c factors and transitions when applying a multi-stage
approach to drug use.
￿.8 Implications of Thesis Findings
￿.8.￿ Prevention and Intervention
The focus of this project on some of the earliest transitions in drug use has
identi￿ed that those at increased likelihood of dependence have the potential to
be identi￿ed at the earliest stage of drug use involvement. Existing research had
identi￿ed age of initiation as a marker for later problematic use (Behrendt et al.,
￿￿￿￿; Lynskey et al., ￿￿￿￿; Swift et al., ￿￿￿8). Research relating to early onset of
drug use often calls for earlier detection and intervention (Chen et al., ￿￿￿￿), and the
time between drug use initiation and the development of SUDs has been found to be
short, leaving only a small window for targeted intervention (Wittchen et al., ￿￿￿8).
The present ￿ndings suggest that those who are at risk can be identi￿ed before
initiating drug use. This raises the prospect of utilising early drug use behaviours
to act as markers for early intervention.
Using the results of the present studymay facilitate identi￿cation of populations
who will bene￿t from interventions. Selective interventions target those groups
who are at increased risk of experiencing an outcome (Poznyak et al., ￿￿￿￿). As
discussed previously, there are a large number of risk factors associated with
SUDs (Hawkins et al., ￿￿￿￿), each providing potential for intervention. Possibly
as a result of the dif￿culty selecting speci￿c risk factors to target, interventions
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for substance use tend to take a universal approach (Teesson et al., ￿￿￿￿) or use
personality factors as the selective methods (Barrett et al., ￿￿￿￿; Newton et al.,
￿￿￿6). By applying the multi-stage approach and avoiding con￿ation of estimates
across drug use stages, the present analyses have narrowed the scope of targets
for intervention. Adolescentswhomeet criteria for conduct disorder, whose parents
have experienced drug problems, who are engaged in weekly tobacco use, or have
had the opportunity to use cannabis at younger ages, may bene￿t from selective
interventions aimed at the prevention of problematic cannabis use.
Indicated interventions target high-risk individuals with early signs of the
emerging disorder (Poznyak et al., ￿￿￿￿). A recent Cochrane review of brief
interventions for substance-using adolescents identi￿ed ￿ randomised controlled
trials, all aimed at adolescents under age ￿￿ who had used alcohol or other drugs
(Carney et al., ￿￿￿6). The evidence that these interventions were effective at
reducing drug or alcohol use was rated as low or very low. Given that the proportion
of individuals who initiate cannabis use is much higher than the proportion that will
progress to problematic, or even regular, cannabis use, it seems likely that using
ever-use of a drug as an indicator for intervention will not maximise effectiveness.
The results of this thesis provided a potential new indicator for interventions in
the form of speed of transition from initiation to subsequent use of cannabis. If
replicated in prospective research, the speed of this transition in cannabis use has
the potential to act as a clinically useful indicator of those individuals likely to bene￿t
from intervention; similar to a biomarker (Rifai et al., ￿￿￿6), but easily and cheaply
tested by medical professionals through patient self-report. Although the odds
ratios obtained indicate that this measure would have low speci￿city, making it
inappropriate for selecting candidates for intensive intervention, brief interventions
such as information provision may be more appropriate.
￿.8.￿ A Measure of Addictive Liability
There is potential to use measures of transition speed as markers of the addictive
liability of a drug. It may be expected that the proportion of a drug using population
that experience dependence would be an appropriate marker of addictive liability,
but there are issues with this measure; as stated throughout this thesis, the
prevalence of dependence is commonly driven by factors separate from the drug
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itself (Anthony et al., ￿￿￿￿; Ridenour et al., ￿￿￿￿). Another previously proposed
measure of addictive liability is speed of transition from development of abuse
symptoms to dependence symptoms (Ridenour et al., ￿￿￿￿), but as discussed in
Chapter ￿ (Section ￿.￿) there are issues with the use of this transition.
Speed of transition may provide a better marker of addictive liability. As
discussed in Chapter 6, the association between injecting IAR and faster transition
to daily heroin use is consistent with what is known about the pharmacology of
heroin administration, and likely re￿ects the higher dependence liability of injection
over non-injection routes of heroin administration. This consistency indicates that
differences in the speed of transition to daily use may be a useful comparator of
drug dependence potential. Given that methodology for assessing transition speed
is non-invasive and low cost, this avenue warrants further investigation andmay be
of use for better understanding emerging novel psychoactive substances.
￿.8.￿ Selection of Controls in Genetic Research
These ￿ndings have additional, important implications for future studies of gene
variants and heritability of SUDs, and in the choice of controls in case-control
studies. The results of this study indicate that only a moderate proportion of
genetic in￿uences on cannabis abuse and/or dependence are unique from those
acting on age of opportunity to use cannabis. Consequently genetic studies that do
not consider their participants’ opportunity to use cannabis risk con￿ating genetic
in￿uences across these stages.
Such arguments have previously been made regarding the importance of
considering drug use opportunity when looking at the genetics of opiate use.
By comparing participants in treatment for opiate dependence with controls
sourced from the ATR (individuals not dependent on alcohol or illicit drugs,
with signi￿cantly lower illicit drug exposure), and separately with nondependent
neighbourhood controls (high exposure to illicit drugs, either via use or from residing
in environments with widespread drug availability), differences were found in the
SNPs associated with heroin dependence (Nelson et al., ￿￿￿￿). When those in
treatment were compared with neighbourhood controls, signi￿cant associations
with gene variants were identi￿ed; these associations were not evident when
the ATR controls formed the comparison group. Until now the importance for
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genetic studies of considering cannabis use opportunity has not been explored,
and no genetic studies of problematic cannabis use have considered cannabis use
opportunity amongst the control group.
Consequently a key implication of the ￿ndings is the necessity of taking into
consideration the stage of drug use reached amongst the controls. Existing
research has utilised information on the extent of cannabis use in controls (e.g.
excluding those who had used cannabis fewer than 6 times) (Hartman et al., ￿￿￿￿),
but such issues are not always being taken into consideration (Benyamina et al.,
￿￿￿￿). Depending on the research question, and on the development of research
identifying genetic overlap between progression to other stages of cannabis use
and problematic cannabis use, screening controls not only for opportunity or
initiation of cannabis use, but also for frequency of usemay have utility in improving
cannabis dependence SNP identi￿cation in the future.
￿.8.￿ Non-Injecting Routes of Heroin Administration
The ￿ndings of the thesis identi￿ed a relationship between IAR and speed of
transition to daily heroin use, with those initiating use through injecting likely to
have faster progression to daily use. Additionally, the ‘IAR injecting’ group had a
higher proportion of individuals ever using daily, compared to ‘IAR non-injecting’
administration groups. Non-injecting administration has previously been shown to
be associated with less harm, and reduced likelihood of developing dependence
(Strang et al., ￿￿￿8), overdosing (Gossop et al., ￿￿￿6) and contracting blood-
borne viruses (Strang et al., ￿￿￿8). The increased latency to daily use amongst
participants whose IAR is chasing or snorting supports the harm-reduction case
for encouraging non-injecting routes of administration (Bridge, ￿￿￿￿; Wodak and
McLeod, ￿￿￿8).
This has implications for drug treatment provision. The shorter window before
daily heroin use for those who initiate through injecting implies that there is a
shorter time in which intervention to prevent problem development could occur.
The need for drug services to attract those whose treatment needs are less
immediate, in order to encourage those already injecting to switch to non-injecting,
has previously been suggested in the literature (Strang, ￿￿88). It may be that focus
needs to shift again to targeting those who have recently begun injecting to provide
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encouragement to non-injecting administration (or indeed, heroin abstinence). One
trialled method where there are at least preliminary data indicating the approach
may be effective is in explicit encouragement and enabling of a switch from
injecting to ‘chasing’ through the distribution of foil packets (required for heroin
chasing) at needle exchange centres (Pizzey and Hunt, ￿￿￿8).
Intervening at the treatment service level will not (and could never be expected
to) reach the complete population of individuals who have recently initiated heroin
use, and therefore further measures may be required. One method of discouraging
injecting drug use amongst these populations is to work with those already
engaged in injecting drug use. Intervention that alters the perceptions of current
injectors, and focuses on the value of dissuading those not currently injecting heroin
from beginning to use this route of administration, has been trialled previously
with some success (Hunt et al., ￿￿￿8). Alternatively, changes can be made at
the policy level to reduce the incentives around injecting drug use. One idea that
has previously been suggested is that of altering policing to penalise the supply of
injectable heroin whilst being more tolerant of the supply of heroin that could only
be smoked (Strang and King, ￿￿￿￿). The ￿ndings of this thesis suggest that doing
so has the potential to limit the harms of heroin use and reduce the prevalence of
dependence by not only reducing the number of heroin users who progress to daily
use, but also to allow a greater window for treatment services to reach heroin users
before a daily habit has developed.
￿.8.￿ Studies of Gene-Environment Interaction
The present study has explored the extent of genetic in￿uences on speed of
transitions in cannabis use, and identi￿ed a number of external factors associated
with progression through the stages of drug use. However, one of the key ￿ndings
was that associated factors, and the extent to which additive genetic effects
in￿uence transitions in drug use, are not consistent across the stages of drug
use. The study of SUD aetiology is increasingly recognising that environmental
in￿uences vary by genotype, and that the environment alters the effect a gene
has on an individual’s physiology (GxE) (Plomin et al., ￿￿￿￿). The present ￿ndings
indicate the potential for GxE to differ at each stage of drug use, given that factors
have been identi￿ed that are uniquely associated with speci￿c stages of use, and
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the genetic correlation between age of opportunity and abuse/dependence was
well below ￿.￿. One study that has looked at the differences in the levels of
individual alcohol use has identi￿ed an interaction between the OPRM￿ G allele
and parental rule setting (van der Zwaluw et al., ￿￿￿￿). Future research applying
a GxExS(tage) approach, whereby the interaction of speci￿c genes and external
factors is considered in light of the stage of drug use, may be key for understanding
what underlies individual variation in the progression of drug use.
This approach will have implications for prevention and intervention methods.
In drug use, these methods often take into account their target age and speci￿c
drug types (Stockings et al., ￿￿￿6), and recent developments have indicated
genotype can underlie differential susceptibility to prevention measures (Brody
et al., ￿￿￿￿). Taking the stages of drug use into consideration opens up the
potential to develop interventions that speci￿cally target the factors associatedwith
progression through the drug use stages.
￿.8.6 Public Health
When studying cannabis use there is a need to consider changes in the drug, both
in terms of legal status and chemical composition. Prevalence of cannabis use
doubled in the US between ￿￿￿￿ and ￿￿￿￿, although the evidence on whether this
has translated into an increase in cannabis use disorders is unclear (Hasin et al.,
￿￿￿￿; Grucza et al., ￿￿￿6). This increase in use may re￿ect changing attitudes
towards cannabis, and in combination with the increasing liberalisation of cannabis
control policies (Hopfer, ￿￿￿￿; Shi et al., ￿￿￿￿) may lead to cohort changes in the
demographics of cannabis use. Additionally, changes in the administration and
chemical composition of cannabis warrant exploration. The strength of cannabis,
in terms of the proportion of the content that is composed of tetrahydrocannabinol
(THC), which causes many of the “high” effects of cannabis use, has been
increasing in recent years (Golick, ￿￿￿6). Understanding how the THC strength
relates to speed of transitions in cannabis use could provide understanding of
any increased addictive liability associated with increased strength (see discussion
above, Section ￿.8.￿). A regulated cannabis market (Pacula et al., ￿￿￿￿), in which
the THC content of the drug is controlled through legislation and a legal supply
market, would be necessary to ensure that forms available were those associated
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with slower transitions.
￿.￿ Methodological Strengths and Limitations
￿.￿.￿ Selection and Testing of Associated Factors
A strength of the studywas that a consistent selection of proximal and distal factors
was tested for their association with multiple drug use transitions. One of the
limitations identi￿ed in the literature on age of initiation, and which also applies
to the review of research on speed of transitions (see Chapter ￿) was that the
factors tested for association with speed of transition varied widely, and in some
cases did not take into account factors beyond those present early in childhood
(Storr et al., ￿￿￿￿). The use of the SSAGA interview (Bucholz et al., ￿￿￿￿) provided
information on a wide range of potential covariates from childhood, adolescence
and into adulthood. As discussed above, this approach revealed a number of novel
￿ndings on the consistency of, and changes in, in￿uences on transition speed
across transitions.
￿.￿.￿ The Use of Multiple Samples
The study utilised multiple samples to address different questions. Cannabis use
has a relatively high base-rate in the general population, and could therefore be
studied using a non-clinical sample. The use of a relatively large (N = ￿8￿￿) twin
sample provided suf￿cient power to conduct genetically informative analyses and
test a range of hypotheses in epidemiological analyses. Although necessarily
smaller, samples incorporating individuals already using heroin allowed the study
of outcomes in a drug that has a low base rate in general population samples.
￿.￿.￿ Self-Report
All data were collected through self-report. Self-report has been recommended as
the gold standard method for collecting data on drug use (Wagner and Anthony,
￿￿￿￿), and all studies guaranteed participant con￿dentiality. However, despite this
there is potential that participants would have provided inaccurate information on
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topics they felt uncomfortable discussing. Given that use of cannabis is illegal in
the countries data were collected in (at time of data collection and thesis writing),
some participants in the ATR studymay have incorrectly reported on their drug use.
However, given the high prevalence of self-reported lifetime cannabis use (68.￿%),
it seems unlikely that this was a problem.
For the heroin samples, which were comprised of individuals already selected
for their heroin use, participants can be expected to be less likely to withhold
information on use of the drug. A review of the reliability and validity of self-report in
populations of injecting drug users found no differences in report accuracy between
those in treatment and those not in treatment, good reliability and validity for self-
report of amount and frequency of drug use in a number of studies, and high
concordance between self-reported drug use and independent measures (Darke,
￿￿￿8). Only one study suggests an issuewhichmay affect the results of the present
study, which is the estimated amount of heroin used was higher when the interview
was conducted by a researcher, compared to when conducted by peer interviewer
(Davies and Baker, ￿￿8￿). Therefore, despite the limitations of the method (and
aside from the unfeasible idea of regular drug testing of an adolescent or young
adult cohort), self-report is the best method available for measuring onset of the
stages of drug use.
￿.￿.￿ Recall Bias
All data were collected retrospectively, introducing the potential for recall bias.
This refers to the phenomenon whereby the exposure is recalled differentially
between groups who did and did not experience the outcome of interest, either as
a result of the outcome affecting recall of the exposure or leading to exaggeration
amongst thosewho experienced it (Hotopf, ￿￿￿￿; Hennekens andBuring, ￿￿8￿). For
example, it is feasible that those who have developed SUDs may have spent more
time re￿ecting back upon their early drug use than those who did not experience
problems, leading to differential recall of the speed of their early transitions in drug
use.
However, research into the reliability of recall of ￿rst use of cannabis, alcohol
and tobacco, tested by asking participants within a longitudinal study the same
questions at a later time point, indicated the there is good recall of these
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milestones (intraclass correlation for recall ￿+ years after ￿rst asking ￿.6￿;
intraclass correlation ￿.￿￿ for recall of cannabis items) (Johnson and Mott, ￿￿￿￿).
Moderate reliability has been found for self-reported age of drug, alcohol and
tobacco onset in an ￿￿-year prospective cohort study, with the age at which onset
was associated found to have no effect on the relationship to later drug outcomes
(Parra et al., ￿￿￿￿). A moderate correlation of r=￿.￿￿ (￿￿% CI: ￿,￿￿-￿.￿￿) and r=￿.￿6
(￿￿% CI: ￿.￿￿-￿,￿8) for males and females respectively was observed in a study
of those asked about age of tobacco initiation at age ￿8-￿￿, and again at ￿￿-￿￿
(Huerta et al., ￿￿￿￿). A study of participants asked about cannabis initiation ￿￿
years after being asked at baseline found ￿￿.￿% of participants reported an age of
onset that matched their baseline reports (Shillington et al., ￿￿￿￿). Age of alcohol
use had amoderate correlationwith report ￿ years after baseline assessment (￿.6￿)
(Green￿eld et al., ￿￿￿￿). In a sample longitudinally followed from 6 to age ￿￿,
cannabis use in adolescence was consistently reported by 6￿% of the sample, with
only ￿% inconsistently reporting their age of onset (Ensminger et al., ￿￿￿￿).
Much prior research utilised retrospective report of age of initiation and
transitions in cannabis and heroin use (Barrio et al., ￿￿￿￿; Grant et al., ￿￿￿￿;
Kendler et al., ￿￿￿￿, ￿￿￿8; Kendler and Prescott, ￿￿￿8; Lopez-Quintero et al., ￿￿￿￿;
Ridenour et al., ￿￿￿￿; Sartor et al., ￿￿￿￿a; van Etten and Anthony, ￿￿￿￿; Wagner
and Anthony, ￿￿￿￿; Winters and Lee, ￿￿￿8; Woodcock et al., ￿￿￿￿). Consequently
retrospective recall can be a said to an appropriate method of assessing early drug
use behaviours, but results would bene￿t from replication in prospective studies.
￿.￿.￿ The Use of Twin Samples
The majority of analyses in this thesis are based on a general population twin
sample. It may be expected that twins will differ from non-twins, which raises
questions as to the extent to which ￿ndings from twin samples can be applied
to the general, non-twin population. However, researchers have consistently
shown that twins sampled from the general population are representative of that
population; particularly in relation to the prevalence of mental health problems,
which have been shown to not differ between twin and non-twin populations
(Kendler et al., ￿￿￿6). Additionally twin environmental similarity has been shown to
not be associated with mental health outcomes (Kendler et al., ￿￿￿￿), whichmeans
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we should not expect twin populations to differ from non-twin samples on such
measures. Publications in multiple journals and ￿elds have utilised a twin sample
as equivalent to a general population sample (Åkerstedt et al., ￿￿￿￿; Ropponen
and Svedberg, ￿￿￿￿; Valdés et al., ￿￿￿￿; Waldron et al., ￿￿￿￿; Wulf-Johansson
et al., ￿￿￿￿), with many epidemiological analyses published from Scandinavian
twin cohorts. Consequently, whilst the use of a twin sample has potential to be
considered a limitation, it is appropriate for the analyses in this thesis.
The Equal Environments Assumption
As stated in Chapter ￿ (Section ￿.￿.￿), one of the key assumptions of twinmodelling
is that, despite the differences in genetic similarity, environmental in￿uences will be
equally correlated in both monozygotic and dizygotic twins. This is important as
estimates of heritability will be incorrectly in￿ated if there is greater similarity in MZ
environments, as the heritability estimate is based on the principle that a greater
correlation with an outcome in MZ twins compared to DZ twins’ results will be
due to the increased genetic similarity of MZ twins (Kendler et al., ￿￿￿￿). Analyses
conducted on twins who reported equal and unequal environments demonstrated
that equality of environment did not affect estimates for cannabis abuse and/or
dependence. These ￿ndings are consistent with existing research demonstrating
that this is not a limitation in analyses of twin data (Kendler and Gardner, ￿￿￿8;
Kendler et al., ￿￿￿￿; LoParo and Waldman, ￿￿￿￿; Plomin et al., ￿￿￿6).
￿.￿￿ Future Research Directions
The study has highlighted the value of applying amulti-stage approach to drug use,
and of considering variation in speed of transition. Doing so has led to interesting
conclusions about the relationship between speed of early transitions and later drug
use outcomes, and the ways in which in￿uences on drug use alter across stages
and transitions. These ￿ndings have also raised a number of questions that would
bene￿t from exploration in future research.
The analyses in this thesis were exploratory, applying the relatively novel
approach of considering speed of transitions in drug use in cross-sectional samples
to gain a broad understanding of the relevance of transitions in drug use. Having
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identi￿ed associations between speed of early transitions in drug use and later
drug use outcomes, and having identi￿ed that there are both consistent and stage
speci￿c in￿uences on progression in drug use, therewould be value in exploring this
topic in more depth. Using prospective cohorts to test whether there is replication
of the associations between early opportunity to use cannabis or heroin and later
drug use outcomes, and between faster transition to subsequent cannabis use and
later cannabis outcomes, would be necessary before progressing to use of these
transitions as markers for intervention. There is also a need to consider the effect
of individual factors on the speed of transitions, and potentially to test mediation
of the relationship to later drug use outcomes. Important targets to incorporate
in future studies of transitions are suggested in research from the alcohol ￿eld.
Social context of drug use (Degenhardt et al., ￿￿￿￿), motives for use (Little￿eld et al.,
￿￿￿￿), and personality changes across adolescence (Hicks et al., ￿￿￿￿) have been
found to affect problematic drinking in adolescence. Finally, given that the early
stages of drug use and progression are so linked to adolescence, there is value
in considering drug use in the context of adolescent transitions. These include
education completion andmoving out of parents home (Eisenberg et al., ￿￿￿￿), and
exploring these in terms of the effect of these on drug use and the associations
between earlier drug use and reaching these stages.
The ￿ndings in this thesis have highlighted that both genetic and environmental
factors contribute to progression in drug use, and as suggested above, there is
scope to develop a GxExS(tage) approach to the study of drug use. With regard to
the environmental exposures selected for study, there are an extensive number of
potential exposures that can be combined with the plethora of gene candidates.
Sher et al. (￿￿￿￿) have highlighted that the unavailability of information on the
number of possible environmental in￿uences means that there is no “environome”
to compare with the genome. Distal factors that are thought to have a long-term
effect (such as childhood family environment) can be differentiated from proximal
exposures (such as availability), and studies of G×ExS in adolescent drug use may
bene￿t from systematically classifying environment in this way. Additionally, for
SUDs as with other psychiatric disorders, despite years of candidate gene studies
there are still few replicated associations (Duncan and Keller, ￿￿￿￿; Bosker et al.,
￿￿￿￿; Reich et al., ￿￿￿￿; Tabor et al., ￿￿￿￿). Focussing research on combinations
of genes or gene systems through the use of polygenic risk scores have produced
￿￿￿
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promising results (Belsky et al., ￿￿￿￿; McGeary et al., ￿￿￿￿; Salvatore et al., ￿￿￿￿),
and may be a more ef￿cient strategy for understanding G×ExS in drug use.
The application of these to stage transitions has the potential to elucidate the
complexities underlying the development of drug dependence.
The ￿ndings of this thesis indicate that those who progress more rapidly to
cannabis dependence are likely to have additional co-occurring drug use and
dependency. Those who use cannabis have been found to be more likely to have
opportunities to use drugs such as heroin (Strang and McCambridge, ￿￿￿￿). It has
also been observed that amongst those who usemultiple drugs, the age of onset of
these drugs has declined across birth cohorts, with the result that thosewho initiate
cannabis use in their teens are likely to be exposed to a broad range of drug use
(Darke et al., ￿￿￿￿). As discussed previously in this thesis, there is common genetic
liability to drug dependencies and there are proposed mechanisms underlying the
co-occurrence of cannabis and tobacco use. However, beyond this there is little
understanding of the ways in which multiple dependencies develop, the levels of
problem use of other drugs amongst those diagnosed as dependent on a speci￿c
drug, and the implications that this has for prevention and treatment of drug
dependencies. Pursuing the following avenues of research could make valuable
contributions to the literature
￿. identifying the extent to which adolescents experience co-occurring
problematic drug use (frequent or heavy use of alcohol, cannabis or
other drugs)
￿. studying whether this use is stable or whether levels of use alter with age
￿. exploring the proximal and distal factors associatedwithmultiple problematic
drug use




Agosti, V., Nunes, E., and Levin, F. (￿￿￿￿). Rates of Psychiatric Comorbidity Among
U.S. Residents with Lifetime Cannabis Dependence. The American Journal of
Drug and Alcohol Abuse, ￿8(￿):6￿￿–6￿￿.
Agrawal, A., Budney, A. J., and Lynskey, M. T. (￿￿￿￿). The co-occurring use and
misuse of cannabis and tobacco: a review. Addiction, ￿￿￿(￿):￿￿￿￿–￿￿￿￿.
Agrawal, A., Grant, J. D., Waldron, M., Duncan, A. E., Scherrer, J. F., Lynskey,
M. T., Madden, P. A. F., Bucholz, K. K., and Heath, A. C. (￿￿￿6). Risk for
initiation of substance use as a function of age of onset of cigarette, alcohol and
cannabis use: Findings in a Midwestern female twin cohort. Preventive Medicine,
￿￿(￿):￿￿￿–￿￿8.
Agrawal, A. and Lynskey, M. T. (￿￿￿6). The genetic epidemiology of cannabis use,
abuse and dependence. Addiction (Abingdon, England), ￿￿￿(6):8￿￿–8￿￿.
Agrawal, A. and Lynskey, M. T. (￿￿￿8). Are there genetic in￿uences on addiction:
evidence from family, adoption and twin studies. Addiction, ￿￿￿(￿):￿￿6￿–8￿.
Agrawal, A., Madden, P. A. F., Martin, N. G., and Lynskey, M. T. (￿￿￿￿). Do
early experiences with cannabis vary in cigarette smokers? Drug and Alcohol
Dependence, ￿￿8(￿):￿￿￿–￿￿￿.
Agrawal, A., Neale, M. C., Prescott, C. A., and Kendler, K. S. (￿￿￿￿). Cannabis and
￿￿￿
BIBLIOGRAPHY
other illicit drugs: comorbid use and abuse/dependence in males and females.
Behav Genet, ￿￿(￿):￿￿￿–￿8.
Agrawal, A., Silberg, J. L., Lynskey, M. T., Maes, H. H., and Eaves, L. J. (￿￿￿￿).
Mechanisms underlying the lifetime co-occurrence of tobacco and cannabis use
in adolescent and young adult twins. Drug andAlcohol Dependence, ￿￿8(￿–￿):￿￿–
￿￿.
Åkerstedt, T., Knutsson, A., Narusyte, J., Svedberg, P., Kecklund, G., and
Alexanderson, K. (￿￿￿￿). Night work and breast cancer in women: a Swedish
cohort study. BMJ Open, ￿(￿):e￿￿8￿￿￿.
Altman, D. G. (￿￿￿￿). Problems in dichotomizing continuous variables. American
Journal of Epidemiology, ￿￿￿(￿):￿￿￿–￿￿￿.
American Psychiatric Association (￿￿￿￿). Diagnostic and statistical manual of
mental disorders: DSM-IV-TR. American Psychiatric Association, Washington,
DC, ￿th ed., text revision edition.
American Psychiatric Association, American Psychiatric Association, and DSM-￿
Task Force (￿￿￿￿). Diagnostic and statistical manual of mental disorders: DSM-￿.
American Psychiatric Association.
Amundsen, E. J. (￿￿￿￿). Drug-related causes of death: Socioeconomic and
demographic characteristics of the deceased. Scandinavian Journal of Public
Health, ￿￿(6):￿￿￿–￿￿￿. WOS:￿￿￿￿6￿￿￿￿6￿￿￿￿￿.
Anthony, J. (￿￿￿6). The Epidemiology of Cannabis Dependence. In Roffman, R. A.
and Stephens, R. S., editors, Cannabis Dependence: Its Nature, Consequences,
and Treatment, pages ￿8–￿￿￿. Cambridge University Press, New York.
Anthony, J. C., Warner, L. A., and Kessler, R. C. (￿￿￿￿). Comparative epidemiology
of dependence on tobacco, alcohol, controlled substances, and inhalants:
Basic ￿ndings from the national comorbidity survey. Experimental and Clinical
Psychopharmacology, ￿(￿):￿￿￿–￿68.
Arendt, M., Rosenberg, R., Fjordback, L., Brandholdt, J., Foldager, L., Sher, L.,
and Munk-Jørgensen, P. (￿￿￿￿). Testing the self-medication hypothesis of
￿￿6
BIBLIOGRAPHY
depression and aggression in cannabis-dependent subjects. Psychological
Medicine, ￿￿(￿￿):￿￿￿–￿￿￿.
Barker, E. D. and Maughan, B. (￿￿￿￿). Differentiating Early-Onset Persistent Versus
Childhood-Limited Conduct Problem Youth. American Journal of Psychiatry,
￿66(8):￿￿￿–￿￿8.
Barrett, E. L., Newton, N. C., Teesson, M., Slade, T., and Conrod, P. J. (￿￿￿￿).
Adapting the personality-targeted Preventure program to prevent substance use
and associated harms among high-risk Australian adolescents. Early Intervention
in Psychiatry, ￿(￿):￿￿8–￿￿￿.
Barrio, G., De La Fuente, L., Lew, C., Royuela, L., Bravo, M. J., and Torrens, M.
(￿￿￿￿). Differences in severity of heroin dependence by route of administration:
the importance of length of heroin use. Drug and Alcohol Dependence, 6￿(￿):￿6￿–
￿￿￿.
Beaver, K. M. (￿￿￿8). Nonshared Environmental In￿uences on Adolescent
Delinquent Involvement and Adult Criminal Behavior*. Criminology, ￿6(￿):￿￿￿–
￿6￿.
Becker, B., Wagner, D., Gouzoulis-Mayfrank, E., Spuentrup, E., and Daumann, J.
(￿￿￿￿). The impact of early-onset cannabis use on functional brain correlates
of working memory. Progress in Neuro-Psychopharmacology and Biological
Psychiatry, ￿￿(6):8￿￿–8￿￿.
Behrendt, S., Beesdo-Baum, K., Ho￿er, M., Perkonigg, A., Buhringer, G., Lieb, R., and
Wittchen, H. U. (￿￿￿￿). The relevance of age at ￿rst alcohol and nicotine use for
initiation of cannabis use and progression to cannabis use disorders. Drug and
alcohol dependence, ￿￿￿(￿-￿):￿8–￿6.
Behrendt, S., Wittchen, H. U., Ho￿er, M., Lieb, R., and Beesdo, K. (￿￿￿￿). Transitions
from ￿rst substance use to substance use disorders in adolescence: is early
onset associated with a rapid escalation? Drug and alcohol dependence, ￿￿(￿-
￿):68–￿8.
Bellera, C. A., MacGrogan, G., Debled, M., Lara, C. T. d., Brouste, V., and Mathoulin-
Pélissier, S. (￿￿￿￿). Variables with time-varying effects and the Coxmodel: Some
￿￿￿
BIBLIOGRAPHY
statistical concepts illustrated with a prognostic factor study in breast cancer.
BMC Medical Research Methodology, ￿￿(￿):￿￿.
Belsky, D. W., Mof￿tt, T. E., Baker, T., Evans, J., Harrington, H., Houts, R., Meier,
M., Sugden, K., Williams, B., Poulton, R., and Caspi, A. (￿￿￿￿). Polygenic risk
and the developmental progression to heavy, persistent smoking and nicotine
dependence: Evidence from a ￿-decade longitudinal study. JAMA Psychiatry,
￿￿(￿):￿￿￿–￿￿￿.
Benjet, C., Borges, G., Medina-Mora, M. E., andMéndez, E. (￿￿￿￿). Chronic childhood
adversity and stages of substance use involvement in adolescents. Drug and
Alcohol Dependence, ￿￿￿(￿–￿):8￿–￿￿.
Benyamina, A., Bonhomme-Faivre, L., Picard, V., Sabbagh, A., Richard, D., Blecha,
L., Rahioui, H., Karila, L., Lukasiewicz, M., Picard, V., Marill, C., and Reynaud, M.
(￿￿￿￿). Association between ABCB￿ C￿￿￿￿t polymorphism and increased risk
of cannabis dependence. Progress in Neuro-Psychopharmacology and Biological
Psychiatry, ￿￿(￿):￿￿￿￿–￿￿￿￿.
Best, D., Gross, S., Manning, V., Gossop, M., Witton, J., and Strang, J. (￿￿￿￿).
Cannabis use in adolescents: the impact of risk and protective factors and social
functioning. Drug and Alcohol Review, ￿￿(6):￿8￿–￿88.
Bogdanowicz, K. M., Stewart, R., Chang, C.-K., Downs, J., Khondoker, M., Shetty,
H., Strang, J., and Hayes, R. D. (￿￿￿6). Identifying mortality risks in patients
with opioid use disorder using brief screening assessment: Secondary mental
health clinical records analysis. Drug and Alcohol Dependence, ￿6￿:8￿–88.
WOS:￿￿￿￿￿8￿688￿￿￿￿￿.
Boker, S. M., Neale, M. C., Maes, H. H., Wilde, M. J., Spiegel, M., Brick, T. R., Spies, J.,
Estabrook, R., Kenny, S., Bates, T. C., Mehta, P., and Fox, J. (￿￿￿￿). OpenMx: An
Open Source Extended Structural EquationModeling Framework. Psychometrika,
￿6(￿):￿￿6–￿￿￿.
Bosker, F., Hartman, C., Nolte, I., Prins, B., Terpstra, P., Posthuma, D., van Veen,
T., Willemsen, G., DeRijk, R., de Geus, E., Hoogendijk, W., Sullivan, P., Penninx,
B., Boomsma, D., Snieder, H., and Nolen, W. (￿￿￿￿). Poor replication of
￿￿8
BIBLIOGRAPHY
candidate genes for major depressive disorder using genome-wide association
data. Molecular Psychiatry, ￿6:￿￿6–￿￿.
Bridge, J. (￿￿￿￿). Route transition interventions: Potential public health gains from
reducing or preventing injecting. International Journal of Drug Policy, ￿￿(￿):￿￿￿–
￿￿8.
Brody, G. H., Chen, Y.-f., and Beach, S. R. H. (￿￿￿￿). Differential susceptibility to
prevention: GABAergic, dopaminergic, and multilocus effects. Journal of Child
Psychology and Psychiatry, and Allied Disciplines, ￿￿(8):86￿–8￿￿.
Broms, U., Silventoinen, K., Madden, P. A. F., Heath, A. C., and Kaprio, J. (￿￿￿6).
Genetic Architecture of Smoking Behavior: A Study of Finnish Adult Twins. Twin
Research and Human Genetics, ￿(￿):6￿–￿￿.
Bucholz, K. K., Cadoret, R., Cloninger, C. R., Dinwiddie, S. H., Hesselbrock, V. M.,
Nurnberger, J., Reich, T., Schmidt, I., and Schuckit, M. A. (￿￿￿￿). A New, Semi-
Structured Psychiatric Interview for Use in Genetic Linkage Studies: A Report on
the Reliability of the SSAGA. Journal of Studies on Alcohol and Drugs, ￿￿(￿):￿￿￿.
Caris, L., Wagner, F. A., Ríos-Bedoya, C. F., and Anthony, J. C. (￿￿￿￿). Opportunities
to use drugs and stages of drug involvement outside the United States: Evidence
from the Republic of Chile. Drug and Alcohol Dependence, ￿￿￿(￿–￿):￿￿–￿￿.
Carney, T., Myers, B. J., Louw, J., and Okwundu, C. I. (￿￿￿6). Brief school-based
interventions and behavioural outcomes for substance-using adolescents. In The
Cochrane Collaboration, editor, Cochrane Database of Systematic Reviews. John
Wiley & Sons, Ltd, Chichester, UK.
Chamla, D., Chamla, J. H., Dabin, W., Delin, H., and Rennes, N. (￿￿￿6). Transition to
injection and sharing of needles/syringes: Potential for HIV transmission among
heroin users in Chengdu, China. Addictive Behaviors, ￿￿(￿):6￿￿–￿￿￿.
Chen, C.-Y., Dormitzer, C. M., Bejarano, J., and Anthony, J. C. (￿￿￿￿). Religiosity and
the Earliest Stages of Adolescent Drug Involvement in Seven Countries of Latin
America. American Journal of Epidemiology, ￿￿￿(￿￿):￿￿8￿–￿￿88.
￿￿￿
BIBLIOGRAPHY
Chen, C.-Y., O’Brien, M. S., and Anthony, J. C. (￿￿￿￿a). Who becomes cannabis
dependent soon after onset of use? Epidemiological evidence from the United
States: ￿￿￿￿–￿￿￿￿. Drug and Alcohol Dependence, ￿￿(￿):￿￿–￿￿.
Chen, C. Y., Storr, C. L., and Anthony, J. C. (￿￿￿￿b). In￿uences of parenting practices
on the risk of having a chance to try cannabis. Pediatrics, ￿￿￿(6):￿6￿￿–￿.
Chen, C.-Y., Storr, C. L., and Anthony, J. C. (￿￿￿￿). Early-onset drug use and risk for
drug dependence problems. Addictive Behaviors, ￿￿(￿):￿￿￿–￿￿￿.
Coffey, C., Lynskey, M., Wolfe, R., and Patton, G. C. (￿￿￿￿). Initiation and progression
of cannabis use in a population-based Australian adolescent longitudinal study.
Addiction, ￿￿(￿￿):￿6￿￿–￿6￿￿.
Conway, K. P., Levy, J., Vanyukov, M., Chandler, R., Rutter, J., Swan, G. E., and Neale,
M. (￿￿￿￿). Measuring addiction propensity and severity: The need for a new
instrument. Drug and Alcohol Dependence, ￿￿￿(￿–￿):￿–￿￿.
Creemers, H. E., Korhonen, T., Kaprio, J., Vollebergh, W. A. M., Ormel, J., Verhulst,
F. C., and Huizink, A. C. (￿￿￿￿a). The role of temperament in the relationship
between early onset of tobacco and cannabis use: The TRAILS study. Drug and
Alcohol Dependence, ￿￿￿(￿–￿):￿￿￿–￿￿8.
Creemers, H. E., Lier, P. A. C. v., Vollebergh, W. A. M., Ormel, J., Verhulst, F. C., and
Huizink, A. C. (￿￿￿￿b). Predicting Onset of Cannabis Use in Early Adolescence:
The Interrelation Between High-Intensity Pleasure and Disruptive Behavior. The
TRAILS Study [Corrected Version]. Journal of Studies on Alcohol and Drugs,
￿￿(6):8￿￿.
Danielsson, A.-K., Lundin, A., Agardh, E., Allebeck, P., and Forsell, Y. (￿￿￿6). Cannabis
use, depression and anxiety: A ￿-year prospective population-based study.
Journal of Affective Disorders, ￿￿￿:￿￿￿–￿￿8. WOS:￿￿￿￿6￿￿86￿￿￿￿￿￿.
Darke, S. (￿￿￿8). Self-report among injecting drug users: A review. Drug and Alcohol
Dependence, ￿￿(￿):￿￿￿–￿6￿.
Darke, S. (￿￿￿￿). The Life of the Heroin User. Cambridge University Press.
￿8￿
BIBLIOGRAPHY
Darke, S., Kaye, S., and Torok, M. (￿￿￿￿). Age-related patterns of drug use initiation
among polydrug using regular psychostimulant users. Drug and Alcohol Review,
￿￿(6):￿8￿–￿8￿.
Darke, S., Marel, C., Mills, K. L., Ross, J., Slade, T., Burns, L., and Teesson, M.
(￿￿￿￿). Patterns and correlates of non-fatal heroin overdose at ￿￿-year follow-
up: Findings from the Australian Treatment Outcome Study. Drug and Alcohol
Dependence, ￿￿￿:￿￿8–￿￿￿. WOS:￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿.
Darke, S., Ross, J., and Kaye, S. (￿￿￿￿). Physical injecting sites among injecting drug
users in Sydney, Australia. Drug and Alcohol Dependence, 6￿(￿):￿￿–8￿.
Davies, J. B. and Baker, R. (￿￿8￿). The Impact of Self-presentation and Interviewer
Bias Effects on Self-reported Heroin Use. British Journal of Addiction, 8￿(8):￿￿￿–
￿￿￿.
Degenhardt, L., Bucello, C., Mathers, B., Briegleb, C., Ali, H., Hickman, M., and
McLaren, J. (￿￿￿￿). Mortality among regular or dependent users of heroin and
other opioids: a systematic review andmeta-analysis of cohort studies. Addiction
(Abingdon, England), ￿￿6(￿):￿￿–￿￿.
Degenhardt, L., Chiu, W.-T., Sampson, N., Kessler, R. C., Anthony, J. C., Angermeyer,
M., Bruffaerts, R., de Girolamo, G., Gureje, O., Huang, Y., Karam, A., Kostyuchenko,
S., Lepine, J. P., Mora, M. E. M., Neumark, Y., Ormel, J. H., Pinto-Meza, A., Posada-
Villa, J., Stein, D. J., Takeshima, T., and Wells, J. E. (￿￿￿8). Toward a Global View
of Alcohol, Tobacco, Cannabis, and Cocaine Use: Findings from the WHO World
Mental Health Surveys. PLoS Med., ￿(￿):e￿￿￿.
Degenhardt, L., Romaniuk, H., Coffey, C., Hall, W. D., Swift, W., Carlin, J. B., O’Loughlin,
C., and Patton, G. C. (￿￿￿￿). Does the social context of early alcohol use affect
risky drinking in adolescents? Prospective cohort study. BMC public health,
￿￿(￿):￿￿￿￿.
Degenhardt, L., Whiteford, H., and Hall, W. D. (￿￿￿￿). The Global Burden of Disease
projects: What have we learned about illicit drug use and dependence and their




Degenhardt, L., Whiteford, H. A., Ferrari, A. J., Baxter, A. J., Charlson, F. J., Hall, W. D.,
Freedman, G., Burstein, R., Johns, N., Engell, R. E., Flaxman, A., Murray, C. J.,
and Vos, T. (￿￿￿￿). Global burden of disease attributable to illicit drug use and
dependence: ￿ndings from the Global Burden of Disease Study ￿￿￿￿. The Lancet,
￿8￿(￿￿￿￿):￿￿6￿–￿￿￿￿.
DeWit, D. J., Hance, J., Offord, D. R., and Ogborne, A. (￿￿￿￿). The In￿uence of Early
and Frequent Use of Marijuana on the Risk of Desistance and of Progression to
Marijuana-Related Harm. Preventive Medicine, ￿￿(￿):￿￿￿–￿6￿.
Dick, D. M., Cho, S. B., Latendresse, S. J., Aliev, F., Nurnberger, J. I., Edenberg, H. J.,
Schuckit, M., Hesselbrock, V. M., Porjesz, B., Bucholz, K., Wang, J.-C., Goate, A.,
Kramer, J. R., and Kuperman, S. (￿￿￿￿). Genetic in￿uences on alcohol use across
stages of development: GABRA￿ and longitudinal trajectories of drunkenness
from adolescence to young adulthood. Addiction Biology, ￿￿(6):￿￿￿￿–￿￿6￿.
Ding, Y., He, N., Shoptaw, S., Gao, M., and Detels, R. (￿￿￿￿). Severity of club drug
dependence and perceived need for treatment among a sample of adult club
drug users in Shanghai, China. Social Psychiatry and Psychiatric Epidemiology,
￿￿(￿):￿￿￿–￿￿￿.
Distel, M. A., Vink, J. M., Bartels, M., van Beijsterveldt, C. E., Neale, M. C., and
Boomsma, D. I. (￿￿￿￿). Age moderates non-genetic in￿uences on the initiation
of cannabis use: a twin-sibling study in Dutch adolescents and young adults.
Addiction, ￿￿6(￿):￿6￿8–66.
Do, E. K., Prom-Wormley, E. C., Eaves, L. J., Silberg, J. L., Miles, D. R., and Maes,
H. H. (￿￿￿￿). Genetic and Environmental In￿uences on Smoking Behavior across
Adolescence and Young Adulthood in the Virginia Twin Study of Adolescent
Behavioral Development and theTransitions to SubstanceAbuse Follow-Up. Twin
Research and Human Genetics, ￿8(￿￿):￿￿–￿￿.
Donovan, J. E. and Molina, B. S. G. (￿￿￿￿). Childhood Risk Factors for Early-Onset
Drinking. Journal of Studies on Alcohol and Drugs, ￿￿(￿):￿￿￿–￿￿￿.
Dube, S. R., Miller, J. W., Brown, D. W., Giles, W. H., Felitti, V. J., Dong, M., and Anda,
R. F. (￿￿￿6). Adverse childhood experiences and the association with ever using
alcohol and initiating alcohol use during adolescence. The Journal of Adolescent
￿8￿
BIBLIOGRAPHY
Health: Of￿cial Publication of the Society for Adolescent Medicine, ￿8(￿):￿￿￿.e￿–
￿￿.
Duncan, L. E. and Keller, M. C. (￿￿￿￿). A critical review of the ￿rst ￿￿ years of
candidate gene-by-environment interaction research in psychiatry. The American
Journal of Psychiatry, ￿68(￿￿):￿￿￿￿–￿￿￿￿.
Efron, B. (￿￿￿￿). The Ef￿ciency of Cox’s Likelihood Function for Censored Data.
Journal of the American Statistical Association, ￿￿(￿￿￿):￿￿￿–￿6￿.
Eisenberg, M. E., Spry, E., and Patton, G. C. (￿￿￿￿). From Emerging to Established
Longitudinal Patterns in the Timing of Transition Events Among Australian
Emerging Adults. Emerging Adulthood, ￿(￿):￿￿￿–￿8￿.
Elkins, I., McGue, M., and Iacono, W. G. (￿￿￿￿). Prospective effects of attention-
de￿cit/hyperactivity disorder, conduct disorder, and sex on adolescent substance
use and abuse. Archives of General Psychiatry, 6￿(￿￿):￿￿￿￿–￿￿￿￿.
Ensminger, M. E., Juon, H.-S., and Green, K. M. (￿￿￿￿). Consistency between
adolescent reports and adult retrospective reports of adolescent marijuana use:
Explanations of inconsistent reporting among an African American population.
Drug & Alcohol Dependence, 8￿(￿):￿￿–￿￿.
Faul, F., Erdfelder, E., Buchner, A., and Lang, A.-G. (￿￿￿￿). G*power ￿: A ￿exible
statistical power analysis program for the social, behavioral, and biomedical
sciences. Behavior Research Methods, ￿￿:￿￿￿–￿￿￿.
Feingold, D., Weiser, M., Rehm, J., and Lev-Ran, S. (￿￿￿￿). The association between
cannabis use and mood disorders: A longitudinal study. Journal of Affective
Disorders, ￿￿￿C:￿￿￿–￿￿8.
Fergusson, D. M. and Horwood, L. J. (￿￿￿￿). Early onset cannabis use and
psychosocial adjustment in young adults. Addiction, ￿￿(￿):￿￿￿–￿￿6.
Fergusson, D. M., Lynskey, M. T., and Horwood, L. J. (￿￿￿￿). Conduct Problems
and Attention De￿cit Behaviour in Middle Childhood and Cannabis Use by Age
￿￿. Australian and New Zealand Journal of Psychiatry, ￿￿(￿):6￿￿–68￿.
￿8￿
BIBLIOGRAPHY
Fisher, L. D. and Lin, D. Y. (￿￿￿￿). Time-Dependent Covariates in the Cox
Proportional-Hazards Regression Model. Annual Review of Public Health,
￿￿(￿):￿￿￿–￿￿￿.
Fowler, T., Lifford, K., Shelton, K., Rice, F., Thapar, A., Neale, M. C., McBride, A.,
and van den Bree, M. B. M. (￿￿￿￿). Exploring the relationship between genetic
and environmental in￿uences on initiation and progression of substance use.
Addiction (Abingdon, England), ￿￿￿(￿):￿￿￿–￿￿￿.
Fuller, E., Jotangia, D., and Farrell, M. (￿￿￿￿). Drug misuse and Dependence.
Technical report, The NHS Information Centre for health and social care.
Gage, S. H., Hickman, M., Heron, J., Munafò, M. R., Lewis, G., Macleod, J., and
Zammit, S. (￿￿￿￿). Associations of cannabis and cigarette use with depression
and anxiety at age ￿8: ￿ndings from the Avon Longitudinal Study of Parents and
Children. PloS One, ￿￿(￿):e￿￿￿￿8￿6.
Galéra, C., Bouvard, M. P., Melchior, M., Chastang, J. F., Lagarde, E., Michel, G.,
Encrenaz, G., Messiah, A., and Fombonne, E. (￿￿￿￿). Disruptive symptoms in
childhood and adolescence and early initiation of tobacco and cannabis use: The
Gazel Youth study. European Psychiatry, ￿￿(￿):￿￿￿–￿￿8.
Gillespie, N. A., Kendler, K. S., Prescott, C. A., Aggen, S. H., Gardner, C. O., Jacobson,
K., and Neale, M. C. (￿￿￿￿). Longitudinal modeling of genetic and environmental
in￿uences on self-reported availability of psychoactive substances: alcohol,
cigarettes, marijuana, cocaine and stimulants. Psychological Medicine,
￿￿(￿￿):￿￿￿–￿￿￿.
Gillespie, N. A. and Martin, N. G. (￿￿￿￿). Multivariate Genetic Analysis. John Wiley
& Sons, Ltd.
Gillespie, N. A., Neale, M. C., and Kendler, K. S. (￿￿￿￿). Pathways to cannabis
abuse: a multi-stage model from cannabis availability, cannabis initiation and
progression to abuse. Addiction, ￿￿￿(￿):￿￿￿–￿￿8.
Golick, J. (￿￿￿6). Shifting the Paradigm: Adolescent Cannabis Abuse and the Need
for Early Intervention. Journal of Psychoactive Drugs, ￿8(￿):￿￿–￿￿.
￿8￿
BIBLIOGRAPHY
González-Sáiz, F., Domingo-Salvany, A., Barrio, G., Sánchez-Niubó, A., Brugal, M. T.,
de la Fuente, L., and Alonso, J. (￿￿￿￿). Severity of Dependence Scale as
a Diagnostic Tool for Heroin and Cocaine Dependence. European Addiction
Research, ￿￿(￿):8￿–￿￿.
González-Saiz, F., Lozano, Ó. M., Ballesta, R., Silva, T., Brugal, M. T., Bilbao, I., Barrio,
G., Domingo-Salvany, A., Bravo, M. J., De la Fuente, L., and del Proyecto ItÍnere,
G. (￿￿￿8). Validity of the Severity of Dependence Scale (SDS) Construct Applying
the Item Response Theory to a Non-Clinical Sample of Heroin Users. Substance
Use & Misuse, ￿￿(￿):￿￿￿–￿￿￿.
Gossop, M., Darke, S., Grif￿ths, P., Hando, J., Powis, B., Hall, W., and Strang, J. (￿￿￿￿).
The Severity of Dependence Scale (SDS): psychometric properties of the SDS
in English and Australian samples of heroin, cocaine and amphetamine users.
Addiction, ￿￿(￿):6￿￿–6￿￿.
Gossop, M., Grif￿ths, P., Powis, B., Williamson, S., and Strang, J. (￿￿￿6). Frequency
of non-fatal heroin overdose: survey of heroin users recruited in non-clinical
settings. BMJ, ￿￿￿:￿￿￿.
Grant, B. and Dawson, D. A. (￿￿￿8). Age of onset of drug use and its association
with dsm-iv drug abuse and dependence: Results from the national longitudinal
alcohol epidemiologic survey. Journal of Substance Abuse, ￿￿:￿6￿–￿￿￿.
Grant, J. D., Agrawal, A., Bucholz, K. K., Madden, P. A. F., Pergadia, M. L., Nelson, E. C.,
Lynskey, M. T., Todd, R. D., Todorov, A. A., Hansell, N. K., Whit￿eld, J. B., Martin,
N. G., and Heath, A. C. (￿￿￿￿). Alcohol consumption indices of genetic risk for
alcohol dependence. Biological Psychiatry, 66(8):￿￿￿–8￿￿.
Grant, J. D., Lynskey, M. T., Madden, P. a. F., Nelson, E. C., Few, L. R., Bucholz, K. K.,
Statham, D. J., Martin, N. G., Heath, A. C., and Agrawal, A. (￿￿￿￿). The role of
conduct disorder in the relationship between alcohol, nicotine and cannabis use
disorders. Psychological Medicine, ￿￿(￿6):￿￿￿￿–￿￿￿￿.
Grant, J. D., Lynskey, M. T., Scherrer, J. F., Agrawal, A., Heath, A. C., and Bucholz,
K. K. (￿￿￿￿). A cotwin-control analysis of drug use and abuse/dependence risk
associated with early-onset cannabis use. Addictive Behaviors, ￿￿(￿):￿￿–￿￿.
￿8￿
BIBLIOGRAPHY
Grant, J. D., Scherrer, J. F., Lynskey, M. T., Lyons, M. J., Eisen, S. A., Tsuang, M. T.,
True, W. R., and Bucholz, K. K. (￿￿￿6). Adolescent alcohol use is a risk factor for
adult alcohol and drug dependence: evidence from a twin design. Psychol Med,
￿6(￿):￿￿￿–￿8.
Green￿eld, T. K., Nayak, M. B., Bond, J., Kerr, W. C., and Ye, Y. (￿￿￿￿). Test–
Retest Reliability and Validity of Life-Course Alcohol ConsumptionMeasures: The
￿￿￿￿ National Alcohol Survey Follow-Up. Alcoholism: Clinical and Experimental
Research, ￿8(￿):￿￿￿￿–￿￿8￿.
Grif￿ths, P., Gossop, M., Powis, B., and Strang, J. (￿￿￿￿). Reaching hidden
populations of drug users by privileged access interviewers: methodological and
practical issues. Addiction (Abingdon, England), 88(￿￿):￿6￿￿–￿6￿6.
Grif￿ths, P., Gossop, M., Powis, B., and Strang, J. (￿￿￿￿). Transitions in patterns of
heroin administration: a study of heroin chasers and heroin injectors. Addiction
(Abingdon, England), 8￿(￿):￿￿￿–￿￿￿.
Grucza, R., Agrawal, A., Krauss, M., Bongu, J., Plunk, A., Cavazos-Rehg, P., and Bierut,
L. (￿￿￿6). Declining prevalence of marijuana use disorders among adolescents
in the united states, ￿￿￿￿ to ￿￿￿￿. Journal of Academic Child and Adolescent
Psychiatry, ￿￿:￿8￿–￿￿￿.
Haas, A. L. and Peters, R. H. (￿￿￿￿). Development of substance abuse problems
among drug-involved offenders: evidence for the telescoping effect. Journal of
Substance Abuse, ￿￿(￿):￿￿￿–￿￿￿.
Hansen, S. E. (￿￿￿￿). CATI Sample Management Systems. In Lepkowski, J. M.,
Tucker, C., Brick, J. M., Leeuw, E. D. d., Japec, L., Lavrakas, P. J., Link, M. W., and
Sangster, R. L., editors, Advances in Telephone Survey Methodology, pages ￿￿￿–
￿￿8. John Wiley & Sons, Inc.
Hartman, C. A., Hopfer, C. J., Haberstick, B., Rhee, S. H., Crowley, T. J., Corley, R. P.,
Hewitt, J. K., and Ehringer, M. A. (￿￿￿￿). The association between cannabinoid
receptor ￿ gene (CNR￿) and cannabis dependence symptoms in adolescents and
young adults. Drug and Alcohol Dependence, ￿￿￿(￿–￿):￿￿–￿6.
￿86
BIBLIOGRAPHY
Hasin, D. S., Saha, T. D., Kerridge, B. T., Goldstein, R. B., Chou, S. P., Zhang, H., Jung,
J., Pickering, R. P., Ruan, W. J., Smith, S. M., Huang, B., and Grant, B. F. (￿￿￿￿).
Prevalence of Marijuana Use Disorders in the United States Between ￿￿￿￿-￿￿￿￿
and ￿￿￿￿-￿￿￿￿. JAMA psychiatry, ￿￿(￿￿):￿￿￿￿–￿￿￿￿.
Hawkins, J. D., Catalano, R. F., and Miller, J. Y. (￿￿￿￿). Risk and protective
factors for alcohol and other drug problems in adolescence and early adulthood:
implications for substance abuse prevention. Psychological Bulletin, ￿￿￿(￿):6￿–
￿￿￿.
Heath, A. C., Bucholz, K. K., Madden, P. A., Dinwiddie, S. H., Slutske, W. S., Bierut,
L. J., Statham, D. J., Dunne, M. P., Whit￿eld, J. B., and Martin, N. G. (￿￿￿￿). Genetic
and environmental contributions to alcohol dependence risk in a national twin
sample: consistency of ￿ndings in women and men. Psychological Medicine,
￿￿(6):￿￿8￿–￿￿￿6.
Heath, A. C., Jardine, R., andMartin, N. G. (￿￿8￿). Interactive effects of genotype and
social environment on alcohol consumption in female twins. Journal of Studies
on Alcohol, ￿￿(￿):￿8–￿8.
Heath, A. C., Kirk, K. M., Meyer, J. M., and Martin, N. G. (￿￿￿￿). Genetic and
social determinants of initiation and age at onset of smoking in Australian twins.
Behavior Genetics, ￿￿(6):￿￿￿–￿￿￿.
Heath, A. C., Martin, N. G., Lynskey, M. T., Todorov, A. A., and Madden, P. A. F.
(￿￿￿￿). Estimating two-stage models for genetic in￿uences on alcohol, tobacco
or drug use initiation and dependence vulnerability in twin and family data.
Twin Research: The Of￿cial Journal of the International Society for Twin Studies,
￿(￿):￿￿￿–￿￿￿.
Hennekens, C. H. and Buring, J. (￿￿8￿). Epidemiology in Medicine. Lippincott,
Williams & Wilkins, Philadelphia, PA.
Heron, J., Barker, E. D., Joinson, C., Lewis, G., Hickman,M., Munafo, M., andMacleod,
J. (￿￿￿￿). Childhood conduct disorder trajectories, prior risk factors and cannabis
use at age ￿6: birth cohort study. Addiction, ￿￿8(￿￿):￿￿￿￿–￿8.
￿8￿
BIBLIOGRAPHY
Hesselbrock, M., Easton, C., Bucholz, K. K., Schuckit, M., and Hesselbrock, V.
(￿￿￿￿). A validity study of the SSAGA-a comparison with the SCAN. Addiction,
￿￿(￿):￿￿6￿–￿￿￿￿.
Hicks, B. M., Durbin, C. E., Blonigen, D. M., Iacono, W. G., and McGue, M. (￿￿￿￿).
Relationship between personality change and the onset and course of alcohol
dependence in young adulthood. Addiction, ￿￿￿(￿):￿￿￿–8.
Hillstrom, R. P., Cohn, A. M., and Mccarroll, K. A. (￿￿￿￿). Vocal cord paralysis
resulting from neck injections in the intravenous drug use population. The
Laryngoscope, ￿￿￿(￿):￿￿￿–￿￿6.
Hindocha, C., Freeman, T. P., Ferris, J. A., Lynskey, M. T., and Winstock, A. R.
(￿￿￿6). No Smokewithout Tobacco: A Global Overview of Cannabis and Tobacco
Routes of Administration and Their Association with Intention to Quit. Addictive
Disorders, page ￿￿￿.
Hindocha, C., Shaban, N. D. C., Freeman, T. P., Das, R. K., Gale, G., Schafer, G.,
Falconer, C. J., Morgan, C. J. A., and Curran, H. V. (￿￿￿￿). Associations between
cigarette smoking and cannabis dependence: A longitudinal study of young
cannabis users in the United Kingdom. Drug and Alcohol Dependence, ￿￿8:￿6￿–
￿￿￿.
Hingson, R. W., Heeren, T., and Edwards, E. M. (￿￿￿8). Age at Drinking Onset,
Alcohol Dependence, and Their Relation to Drug Use and Dependence, Driving
Under the In￿uence of Drugs, and Motor-Vehicle Crash Involvement Because of
Drugs. Journal of Studies on Alcohol and Drugs, 6￿(￿):￿￿￿.
Hingson, R. W., Heeren, T., and Winter, M. R. (￿￿￿6). Age of Alcohol-Dependence
Onset: Associations With Severity of Dependence and Seeking Treatment.
Pediatrics, ￿￿8(￿):e￿￿￿–e￿6￿.
Hingson, R. W. and Zha, W. (￿￿￿￿). Age of Drinking Onset, Alcohol Use Disorders,
Frequent Heavy Drinking, and Unintentionally Injuring Oneself and Others After
Drinking. Pediatrics, ￿￿￿(6):￿￿￿￿–￿￿8￿.
Hopfer, C. (￿￿￿￿). Implications of Marijuana Legalization for Adolescent Substance
Use. Substance Abuse, ￿￿(￿):￿￿￿–￿￿￿.
￿88
BIBLIOGRAPHY
Hopper, J. L. (￿￿￿￿). The Australian Twin Registry. Twin Research, ￿(￿):￿￿￿–￿￿6.
WOS:￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿.
Hopper, J. L., Foley, D. L., White, P. A., and Pollaers, V. (￿￿￿￿). Australian Twin
Registry: ￿￿ years of progress. Twin Research and Human Genetics: The Of￿cial
Journal of the International Society for Twin Studies, ￿6(￿):￿￿–￿￿.
Horyniak, D., Stoové, M., Degenhardt, L., Aitken, C., Kerr, T., and Dietze, P. (￿￿￿￿).
How do drug market changes affect characteristics of injecting initiation and
subsequent patterns of drug use? ￿ndings from a cohort of regular heroin and
methamphetamine injectors in melbourne, australia. Int. J. Drug Policy, ￿6.
Hosmer, David W., J., Lemeshow, S., and Sturdivant, R. X. (￿￿￿￿). Model-Building
Strategies and Methods for Logistic Regression. In Applied Logistic Regression,
pages 8￿–￿￿￿. John Wiley & Sons, Inc.
Hotopf, M. (￿￿￿￿). The case–control study. In Prince, M., Stewart, R., Ford, T., and
Hotopf, M., editors, Practical Psychiatric Epidemiology, pages ￿￿￿–￿￿￿. Oxford
University Press.
Hudziak, J. J., van Beijsterveldt, C. E. M., Bartels, M., Rietveld, M. J. H., Rettew, D. C.,
Derks, E. M., and Boomsma, D. I. (￿￿￿￿). Individual Differences in Aggression:
Genetic Analyses by Age, Gender, and Informant in ￿-, ￿-, and ￿￿-Year-Old Dutch
Twins. Behavior Genetics, ￿￿(￿):￿￿￿–￿8￿.
Huerta, M., Chodick, G., Balicer, R. D., Davidovitch, N., andGrotto, I. (￿￿￿￿). Reliability
of self-reported smoking history and age at initial tobacco use. Preventive
Medicine, ￿￿(￿):6￿6–6￿￿. WOS:￿￿￿￿￿￿￿￿8￿￿￿￿￿6.
Huizink, A. C., Levälahti, E., Korhonen, T., Dick, D. M., Pulkkinen, L., Rose, R. J., and
Kaprio, J. (￿￿￿￿). Tobacco, Cannabis, and Other Illicit Drug Use Among Finnish
Adolescent Twins: Causal Relationship or Correlated Liabilities? Journal of
Studies on Alcohol and Drugs, ￿￿(￿):￿.
Hung, C.-C., Chang, H.-Y., Luh, D.-L., Wu, C.-C., and Yen, L.-L. (￿￿￿￿). Do parents
play different roles in drinking behaviours of male and female adolescents? A
longitudinal follow-up study. BMJ Open, ￿(￿):e￿￿￿￿￿￿.
￿8￿
BIBLIOGRAPHY
Hunt, N., Stillwell, G., Taylor, C., and Grif￿ths, P. (￿￿￿8). Evaluation of a Brief
Intervention to Prevent Initiation into Injecting. Drugs: Education, Prevention and
Policy, ￿(￿):￿8￿–￿￿￿.
Jamal, M., Does, A. J., Penninx, B. W. J. H., and Cuijpers, P. (￿￿￿￿). Age at Smoking
Onset and the Onset of Depression and Anxiety Disorders. Nicotine & Tobacco
Research, ￿￿(￿):8￿￿–8￿￿.
Jenkins, S. P. (￿￿￿8). Preparing survival time data for analysis and estimation.
Johnson, B. A., Cloninger, C. R., Roache, J. D., Bordnick, P. S., and Ruiz, P. (￿￿￿￿). Age
of Onset as a Discriminator Between Alcoholic Subtypes in a Treatment-Seeking
Outpatient Population. The American Journal on Addictions, ￿(￿):￿￿–￿￿.
Johnson, T. P. and Mott, J. A. (￿￿￿￿). The reliability of self-reported age of onset of
tobacco, alcohol and illicit drug use. Addiction (Abingdon, England), ￿6(8):￿￿8￿–
￿￿￿8.
Kempel, P., Lampe, K., Parnefjord, R., Hennig, J., and Kunert, H. J. (￿￿￿￿).
Auditory-evoked potentials and selective attention: different ways of information
processing in cannabis users and controls. Neuropsychobiology, ￿8(￿):￿￿–￿￿￿.
Kendler, K. S. and Baker, J. H. (￿￿￿￿). Genetic in￿uences on measures of the
environment: a systematic review. Psychological Medicine, ￿￿(￿):6￿￿–6￿6.
Kendler, K. S. and Gardner, C. O. (￿￿￿8). Twin studies of adult psychiatric
and substance dependence disorders: are they biased by differences in the
environmental experiences of monozygotic and dizygotic twins in childhood and
adolescence? Psychological Medicine, ￿8(￿):6￿￿–6￿￿.
Kendler, K. S., Jacobson, K. C., Prescott, C. A., and Neale, M. C. (￿￿￿￿). Speci￿city
of Genetic and Environmental Risk Factors for Use and Abuse/Dependence of
Cannabis, Cocaine, Hallucinogens, Sedatives, Stimulants, and Opiates in Male
Twins. American Journal of Psychiatry, ￿6￿(￿):68￿–6￿￿.
Kendler, K. S., Karkowski, L. M., Corey, L. A., Prescott, C. A., and Neale, M. C. (￿￿￿￿a).
Genetic and environmental risk factors in the aetiology of illicit drug initiation and
subsequent misuse in women. The British Journal of Psychiatry, ￿￿￿(￿):￿￿￿–￿￿6.
￿￿￿
BIBLIOGRAPHY
Kendler, K. S., Neale, M. C., Kessler, R. C., Heath, A. C., and Eaves, L. J. (￿￿￿￿). A
test of the equal-environment assumption in twin studies of psychiatric illness.
Behavior Genetics, ￿￿(￿):￿￿–￿￿.
Kendler, K. S., Neale, M. C., Sullivan, P., Corey, L. A., Gardner, C. O., and Prescott,
C. A. (￿￿￿￿b). A population-based twin study in women of smoking initiation and
nicotine dependence. Psychol Med, ￿￿(￿):￿￿￿–￿￿8.
Kendler, K. S., Pedersen, N. L., Farahmand, B. Y., and Persson, P. G. (￿￿￿6). The
treated incidence of psychotic and affective illness in twins compared with
population expectation: a study in the Swedish Twin and Psychiatric Registries.
Psychological Medicine, ￿6(6):￿￿￿￿–￿￿￿￿.
Kendler, K. S. and Prescott, C. A. (￿￿￿8). Cannabis Use, Abuse, and Dependence
in a Population-Based Sample of Female Twins. American Journal of Psychiatry,
￿￿￿(8):￿￿￿6–￿￿￿￿.
Kendler, K. S., Schmitt, E., Aggen, S. H., and Prescott, C. A. (￿￿￿8). Genetic
and Environmental In￿uences on Alcohol, Caffeine, Cannabis, and Nicotine Use
From Early Adolescence to Middle Adulthood. Archives of general psychiatry,
6￿(6):6￿￿–68￿.
Kessler, R. C., Berglund, P., Demler, O., Jin, R., Merikangas, K. R., and Walters, E.
(￿￿￿￿). LIfetime prevalence and age-of-onset distributions of dsm-iv disorders
in the national comorbidity survey replication. Archives of General Psychiatry,
6￿(6):￿￿￿–6￿￿.
Kirkwood, B. R. and Sterne, J. A. C. (￿￿￿￿). Essential medical statistics. Blackwell
Science, Malden, Mass., ￿ edition.
Kleinbaum, D. G. and Klein, M. (￿￿￿￿). Survival Analysis - A Self-Learning Text, Third
Edition. Springer-Verlag New York.
Laucht, M., Becker, K., Blomeyer, D., and Schmidt, M. H. (￿￿￿￿). Novelty seeking
involved in mediating the association between the dopamine D￿ receptor gene
exon III polymorphism and heavy drinking in male adolescents: results from a
high-risk community sample. Biological Psychiatry, 6￿(￿):8￿–￿￿.
￿￿￿
BIBLIOGRAPHY
Lawrinson, P., Ali, R., Buavirat, A., Chiamwongpaet, S., Dvoryak, S., Habrat, B., Jie,
S., Mardiati, R., Mokri, A., Moskalewicz, J., Newcombe, D., Poznyak, V., Subata, E.,
Uchtenhagen, A., Utami, D. S., Vial, R., and Zhao, C. (￿￿￿8). Key ￿ndings from
the WHO collaborative study on substitution therapy for opioid dependence and
HIV/AIDS. Addiction, ￿￿￿(￿):￿￿8￿–￿￿￿￿.
Little, R. J. A. and Rubin, D. B. (￿￿￿￿). Statistical Analysis with Missing Data. John
Wiley & Sons.
Little￿eld, A. K., Sher, K. J., and Wood, P. K. (￿￿￿￿). Do changes in drinking motives
mediate the relation between personality change and "maturing out" of problem
drinking? Journal of Abnormal Psychology, ￿￿￿(￿):￿￿–￿￿￿.
LoParo, D. and Waldman, I. (￿￿￿￿). Twins’ Rearing Environment Similarity
and Childhood Externalizing Disorders: A Test of the Equal Environments
Assumption. Behavior Genetics, ￿￿(6):6￿6–6￿￿. WOS:￿￿￿￿￿￿￿8￿￿￿￿￿￿6.
Lopez-Quintero, C., Cobos, J. P. d. l., Hasin, D. S., Okuda, M., Wang, S., Grant, B. F.,
and Blanco, C. (￿￿￿￿). Probability and predictors of transition from ￿rst use to
dependence on nicotine, alcohol, cannabis, and cocaine: Results of the National
Epidemiologic Survey on Alcohol and Related Conditions (NESARC). Drug and
Alcohol Dependence, ￿￿￿(￿–￿):￿￿￿–￿￿￿.
Lynskey, M. and Agrawal, A. (￿￿￿￿). Psychometric properties of dsm assessments
of illicit drug abuse and dependence: results from the national epidemiologic
survey on alcohol and related conditions (nesarc. Psychological Medicine,
￿:￿￿￿￿–￿￿￿￿.
Lynskey, M. T., Agrawal, A., and Heath, A. C. (￿￿￿￿). Genetically informative research
on adolescent substance use: methods, ￿ndings and challenges. Journal of the
American Academy of Child and Adolescent Psychiatry, ￿￿(￿￿):￿￿￿￿–￿￿￿￿.
Lynskey, M. T., Agrawal, A., Henders, A., Nelson, E. C., Madden, P. A. F., and Martin,
N. G. (￿￿￿￿). An Australian Twin Study of Cannabis and Other Illicit Drug Use




Lynskey, M. T., Fergusson, D. M., and Horwood, L. J. (￿￿￿8). The Origins of the
Correlations between Tobacco, Alcohol, and Cannabis Use During Adolescence.
Journal of Child Psychology and Psychiatry, ￿￿(￿):￿￿￿–￿￿￿￿.
Lynskey, M. T. and Hall, W. (￿￿￿8). Cohort trends in age of initiation to heroin use.
Drug and Alcohol Review, ￿￿(￿):￿8￿–￿￿￿.
Lynskey, M. T., Heath, A. C., Bucholz, K. K., Slutske, W. S., Madden, P. A., Nelson, E. C.,
Statham, D. J., and Martin, N. G. (￿￿￿￿). Escalation of drug use in early-onset
cannabis users vs co-twin controls. JAMA, ￿8￿(￿):￿￿￿–￿￿.
Lynskey, M. T., Heath, A. C., Nelson, E. C., Bucholz, K. K., Madden, P. A. F., Slutske,
W. S., Statham, D. J., and Martin, N. G. (￿￿￿￿). Genetic and environmental
contributions to cannabis dependence in a national young adult twin sample.
Psychological Medicine, ￿￿(￿￿):￿￿￿–￿￿￿.
Lynskey, M. T., Vink, J. M., and Boomsma, D. I. (￿￿￿6). Early Onset Cannabis Use and
Progression to other Drug Use in a Sample of Dutch Twins. Behavior Genetics,
￿6(￿):￿￿￿–￿￿￿.
Lytton, H. (￿￿￿￿). Do parents create, or respond to, differences in twins?
Developmental Psychology, ￿￿(￿):￿￿6–￿￿￿.
Maas, C. J. M. and Hox, J. J. (￿￿￿￿). Robustness issues in multilevel regression
analysis. Statistica Neerlandica, ￿8(￿):￿￿￿–￿￿￿.
Maes, H. H., Sullivan, P. F., Bulik, C. M., Neale, M. C., Prescott, C. A., Eaves, L. J., and
Kendler, K. S. (￿￿￿￿a). A twin study of genetic and environmental in￿uences on
tobacco initiation, regular tobacco use and nicotine dependence. Psychological
Medicine, ￿￿(￿):￿￿￿￿–￿￿6￿. WOS:￿￿￿￿￿￿￿￿8￿￿￿￿￿￿.
Maes, H. H., Sullivan, P. F., Bulik, C. M., Neale, M. C., Prescott, C. A., Eaves, L. J., and
Kendler, K. S. (￿￿￿￿b). A twin study of genetic and environmental in￿uences on
tobacco initiation, regular tobacco use and nicotine dependence. Psychological
Medicine, ￿￿(￿):￿￿￿￿–￿￿6￿.
Maliphant, J. and Scott, J. (￿￿￿￿). Use of the femoral vein (’groin injecting’) by a
sample of needle exchange clients in Bristol, UK. Harm Reduction Journal, ￿:6.
￿￿￿
BIBLIOGRAPHY
Martins, S. S., Sampson, L., Cerdá, M., and Galea, S. (￿￿￿￿). Worldwide Prevalence
and Trends in Unintentional Drug Overdose: A Systematic Review of the
Literature. American Journal of Public Health, ￿￿￿(￿￿):￿￿￿￿–￿￿￿￿.
McCutcheon, V. V., Grant, J. D., Heath, A. C., Bucholz, K. K., Sartor, C. E., Nelson, E. C.,
Madden, P. a. F., and Martin, N. G. (￿￿￿￿). Environmental in￿uences predominate
in remission from alcohol use disorder in young adult twins. Psychological
Medicine, ￿￿(￿￿):￿￿￿￿–￿￿￿￿.
McGeary, J. E., Knopik, V. S., Hayes, J. E., Palmer, R. H., Monti, P. M., and Kalman,
D. (￿￿￿￿). Predictors of relapse in a bupropion trial for smoking cessation in
recently-abstinent alcoholics: preliminary results using an aggregate genetic risk
score. Substance Abuse: Research and Treatment, 6:￿￿￿–￿￿￿.
McGue, M. and Bouchard, T. J. (￿￿8￿). Adjustment of twin data for the effects of
age and sex. Behavior Genetics, ￿￿(￿):￿￿￿–￿￿￿.
Merikangas KR, Stolar M, Stevens DE, and et al (￿￿￿8). Familial transmission of
substance use disorders. Archives of General Psychiatry, ￿￿(￿￿):￿￿￿–￿￿￿.
Miles, D. R., Stallings, M. C., Young, S. E., Hewitt, J. K., Crowley, T. J., and Fulker, D. W.
(￿￿￿8). A family history and direct interview study of the familial aggregation
of substance abuse: the adolescent substance abuse study. Drug and Alcohol
Dependence, ￿￿(￿):￿￿￿–￿￿￿.
Miller, J. E., Nugent, C. N., and Russell, L. B. (￿￿￿￿). Risk factors for family time
burdens providing and arranging health care for children with special health care
needs: Lessons from nonproportional odds models. Social Science Research,
￿￿:6￿￿–6￿￿.
Miller, P. G., Hyder, S., Zinkiewicz, L., Droste, N., and Harris, J. B. (￿￿￿￿). Comparing
subjective well-being and health-related quality of life of Australian drug users in
treatment in Regional and Rural Victoria. Drug and Alcohol Review, ￿￿(6):6￿￿–
6￿￿.
Mills, K. L., Teesson, M., Darke, S., Ross, J., and Lynskey, M. (￿￿￿￿). Young people
with heroin dependence: Findings from the Australian Treatment Outcome Study
(ATOS). Journal of Substance Abuse Treatment, ￿￿(￿):6￿–￿￿.
￿￿￿
BIBLIOGRAPHY
Mof￿tt, T. E. (￿￿￿￿). Adolescence-limited and life-course-persistent antisocial
behavior: a developmental taxonomy. Psychological Review, ￿￿￿:6￿￿–￿￿￿.
Mof￿tt, T. E., Caspi, A., and Rutter, M. (￿￿￿￿). Strategy for investigating interactions
between measured genes and measured environments. Archives of General
Psychiatry, 6￿(￿):￿￿￿–￿8￿.
Morley, K. I., Lynskey, M. T., Madden, P. A. F., Treloar, S. A., Heath, A. C., and Martin,
N. G. (￿￿￿￿). Exploring the inter-relationship of smoking age-at-onset, cigarette
consumption and smoking persistence: genes or environment? Psychological
Medicine, ￿￿(￿):￿￿￿￿–￿￿6￿. WOS:￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿.
Morral, A. R., McCaffrey, D. F., and Paddock, S. M. (￿￿￿￿). Reassessing the
marijuana gateway effect. Addiction (Abingdon, England), ￿￿(￿￿):￿￿￿￿–￿￿￿￿.
Neale, M. and Cardon, L. (￿￿￿￿). Methodology for genetic studies of twins and
families. Kluwer Academic Publications, Dordrecht, The Netherlands.
Neale, M. C., Aggen, S. H., Maes, H. H., Kubarych, T. S., and Schmitt, J. E.
(￿￿￿6a). Methodological issues in the assessment of substance use phenotypes.
Addictive Behaviors, ￿￿(6):￿￿￿￿–￿￿￿￿.
Neale, M. C., Eaves, L. J., and Kendler, K. S. (￿￿￿￿). The power of the classical twin
study to resolve variation in threshold traits. Behavior Genetics, ￿￿(￿):￿￿￿–￿￿8.
Neale, M. C., Harvey, E., Maes, H. H., Sullivan, P. F., and Kendler, K. S. (￿￿￿6b).
Extensions to the modeling of initiation and progression: applications to
substance use and abuse. Behav Genet, ￿6(￿):￿￿￿–￿￿.
Neale, M. C., Røysamb, E., and Jacobson, K. (￿￿￿6c). Multivariate Genetic Analysis
of Sex Limitation and G × E Interaction. Twin research and human genetics : the
of￿cial journal of the International Society for Twin Studies, ￿(￿):￿8￿–￿8￿.
Nelson, E. C., Lynskey, M. T., Heath, A. C., Wray, N., Agrawal, A., Shand, F. L., Henders,
A. K., Wallace, L., Todorov, A. A., Schrage, A. J., Saccone, N. L., Madden, P. A.,
Degenhardt, L., Martin, N. G., and Montgomery, G. W. (￿￿￿￿). ANKK￿, TTC￿￿, and
NCAM￿ polymorphisms and heroin dependence: importance of considering drug
exposure. JAMA Psychiatry, ￿￿(￿):￿￿￿–￿￿.
￿￿￿
BIBLIOGRAPHY
Newton, N. C., Conrod, P. J., Slade, T., Carragher, N., Champion, K. E., Barrett, E. L.,
Kelly, E. V., Nair, N. K., Stapinski, L., and Teesson, M. (￿￿￿6). The long-term
effectiveness of a selective, personality-targeted prevention program in reducing
alcohol use and related harms: a cluster randomized controlled trial. Journal of
Child Psychology and Psychiatry, and Allied Disciplines, ￿￿(￿):￿￿￿6–￿￿6￿.
of Health and Welfare, A. I. (￿￿￿￿). National Drug Strategy Household Survey
detailed report: ￿￿￿￿. Technical report, AIHW, Canberra.
O’Keefe, D., Horyniak, D., and Dietze, P. (￿￿￿6). From initiating injecting drug use to
regular injecting: Retrospective survival analysis of injecting progression within
a sample of people who inject drugs regularly. Drug and Alcohol Dependence,
￿￿8:￿￿￿–￿8￿.
Ottena, R., Barkerb, E. D., Maughanc, B., Arseneault, L., and Engelsa, R. C. (￿￿￿￿).
Self-control and its relation to joint developmental trajectories of cannabis use
and depressivemood symptoms. Drug and Alcohol Dependence, ￿￿￿(￿):￿￿￿–￿￿8.
Pacek, L. R., Martins, S. S., and Crum, R. M. (￿￿￿￿). The bidirectional relationships
between alcohol, cannabis, co-occurring alcohol and cannabis use disorderswith
major depressive disorder: results from a national sample. Journal of Affective
Disorders, ￿￿8(￿-￿):￿88–￿￿￿.
Pacula, R. L., Kilmer, B., Wagenaar, A. C., Chaloupka, F. J., and Caulkins, J. P. (￿￿￿￿).
Developing public health regulations for marijuana: Lessons from alcohol and
tobacco. American Journal of Public Health, ￿￿￿(6):￿￿￿￿–￿￿￿8.
Pagan, J. L., Rose, R. J., Viken, R. J., Pulkkinen, L., Kaprio, J., and Dick, D. M.
(￿￿￿6). Genetic and Environmental In￿uences on Stages of Alcohol Use Across
Adolescence and into Young Adulthood. Behavior Genetics, ￿6(￿):￿8￿–￿￿￿.
Palmer, R. H. C., Button, T. M., Rhee, S. H., Corley, R. P., Young, S. E., Stallings, M. C.,
Hopfer, C. J., and Hewitt, J. K. (￿￿￿￿). Genetic etiology of the common liability
to drug dependence: evidence of common and speci￿c mechanisms for DSM-IV
dependence symptoms. Drug and Alcohol Dependence, ￿￿￿ Suppl ￿:S￿￿–￿￿.
Parra, G. R., O’Neill, S. E., and Sher, K. J. (￿￿￿￿). Reliability of self-reported age of
substance involvement onset. Psychology of Addictive Behaviors, ￿￿(￿):￿￿￿–￿￿8.
￿￿6
BIBLIOGRAPHY
Patton, G. C., Coffey, C., Carlin, J. B., Degenhardt, L., Lynskey, M., and Hall, W.
(￿￿￿￿). Cannabis use and mental health in young people: cohort study. BMJ,
￿￿￿(￿￿￿￿):￿￿￿￿–￿￿￿8.
Pedersen, W., Mastekaasa, A., and Wichstrøm, L. (￿￿￿￿). Conduct problems and
early cannabis initiation: a longitudinal study of gender differences. Addiction,
￿6(￿):￿￿￿–￿￿￿.
Pinchevsky, G. M., Arria, A. M., Caldeira, K. M., Garnier-Dykstra, L. M., Vincent, K. B.,
and O’Grady, K. E. (￿￿￿￿). Marijuana Exposure Opportunity and Initiation during
College: Parent and Peer In￿uences. Prevention Science, ￿￿(￿):￿￿–￿￿.
Pitkänen, T., Lyyra, A.-L., and Pulkkinen, L. (￿￿￿￿). Age of onset of drinking and the
use of alcohol in adulthood: a follow-up study from age 8–￿￿ for females and
males. Addiction, ￿￿￿(￿):6￿￿–66￿.
Pizzey, R. and Hunt, N. (￿￿￿8). Distributing foil from needle and syringe
programmes (NSPs) to promote transitions from heroin injecting to chasing: an
evaluation. Harm Reduction Journal, ￿:￿￿.
Plomin, R., DeFries, J. C., Knopik, V. S., and Neiderheiser, J. (￿￿￿￿). Behavioral
Genetics. Worth Publishers, New York, 6 edition.
Plomin, R., Willerman, L., and Loehlin, J. C. (￿￿￿6). Resemblance in appearance and
the equal environments assumption in twin studies of personality traits. Behavior
Genetics, 6(￿):￿￿–￿￿.
Posthuma, D., Beem, A. L., de Geus, E. J. C., van Baal, G. C. M., von Hjelmborg,
J. B., Iachine, I., and Boomsma, D. I. (￿￿￿￿). Theory and Practice in Quantitative
Genetics. Twin Research, 6(￿):￿6￿–￿￿6.
Poznyak, V. B., White, J., and Clark, N. (￿￿￿￿). Substance Abuse Disorders: Evidence
and Experience, chapter Drug Abuse: Prevention. John Wiley and Sons.
Prince, M. (￿￿￿￿). Cross-sectional surveys. In Prince, M., Stewart, R., Ford, T., and
Hotopf, M., editors, Practical Psychiatric Epidemiology, pages ￿￿￿–￿￿￿. Oxford
University Press.
R Core Team (￿￿￿￿). R: A language and environment for statistical computing.
￿￿￿
BIBLIOGRAPHY
Rang, H. P. and Dale, M. M., editors (￿￿￿6). Rang and Dale’s pharmacology.
Elsevier/Churchill Livingstone, Edinburgh, 8th ed edition.
Reboussin, B. A., Hubbard, S., and Ialongo, N. S. (￿￿￿￿). Marijuana Use Patterns
among African-AmericanMiddle-School Students. Drug and alcohol dependence,
￿￿(￿):￿￿–￿￿.
Reboussin, B. A., Ialongo, N. S., and Green, K. M. (￿￿￿￿). In￿uences of behavior
and academic problems at school entry on marijuana use transitions during
adolescence in an African American sample. Addictive behaviors, ￿￿:￿￿–￿￿.
Reef, J., Diamantopoulou, S., Meurs, I. v., Verhulst, F. C., and Ende, J. v. d. (￿￿￿￿).
Developmental trajectories of child to adolescent externalizing behavior and adult
DSM-IV disorder: results of a ￿￿-year longitudinal study. Social Psychiatry and
Psychiatric Epidemiology, ￿6(￿￿):￿￿￿￿–￿￿￿￿.
Reich, T., Hinrichs, A., Culverhouse, R., , and Bierut, L. (￿￿￿￿). Genetic studies of
alcoholism and substance dependencependence. Psychiatric Genetics, 6￿:￿￿￿–
6￿￿.
Rice, J. P., Reich, T., Bucholz, K. K., Neuman, R. J., Fishman, R., Rochberg,
N., Hesselbrock, V. M., Nurnberger, J. I., Schuckit, M. A., and Begleiter, H.
(￿￿￿￿). Comparison of direct interview and family history diagnoses of alcohol
dependence. Alcoholism, Clinical and Experimental Research, ￿￿(￿):￿￿￿8–￿￿￿￿.
Ridenour, T. A., Lanza, S. T., Donny, E. C., and Clark, D. B. (￿￿￿6). Different
lengths of times for progressions in adolescent substance involvement. Addictive
behaviors, ￿￿(6):￿6￿–￿8￿.
Ridenour, T. A., Maldonado-Molina, M., Compton, W.M., Spitznagel, E. L., and Cottler,
L. B. (￿￿￿￿). Factors associated with the transition from abuse to dependence
among substance abusers: Implications for a measure of addictive liability. Drug
and alcohol dependence, 8￿(￿):￿–￿￿.
Rifai, N., Gillette, M. A., and Carr, S. A. (￿￿￿6). Protein biomarker discovery and




Ropponen, A. and Svedberg, P. (￿￿￿￿). Single and additive effects of health
behaviours on the risk for disability pensions among Swedish twins. The
European Journal of Public Health, ￿￿(￿):6￿￿–6￿8.
Ross, J., Teeson, M., Darke, S., Lynskey, M., Hetherington, K., Mills, K., Williamson, S.,
and Fairburn, S. (￿￿￿￿). Characteristics of heroin users entering three treatment
modalities in New South Wales: Baseline ￿ndings from the Australian Treatment
Outcome Study (ATOS). Technical Report ￿￿￿, NDARC.
Salvatore, J. E., Aliev, F., Edwards, A. C., Evans, D. M., Macleod, J., Hickman, M.,
Lewis, G., Kendler, K. S., Loukola, A., Korhonen, T., Latvala, A., Rose, R. J., Kaprio,
J., and Dick, D. M. (￿￿￿￿). Polygenic scores predict alcohol problems in an
independent sample and showmoderation by the environment. Genes, ￿(￿):￿￿￿–
￿￿6.
Sartor, C. E., Agrawal, A., Grant, J. D., Duncan, A. E., Madden, P. A. F., Lynskey, M. T.,
Heath, A. C., and Bucholz, K. K. (￿￿￿￿). Differences Between African-American
and European- American Women in the Association of Childhood Sexual Abuse
With Initiation of Marijuana Use and Progression to Problem Use. Journal of
Studies on Alcohol and Drugs, ￿6(￿):￿6￿–￿￿￿.
Sartor, C. E., Agrawal, A., Lynskey, M. T., Bucholz, K. K., and Heath, A. C. (￿￿￿8).
Genetic and environmental in￿uences on the rate of progression to alcohol
dependence in young women. Alcoholism, clinical and experimental research,
￿￿(￿):6￿￿–8.
Sartor, C. E., Agrawal, A., Lynskey, M. T., Bucholz, K. K., Madden, P. A., and Heath,
A. C. (￿￿￿￿a). Common genetic in￿uences on the timing of ￿rst use for alcohol,
cigarettes, and cannabis in young African-American women. Drug and alcohol
dependence, ￿￿￿(￿-￿):￿￿–￿￿.
Sartor, C. E., Agrawal, A., Lynskey, M. T., Duncan, A. E., Grant, J. D., Nelson, E. C.,
Madden, P. a. F., Heath, A. C., and Bucholz, K. K. (￿￿￿￿a). Cannabis or alcohol
￿rst? Differences by ethnicity and in risk for rapid progression to cannabis-related
problems in women. Psychological Medicine, ￿￿(￿):8￿￿–8￿￿.
Sartor, C. E., Grant, J. D., Bucholz, K. K., Madden, P. A. F., Heath, A. C., Agrawal,
A., Whit￿eld, J. B., Statham, D. J., Martin, N. G., and Lynskey, M. T. (￿￿￿￿).
￿￿￿
BIBLIOGRAPHY
Common Genetic Contributions to Alcohol and Cannabis Use and Dependence
Symptomatology. Alcoholism-Clinical and Experimental Research, ￿￿(￿):￿￿￿–
￿￿￿. WOS:￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿.
Sartor, C. E., Lynskey, M. T., Bucholz, K. K., Madden, P. A. F., Martin,
N. G., and Heath, A. C. (￿￿￿￿b). Timing of ￿rst alcohol use and alcohol
dependence: evidence of common genetic in￿uences. Addiction, ￿￿￿(￿):￿￿￿￿–
￿￿￿8. WOS:￿￿￿￿686￿￿￿￿￿￿￿￿.
Sartor, C. E., Lynskey, M. T., Heath, A. C., Jacob, T., and True, W. (￿￿￿￿). The role
of childhood risk factors in initiation of alcohol use and progression to alcohol
dependence. Addiction, ￿￿￿(￿):￿￿6–￿￿￿. WOS:￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿.
Sartor, C. E., Waldron, M., Duncan, A. E., Grant, J. D., McCutcheon, V. V., Nelson, E. C.,
Madden, P. A., Bucholz, K. K., and Heath, A. C. (￿￿￿￿b). Childhood Sexual Abuse
and Early Substance Use in Adolescent Girls: The Role of Familial In￿uences.
Addiction (Abingdon, England), ￿￿8(￿):￿￿￿–￿￿￿￿.
SAS Institute Inc (￿￿￿￿). SAS Software version ￿.￿.
Schemper, M. (￿￿￿￿). Cox Analysis of Survival Data with Non-Proportional Hazard
Functions. Journal of the Royal Statistical Society. Series D (The Statistician),
￿￿(￿):￿￿￿–￿6￿.
Schulenberg, J. E. and Maggs, J. L. (￿￿￿￿). A developmental perspective on
alcohol use and heavy drinking during adolescence and the transition to young
adulthood. Journal of Studies on Alcohol, Supplement, (s￿￿):￿￿–￿￿.
Sher, K. J., Dick, D. M., Crabbe, J. C., Hutchison, K. E., O’Malley, S. S., and Heath,
A. C. (￿￿￿￿). Consilient research approaches in studying gene × environment
interactions in alcohol research. Addiction Biology, ￿￿(￿):￿￿￿–￿￿6.
Sherva, R., Wang, Q., Kranzler, H., Zhao, H., Koesterer, R., Herman, A., Farrer,
L., and Gelernter, J. (￿￿￿6). GEnome-wide association study of cannabis




Shi, Y., Lenzi, M., and An, R. (￿￿￿￿). Cannabis Liberalization and Adolescent
Cannabis Use: A Cross-National Study in ￿8 Countries. PloS One,
￿￿(￿￿):e￿￿￿￿￿6￿.
Shillington, A.M., Cottler, L. B., Mager, D. E., andCompton III,W.M. (￿￿￿￿). Self-report
stability for substance use over ￿￿ years: data from the St. Louis Epidemiologic
Catchment Study. Drug and Alcohol Dependence, ￿￿(￿):￿￿￿–￿￿￿.
Singer, E. and Presser, S. (￿￿￿￿). Privacy, Con￿dentiality, and Respondent Burden
as Factors in Telephone Survey Nonresponse. In Lepkowski, J. M., Tucker, C.,
Brick, J. M., Leeuw, E. D. d., Japec, L., Lavrakas, P. J., Link, M. W., and Sangster,
R. L., editors, Advances in Telephone Survey Methodology, pages ￿￿￿–￿￿￿. John
Wiley & Sons, Inc.
Skosnik, P. D., Krishnan, G. P., Vohs, J. L., and O’Donnell, B. F. (￿￿￿6). The
effect of cannabis use and gender on the visual steady state evoked potential.
Clinical Neurophysiology: Of￿cial Journal of the International Federation of Clinical
Neurophysiology, ￿￿￿(￿):￿￿￿–￿￿6.
Stallings, M. C., Hewitt, J. K., Beresford, T., Heath, A. C., and Eaves, L. J. (￿￿￿￿).
A Twin Study of Drinking and Smoking Onset and Latencies from First Use to
Regular Use. Behavior Genetics, ￿￿(6):￿￿￿–￿￿￿.
StataCorp (￿￿￿￿). Stata Statistical Software: Release ￿￿.
Stockings, E., Hall, W. D., Lynskey, M., Morley, K. I., Reavley, N., Strang, J., Patton,
G., and Degenhardt, L. (￿￿￿6). Prevention, early intervention, harm reduction, and
treatment of substance use in young people. The Lancet Psychiatry, ￿(￿):￿8￿–
￿￿6.
Stoltman, J. J. K., Woodcock, E. A., Lister, J. J., Greenwald, M. K., and Lundahl, L. H.
(￿￿￿￿). Exploration of the telescoping effect among not-in-treatment, intensive
heroin-using research volunteers. Drug and Alcohol Dependence, ￿￿8:￿￿￿–￿￿￿.
Storr, C. L., Wagner, F. A., Chen, C. Y., and Anthony, J. C. (￿￿￿￿). Childhood predictors




Strang, J. (￿￿88). Changing Injecting Practices: blunting the needle habit. British
Journal of Addiction, 8￿(￿):￿￿￿–￿￿￿.
Strang, J., Bearn, J., Farrell, M., Finch, E., Gossop, M., Grif￿ths, P., Marsden, J., and
Wolff, K. (￿￿￿8). Route of drug use and its implications for drug effect, risk of
dependence and health consequences. Drug and Alcohol Review, ￿￿(￿):￿￿￿–￿￿￿.
Strang, J., Grif￿ths, P., Powis, B., and Gossop, M. (￿￿￿￿). First use of heroin: changes
in route of administration over time. BMJ (Clinical research ed.), ￿￿￿(68￿6):￿￿￿￿–
￿￿￿￿.
Strang, J. and King, L. (￿￿￿￿). Heroin is more than just diamorphine. Addiction
Research, ￿(￿).
Strang, J. and McCambridge, J. (￿￿￿￿). Are cannabis users exposed to other drug
use opportunities? Investigation of high-risk drug exposure opportunities among
young cannabis users in London. Drug and Alcohol Review, ￿￿(￿):￿8￿–￿￿￿.
Sun, G. W., Shook, T. L., and Kay, G. L. (￿￿￿6). Inappropriate use of bivariable
analysis to screen risk factors for use inmultivariable analysis. Journal of Clinical
Epidemiology, ￿￿(8):￿￿￿–￿￿6.
Swendsen, J., Anthony, J. C., Conway, K. P., Degenhardt, L., Dierker, L., Glantz, M.,
He, J., Kalaydjian, A., Kessler, R. C., Sampson, N., and Merikangas, K. R. (￿￿￿8).
Improving targets for the prevention of drug use disorders: Sociodemographic
predictors of transitions across drug use stages in the national comorbidity
survey replication. Preventive Medicine, ￿￿(6):6￿￿–6￿￿.
Swift, W., Coffey, C., Carlin, J. B., Degenhardt, L., andPatton, G. C. (￿￿￿8). Adolescent
cannabis users at ￿￿ years: trajectories to regular weekly use and dependence in
young adulthood. Addiction, ￿￿￿(8):￿￿6￿–￿￿.
Tabor, H. K., Risch, N. J., and Myers, R. M. (￿￿￿￿). Candidate-gene approaches
for studying complex genetic traits: practical considerations. Nature Reviews
Genetics, ￿:￿￿￿–￿￿￿.
Tas, B. and Day, E. (￿￿￿6). Pharmacology and physiological mechanisms of opioid
overdose and reversal. In Preventing opioid overdose deaths with take-home
￿￿￿
BIBLIOGRAPHY
naloxone, number ￿￿ in Insights. EMCDDA, EuropeanMonitoring Centre for Drugs
and Drug Addiction, Lisbon.
Teesson, M., Newton, N. C., Slade, T., Chapman, C., Allsop, S., Hides, L., McBride,
N., Mewton, L., Tonks, Z., Birrell, L., Brownhill, L., and Andrews, G. (￿￿￿￿).
The CLIMATE schools combined study: a cluster randomised controlled trial
of a universal Internet-based prevention program for youth substance misuse,
depression and anxiety. BMC psychiatry, ￿￿:￿￿.
Tsuang, M. T., Lyons, M. J., Harley, R. M., Xian, H., Eisen, S., Goldberg, J., True, W. R.,
and Faraone, S. V. (￿￿￿￿). Genetic and environmental in￿uences on transitions in
drug use. Behav Genet, ￿￿(6):￿￿￿–￿.
Tsuang, M. T., Lyons, M. J., Meyer, J. M., Doyle, T., Eisen, S. A., Goldberg, J., True,
W., Lin, N., Toomey, R., and Eaves, L. (￿￿￿8). Co-occurrence of abuse of different
drugs in men: the role of drug-speci￿c and shared vulnerabilities. Archives of
General Psychiatry, ￿￿(￿￿):￿6￿–￿￿￿.
UNODC (￿￿￿￿). World Drug Report ￿￿￿￿. United Nations publication, Sales No.
E.￿￿.XI.￿), United Nations publication.
Valdés, E. G., Andel, R., Sieurin, J., Feldman, A. L., Edwards, J. D., Långström, N., Gatz,
M., and Wirdefeldt, K. (￿￿￿￿). Occupational Complexity and Risk of Parkinson’s
Disease. PLoS ONE, ￿(￿).
van der Zwaluw, C. S., Otten, R., Kleinjan, M., and Engels, R. C. M. E. (￿￿￿￿). Different
trajectories of adolescent alcohol use: testing gene-environment interactions.
Alcoholism, Clinical and Experimental Research, ￿8(￿):￿￿￿–￿￿￿.
van Etten, M. L. and Anthony, J. C. (￿￿￿￿). Comparative epidemiology of initial drug
opportunities and transitions to ￿rst use: marijuana, cocaine, hallucinogens and
heroin. Drug and Alcohol Dependence, ￿￿(￿):￿￿￿–￿￿￿.
van Etten, M. L., Neumark, Y., and Anthony, J. C. (￿￿￿￿). Initial opportunity to use
marijuana and the transition to ￿rst use: United states, ￿￿￿￿–￿￿￿￿. Drug and
Alcohol Dependence, ￿￿:￿–￿.
van Etten, M. L., Neumark, Y. D., and Anthony, J. C. (￿￿￿￿). Male-female differences
in the earliest stages of drug involvement. Addiction, ￿￿(￿):￿￿￿￿–￿￿￿￿.
￿￿￿
BIBLIOGRAPHY
Verweij, K. J. H., Creemers, H. E., Korhonen, T., Latvala, A., Dick, D. M., Rose,
R. J., Huizink, A. C., and Kaprio, J. (￿￿￿6). Role of overlapping genetic and
environmental factors in the relationship between early adolescent conduct
problems and substance use in young adulthood. Addiction, ￿￿￿(6):￿￿￿6–￿￿￿￿.
Verweij, K. J. H., Mosing, M. A., Zietsch, B. P., and Medland, S. E. (￿￿￿￿). Estimating
Heritability from Twin Studies. In Elston, R. C., Satagopan, J. M., and Sun, S.,
editors, Statistical HumanGenetics, number 8￿￿ inMethods inMolecular Biology,
pages ￿￿￿–￿￿￿. Humana Press.
Verweij, K. J. H., Zietsch, B. P., Lynskey, M. T., Medland, S. E., Neale, M. C., Martin,
N. G., Boomsma, D. I., and Vink, J. M. (￿￿￿￿). Genetic and environmental
in￿uences on cannabis use initiation and problematic use: a meta-analysis of
twin studies. Addiction, ￿￿￿(￿):￿￿￿–￿￿￿.
Vitaro, F., Brendgen, M., and Arseneault, L. (￿￿￿￿). The discordant MZ-twin method:
One step closer to the holy grail of causality. International Journal of Behavioral
Development, ￿￿(￿):￿￿6–￿8￿. WOS:￿￿￿￿6￿￿￿￿6￿￿￿￿￿.
Vittinghoff, E., Glidden, D. V., Shiboski, S. C., andMcCulloch, C. E. (￿￿￿￿). Regression
Methods in Biostatistics. Statistics for Biology and Health. Springer, New York.
Vogt, W. P. and Johnson, R. B. (￿￿￿6). Dictionary of Statistics & Methodology: A
Nontechnical Guide for the Social Sciences. Sage Publications, ￿ edition.
Wagner, F. A. and Anthony, J. C. (￿￿￿￿). Into the world of illegal drug use: Exposure
opportunity and othermechanisms linking the use of alcohol, tobacco,marijuana,
and cocaine. Journal of Epidemiology, pages ￿￿8–￿￿￿.
Wagner, F. A. and Anthony, J. C. (￿￿￿￿). Male–female differences in the risk of
progression from ￿rst use to dependence upon cannabis, cocaine, and alcohol.
Drug and Alcohol Dependence, 86(￿–￿):￿￿￿–￿￿8.
Waldron, M., Grant, J. D., Bucholz, K. K., Lynskey, M. T., Slutske, W. S., Glowinski,
A. L., Henders, A., Statham, D. J., Martin, N. G., and Heath, A. C. (￿￿￿￿). Parental
separation and early substance involvement: Results from children of alcoholic
and cannabis dependent twins. Drug and Alcohol Dependence, ￿￿￿:￿8–8￿.
￿￿￿
BIBLIOGRAPHY
Warner-Smith, M., Darke, S., Lynskey, M., and Hall, W. (￿￿￿￿). Heroin overdose:
causes and consequences. Addiction (Abingdon, England), ￿6(8):￿￿￿￿–￿￿￿￿.
Weiss, R. D., Grif￿n, M. L., and Mirin, S. M. (￿￿￿￿). Drug Abuse as Self-Medication
for Depression: An Empirical Study. The American Journal of Drug and Alcohol
Abuse, ￿8(￿):￿￿￿–￿￿￿.
West, R. and Brown, J. (￿￿￿￿). Addiction, habit and instrumental learning. In Theory
of Addiction, pages ￿￿￿–￿￿￿. John Wiley & Sons, Ltd.
Williams, J. and Hagger-Johnson, G. (￿￿￿￿). Childhood academic ability in relation
to cigarette, alcohol and cannabis use from adolescence into early adulthood:
Longitudinal study of young people in england (lsype). BMJ Open, ￿(￿).
Williams, R. (￿￿￿6). Generalized ordered logit/partial proportional odds models for
ordinal dependent variables. Stata Journal, 6(￿):￿8–8￿.
Winters, K. C. and Lee, C.-Y. S. (￿￿￿8). Likelihood of developing an alcohol and
cannabis use disorder during youth: Association with recent use and age. Drug
and Alcohol Dependence, ￿￿(￿–￿):￿￿￿–￿￿￿.
Wittchen, H.-U., Behrendt, S., Hö￿er, M., Perkonigg, A., Lieb, R., Bühringer, G., and
Beesdo, K. (￿￿￿8). What are the high risk periods for incident substance use
and transitions to abuse and dependence? Implications for early intervention and
prevention. International Journal of Methods in Psychiatric Research, ￿￿(S￿):S￿6–
S￿￿.
Wodak, A. and McLeod, L. (￿￿￿8). The role of harm reduction in controlling hiv
among injecting drug users. AIDS, ￿￿:8￿–￿￿.
Woodcock, E. A., Lundahl, L. H., Stoltman, J. J. K., and Greenwald, M. K. (￿￿￿￿).
Progression to regular heroin use: Examination of patterns, predictors, and
consequences. Addictive Behaviors, ￿￿:￿8￿–￿￿￿.
Wu, P., Bird, H. R., Liu, X., Fan, B., Fuller, C., Shen, S., Duarte, C. S., and Canino,




Wulf-Johansson, H., Thinggaard, M., Tan, Q., Johansson, S. L., Schlosser, A.,
Christensen, K., Holmskov, U., and Sorensen, G. L. (￿￿￿￿). Circulating
surfactant protein D is associated to mortality in elderly women: A twin study.
Immunobiology, ￿￿8(￿):￿￿￿–￿￿￿.
Young, S. E., Corley, R. P., Stallings, M. C., Rhee, S. H., Crowley, T. J., and Hewitt,
J. K. (￿￿￿￿). Substance use, abuse and dependence in adolescence: prevalence,
symptom pro￿les and correlates. Drug and Alcohol Dependence, 68(￿):￿￿￿–￿￿￿.
Zohsel, K., Baldus, C., Schmidt, M. H., Esser, G., Banaschewski, T., Thomasius,
R., and Laucht, M. (￿￿￿6). Predicting later problematic cannabis use from
psychopathological symptoms during childhood and adolescence: Results of
a ￿￿-year longitudinal study. Drug and Alcohol Dependence, ￿6￿:￿￿￿–￿￿￿.
WOS:￿￿￿￿￿8￿￿￿￿￿￿￿￿￿.
￿￿6
.￿. APPENDIX ￿: QUALITY RATING TABLE
.￿ Appendix ￿: Quality Rating Table
Guide to quality ratings assigned to papers identi￿ed through the systematic
literature search (Chapter ￿).
Criteria Score ￿ Score ￿ Score ￿ Score ￿
Type of Study - Observations Cohort -
without control or case control
Selection Method Non-random/ Record review/ Random/ -
Convenience sample Clinic sample Representative Sample
Study Aim Unrelated to Aimed to - -
transition speed study transition
Prospective No Yes - -
Control Group No control Non-Users/ Slower/Faster -
Had not reached stage transitioners
Measure of Speed By speci￿ed point Continuous age Time from one -
e.g. "early" at stage stage to next
Analysis Method Other Linear/Logistic Survival Analysis/Discrete -
regresison Time Hazard Model
Sample Size ￿￿￿ ￿￿￿ - ￿￿￿￿ ￿￿￿￿ - ￿￿￿￿  ￿￿￿￿
Response Rate No/NA Yes - -
.￿ Appendix ￿: Missing Data
Table of all analysis variables for each sample, and missing data for each variable
(starts on next page).
￿￿￿


























































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































.￿. APPENDIX ￿: ASSOCIATION BETWEEN ATR ANALYSIS OUTCOMES AND STUDY
COVARIATES
.￿ Appendix ￿: Association Between ATR Analysis
Outcomes and Study Covariates
Table of OR (￿￿% CI) for the associaiton between model covariates and cannabis
outcomes included in analyses in Chapters ￿ and ￿.
Covariate Daily cannabis use Cannabis Abuse and/or Dependence Cannabis Treatment Seeking
OR (￿￿ % CI) P OR (￿￿ % CI) P OR (￿￿ % CI) P
Gender - male ￿.86 (￿.￿8-￿.￿￿) ￿.￿￿￿ ￿.￿￿ (￿.￿￿-￿.8￿) ￿.￿￿￿ ￿.￿￿ (￿.￿￿-￿.￿￿) ￿.￿￿
Lower level of ￿.￿8 (￿.￿￿-￿.￿￿) ￿.￿￿￿ ￿.￿8 (￿.￿￿-￿.6￿) ￿.￿￿ ￿.￿￿ (￿.￿￿-￿.￿￿) ￿.￿￿
completed education
Conduct Disorder ￿.￿￿ (￿.￿￿-￿.￿￿) ￿.￿￿￿ ￿.86 (￿.￿6-￿.￿￿) ￿.￿￿￿ ￿.￿8 (￿.88-￿.￿6) ￿.￿6
Non-clinical ￿.￿￿ (￿.￿￿-￿.￿￿) ￿.￿8 ￿.￿￿ (￿.￿￿-￿.￿￿) ￿.￿￿￿ ￿.￿￿ (￿.￿￿-￿.8￿) ￿.￿￿￿
depressive episode
Parental alcohol problems ￿.￿￿ (￿.8￿-￿.￿6) ￿.￿￿ ￿.￿￿ (￿.8￿-￿.￿8) ￿.￿￿ ￿.￿￿ (￿.8￿-￿.￿￿) ￿.￿￿
Parental Drug Problems ￿.6￿ (￿.￿￿-￿.￿￿) ￿.￿￿ ￿.￿￿ (￿.￿￿-￿.6￿) ￿.￿￿ ￿.8￿ (￿.￿￿-￿.88) ￿.￿￿
Single parent family ￿.￿￿ (￿.￿￿-￿.6￿) ￿.8￿ ￿.￿￿ (￿.6￿-￿.￿￿) ￿.8￿ ￿.￿￿ (￿.￿￿-￿.￿8) ￿.￿￿
High parental con￿ict ￿.8￿ (￿.6￿-￿.￿￿) ￿.￿￿ ￿.￿6 (￿.￿￿-￿.￿￿) ￿.￿￿ ￿.￿￿ (￿.88-￿.￿￿) ￿.￿￿
Strict parenting ￿.￿8 (￿.8￿-￿.￿￿) ￿.6￿ ￿.￿￿ (￿.8￿-￿.￿￿) ￿.￿￿ ￿.8￿ (￿.￿8-￿.￿￿) ￿.￿￿
High levels of high ￿.￿￿ (￿.￿￿-￿.￿￿) ￿.6￿ ￿.￿6 (￿.6￿-￿.￿￿) ￿.￿￿ ￿.￿￿ (￿.6￿-￿.￿￿) ￿.￿￿
school peer cannabis use
Childhood sexual abuse ￿.￿￿ (￿.￿￿-￿.￿￿) ￿.￿6 ￿.￿￿ (￿.6￿-￿.￿￿) ￿.￿￿ ￿.￿6 (￿.8￿-￿.￿￿) ￿.￿￿
Infrequent childhood ￿.￿￿ (￿.￿￿-￿.6￿) ￿.￿￿ ￿.￿￿ (￿.8￿-￿.￿￿) ￿.￿￿ ￿.￿￿ (￿.6￿-￿.￿￿) ￿.￿￿
religious attendance
Lifetime monthly ￿.￿￿ (￿.￿￿-￿.￿￿) ￿.￿￿ ￿.8￿ (￿.￿￿-￿.8￿) ￿.68 ￿.6￿ (￿.￿6-￿.￿￿) ￿.￿￿
alcohol use
Lifetime weekly ￿.￿￿ (￿.￿￿-￿.￿8) ￿.￿￿￿ ￿.￿￿(￿.￿￿-￿.6￿) ￿.￿￿￿ ￿.6￿(￿.￿￿-￿.￿￿) ￿.￿￿
tobacco use
Lifetime other ￿.￿￿ (￿.88-￿.￿￿) ￿.￿￿￿ ￿.￿6 (￿.￿8-￿.￿￿) ￿.￿￿￿ ￿.￿￿ (￿.￿￿-6.68) ￿.￿￿￿
drug use
Lifetime alcohol ￿.￿￿ (￿.￿6-￿.￿￿) ￿.￿￿ ￿.￿￿ (￿.8￿-￿.￿￿) ￿.￿8 ￿.￿￿ (￿.6￿-￿.6￿) ￿.￿￿
dependence
Lifetime tobacco ￿.￿￿ (￿.￿6-￿.￿￿) ￿.￿￿ ￿.8￿ (￿.￿￿-￿.￿8) ￿.￿￿￿ ￿.￿6 (￿.68-￿.￿￿) ￿.￿8
dependence
Lifetime other drug ￿.￿￿ (￿.6￿-￿.6￿) ￿.￿￿￿ ￿.6￿ (￿.￿6-￿.￿￿) ￿.￿￿￿ ￿.￿￿ (￿.￿￿-￿.￿￿) ￿.￿￿￿
drug dependence
Early initiation ￿.￿￿ (￿.￿￿-￿.￿￿) ￿.￿￿￿ ￿.8￿ (￿.￿￿-￿.￿8) ￿.￿￿￿ ￿.￿6 (￿.￿￿-￿.￿￿) ￿.￿￿
cannabis use (￿6)
.￿ Appendix ￿: SLAM Clinic Data Collection Materials





What does the study involve? 
If you agree take part the researcher will ask you to fill in two 
copies of a consent form before accompanying you to a private 
area. The study involves an interview which will take 20—
40 minutes to complete, depending on your answers.  This 
study is not related to your clinical care, and choosing to 
participate will not alter your clinical care in any way. 
The interview asks about: 
x Your early use of heroin and other drugs 
x Your current drug use 
x Problems you have experienced as a result of opiate use 
x The reasons you came for treatment. 
Participants will be reimbursed £10 cash when they complete 
the interview. 
 
Can I take part? 
Anyone can take part if they are: 
x Over 18 
x In treatment for opiate dependence  
x On a methadone/buprenorphine prescription  
You CANNOT take part if you are under 18 years old. 
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What are the possible benefits of taking part in the study? 
The results of this study may help to improve identification of 
individuals who would benefit from early drug use interventions. 
There are no direct benefits to you for taking part, but you may 
appreciate the opportunity to reflect and gain insight into your 
earlier drug use, and the circumstances surrounding treatment 
seeking. 
 
What are the possible disadvantages and risks of taking 
part? 
There are no risks associated with this study. However, please 
be aware that the interview will involve talking about early drug 
use experiences, current drug use and problems encountered 
as a result of use.  
 
How will my information be kept confidential? 
o Your name is not written on your responses, and all 
information is kept private by using anonymous ID 
numbers. No identifying information such as addresses or 
the names of other people will be recorded. 
o Only researchers will have access to the information in the 
study.  
o Responses are confidential, and will not be passed on to 
key workers or clinic staff UNLESS you indicate that you 
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are going to harm yourself, harm someone else, or have 
caused a death in the past. Only in this situation will the 
researcher pass information to the clinical team.  
o Paper copies of the interview responses and consent 
forms will be stored securely at the Institute of Psychiatry, 
Psychology and Neuroscience for up to 3 years before 
being safely destroyed.  
o Computer data are password-encrypted. 
 
What if I don’t want to take part? 
If you do not want to take part after reading the information 
sheet, please let the researcher know. If you are happy to tell 
us the reason why you don’t wish to take part please tell the 
researcher, however you are under no obligation to do this. 
This will have no impact on your clinical care. 
 
What will happen if I don't want to carry on with the study? 
If you agree to take part, but change your mind once the 
interview has started, you are free to leave the study at any 
time, and this will have no impact on your clinical care. Please 






What will happen if I become upset during the study? 
Anyone who becomes upset will be encouraged to discuss their 
feelings with their keyworker. The researcher will not inform 
clinic staff that you have become upset during the interview 
unless you ask them to do so.  
However, the researcher will have to inform staff if you indicate 
that you are going to harm yourself, harm someone else, or 
have caused a death in the past. 
Anyone taking part is free to end the interview at any time. 
 
What will happen to the results of this study? 
Results will be analysed as part of a doctoral project, will be 
published in academic journals and may be presented at 
conferences and talks. Participants will not be individually 
identifiable, as all responses will be presented as a group. 
 
Who is organising and funding this study? 
The study is funded through a PhD Studentship paid for by the 
Medical Research Council and the Institute of Psychiatry, 
Psychology and Neuroscience (IoPPN). The study is organised 
by PhD Student Lindsey Hines and Professor Michael Lynskey, 





Who has reviewed this study? 
The study was reviewed by the IoPPN Research and 
Development Department, and by the NHS Research Ethics 
Committee. 
 
How have patients and the public been involved in this 
study? 
Drug use service users and ex-service users at the Aurora  
Project (Lambeth) were consulted about the content of the 
interview. 
 
Further information and contact details 
For more information or if you have any questions please email 
Lindsey Hines at lindsey.hines@kcl.ac.uk. 
 
Complaints 
If you have any complaints about the study or the behaviour of 
the researcher please contact the study supervisor 
michael.lynskey@kcl.ac.uk. 
	 
When completed: 1 for participant; 1 for researcher site file; 1 (original) to be kept in medical notes. Version  2 30/4/2015 
Centre Number: 0  
Study Number: 15/LO/0705 
Participant Identification Number for this trial: 0__ __ __ 
CONSENT FORM 
Title of Project: Early Drug Use and Later Dependence Severity in Opiate Users 
Name of Researcher: Lindsey Hines 
Please initial box  
1. I confirm that I have read the information sheet dated 4 June 2015 (version 3) for the 
above study. I have had the opportunity to consider the information, ask questions and  
have had these answered satisfactorily. 
 
2. I understand that my participation is voluntary and that I am free to withdraw at any time 
without giving any reason, without my medical care or legal rights being affected. 
 
3. I understand that the information collected about me will be used to support 
other research in the future, and may be shared anonymously with other researchers. 
 
4. I understand that relevant sections of my medical notes and data collected during the  
 study, may be looked at by individuals from King’s College London, from regulatory  
 authorities or from the NHS Trust, where it is relevant to my taking part in this research.  
I give permission for these individuals to have access to my records. 
 




            
Name of Participant  Date    Signature 
 
Lindsey Hines           







An Exploratory Study of Early Drug Use and Later Dependence 
Severity in Opiate Users 
 
• This interview will focus on your early drug use, your treatment seeking, and 
dependence severity. The questions are mostly closed (e.g. yes/no) which 
mean you should be able to give a one or two word answer to each one. 
• Responses are confidential, and will not be passed on to key workers or clinic 
staff UNLESS you indicate that you may harm yourself, harm someone else, 
or have caused a death in the past. Only in this situation will I pass 
information to the clinical team. 
• If you agree to take part, but change your mind once the interview has started, 
you are free to end the interview at any time, and this will have no impact on 
your clinical care. Please let me know if you’d like to end the interview. 
• If you become upset, I’ll encourage you to discuss this with your keyworker. I 
won’t inform clinic staff that you have become upset during the interview 








Age at questionnaire: 
                                      
___ ___ 
 
Date of questionnaire: 
                                ___ ___/___ ___/___ ___ ___ ___ 
Sex Male 
Female 
Ethnicity White British  
White Irish  
Other White  
White & Black Caribbean  
White & Black African  
White & Asian  




Other Asian  
Caribbean  
African  
Other Black  
Chinese  
Other 
Highest level of education High school 
Sixth Form/College 
University 













Primary drug used Opiates Only  If so, is heroin the sole opiate? 
YES     
 
NO 
Opiates & Crack  If so, is heroin the sole opiate? 




Crack Only  
Benzodiazepines  
Amphetamines (excl. Ecstasy)  






Major Tranquilisers  
Anti-depressants  
Other Drugs  
Polydrug  
Prescription Drugs  





Length of time in 
prescribing 
Less than 12 months  
1 to 2 Years  
2 to 3 Years  
3 to 4 Years  
4 to 5 Years  
5+ years  
Referred to treatment by A&E  
Arrest Referral/DIP  
CARAT/Prison  
Community Care Assessment  
Connexions  
DRR  
Drug Service Non-statutory  
Drug Service Statutory  
Education Service  





Social Services  





Current treatment type Prescribing (including key working)  
Structured Intervention  
Psychosocial  
Structured Day Programme (SDP)  
Prescribing (inc. key working) and psychosocial  
Prescribing (inc. key working) and Structured Day 
Programme  
Inpatient detoxification (IP)  
Residential Rehabilitation (RR)  
Prescribing (inc. key working) and IP  
Prescribing (inc. key working) and RR  
Prescribing(inc. key working), psychosocial/SDP and 
RR  
Psychosocial/SDP and RR  
Prescribing (inc. key working), SDP and psychosocial  
All other combinations  
No adult modality  
Receiving any other 










 Alcohol Tobacco Cannabis Cocaine Heroin 
Have you ever used? 
 
     
Age at first opportunity 
to use: 
“By an opportunity I 
mean someone either 
offered you [drug], or 
you were present when 
others were using and 
you could have used if 
you wanted to. Thinking 
back your entire 
lifetime, how old were 
you the very first time 
you had an opportunity 




    
Age when first used 
 











     
Weeks  
 
    
Months 
 
     
Years  
 
    
Age at second use   
 
 











     
Weeks   
 
   
Months 
 
     
Years   
 







Who were you with when: 































Looking back on your heroin use, what do you consider to be the first sign that you 















First solitary use  
 
 
First daily use  
 




First experiencing relationship 
problems as a result of heroin use 
 
 
First experiencing problems with 
employment/studies as a result of 
heroin use 
 
First injecting (if ever)  
 
 




Have you used other opiates aside from heroin, e.g. illegal use of prescription 
medications. 
YES / NO 
 















How much do you agree with the following statements relating to the PRESENT – 
referring to opiates other than methadone: 
Do you think your use of opiates is out of control? 
  
                             0                                  1                           2                                   3                             
            Never/Almost never       Sometimes               Often              Nearly always/Always 
Does the prospect of missing a fix (or dose) or not chasing make you anxious or worried? 
 
                             0                                  1                           2                                   3                             
            Never/Almost never       Sometimes               Often              Nearly always/Always 
D0 you worry about your use of opiates? 
 
                             0                                  1                           2                                   3                             
            Never/Almost never       Sometimes               Often              Nearly always/Always 
Do you wish you could stop using opiates? 
 
                             0                                  1                           2                                   3                             
            Never/Almost never       Sometimes               Often              Nearly always/Always 
How difficult do you find it to stop or go without opiates?      
       
                      0                          1                           2                              3                             




Which of the following have you encountered as a result of your opiate use? 
Issue Yes No  
Overdose (number)   Number of instances: 
 
Femoral injecting   
 











How many OPIATE treatment episodes have you had? 
 
At what age did you first seek help from a professional for your opiate use? 
 












Looking back, should you have sought help earlier than you did?  
YES / NO 
 










Think back to the time you first sought treatment for your opiate use. How much do 
you agree with the following statements relating to your opiate use when you sought 
treatment for the FIRST time: 
Did you think your use of opiates was out of control? 
  
                             0                                  1                           2                                   3                             
            Never/Almost never       Sometimes               Often              Nearly always/Always 
Did the  prospect of missing a fix (or dose) or not chasing made you anxious or worried? 
 
                             0                                  1                           2                                   3                             
            Never/Almost never       Sometimes               Often              Nearly always/Always 
Did you worry about your use of opiates? 
 
                             0                                  1                           2                                   3                             
            Never/Almost never       Sometimes               Often              Nearly always/Always 
Did you wish you could stop using opiates? 
 
                             0                                  1                           2                                   3                             
            Never/Almost never       Sometimes               Often              Nearly always/Always 
How difficult did you find it to stop or go without opiates?      
       
                      0                          1                           2                              3                             
            Not difficult       Quite difficult      Very difficult            Impossible 
 
.￿. APPENDIX ￿: EARLY ONSET SENSITIVITY TESTS
.￿ Appendix ￿: Early Onset Sensitivity Tests
Table of MZ/DZ male and female and opposite sex twin pair correlations, testing
sensitivty of the early cannabis use opportunity cut off point used in Chapter ￿.
Opportunity/Abuse and/or Age of opportunity Abuse and/or dependence
dependence twin ￿/twin ￿ twin ￿/twin ￿ twin ￿/twin ￿
Early Opportunity Cut Point Correlation ￿￿% CI Correlation ￿￿% CI Correlation ￿￿% CI
￿￿ and under
MZ males ￿.￿￿ (￿.￿￿ – ￿.￿￿) ￿.￿6 (￿.6￿ – ￿.8￿) ￿.￿￿ (￿.6￿ – ￿.8￿)
DZ males ￿.￿6 (￿.￿￿ – ￿.￿￿) ￿.￿￿ (-￿.￿6 – ￿.￿￿) ￿.￿￿ (￿.￿8 – ￿.￿￿)
MZ females ￿.￿￿ (￿.￿￿ – ￿.￿￿) ￿.6￿ (￿.￿￿ – ￿.6￿) ￿.8￿ (￿.￿￿ – ￿.￿￿)
DZ females ￿.￿￿ (￿.￿￿ – ￿.￿￿) ￿.￿8 (￿.￿￿ – ￿.￿￿) ￿.￿￿ (￿.￿￿ – ￿.6￿)
DZ opposite sex ￿.￿￿ (￿.￿6 – ￿.￿6) ￿.￿￿ (￿.￿￿ – ￿.￿￿) ￿.￿￿ (￿.￿￿ – ￿.￿￿)
￿￿ and under
MZ males ￿.￿￿ (￿.￿6 – ￿.￿￿) ￿.￿￿ (￿.￿￿ – ￿.8￿) ￿.￿￿ (￿.￿￿ – ￿.8￿)
DZ males ￿.￿￿ (￿.￿6 – ￿.6￿) ￿.￿8 (￿.￿￿ – ￿.68) ￿.￿6 (￿.￿6 – ￿.6￿)
MZ females ￿.￿￿ (￿.￿￿ – ￿.￿￿) ￿.6￿ (￿.￿￿ – ￿.￿￿) ￿.8￿ (￿.￿￿ – ￿.8￿)
DZ females ￿.￿￿ (￿.￿￿ – ￿.￿￿) ￿.￿￿ (￿.￿8 – ￿.￿￿) ￿.￿8 (￿.￿￿ – ￿.6￿)
DZ opposite sex ￿.￿￿ (￿.￿6 – ￿.￿￿) ￿.￿6 (￿.￿￿ – ￿.￿￿) ￿.￿￿ (￿.￿￿ – ￿.￿￿)
￿6 and under
MZ males ￿.￿￿ (￿.￿￿ – ￿.￿6) ￿.￿￿ (￿.￿￿ – ￿.8￿) ￿.￿￿ (￿.￿￿ – ￿.86)
DZ males ￿.￿￿ (￿.￿8 – ￿.￿￿) ￿.￿￿ (￿.￿￿ – ￿.￿￿) ￿.￿6 (￿.￿￿ – ￿.6￿)
MZ females ￿.￿￿ (￿.￿￿ – ￿.￿￿) ￿.6￿ (￿.￿￿ – ￿.6￿) ￿.8￿ (￿.￿￿ – ￿.￿￿)
DZ females ￿.￿8 (￿.￿￿ – ￿.￿￿) ￿.￿￿ (￿.￿￿ – ￿.6￿) ￿.￿6 (￿.￿￿ – ￿.66)
DZ opposite sex ￿.￿6 (￿.￿￿ – ￿.￿￿) ￿.￿￿ (￿.￿￿ – ￿.￿6) ￿.￿￿ (￿.￿8 – ￿.￿￿)
￿￿8
.6. PAPERS PUBLISHED FROM THESIS
Table of associaiton between speed of early heroin transitions and later heroin
use outcomes, testing sensitivity of cut points used in Chapter 6.
Transition Speed of transition Overdose Groin/Neck Injecting
OR (￿￿% CI) OR (￿￿% CI)
Early opportunity ￿￿ and under ￿.￿￿ (￿.8￿ - ￿.8￿) ￿.￿6 (￿.￿￿ - ￿￿.￿￿)
to use heroin N = ￿8
￿6 and under ￿.￿￿ (￿.￿￿ - 8.66) ￿.￿￿ (￿.￿￿ - ￿.6￿)
N = ￿￿
￿￿ and under ￿.￿￿ (￿.￿￿ - ￿.￿￿) ￿.￿￿ (￿.￿￿ - 8.￿￿)
N = ￿￿
￿8 and under ￿.￿8 (￿ .8￿ - ￿.8￿) ￿.8￿ (￿.6￿ - ￿.￿8)
N = ￿￿
￿￿ and under ￿.￿￿ (￿.￿￿ - ￿.6￿) ￿.￿6 (￿.￿￿ -￿￿.￿8)
N = ￿￿
Time from opportunity Less than a week ￿.￿￿ (￿.￿￿ - ￿.￿￿) ￿.￿￿ (￿.￿￿ - ￿.￿￿)
to initiation N = ￿￿
Within a week ￿.￿￿ (￿.￿￿ - ￿.￿￿) ￿.66 (￿.￿￿ - ￿.6￿)
N = ￿8
Within ￿months ￿.86 (￿.￿￿ - ￿.￿￿) ￿.￿￿ (￿.￿￿ - ￿.8￿)
N = 6￿
Within ￿ year ￿.86 (￿.￿￿ - ￿.￿￿) ￿.￿￿ (￿.￿￿ - ￿.8￿)
N = 6￿
More than ￿ year ￿.6￿ (￿.￿￿ - ￿.88) ￿.￿￿ (￿.￿8 - ￿.￿￿)
N = ￿￿
Time from initiation Less than a week ￿.￿￿ (￿.￿￿ - ￿.8￿) ￿.￿￿ (￿.￿￿ - ￿.￿￿)
to subsequent heroin use N = ￿￿
Within a week ￿.8￿ (￿.￿￿ - ￿.￿￿) ￿.￿8 (￿.6￿ - ￿.￿￿)
N = ￿8
Within ￿months ￿.￿￿ (￿.￿￿ - 8.￿￿) ￿.￿8 (￿.￿￿ - ￿.￿￿)
N = ￿￿
Within ￿ year ￿.￿6 (￿.￿￿ - ￿.8￿) ￿.￿6 (￿.￿￿ - ￿.￿￿)
N = ￿￿
More than ￿ year ￿.88 (￿.￿￿ - ￿.￿￿) ￿.￿￿ (￿.￿￿ - ￿.￿6)
N = ￿8
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ABSTRACT
Aims To test whether speed of transition from initiation use to subsequent use of cannabis is associatedwith likelihood of
later cannabis dependence and other outcomes, and whether transition speed is attributable to genetic or environmental
factors. Design Cross-sectional interview study. Setting Australia. Participants A total of 2239 twins and siblings
who reported using cannabis at least twice [mean age at time of survey=32.0, 95% conﬁdence interval (CI) =31.9 –
32.1, range=22–45]. Measurements Time between initiation and subsequent cannabis use (within 1week; within
3months; between 3 and 12months; more than 1year later), later use of cannabis and symptoms of DSM-IV cannabis
abuse/dependence. Multinomial regression analyses (comparison group: more than 1 year later) adjusted the association
between speed of transition and the outcomes of cannabis daily use, abuse/dependence and treatment-seeking after con-
trolling for socio-demographic, childhood, mental health, peer and licit drug factors. Twinmodelling estimated the propor-
tion of variance in transition speed attributable to genetic (A), common environment (C) and unique environmental (E)
factors. Findings Subsequent use of cannabis within 1week of initiation was associated with daily use [odds ratio
(OR)=2.64, 95% CI=1.75–3.99], abuse and/or dependence (OR=3.25, 95% CI=2.31–4.56) and treatment-seeking
for cannabis problems (OR=1.89, 95% CI=1.03–3.46). Subsequent use within 3months was associated with abuse
and/or dependence (OR=1.61, 95% CI=1.18–2.19). The majority of the variation of the speed of transition was
accounted for by unique environment factors (0.75). Conclusions Rapid transition from initiation to subsequent use
of cannabis is associated with increased likelihood of subsequent daily cannabis use and abuse/dependence.
Keywords Cannabis, cannabis abuse, cannabis dependence, initiation, subsequent use, transitions, twin study.
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INTRODUCTION
Cannabis is themost commonly used illicit drug, with prev-
alence of life-time use estimated at between 2.7 and 4.9%
of the global population aged 15–64 years [1]. Although
many individuals use cannabis infrequently and without
problematic consequences, globally an estimated 13.1
million individuals experience cannabis dependence, con-
tributing 10.3% of the illicit drug use global burden of dis-
ease [2].
Existing research has identiﬁed a number of genetic and
environmental factors associated with increased risks for
cannabis dependence [3–12]. However, a number of inter-
mediate stages of use occur necessarily before an individual
develops dependence. These include opportunity to use,
initiation, repeated use and escalation to regular use, and
genetic and environmental factors are associated differen-
tially with progression through these stages [8,10,12–15].
Less is known about variation in progression through
the stages of substance use. Research in this area focuses
on speed of transition, including speed from initiation of
use to: daily use [16]; regular use [17]; and abuse or depen-
dence [17–19]. More research has focused on early onset of
use, which can be used as an exemplar of the speed of
© 2015 Society for the Study of Addiction Addiction
RESEARCH REPORT doi:10.1111/add.12963
transition literature by representing early onset of drug use
as a faster rate of transition from non-use to initiation. This
is associated with alcohol, tobacco and cannabis depen-
dence [18,20–22], suggesting a relationship between rate
of transition and later substance use outcomes. Given that
there is thought to be a short period after substance use ini-
tiation for implementation of prevention interventions
[23,24], the potential for speed of transition to act as an
early marker for later problems is a worthwhile avenue
for exploration.
The relationship between transition speed and later
drug-use outcomes is not straightforward. Those at risk of
dependence may be expected to begin and continue on a
faster trajectory through the stages of substance use, but
research demonstrates that those who progress faster from
non-use to initiation often exhibit a slower progression to
dependence than those who experience later initiation
[18,25]. Additionally, faster transition from initiation to
regular use has not been associated consistently with later
outcomes of dependence [17]. Further research on a
broader range of transitions is required to understandmore
clearly the relationship between speed of transition and
later outcomes, and to identify whether similar factors de-
termine speed between each stage [13].
One previously unstudied transition is that from initia-
tion (ﬁrst use) to the subsequent (second) use of cannabis.
Utilizing cross-sectional data from a sample of Australian
twins, this paper aims to:
1) Test whether speed of transition from initiation to subse-
quent use of cannabis is associated with increased
likelihood of later daily cannabis use, abuse and/or depen-
dence and cannabis-related treatment-seeking when
accounting for the inﬂuence of socio-demographic, child-
hood, mental health, peer and licit drug factors that may
be predictive of faster transitions in the subsequent use of
cannabis.
2) Determine the extent to which the speed of this transi-
tion is attributable to additive genetic, shared environ-
mental or non-shared environmental factors.
METHODS
Sample
From Australian Twin Registry members born between
1972 and 1979, 3348 monozygotic (MZ) and dizygotic
(DZ) twins and 476 of their siblings completed a drug mis-
use study (see [26] for a recruitment outline). Of the com-
plete cohort sample, 2601 (68.5%) reported life-time use of
cannabis. The subset of the sample selected for the analyses
in this paper were the 2239 participants [mean age at time
of survey=32.0, 95% conﬁdence interval (CI) =31.9–
32.1, range=22–45] who had reported using cannabis
at least twice in their lives (58.6% of the entire sample,
86.1% of life-time cannabis users). Of this subset, 58.7%
were female.
Assessment
Participants were assessed through computer-assisted tele-
phone interviews, and were provided with a respondent
booklet so that answers would be unidentiﬁable to anyone
overhearing. The interview collected information on socio-
demographics, childhood experiences, substance use and
commonmental health disorders, including conduct disor-
der, assessed using the Semi-Structured Assessment for the
Genetics of Alcoholism (SSAGA)-II interview [27]. The
SSAGA is a validated measure of mental health that uses




Those who reported using cannabis more than once were
asked: ‘How soon after you ﬁrst tried marijuana did you
try it again?’. Data were recorded categorically, and re-
sponses were further collapsed for analysis into the follow-
ing categories: within 1week (19.8%), within 3months
(but not including those who transitioned within 1week)
(37.7%), between 3months and 12months (21.7%) and
more than 1 year later (20.8%).
Life-time cannabis involvement
Daily use of cannabis
In the subsample used in this analysis 16.6% self-reported
using cannabis daily during their period of heaviest use.
Cannabis abuse and/or dependence
In the subsample used in this analysis, 27.9% reported
cannabis abuse and/or dependence. Participants were clas-
siﬁed as meeting DSM-IV criteria for life-time cannabis
abuse if they reported one or more of the following: often
using cannabis in a situation where they might get hurt;
arrested more than twice within a 12-month period as a
result of their cannabis use; cannabis use having caused
difﬁculty with work, study or household responsibilities;
and cannabis having caused social and interpersonal prob-
lems more than three times within a 12-month period.
Participants were classiﬁed as meeting life-time criteria
for DSM-IV cannabis dependence if they reported three or
more of the following symptoms occurringwithin the same
12-month period: using cannabis a greater number of
times/greater amount than was intended, tolerance,
wanting to cut down/stop use, spending so much time
obtaining/using/recovering from the effects of cannabis
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that the participant had little time for anything else, reduc-
ing important activities as a result of cannabis use and
continuing use despite it worsening health/emotional
problems. Withdrawal was not included, as it was not part
of DSM-IV criteria for cannabis dependence.
Cannabis-related treatment-seeking
In the subsample used in this analysis, 6% self-reported
having discussed cannabis-related problems with a profes-
sional. Participants were able to endorse seeking treat-
ment from multiple sources: psychiatrist (n=45), general
practitioner or other medical doctor (n=80), psychologist
(n=42), another mental health professional (n=61),
member of the clergy (n=7) or another source (n=9).
Covariates
Early cannabis onset
Individuals reporting life-time cannabis use were asked the
age at which they ﬁrst used cannabis. In line with existing
literature [26,28,29], those who were aged 16 and under
when cannabis was ﬁrst used were classiﬁed as having
early onset of cannabis use. Additionally, a series of sensitiv-
ity tests were conducted to test the effect of different early-
onset cut-off points (<13, <14, <15 and <17), which
showed that selecting 16 as the cut-off had no effect on
the results of the analyses (full results available upon re-
quest). Mean age of cannabis onset in the analytical sample
was 17.46 [standard deviation (SD)=2.99] with a range
of 6–34years.
Education
Participants were asked to report the highest level of educa-
tion they had obtained, and for analysis respondents were
classiﬁed by whether or not their highest level of education
was post-secondary/higher education.
Parental characteristics
Parental alcohol problems were determined through par-
ticipant self-report of their mother or father’s problems
with health/family/job/police/other as a result of drinking,
or their mother or father drinking excessively. Speciﬁcally,
participants were asked: ‘Did drinking ever cause [your
biological father/mother] to have problems with health,
family, job or police, or other problems?’ and ‘Did you ever
feel that [your biological father/mother] were excessive
drinkers?’. Responding ‘yes’ to either of these questions
constituted being a case for parental alcohol problems.
Parental drug problems were determined through par-
ticipant self-report of their mother or father’s problems
with health/family/job/police/other as a result of drug
use, or the participant reporting that they felt their
mother or father had a problem with drugs. Speciﬁcally,
participants were asked: ‘Did using drugs ever cause [your
biological father/mother] to have problems with health,
family, job or police, or other problems?’ and ‘Did you ever
feel that [your biological father/mother] had a problem
with drugs?’. Responding ‘yes’ to either of these questions
constituted being a case for parental drug problems.
Parental conﬂict was determined by participant re-
sponses to the questions: ‘How often did your parents ﬁght
or argue in front of you?’ and ‘How much conﬂict and
tension was there between your parents?’. Both questions
focused on the period when the participant was aged
6–13years. Participants reporting parents ‘sometimes’ or
‘always’ fought or argued, or reporting ‘a lot’ or ‘some’
conﬂict/tension, were coded as experiencing high parental
conﬂict.
Childhood sexual abuse
Participants who self-reported being forced into sexual in-
tercourse or any other forms of sexual activity before age
18 were classiﬁed as having experienced childhood sexual
abuse.
Conduct disorder
Participants were coded asmeeting criteria for conduct dis-
order if they reported at least three of the 15 DSM-IV
criteria occurring within the same 12-month period, prior
to age 18.
Depressed mood before cannabis onset
Participants were classiﬁed as having experienced de-
pressed mood if they had reported feeling depressed/down/
low ‘most of the day’ and ‘nearly every day’, or feeling a
great deal less interested in or able to enjoy most things
‘most of the day’ and ‘nearly every day’ for at least 2weeks
in their life-time before the onset of cannabis use.
Peer use
The extent of substance misuse among high school peers
was measured through self-report questions asking
whether ‘hardly any’, ‘some’, ‘half ’, ‘three-quarters’ or
‘almost all’ the students who were in their grade in high-
school used illegal drugs while of school age. Participants
were categorized as being exposed to high levels of illicit
drug use during high school if they reported that at least
three-quarters of their peers had been using cannabis.
Regular alcohol use before cannabis onset
Age of onset of regular alcohol use (once a month for
6months or longer) and age of cannabis onset were used
to determine whether regular alcohol use occurred before
onset of cannabis use.
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Regular tobacco use before cannabis onset
The age of onset of regular tobacco use (at least once a
week for at least 2months) and age of cannabis onset were
used to determine whether regular tobacco use occurred
before onset of cannabis use.
Statistical analysis
Epidemiological analyses were conducted in SAS statistical
software version 9.3 for Windows (SAS Institute Inc.,
Cary, NC, USA) and Stata statistical software version 11
(StataCorp, College Station TX, USA, 2009). χ2 tests and
phi coefﬁcients assessed the association between the speed
of transition from initiation to subsequent use of cannabis
and life-time cannabis daily use, abuse and/or dependence
and treatment-seeking. All associations were deemed sig-
niﬁcant at the P<0.05 level. Multinomial logistic regres-
sion analysis (reference category: subsequent use more
than a year after initiation) determined the association be-
tween the speed of transition from initiation to subsequent
use of cannabis and the outcomes daily cannabis use,
abuse/dependence and treatment-seeking for cannabis
use problems after adjustment for socio-demographic,
childhood, mental health, peer and licit drug factors.
Covariates were included in the models if they were associ-
ated signiﬁcantly with both the exposure and outcome var-
iables through χ2 tests (analyses not reported). To correct
for the non-independence of observations, Huber–White
analysis for clustered data was implemented in Stata to
provide robust standard errors. Post-hoc comparisons
across the varying speeds of transition were conducted
using Wald χ2 tests.
Twin modelling was conducted using OpenMX [30] for
the statistical software R [31]. As there were low numbers
of concordant twins, univariate analyses used raw ordinal
data and full-information maximum-likelihood (FIML) esti-
mation, which makes use of twin pairs where data from a
co-twin is unavailable. Composition of the twin sample is
described in Table 1. Model-ﬁtting was conducted using a
stepwise approach. A liability-threshold model including
an adjustment for twin sex and estimating co-twin correla-
tions was ﬁtted to the data set and used to test assumptions
regarding the equality of thresholds within and between
MZ and DZ twin groups. Based on these results, a univari-
ate variance components model was ﬁtted, partitioning
the variance attributable to additive genetic (A), shared
environmental (C) and unique environmental (E) factors.
Difference in model ﬁt was assessed via the likelihood-ratio
χ2 test and examination of the Akaike information criterion
(AIC) and Bayesian information criterion (BIC).
RESULTS
Associations between speed of transition and daily use,
abuse/dependence and treatment-seeking
Speed of transition was associated signiﬁcantly with each
of the three cannabis use outcomes (P<0.0001 for all out-
comes; see Table 2). Those whose second use of cannabis
was within 1week of initiation had the highest rate of daily
cannabis use (28.4%), abuse and/or dependence (46.0%)
or cannabis-related treatment-seeking (10.6%). For all out-
comes, the proportion that would go on to develop prob-
lems decreased approximately linearly across the groups.
Demographic, childhood and peer use associations with
transition speed
Signiﬁcant differences were observed between the different
transition speed groups for almost all the socio-demographic,
childhood,mental health, peer and licit drug factors tested in
this analysis (see Table 3). Parental drug problems, parental
conﬂict and depressed mood before cannabis onset were not
associated signiﬁcantly with transition speed.
Multinomial logistic regression of the outcomes associated
with transition speed
After controlling for early onset of cannabis use, socio-
demographic, childhood, mental health, peer and licit
Table 1 Speed of transition from initiation to subsequent use of cannabis by zygosity for twin analysis sample.
Twin sample Within a week n=400 Within 3months n=746 3months to 1 year n=412 More than a year n=411
MZ twin 1 73 145 83 94
n=395 18.5% 36.7% 21.0% 23.8%
MZ twin 2 99 147 90 93
n =429 23.1% 34.3% 20.9% 21.7%
DZ twin 1 101 235 126 113
n=575 17.6% 40.9% 21.9% 19.6%
DZ twin 2 127 219 113 111
n=570 22.3% 38.4% 19.8% 19.5%
DZ = dizygotic; MZ =monozygotic.
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drug factors, those whose second use of cannabis was
within a week were at increased odds of meeting criteria
for abuse/dependence [odds ratio (OR)=3.25, 95%
conﬁdence interval (CI) =2.31–4.56], reporting daily
use (OR=2.64, 95% CI=1.75–3.99) and treatment-
seeking (OR=1.89, 95% CI=1.03–3.46) (see Table 4).
Those whose subsequent use of cannabis was within
3months of initiation were just under twice as likely
to develop abuse and/or dependence (OR=1.61, 95%
CI= 1.18–2.19).
Post-hoc analysis of age of onset
Stratifying the analysis by early or later onset revealed
differences in the association between transition speed
and all later outcomes, which remained after adjustment









week n= 443 Phi P-value
Daily use 45 67 134 126 0.17 <0.0001
n=372 9.7% 13.8% 15.9% 28.4%
Abuse and/or dependence 82 100 238 204 0.22 <0.0001
n=624 17.6% 20.5% 28.2% 46.0%
Treatment-seeking 19 21 <0.0001
n=132 45 47 0.10 10.6%
Table 3 Associations between speed of transition from initiation to subsequent cannabis use and socio-demographic, childhood, mental









n= 443 Phi P-value
Mean age at cannabis initiation 17.60 (SD=2.95) 17.94 (SD= 3.16) 17.24 (SD=2.89) 17.23 (SD= 2.98) 0.20 0.1009
Gender: female 297 289 489 239 0.06 0.0230
n =1314 63.9% 59.3% 57.9% 53.9%
Education: any high school 98 131 207 159 0.11 <0.0001
n=595 21.1% 26.9% 24.5% 35.9%
Parental alcohol problems 137 118 225 147 0.07 0.0082
n=627 30.0% 24.6% 27.1% 34.3%
Parental drug problems 19 21 36 30 0.05 0.1528
n=106 4.2% 4.4% 4.3% 6.9%
Parental conﬂict 202 176 321 185 0.05 0.0925
n=884 45.3% 38.1% 41.0% 44.6%
Experienced sexual abuse
before age 18
53 40 80 59 0.06 0.0504
n=232 11.4% 8.2% 9.5% 13.4%
Conduct disorder 35 46 106 98 0.15 <0.0001
n=285 7.5% 9.4% 12.6% 22.1%
Depressed mood before
cannabis onset
29 51 73 46 0.05 0.0778
n=199 6.2% 10.5% 8.7% 10.4%
Peer use: more than ¾ of
high school peers used cannabis
38 28 87 56 0.08 0.0020
n=209 8.2% 5.7% 10.3% 12.6%
Early cannabis onset: 16 and under 178 173 380 198 0.08 0.0016
n=929 38.3% 35.5% 45.0% 44.7%
Regular nicotine use before
cannabis onset
80 96 151 123 0.10 <0.0001
n=450 17.2% 19.7% 17.9% 27.8%
Regular alcohol use before
cannabis onset
165 182 256 127 0.07 0.0077
n=730 35.5% 37.4% 30.3% 28.7%
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for the other covariates. For the association between
transitions within a week and daily use, those with earlier
onset had an increase in likelihood of`1.83 (95%
CI=1.05–3.17) compared to 4.32 (95% CI=2.27–8.21)
for those with later onset.
For the association between transitions within a week
and abuse/dependence, those with earlier onset had an
increase in likelihood of 2.14 (95% CI=1.33–3.42) com-
pared to 4.86 (95% CI=2.97–7.94) for those with later
onset. For the association between transitions within a
week and later treatment-seeking, those with earlier onset
had an increase in likelihood of 1.63 (95%CI=0.72–3.70)
compared to 2.19 (95% CI=0.92–5.17) for those with
later onset.
There was a signiﬁcant interaction between early/later
cannabis onset and (1) transition within a week, with
those in the early-onset group having a decrease in likeli-
hood of abuse and/or dependence of 0.50 (95%
CI=0.26–0.94) and (2) transition 3months–1year, with
those in the early-onset group having an increase in likeli-
hood of daily use (OR=2.55, 915% CI=1.04–6.27) and
treatment-seeking (OR=8.38, 95% CI=1.35–2.1).
Modelling additive genetic, shared and non-shared
environmental inﬂuences on speed of transition between
initiation and subsequent cannabis use
Data on speed of transition from initiation to subsequent
use of cannabis for twin modelling was available for 824
MZ twins and 1145 DZ twins (see Table 1 for full informa-
tion). Tetrachoric correlations were similar for MZ (0.27)
and DZ (0.23) pairs. A univariate variance component
twin model was ﬁtted, with thresholds equated within
and between zygosity groups, as initial analyses did not
identify any signiﬁcant differences (P=0.17). The estimate
for additive genetic inﬂuences for the full model was small
(0.002, 95% CI=1.446372e-09–0.35), and could be
dropped from the model without a signiﬁcant loss of ﬁt
(P=1). A model specifying only environmental inﬂuences
(C and E) provided the best ﬁt, with moderate shared
environmental inﬂuences (0.25, 95% CI=0.15–0.34)
and large unique environmental inﬂuences (0.75, 95%
CI=0.66–0.84) on the variation in speed of this transition
(see Table 5).
DISCUSSION
The key ﬁnding of this paper was the signiﬁcant association
between speed of transition from initiation to subsequent
use of cannabis and later likelihood of daily cannabis
use, cannabis abuse/dependence and cannabis-related
treatment-seeking. This association remained after con-
trolling for potential confounders. The unique environ-
ment accounted for most (0.75) of the variance in the
speed of transition from initiation of cannabis to subse-
quent use, and measured risk factors including conduct
disorder, education and regular use of nicotine before can-
nabis initiation were associated with a more rapid transi-
tion to subsequent use. Given the absence of prior
research on this transition, these ﬁndings provide an origi-
nal and intriguing contribution to the literature.
Previous research has found that earlier use is
associated with later problematic drug use/dependence
[18,21,22,32–34], and by studying the novel transition
from initiation to subsequent use this paper has established
that the association between speed of transition and later
negative outcomes remains after controlling for factors
that would be expected to predispose individuals towards
cannabis use problems. Stratifying analyses by onset
showed the association between transition speed and all
studied outcomes was stronger among those with later
cannabis onset, suggesting that transition speed is indica-
tive of later problems even beyond the high-risk period of
early adolescence. This highlights the importance of
accounting for age when applying a stage-sequential
approach to the study of substance use [13].
Additive genetic effects have no inﬂuence on variation
in the speed of this transition, which is in contrast to ﬁnd-
ings of moderate heritability for other transitions
[5,26,28,35]. Similarly, the speed of other speciﬁc transi-
tions has been found to be moderately heritable, with
0.30 (95% CI=0.15–0.46) of the rate of transition from
non-use to initiation attributed to additive genetic effects
Table 5 Twice ACE model ﬁtting results and variance components point estimates with 95% conﬁdence intervals for speed of transition
from initiation to subsequent use of cannabis.
Model Proportion of variance –2 log likelihood df AIC BIC
A C E




0.75 (0.63–0.84) 5268.96 1963 1342.96 –9004.02
CE submodel – 0.25 (0.15–0.34) 0.75 (0.66–0.85) 5268.96 1964 1340.96 –9011.30
AIC = Akaike information criterion; BIC = Bayesian information criterion. Model is adjusted for sex. A = additive genetic factors; C = common environmental
factors; E = speciﬁc environmental factors.
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and similar ﬁndings observed for the rate of transition from
initiation to ﬁrst dependence symptom (0.36, 95%
CI=0.19–0.44) and ﬁrst dependence symptom to the de-
velopment of dependence (0.37, 95% CI=0.00–0.58)
[36]. In contrast, our ﬁndings show the speed of transition
from initiation to subsequent use of cannabis is inﬂuenced
predominately by environmental factors, demonstrating
the importance of utilizing a stage-sequential approach in
order to understand fully how genetic and environmental
factors vary throughout substance use.
Signiﬁcant differences were observed between transi-
tion speed groups for measured environmental risk
factors. Studies of the speed of other transitions have iden-
tiﬁed similar environmental risk factors, including child-
hood sexual abuse [37,38], parental substance abuse
[37], peer use of substances [39,40], parental substance
dependence [41] and conduct disorder [41–44]. The
majority of the variance in the speed of the transition from
initiation to subsequent use was attributable to the unique
environment, which can represent measurement error in
the analysis. However, we speculate that availability, which
has been found previously to account for variation in drug
use progression [45], is likely to form part of the environ-
mental factors at play in the speed of transition from
initiation to subsequent use. Further exploration is needed
to understand the determinants of speed of transition from
initiation to subsequent use.
Limitations and future research
First, these data were based on retrospective self-report
which introduces the possibility of recall bias. Secondly,
the measure of transition speed was comprised of relatively
wide categories. Thirdly, there was a low number of twin
pairs concordant for speed of transition from initiation to
subsequent use, which was overcome through the use of
raw data for the twinmodelling. Ordinal analysis can result
in lower power, and may result in an underestimate of the
true liability correlation [46]. Fourthly, the study lacked
temporal information on a number of covariates within
the analysis, and including these variables in the analysis
represents a cautious approach to adjustment for con-
founding variables which may lead to underestimation of
the effect of this transition. Fifthly, while probably represen-
tative of base population [47], the prevalence of life-time
cannabis use in this sample is relatively high at 68.2%,
which may limit generalizability.
It is unknown whether these ﬁndings will translate to
alcohol and nicotine use or to other illicit drugs, given that
differences have been observed previously in the rate of
transition to cannabis disorder compared to nicotine or al-
cohol dependence [18], but the results of the current study
suggest that study of this transition across drug classes is
warranted.
Implications
We suggest that faster transition from initiation to subse-
quent use is unlikely to have a traditional causal relation-
ship with cannabis dependence. The association probably
reﬂects a combination of individual and contextual factors,
such as availability, that surround the rapid escalation. If
replicated in prospective research, these ﬁndings may have
practical utility for clinical practice, with the prospect of
translation into a clinically useful marker with which to
identify individuals likely to beneﬁt from intervention.
These ﬁndings have also highlighted the utility of studying
different transitions in substance use to disentangle the
complex aetiology of drug use disorders [13].
CONCLUSIONS
Those whose subsequent use is within 1week have the
greatest likelihood of future cannabis use problems. The
novel demonstration that the speed of transition from initi-
ation to subsequent cannabis use is predictive of later can-
nabis outcomes is striking, and is of potentially major
importance to understanding of the development of canna-
bis dependence and problems. Given that the variance in
the speed of this transition is due predominately to unique
environmental factors, it may be that speed of the transi-
tion from initiation to subsequent use acts as a proxy mea-
sure of a number of the contextual factors that contribute
to the development of addiction.
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Abstract Adolescent substance use is of considerable public
health importance. This narrative review provides a brief back-
ground to genetically informative research methodologies and
highlights key recent literature examining the interplay be-
tween genetic and environmental influences in the etiology of
substance use. Twin studies have quantified the magnitude of
genetic and environmental influences, and more recently, co-
relative and Children of Twin designs have shown environ-
ments can moderate heritability. Studies have identified a num-
ber of specific gene variants (e.g. OPRM1, DRD4, 5HTTLPR)
that interact with parenting and peer influence, and the effec-
tiveness of interventions may vary by genotype. However, little
research has taken into account the stage-sequential nature of
substance use. This may obscure important differences in the
genetic and environmental influences, and their interplay, at the
stages of escalation to problem use. Future research needs to
build on existing methodologies to disentangle the complexi-
ties of progression in adolescent substance use.
Keywords Adolescence . Gene × environment interaction .
Substance use . Genetic . Environmental
Introduction
Substance use is an area of considerable public and research
importance due to the associated health and social conse-
quences [1]. Use during adolescence is an area of particular
research focus, not just because adolescence is the typical
period for substance use initiation [2] but also because of the
acute risks and harms [3–5] from substance use and the strong
association between onset, extent of use during adolescence
and risks for the subsequent development of substance depen-
dence and related harms [6–12]. There has been a long history
of research into environmental risk factors for the initiation of
substance use [13] and more recently a recognition of strong
genetic influences on substance use and substance use disor-
ders, derived principally from the findings of twin studies [12,
14–18]. Advances in genotyping technologies have permitted
the expansion of research on these genetic influences to the
identification of specific genetic variants associated with drug
use. Despite this, relatively few genetic variants have been
identified as being robustly associated with substance depen-
dence, with some notable exceptions [19–21].
The limited number of genetic variants with strong, robust
associations with substance use has led to increasing focus on
the interplay between genetic predispositions and environ-
mental exposures in the etiology of substance use and escala-
tion to problems [22–26]. Gene by environmental interplay
encompasses both gene by environment interaction and gene
by environment correlation. Three main categories of gene by
environmental correlation have been identified. These are ac-
tive correlation, whereby individuals select, modify or con-
struct experiences that are correlated with their genetic
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predisposition; passive correlation, whereby individuals are
passively exposed to environments that are correlated with
their genetic predispositions; and evocative correlation,
whereby the individual’s genotype elicits a certain response
from the environment around them [27]. Gene by Environ-
ment Interactions (G×E) occur when environmental effects on
individuals vary by genotype or when the environment alters
the effect a gene has on an individual’s physiology [27, 28].
In this review, we focus on the recent literature exploring
genetic and environmental influences on the development of
substance use and dependence during adolescence. By
highlighting methodological approaches, preliminary findings
and the necessity of considering the stage-sequential nature of
substance use, we identify areas that show the greatest prom-
ise for disentangling this complex etiology.
Genetically Informative Research and the Risk
Factors for Adolescent Substance Use
The magnitude of genetic and environmental influences on
substance use disorders has been broadly quantified by twin
studies. Agrawal and Lynskey [17] noted that estimates of the
heritability of substance dependence ranged from 0.30 to 0.70
and were broadly equivalent across individual substances.
Twinmethodologies allow the quantification of the magnitude
of both shared environmental influences that increase twin
similarity on a trait and non-shared environmental influences
that do not increase similarity on a trait [27]. Shared genetic
influences are typically less prominent than non-shared envi-
ronmental influences in the etiology of substance dependence;
although in adolescence, the shared environment may be rel-
atively more prominent. In addition to quantifying the magni-
tude of genetic and shared environmental influences on sub-
stance dependence, twin studies have also demonstrated that
there are likely to be genetic influences that form a vulnera-
bility to substance use across drug classes [29, 30], although
some evidence has been found for separate, albeit highly cor-
related, licit and illicit drug genetic factors [31].
Utilising Traditional Twin Studies to Explore Gene
by Environment Interplay
Twin studies have not only allowed quantification of the mag-
nitude of genetic effects but have also provided strong evi-
dence that the magnitude of genetic influences is altered by the
environment. For example, Boardman et al. have demonstrat-
ed the impact of public health policies, finding that the mag-
nitude of genetic influences on smoking desistance increased
following the introduction of restrictive legislation on
smoking behaviours [32] and that genetic influences on daily
smoking in adolescents were lower in states with more restric-
tive access to tobacco products [33]. Social factors also play
an important role. For example, the heritability of smoking is
higher in schools where the most popular students smoke [34];
genetic influences on adolescent smoking are more prominent
in the presence of low parental monitoring [35]; and heritable
influences on adolescent substance use are more prominent in
environments characterised by high levels of peer substance
use [36].
The Utility of Large, Linked Administrative Data Sets
In addition to results from twin studies, Kendler and his col-
leagues have recently used a novel research strategy to exam-
ine genetic influences, based on the analysis of whole popu-
lation administrative data sets from Sweden, with sample sizes
exceeding one million individuals. Combining official records
of treatment seeking, official police contact and related infor-
mation at a whole population level with information on out-
comes in relatives (e.g. full siblings, cousins), they have con-
firmed substantial heritability for drug abuse in both males
(55 %) and females (73 %), with environmental factors shared
by siblings operating only in males [37]. The convergence of
these findings with those from traditional twin studies, which
have typically studied less severe phenotypes based on self-
report symptom data, is impressive. Using a similar approach
to examine concordance for drug abuse in pairs of related
individuals, the authors demonstrated the importance of fam-
ily environmental influences on drug abuse in sibling pairs,
where those whose older sibling had recorded drug abuse had
a 1.42 (95 % CI, 1.31–1.54) increased likelihood of drug
abuse compared to those whose younger siblings had recorded
drug abuse [38••]. Similar findings were reported for cousin
pairs, who were found to be significantly more similar in
recorded drug abuse if they were close in age and location
when growing up [39].
In addition to confirming the importance of both (latent)
genetic and environmental influences on risks for drug abuse,
these authors have presented a number of analyses examining
the extent to which specific, measured environmental expo-
sures are associated with risks for drug abuse while controlling
for heritable influences on such risk. For example, Giordano
et al. [40], using a co-relative comparison within sibling and
cousin pairs discordant for exposure to trauma, demonstrated
that experiencing a second-hand traumatic event (e.g. having a
parent or sibling be assaulted or die) before age 15 was associ-
ated with twice the risk for the development of drug abuse.
They used a similar approach to highlight the importance of
neighbourhood social deprivation on the development of drug
abuse [41]. Kendler et al. [42] highlighted risks for drug abuse
associated with exposure to both peer deviance and parental
divorce while also implicating interactions between genetic li-
ability for drug abuse and peer deviance and between parental
divorce and peer deviance in the etiology of officially recorded
drug abuse. For those with low genetic risk (determined by the
Curr Addict Rep
drug abuse records of relatives), living in an area with high peer
deviance was associated with an increase in 28.1 cases of drug
abuse per 10,000 person-years. In comparison, being at very
high genetic risk in a high risk area was associated with an
increase of 78.0 cases per 10,000 person-years.
The Use of Children of Twins Design
One potential liability of the traditional twin method is that
any G×E will be confounded with, and therefore inflate, esti-
mates of heritability unless measured environmental expo-
sures are explicitly modelled [43]. One design which can
model both main effects of genes and environment and gene
by environmental interactions is the children of twins (CoT)
design. This design allows a comparison of outcomes in (1)
children at high genetic risk and high environmental risk (e.g.
parent is alcohol dependent), (2) high genetic risk but reduced
environmental risk (parent is not alcohol dependent but their
MZ co-twin is), (3) intermediate genetic risk but reduced en-
vironmental risk (parent is not alcohol dependent but their DZ
co-twin is) and (4) children at low genetic and low environ-
mental risk (control families; both parent and co-twin are not
alcohol dependent). Thus, it allows detection not only of ge-
netic transmission but also environmental consequences of
parental alcohol dependence that may depend upon offspring
genotype (Gene × Shared Environment interaction [43]) or be
masked by genetic nonadditivity.
Applying the CoT design to study the links between paren-
tal drug dependence (alcohol or cannabis) and onset of sub-
stance use in offspring,Waldron et al. [44••] reported that both
children of parents who were drug dependent (high genetic/
high environmental risk) and those of non-drug-dependent
parents whose MZ co-twin was drug dependent (high
genetic/low environmental risk) had elevated rates of early
onset tobacco (7.30 and 2.22 times higher risk, respectively),
alcohol (1.43 and 2.82 times higher risk, respectively) and
cannabis use (only significant for those with high genetic/
low environmental risk, where it was 3.03 times higher).
While this pattern of results strongly implicates heritable in-
fluences in transmission of risks associated with parental drug
dependence, further analyses also highlighted that, indepen-
dent of these influences, exposure to parental divorce signifi-
cantly elevated risks of early onset substance use.
Interactions of Specific Genetic Variants
with Environmental Exposures
While the research above has focussed on latent genetic influ-
ences, research that has explored specific genes in relation to
the environment has also found encouraging results for G×E.
There are a number of considerations when selecting specific
gene variants to be tested against specific environmental ex-
posures. What is considered a large sample for environmental
research may be underpowered for genetic studies, with ex-
tremely high numbers of participants required to identify
strong G×E between genotypes and environmental exposures
that commonly occur [45, 46], resulting in the employment of
prioritisation strategies for investigation of G×E that focus on
genetic variants that are common in the population; that are
associated with the disorder being studied; or that are associ-
ated with individual response to the environmental factor un-
der consideration [28, 45]. Consequently, the genetic variants
that have been studied to date are those commonly studied in
the mental health G×E literature.
There is some evidence that the influence of specific gene
variants may be moderated by environmental exposures such
as neighbourhood peer substance use, parental supervision,
and parent-child attachment. For example, Daw et al. [47]
studied the influence of 5HTTLPR in combination with mea-
sures of peer smoking. There was not a statistically significant
main effect of neighbourhood peer cigarette use, but those
with more copies of the 5HTTLPR short allele had a signifi-
cantly higher hazard of smoking initiation in environments
where a higher proportion of neighbourhood peers smoked.
Specifically, the hazard ratio for the interaction between peer
use and number of 5HTTLPR short alleles on any smoking
was 3.532 (P=0.002) and 5.686 (P<0.001) for regular
smoking. In addition, COMT has been found to interact with
parental supervision to affect frequency of drinking at age 19
and with parental involvement to affect amount consumed at
age 19 [48]. The interaction between OPRM1 and parental
rule setting was also found to significantly differentiate heavy
drinkers from light drinkers [49]. Further, the effect of an
ADH1B variant has been found to be moderated by the drink-
ing behaviour of peers, with a protective effect on reaching
drinking milestones observed when no friends were reported
to be drinking that was significantly reduced when most or all
best friends were reported to be drinking [50]. Finally, higher
numbers of DRD4 alleles significantly interacted with parent-
child attachment to increase risk of problematic smoking (anx-
ious attachment) and cannabis use (avoidant and anxious at-
tachments) [51].
Genetic Variants and Response to Substance Use
Interventions
A new and emerging research area is the examination of how
specific genetic variants may alter response to treatment or
prevention interventions. Understandingwhy certain interven-
tions are successful for some people and less so for others
would allow for the development of tailored intervention
programmes and represent an example of potential G×E inter-
actions. However, only recently has research begun to consid-
er whether an individual’s genetic risk can moderate the ef-
fects of participation in an intervention for substance use.
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Brody et al. [52••] reported the results of two longitudinal
family-centred randomised controlled trials designed to re-
duce alcohol use in 900 11–17 year olds. They examined
whether adolescents assigned to the intervention condition
who carried a dopaminergic or GABAergic susceptibility
gene would demonstrate greater decreases in alcohol use than
adolescents who did not carry either susceptibility gene. They
found that participants within the intervention condition car-
rying two or three susceptibility genes evinced smaller in-
creases in alcohol use than participants with none or only
one susceptibility gene. Regression estimates for the interac-
tion between gene and intervention (significant after adjust-
ment for multiple comparisons) were −0.86 (SE 0.22) for
GABRG1, −0 .67 (SE 0.21) for GABRA2 and −1.19 (SE
0.29) for DRD2. These findings provide support for the dif-
ferential susceptibility theory [53] which suggests that the
genetic make-up of some individuals may increase malleabil-
ity or susceptibility to both negative and positive environmen-
tal influences. Thus, some individuals may be adversely af-
fected by negative exposures and may also be more likely to
benefit from positive environments. Therefore, inter-
individual variability can exist in response to positive experi-
ences such as programmes designed to address substance use.
Methodological Challenges of Specific Genetic Variants
Research is providing promising results for G×E and has
highlighted genes that warrant further exploration. How-
ever, the selection of specific genetic variants for study
has limitations. With regard to the environmental expo-
sures selected for study, there are an extensive number
of potential exposures that can be combined with the
plethora of gene candidates. Sher and colleagues [54]
have highlighted that the unavailability of information
on the number of possible environmental influences
means that there is no Benvironome^ to compare with
the genome. Distal factors that are thought to have a
long-term effect (such as childhood family environment)
can be differentiated from proximal exposures (such as
availability), and studies of G×E in adolescent substance
use may benefit from systematically classifying environ-
ment in this way. There is also a need to identify whether
G×E findings remain stable at different time points. De-
velopmental stage has previously been shown to affect
gene associations [55], and specifically for adolescent
substance use, it is important to confirm whether associa-
tions differ depending on the type of drug, the stage of
substance use, the developmental stage of the tested pop-
ulation and across subgroups. Finally, despite years of
candidate gene studies, there are still few replicated asso-
ciations [46]. Additional lines of G×E research may iden-
tify more robust associations.
Polygenic Risk Scores
Focussing research on combinations of genes or gene systems
may be a more efficient strategy for understanding G×E in
substance use. The advent of genome-wide association studies
(GWAS) has implicated multiple genes from multiple biolog-
ical pathways in the etiology of substance use [19, 56]. How-
ever, as for other complex traits, the effect sizes of individual
gene variants associated with substance use are small and fall
short of accounting for the expected amount of variability
based on heritability estimates [57]. Taking this into account,
some researchers have moved from examining single genes
for G×E to considering polygenic risk scores [58•, 59, 60]. In
principle, these scores work in the same way as other risk
prediction models, aggregating the effects of multiple genetic
variants to produce a quantitative estimate of (genetic) risk for
a particular trait for each individual.
While risk scores do have the potential to be useful and
informative, careful consideration must be given to (i)
methods used to develop these scores, (ii) the strength of as-
sociation between the polygenic score and the outcome(s) of
interest and (iii) whether the results are applicable beyond the
study sample [61]. An illustrative paper on this topic used a
longitudinal community sample to investigate the interaction
between a polygenic risk score and age in relation to tobacco
consumption [62•]. The authors demonstrated that, even when
multiple genetic factors were combined, the polygenic score
only accounted for a small proportion of the variance in a trait
for nicotine (in their example, from 0.1 to 1 % of the variance
in cigarette consumption between the ages of 14 and 24) and
did not show the same relationship for alcohol. This does not
rule out the use of polygenic risk scores but does serve to
underline the need for realistic expectations about their likely
predictive power and the importance of considering their po-
tential contribution in combination with other, nongenetic,
risk factors [63].
Considering the Stage-Sequential Nature of Drug
Dependence
There are three key features of the relationship between ge-
netic and environmental influences on the development of
substance use and dependence that require further elaboration.
Firstly, it is important to note that the development of sub-
stance dependence is a stage-sequential process in which a
number of different transitions must first occur (see Fig. 1).
Many individuals will reach different stages without
progressing to dependence, but traditionally, most studies of
dependence have conflated these stages. For example, the
common comparison of individuals who are substance depen-
dent against those who are not dependent often fails to distin-
guish between non-cases whomay have never used a drug and
Curr Addict Rep
those who used the drug (potentially regularly) but did not
progress to dependence. There is also value in exploring var-
iation amongst those who reach different stages, differentiat-
ing not only those who do or do not initiate use but also those
who initiate use earlier or later [64]. Despite research
highlighting the necessity of considering early substance use
stages, this has rarely been considered, making it unclear at
which stages in the development of drug dependence specific
genetic or environmental influences are most prominent [65].
Secondly, research suggests that the relative strength of
genetic and environmental influences on the development of
substance dependence varies by both stage of substance use
and by developmental age [12, 66–70]. For example, there is
evidence that, in their aggregate, genetic influences are rela-
tively weaker in younger aged samples [71] and at earlier
stages (e.g. initiation) in the development of substance depen-
dence [16] (see Fig. 1). Nonetheless, there is also evidence of
substantial, albeit incomplete, overlap in the genetic influ-
ences on initiation and problem use [72–74].
A third feature that deserves further exploration is the ex-
tent to which the importance of measured genetic and envi-
ronmental influences on substance dependence may vary
across stages of substance involvement (see Fig. 1). Early
stages of substance use, such as initiation, might be genetical-
ly influenced through personality traits such as novelty seek-
ing [75], while genetic factors associated with sensitivity to
drug effects may influence progression of use. At subsequent
stages, such as drug dependence and withdrawal, genetic in-
fluences on drug metabolism may have stronger associations.
Similarly, there may be distal and proximal environmental risk
factors that are unique to specific stages of substance involve-
ment, while others may act across multiple stages or show
correlation while not being identical [72]. Research is also
emerging into how external influences can lead to changes
in gene function at a cellular level [76], and these epigenetic
mechanisms have recently begun to attract interest in the field
of substance use [77–79]. Speculatively, early stages of use
may be influenced by pre-existing epigenetic modification
(resulting, for example, from childhood stressors [80–83])
with later stages influenced by epigenetic modifications
brought about by substance use. Consequently, it is expected
that the use of the stage-sequential approach will reveal that
observed genetic and environmental associations will alter
throughout the sequence towards dependence.
Recent research utilising the stage-sequential approach
has demonstrated differences in association by stage of
use for both environmental and genetic factors. For ex-
ample, Sartor et al. [68] reported a number of associa-
tions with environmental factors that were unique to on-
set of alcohol use (e.g. male gender, attention deficit
hyperactivity disorder, parental divorce and maternal al-
cohol dependence), while others were unique to the tran-
sition from alcohol use to dependence (e.g. nicotine de-
pendence, cannabis abuse, generalised anxiety disorder).
Similar results have been obtained for genetic risk fac-
tors. Belsky et al. [58•] reported that a multi-locus ge-
netic risk score, derived from the results of meta-
analyses for nicotine dependence, was unrelated to initi-
ation of tobacco use but was significantly associated with
increased risks for daily tobacco use, more rapid progres-
sion from initiation to heavy use, increased risks for the
development of nicotine dependence and reduced likeli-
hood of successful cessation. The literature on substance
use behaviour trajectories has typically studied behaviour
change that occurs between substance use stages, and
modelling development and changes in substance use
over time has found that GABRA2 is associated with
an increase in drunkenness between ages 18–19, sug-
gested to be due to the enhanced independence related
to reaching adulthood [84]. Similarly, OPRM1 has been
found to differentiate those who were light drinkers from
those who had progressed to moderate drinking in par-
ticipants followed up over 6 years (participants on aver-
age aged 14.3 at start of study) [49].
Fig. 1 Diagram of stage-
sequential drug use, depicting
plausible stage-specific genetic
and environmental influences,
and the increasing magnitude of
genetic influences on later stages
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In summary, studies utilising the stage-sequential approach
are likely to reveal differential genetic influences at different
stages, with substance-specific genes more likely to operate at
later stages [85]. Different environmental influences are also
likely to operate at each stage, and research into trajectories
suggests that environmental change should be incorporated
into analysis [84]. Taking this approach to research is key
for gaining a comprehensive understanding of G×E in the
development of adolescent substance use and to reaching
meaningful conclusions about opportunities for intervention.
Conclusions
The research currently available highlights the role of genetic
and environmental influences and, importantly, their interplay
in the development of adolescent substance use and provides
intriguing avenues for potential interventions. The evidence
shows promising leads with regard to gene variants that war-
rant further exploration, the composite effects of genes on
substance use and the importance of the type and timing of
environmental influences in shaping adolescent substance use
behaviour.
Genetic and environmental interplay continues to be a
promising avenue for exploration in order to understand
the underlying causes of adolescent substance use and pro-
gression and future research will need to apply the optimal
strategies for investigating this area [28, 45, 61], demon-
strate the replicability of findings and overcome issues
around the measurement of phenotypes. Incorporation of
new methodologies provides the best opportunity to over-
come the barriers to these aims. As discussed in this re-
view, the innovative use of noninvasive methods for re-
search through administrative data sets [38••, 39, 41, 42]
shows promise for analysis of large samples with measured
phenotypes at relatively low cost and effort. Combining
such methods with a stage-sequential approach to under-
standing genetic and environmental influences on drug in-
volvement and response to intervention may be key to
disentangling the complex etiology of one of the great
public health issues of our time.
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a  b  s  t  r  a  c  t
Background:  There  is  a developing  body  of  research  looking  at  cannabis  use  opportunity,  but little  research
examining  timing  of  opportunity  to  use  cannabis.
Aims: Identify  factors  associated  with  (1)  earlier  opportunity  to  use  cannabis  and  (2) faster  progression
from  opportunity  to cannabis  dependence.
Method:  Cross-sectional  study  of 3824  Australian  twins  and  siblings,  measuring  age  of  onset  of  cannabis
use  opportunity  and  DSM-IV  cannabis  dependence.  Survival  analysis  identified  factors  associated  with
faster  progression  to  opportunity  or  dependence.
Results: Factors  associated  with  both  speed  of  progression  to  opportunity  and  dependence  were  con-
duct  disorder  (opportunity  HR 5.57,  95%CI  1.52–20.47;  dependence  HR  2.49,  95%CI  1.91–3.25),  parental
drug  problems  (opportunity  HR  7.29,  95%CI  1.74–30.62;  dependence  HR  3.30,  95%CI  1.63–6.69), weekly
tobacco  use  (opportunity  HR  8.57,  95%CI  3.93–18.68;  dependence  HR  2.76, 95%  CI  2.10–3.64),  and
female  gender  (opportunity  HR  0.69,  95%CI  0.64–0.75;  dependence  HR  0.44,  95%CI  0.34–0.55).  Fre-
quent  childhood  religious  attendance  (HR  0.74,  95%CI  0.68–0.80),  parental  conflict  (HR  1.09,  95%CI
1.00–1.18),  parental  alcohol  problems  (HR 1.19,  95%CI  1.08–1.30)  and childhood  sexual  abuse  (HR 1.17,
95%CI  1.01–1.34)  were  uniquely  associated  with  transition  to  opportunity.  Depressive  episode  (HR  1.44,
95%CI  1.12–1.85),  tobacco  dependence  (HR  1.36,  95%CI  1.04–1.78),  alcohol  dependence  (HR  2.64, 95%CI
1.53–4.58),  other  drug  use  (HR  2.10,  95%CI  1.64–2.69)  and  other  drug  dependence  (HR 2.75,  95%CI
1.70–4.43)  were  uniquely  associated  with  progression  to  dependence.
Conclusion:  The  profile  of  factors  associated  with  opportunity  to  use  cannabis  and  dependence  only  par-
tially  overlaps,  suggesting  targeting  of  interventions  may  benefit  from  being  tailored  to the  stages  of drug
use.
©  2016  Elsevier  Ireland  Ltd.  All  rights  reserved.
1. Introduction
Cannabis is widely used, with cumulative lifetime incidence of
use estimated to range from 6%-20% in Europe, 3–11% in the Mid-
dle East and Africa, and to exceed 40% in the US and New Zealand
(Degenhardt et al., 2008). Lifetime prevalence of cannabis use in
Australian adolescents has been estimated at 60% (Patton et al.,
2002). Although many individuals use cannabis infrequently and
∗ Corresponding author.
E-mail address: lindsey.hines@kcl.ac.uk (L.A. Hines).
without experiencing problems, globally an estimated 13.1 million
individuals meet criteria for cannabis dependence, contributing
10.3% of the illicit drug use global burden of disease (Degenhardt
et al., 2014). It is estimated 10–16% of cannabis users develop
dependence (Anthony, 2006), but before progressing to depen-
dence individuals must pass through a number of preceding stages.
Examining the multiple stages of drug use before dependence
develops is necessary for gaining a comprehensive understanding
of factors involved in drug use, and for identifying opportunities for
early intervention (Hines et al., 2015a).
The first stage of drug involvement is having the opportunity
to use (regardless of whether the individual uses the drug or not),
http://dx.doi.org/10.1016/j.drugalcdep.2015.12.032
0376-8716/© 2016 Elsevier Ireland Ltd. All rights reserved.
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which forms the “exposure opportunity” in the epidemiology of
drug use (Wagner and Anthony, 2002). Opportunity is required for
use to occur, and forms an individual’s earliest necessary condition
from which they are at risk of developing cannabis dependence.
Recent research indicates the majority of adolescents who  have an
opportunity to use cannabis progress to initiation of use (Caris et al.,
2009; Lopez-Quintero and Neumark, 2015; Pinchevsky et al., 2011),
making the opportunity to use an important target for intervention
(Neumark et al., 2012).
There is a developing body of research looking at the oppor-
tunity to use. Factors associated with opportunity to use cannabis
include using alcohol, using tobacco and the combination of alcohol
and tobacco use (Caris et al., 2009; Neumark et al., 2012; Wagner
and Anthony, 2002). In Chile and the US, males have been found to
be slightly more likely than females to have a chance to use cannabis
(Caris et al., 2009; Van Etten and Anthony, 1999), but these gen-
der differences have not been consistently observed (Wells et al.,
2011). Childhood religious practices are associated with decreased
likelihood of cannabis use opportunity (Chen et al., 2004), and
those with externalising behaviour problems have been found to
be more likely to have a cannabis use opportunity (Neumark et al.,
2012; Reboussin et al., 2015). Perhaps unsurprisingly given that
first cannabis use opportunity typically occurs in late childhood or
early adolescence, lower parental involvement and higher levels of
coercive discipline have been found to be associated with increased
likelihood of cannabis use opportunity (Chen et al., 2005). The effect
of parenting continues throughout adolescence, with those who
reported low parental monitoring in high school more likely to have
cannabis use opportunity once they started college (Pinchevsky
et al., 2011).
Amongst this existing evidence, there is little research exam-
ining the timing of opportunity to use cannabis. The study of
transitions, and the timing of these transitions, can provide unique
insights into influences on substance use (Behrendt et al., 2012;
Hines et al., 2015b; Sartor et al., 2009, 2008), but only a limited num-
ber of factors have been studied in relation to speed of transition
to cannabis use opportunity (with earlier opportunity represent-
ing a faster transition) These have focussed on early childhood
behaviours, with disruptive behaviour early in school in males and
better reading scores in females associated with earlier cannabis
use opportunity (Storr et al., 2011). Similarly, no research to date
has explored whether there is overlap between factors associ-
ated with earlier opportunity and those associated with the speed
of progression to dependence. These include other substance use
(Behrendt et al., 2009), some mental health factors (Behrendt et al.,
2011) and gender (Ridenour et al., 2006; Wittchen et al., 2008).
Exploring speed of transition to cannabis opportunity will deter-
mine whether risk factors for dependence are already exerting
influence on drug use behaviours at the start of an individual’s
cannabis involvement, which has utility for improving understand-
ing of how dependence develops (Hines et al., 2015a). Applying
survival analysis methodology to this area allows for quantifica-
tion of time to cannabis use opportunity and from opportunity to
dependence, and identification of what factors may  impact upon
the speed of these transitions.
This paper aims to:
1. Identify factors associated with earlier opportunity to use
cannabis.
2. Identify factors associated with progression from cannabis use
opportunity to cannabis dependence.
3. Determine whether factors associated with opportunity to use
cannabis are also associated with more rapid progression from
first opportunity to dependence.
2. Methods
2.1. Sample
The sample was  drawn from the Australian Twin Registry. From
a pool of twin pairs born between 1972 and 1979, 3348 MZ  and DZ
twins and 476 of their siblings (mean age at time of interview = 32.1,
SD 3.04, range 21–46) completed the interview component of a
study of cannabis and other drug misuse. A full description of the
study methodology and of the characteristics of participants has
been published previously (Lynskey et al., 2012).
2.2. Assessment
Participants were assessed through computer-assisted
telephone interviews which collected information on socio-
demographics, childhood experiences, drug use and common
mental health disorders, including conduct disorder and major
depressive disorder, assessed using the SSAGA-OZ interview
(Bucholz et al., 1994; Heath et al., 1997). The SSAGA-OZ is a
validated measure of mental health using DSM-IV criteria, and
includes assessment of cannabis and other drug abuse and depen-




2.3.1.1. Opportunity to use cannabis. Participants were asked “have
you ever been offered, or had the opportunity to use cannabis, even
if you did not use it at the time? How old were you the first time?”
Of 3,824 individuals interviewed, 3,798 provided information on
whether or not they had ever had the opportunity to use cannabis.
Of these, 85% (N = 3399) reported they had an opportunity to use
cannabis. A continuous measure of age of first opportunity was  used
for both survival analysis models.
2.3.1.2. Cannabis dependence. Participants were classified as meet-
ing lifetime criteria for DSM-IV cannabis dependence (American
Psychiatric Association, 2000) if they reported three or more of the
following symptoms occurring within the same 12 month period:
using cannabis a greater number of times/greater amount than was
intended, tolerance, wanting to cut down/stop use, spending so
much time obtaining/using/recovering from the effects of cannabis
the participant had little time for anything else, reducing important
activities as a result of cannabis use, continuing use despite it wors-
ening health/emotional problems. Withdrawal was  not included as
it was not part of DSM-IV criteria for cannabis dependence. Partici-
pants were also asked the age at which they first experienced three
or more of these symptoms occurring within a 12 month period.
Of those reporting lifetime opportunity to use cannabis, 10.9%
(N = 371) met  criteria for cannabis dependence, and a continuous
measure of age at onset of cannabis dependence was used in sur-
vival analysis.
2.3.2. Covariates.
2.3.2.1. Gender. Gender was determined through self-report.
2.3.2.2. Parental alcohol problems. Parental alcohol problems were
determined through participant self-report of their mother or
father experiencing problems with health/family/job/police/other
as a result of drinking, or their mother or father drinking exces-
sively.
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2.3.2.3. Parental drug problems. Parental drug problems were
determined through participant self-report of their mother or
father experiencing problems with health/family/job/police/other
as a result of drug use, or the participant reporting they felt their
mother or father had a problem with drugs.
2.3.2.4. Parental conflict. Parental conflict was determined by par-
ticipant responses to the questions “how often did your parents
fight or argue in front of you?” and “how much conflict and tension
was there between your parents?” Both questions focused on the
period when the participant was aged 6–13. Participants reporting
parents ‘sometimes’ or ‘always’ fought or argued, or ‘a lot’ or ‘some’
conflict/tension, were coded as experiencing high parental conflict.
2.3.2.5. Single parent family. Single parent family was determined
by participants’ report of whether their mother or father was
absent. Interviewers recorded whether participants lived with their
mother/mother figure and/or their father/father figure for at least
4 full years between 6 and 13.
2.3.2.6. Strict parenting. Strict parenting was determined through
participants response to the items “In your opinion, when you
were 6–13, was your mother/mother figure more strict than most
mothers?” and “ In your opinion, when you were 6–13, was your
father/father figure more strict than most fathers?”. Those who
endorsed either of these items were classified as having experi-
enced strict parenting.
2.3.2.7. Childhood sexual abuse. Childhood sexual abuse was
recorded for individuals who reported being forced into sexual
intercourse or any other forms of sexual activity before age 18. Self-
reported age of sexual abuse onset was used to create a time varying
covariate for sexual abuse.
2.3.2.8. Frequent childhood religious attendance. Frequent child-
hood religious attendance was determined through participant
self-report of their frequency of attendance at religious services
between ages 6 and 13. Participants were coded as frequently
attending religious services if they reported attendance more than
once a week, once a week, once or twice a month or every couple
of months.
2.3.2.9. Conduct disorder. Conduct disorder was  determined by
participant self-report of at least 3 of the 15 DSM-IV criteria
(American Psychiatric Association, 2000) occurring within the
same 12-month period, prior to age 18. Participants’ self-reported
age of onset of 3 symptoms occurring within a 12 month period
was used to create a time varying covariate for conduct disorder.
2.3.2.10. Depressive episode. Depressive episode was recorded
if participants reported a two week period where they were
more irritable than usual (if under age 18 at the time), felt
depressed/down/sad/blue/discouraged, or had a lot less interest in
things. Self-reported age of the first occurring depressive episode
was used to make time varying covariates for survival analysis.
2.3.2.11. Weekly tobacco use. Weekly tobacco use was  measured
through the interview item “Was there ever a time in your life when
you smoked cigarettes at least once a week for at least two months
in a row?” Self-reported age of onset of weekly tobacco use was
used to make time varying covariates for survival analysis.
2.3.2.12. Tobacco dependence. Tobacco dependence was measured
through participants reporting 3 or more of the DSM-IV tobacco
dependence criteria (American Psychiatric Association, 2000)
occurring within a 12 month period. Self-reported age of onset of
tobacco dependence was  used to make time varying covariates for
survival analysis.
2.3.2.13. Monthly alcohol use. Monthly alcohol use was measured
through the interview item “At what age did you start to drink
regularly—that is, drinking at least once a month for 6 months or
more?” Self-reported age of onset of monthly alcohol use was  used
to make time varying covariates for survival analysis.
2.3.2.14. Alcohol dependence. Alcohol dependence was  measured
through participants reporting 3 or more of the DSM-IV alco-
hol dependence criteria (American Psychiatric Association, 2000)
occurring within a 12 month period. Self-reported age of onset of
alcohol dependence was  used to make time varying covariates for
survival analysis.
2.3.4.15. Other drug use. Other drug use was  recorded if partici-
pants reported lifetime non-prescribed use of any of the following:
cocaine (all forms), stimulants, opiates and major painkillers,
sedatives, hallucinogens, dissociatives, solvents or inhalants. Self-
reported age of drug use onset was used to create a time varying
covariate for first other drug use.
2.3.2.16. Other drug dependence. Other drug dependence was
recorded if participants reported lifetime dependence on any of
the following: cocaine (all forms), stimulants, opiates and major
painkillers, sedatives, hallucinogens, dissociatives, solvents and
inhalants. Participants were classified as meeting lifetime crite-
ria for DSM-IV drug dependence if they reported 3 or more of
the 7 DSM-IV symptoms of dependence (American Psychiatric
Association, 2000) occurring within the same 12 month period.
Self-reported age of onset of dependence was used to create a time
varying covariate for other drug dependence. This covariate was
only included in the model of progression to the development of
dependence.
2.4. Statistical analyses
All analyses were conducted in Stata statistical software version
11 (StataCorp, 2009). Two separate Cox proportional hazard models
were fitted to the data to test the association between a number of
potential associated factors and speed of progression from (1) birth
to opportunity to use cannabis and (2) opportunity to use cannabis
to the development of cannabis dependence. Both were assessed as
time in years. Details of the two Cox Proportional Hazards models
are provided below:
Model one: To identify factors associated with hazard of the
opportunity to use cannabis survival data (time in years, starting
from birth) were used for analysis of 3,798 participants who had
provided information on opportunity to use cannabis. Failure event
was opportunity to use cannabis, and 3398 failure events were
observed (one participant was excluded from analysis, see descrip-
tion below). Due to missing covariate data, 3,763 participants were
included in the final model (3367 failure events).
Model two: To identify factors associated with hazard of the
development of dependence following the opportunity to use
cannabis survival data (time in years, starting from age of first
opportunity to use cannabis) were used for analysis of 2,593 partic-
ipants who had reported their age of opportunity to use cannabis
and who  had also reported lifetime cannabis use (those who  had
not reported lifetime cannabis use were removed from the model
in order to avoid the inverse association that would exist between
never-use of cannabis and cannabis dependence; additionally, one
participant was omitted as their recorded age of dependence was
earlier than recorded age of opportunity). The failure event was
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cannabis dependence, and 371 failures were observed. Due to miss-
ing covariate data, 2,565 participants were included in the final
model (363 failure events).
Person year data sets were constructed providing a separate row
of participant data for each year from birth for model 1, and for each
year from age of opportunity for model 2. In order to account for
multiple participants experiencing failures events in the same year,
the Efron adjustment for survival ties (Efron, 1977) was  applied.
Participants were right-censored at age of interview.
Factors described above were included in the model. Time vary-
ing measures were produced for conduct disorder, monthly alcohol
use, alcohol dependence, weekly tobacco use, tobacco dependence,
other drug use, other drug dependence, childhood sexual abuse,
and depressive episode. These variables were coded as present for
each year after the age of onset, and were only included in the model
if they were positive prior to the onset of cannabis use opportunity
for model one, or prior to the onset of dependence for model two
(e.g., if age at opportunity to use cannabis was 13, then conduct
disorder with an age of onset of 14 was coded as absent prior to the
onset of opportunity).
To minimise the likelihood that the effect of childhood covari-
ates where the specified time periods were ages 6–13 (parental
conflict, single parent family, strict parenting, frequent childhood
religious attendance) may  have occurred after the point of cannabis
use opportunity, any individuals who reported use opportunity
before the age of 6 were removed from model one. This resulted
in the observations of only one participant being removed from the
model. Huber-White analysis for clustered data was  implemented
to adjust for the non-independence of observations from mem-
bers of a twin pair. The assumption of proportional hazards was
assessed through tests of Schoenfeld residuals and modelling of
the interaction of covariates with time in the analysis (represented
as ‘ t’) (P = ≤0.05). Any variables found to violate the proportional
hazards assumption were reparameterized via modelling interac-
tions between the variable and time in the analysis, resulting in an
extended Cox Proportional Hazards model.
Analyses on the transition from opportunity to first use of
cannabis could not be conducted due to insufficient variation in
this measure (the majority of participants progressed from oppor-
tunity to first use 0 or 1 years after having the opportunity to use,
data available on request).
3. Results
3.1. Sample, survival data and the proportional hazards
assumption
Comparisons between those who did and did not report lifetime
cannabis use opportunity, and those who did and did not progress
to cannabis use following opportunity, show these groups differ
on the majority of the covariates tested within the survival models
(see Tables 1). Mean age of first cannabis use opportunity was 17.6
(s.d. 3.2) and the mean age of cannabis dependence 21.4 (s.d. 4.1).
The mean survival time for the participants in the cannabis use
opportunity model was 19.1 years (s.d. 5.1) (age at opportunity, or
for those who did not report opportunity, age at interview.) This
figure is higher than the mean opportunity age as individuals who
have not experienced opportunity by the point of interview are also
included in the survival model, with their age at time of interview in
place of age of opportunity. The mean survival time for participants
in the cannabis dependence model was 13.4 years (s.d. 4.9) (time
from opportunity to dependence, or for those who did not develop
dependence, time from opportunity to age at interview). This figure
is higher than may  be expected from the mean dependence age as
individuals who have not developed dependence by the point of
interview are also included in the survival time, with their time
from opportunity to age at interview in place of time to dependence.
All covariates were tested for breach of the proportional hazards
assumption, as outlined in the methods section. The following did
not satisfy the proportional hazards assumption for the opportunity
to use model and therefore the interaction term between the fac-
tor and analysis time was modelled in the cannabis use opportunity
analysis (Bellera et al., 2010): conduct disorder, parental drug prob-
lems, weekly tobacco use and monthly alcohol use. Similarly, for
the cannabis dependence analysis the following variables had the
interaction with analysis time modelled in the analysis: parental
drug problems, alcohol dependence and other drug use.
3.2. Factors uniquely associated with opportunity to use cannabis
Results from the Cox proportional hazards model for transition
to opportunity to use cannabis are presented in Table 3. Conduct
disorder, high parental conflict, parental alcohol problems, parental
drug problems, childhood sexual abuse and weekly tobacco use
were associated with increased hazard of earlier opportunity to
use cannabis. Frequent childhood religious attendance and female
gender were independently associated with slower transition to
cannabis use opportunity.
3.3. Factors uniquely associated with progression to cannabis
dependence
Results from the Cox proportional hazards model for transition
from opportunity to use cannabis to dependence are presented in
Table 3. Conduct disorder, parental drug problems, weekly tobacco
use, depressive episode, tobacco dependence, alcohol dependence,
other drug use and other drug dependence were associated with
increased hazard of faster transition cannabis dependence. Female
gender was  independently associated with slower transition to
cannabis dependence.
3.4. Factors consistently associated across transitions
Factors associated with increased hazard of both earlier
cannabis use opportunity and faster progression to cannabis depen-
dence were conduct disorder, parental drug problems, and weekly
tobacco use (see Table 3). Female gender was associated with
slower progression to both cannabis use opportunity and depen-
dence.
4. Discussion
This paper identifies a number of factors uniquely associated
with the transition to cannabis use opportunity and with the
transition from opportunity to cannabis dependence, and several
factors that increase hazards of both these transitions. Parental
conflict, parental alcohol problems and childhood sexual abuse
were uniquely associated with faster transition to opportunity,
whilst frequent childhood religious attendance was  associated
with slower transition to opportunity. Depressive episode, tobacco
dependence, alcohol dependence, other drug use and other drug
dependence were uniquely associated with faster progression
from opportunity to dependence. Conduct disorder, parental drug
problems and weekly tobacco use were associated with faster
progression to both opportunity and from opportunity and depen-
dence, with female gender associated with slower transition for
both.
Exploring a broad range of factors has identified similarities
and inconsistencies with the existing literature. Frequent child-
hood religious attendance, associated with reduced likelihood of
cannabis use opportunity, was consistent with existing literature
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Table  1
Comparison of characteristics of those who reported no lifetime cannabis use opportunity with those who  reported lifetime cannabis use opportunity, and those who reported
cannabis use opportunity and did not progress to use with those who  did progress to use (proportions and odds ratios).
No opportunity to use
cannabis N = 399 N (%)
Opportunity to use







N = 805 N (%)
Opportunity and
initiated cannabis
use N = 2593 N (%)
Odds ratio (95%
CI)
Female gender 326 (81.7) 2099 (61.8) 0.36 (0.28–0.47) 535 (66.5) 1563 (60.3) 0.77 (0.65–0.91)
Conduct disorder 4 (1.0) 320 (9.4) 10.30 (3.82–27.76) 24 (2.98) 296 (11.4) 4.21 (2.76–6.43)
Depressive episode 185 (46.5) 1636 (48.3) 1.08 (0.87–1.32) 374 (46.5) 1262 (48.9) 1.10 (0.94–1.29)
High  parental conflict† 128 (32.1) 1272 (37.4) 1.27 (1.02–1.58) 257 (31.9) 1015 (39.2) 1.37 (1.16–1.62)
Parental alcohol problems 57 (14.3) 895 (26.3) 2.15 (1.61–2.87) 183 (22.7) 712 (27.5) 1.29 (1.07–1.55)
Parental drug problems 5 (1.3) 125 (3.7) 3.03 (1.23–7.46) 19 (2.36) 106 (4.1) 1.78 (1.09–2.92)
Single  parent family† 14 (3.5) 203 (6.0) 1.75 (1.01–3.03) 48 (6.0) 155 (6.0) 1.00 (0.72–1.40)
Strict  parenting† 183 (45.9) 1672 (49.2) 1.14 (0.93–1.41) 371 (46.1) 1301 (50.3) 1.18 (1.01–1.38)
Frequent childhood religious
attendance†
299 (74.9) 1981 (58.3) 0.47 (0.37–0.59) 512 (63.6) 1468 (56.6) 0.75 (0.63–0.88)
Childhood sexual abuse 20 (5.1) 303 (9.0) 1.86 (1.17–2.95) 48 (6.0) 255 (9.9) 1.73 (1.26–2.38)
Weekly tobacco use 30 (7.5) 1493 (44.0) 9.65 (6.61–14.09) 110 (13.7) 1382 (53.4) 7.23 (5.83–8.96)
Tobacco dependence 15 (3.8) 946 (27.8) 9.89 (5.87–16.65) 50 (6.2) 895 (34.5) 7.97 (5.92–10.73)
Monthly alcohol use 274 (68.7) 3182 (93.6) 6.72 (5.22–8.65) 682 (84.7) 2500 (96.5) 4.90 (3.69–6.51)
Alcohol dependence 19 (4.8) 928 (27.3) 7.51 (4.71–11.98) 85 (10.6) 843 (32.5) 4.08 (3.21–5.18)
Other drug use 49 (12.3) 1623 (47.8) 6.54 (4.81–8.88) 140 (17.4) 1483 (57.2) 6.36 (5.21–7.75)
Other  drug dependence 0 (0.0) 178 (5.2) – 5 (0.6) 173 (6.7) 11.51 (4.71–28.10)
† When participant was  aged 6–13 years old.
Table 2
Mean age (standard deviation) of behaviour onsets of those who reported no lifetime cannabis use opportunity with those who  reported lifetime cannabis use opportunity,









N  = 805
Opportunity and
initiated cannabis
use N = 2593
Conduct disorder 12.5 (s.d. 4.20) 14.2 (s.d. 2.31) 14.0 (s.d. 2.88) 14.2 (s.d. 2.26)
Depressive episode 22.4 (s.d. 6.26) 21.8 (s.d. 6.42). 21.8 (s.d. 6.51) 21.8 (s.d. 6.40)
Childhood sexual abuse 11.9 (s.d. 4.56) 11.1 (s.d. 4.68) 10.2 (s.d. 4.58) 11.3 (s.d. 4.69)
Weekly tobacco use 17.2 (s.d. 2.64) 17.3 (s.d. 3.44). 18.3 (s.d. 3.58) 17.3 (s.d. 3.42)
Tobacco dependence 23.8 (s.d. 7.77) 21.9 (s.d. 4.47). 23.5 (s.d. 4.62) 21.8 (s.d. 4.45)
Monthly alcohol use 20.4 (s.d. 3.72) 18.0 (s.d. 2.57). 19.1 (s.d. 3.14) 17.7 (s.d. 2.31)
Alcohol dependence 22.6 (s.d. 4.79) 22.5 (s.d. 4.20). 22.7 (s.d. 4.27) 22.5 (s.d. 4.19)
Other  drug use 23.7 (s.d. 6.20) 21.6 (s.d. 4.26) 21.9 (s.d. 5.45) 21.6 (s.d. 4.13)
Other  drug dependence 0 (0.0) 23.0 (s.d. 4.52) 25.8 (s.d. 3.90) 22.9 (s.d. 4.52)
Table 3
Hazard ratios (95%CI) from cox regression models: factor associated with earlier opportunity to use cannabis, and for progression from opportunity to use cannabis to cannabis
dependence.
Covariate Transition to cannabis use opportunity N = 3763 Transition to cannabis dependence N = 3367
Unadjusted HR (95% CI) Adjusted HR (95% CI) Unadjusted HR (95% CI) Adjusted HR  (95% CI)
Female gender 0.70*** (0.65–0.75) 0.69*** (0.64–0.75) 0.50*** (0.40–0.62) 0.44*** (0.34–0.55)
Conduct disordera b7.54*** (2.39–23.76) b5.57** (1.52–20.47) 4.57*** (3.63–5.75) 2.49*** (1.91–3.25)
Depressive episodea 1.04 (0.93–1.17) 0.98 (0.87–1.10) 1.95*** (1.55–2.42) 1.44*** (1.12–1.85)
High  parental conflict† 1.09* (1.01–1.18) 1.09* (1.00–1.18) 1.16 (0.94–1.44) 1.02 (0.79–1.31)
Parental alcohol problems 1.27*** (1.16–1.38) 1.19*** (1.08–1.30) 1.29** (1.03–1.62) 1.11 (0.86–1.43)
Parental drug problems b8.26** (2.12–32.15) b7.29** (1.74–30.62) b4.14*** (2.07–8.27) b3.30*** (1.63–6.69)
Single  parent family† 1.30** (1.10–1.53) 1.13 (0.95–1.35) 1.60* (1.11–2.32) 1.19 (0.78–1.81)
Strict  parenting† 1.03 (0.96–1.10) 1.02 (0.95–1.09) 1.32** (1.07–1.62) 1.11 (0.88–1.39)
Frequent childhood religious attendance† 0.72*** (0.66–0.78) 0.74*** (0.68–0.80) 0.86 (0.69–1.07) 0.84 (0.67–1.06)
Childhood sexual abusea 1.25** (1.08–1.42) 1.17* (1.01–1.34) 1.98*** (1.49–2.64) 1.35 (0.95–1.92)
Weekly tobacco usea b10.17*** (5.00–20.71) b8.57*** (3.93–18.68) 3.98*** (3.12–5.07) 2.76*** (2.10–3.64)
Tobacco dependencea 1.82* (1.29–2.56) 0.89 (0.63–1.25) 2.77*** (2.18–3.52) 1.36* (1.04–1.78)
Monthly alcohol usea b1.65 (0.78–3.50) b0.75 (0.34–1.64) 1.03 (0.75–1.41) 0.94 (0.69–1.30)
Alcohol dependencea 1.79*** (1.29–2.48) 1.26 (0.89–1.78) b2.94*** (1.69–5.12) b2.64*** (1.53–4.58)
Other  drug usea 1.31** (1.05–1.65) 1.20 (0.94–1.52) 2.76*** (2.22–3.42) 2.10*** (1.64–2.69)
Other drug dependencea – – 5.70*** (4.77–10.94) 2.75*** (1.70–4.43)
Note: Cannabis dependence N = 363 (due to missing covariate data). HR = Hazard ratio.
*P < 0.05 **P < 0.01 ***P < 0.001.
a Time Varying Covariate.
b interaction with t included in the model to account for breach of the proportional hazards assumption.
† When participant was  aged 6 – 13 years old.
(Chen et al., 2004). In contrast to prior literature (Miller et al.,
2000) this protective effect did not extend to dependence. Depres-
sive episode was  associated with increased speed of transition to
dependence, which is consistent with emerging findings of an asso-
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ciation between depression and cannabis use disorders (Feingold
et al., 2015; Pacek et al., 2013), but was not found to be associ-
ated with earlier opportunity to use cannabis. This may  be due to
the age of depressive episode onset occurring after age of cannabis
use opportunity for the majority of participants. Previous research
has reported that childhood adversity and sexual abuse are asso-
ciated with other drug use opportunity and cannabis dependence
(Benjet et al., 2013; Duncan et al., 2008) but, while the present
analyses identified an association between childhood sexual abuse
and earlier cannabis use opportunity, there was no association
between childhood sexual abuse and progression from opportu-
nity to dependence. Differences between the present findings and
existing research may  be due to the relatively novel exploration of
speed of transitions between stages rather than the likelihood of
outcomes, which has been the focus of much existing research.
The identification of tobacco, alcohol and other drug involve-
ment as factors associated with progression from opportunity to
dependence suggests that a pattern of poly-use emerges. Although
alcohol use has previously been found to be associated with early
onset of cannabis use (Coffey et al., 2000) it was not associated
with opportunity to use cannabis in the present analyses, which
may  partially reflect the high prevalence of monthly alcohol use in
the current sample. The comparatively rarer outcomes of tobacco
dependence, other drug use and other drug dependence were found
to be associated with increased speed of progression to cannabis
dependence. The use of both tobacco and cannabis has been fre-
quently observed (Agrawal et al., 2012, 2010; Hindocha et al., 2015),
and regular cigarette smokers are more likely to report earlier
cannabis use opportunity (Agrawal et al., 2013). Present results
strongly supported this finding, and extend it to show weekly
tobacco use and dependence were significantly associated with
speed of progression to cannabis dependence. The observed asso-
ciation between cannabis dependence and tobacco may  be due
to a number of factors including shared genetic and environmen-
tal influences, the co-administration of tobacco and cannabis, and
smoking habituation (Agrawal et al., 2012).
A number of factors were associated with both transitions stud-
ied. Female gender was associated with slower progression to both
opportunity and dependence. It is interesting to note that gen-
der differences held across both transitions given that previous
research has found males more likely to have opportunity to use
cannabis, but has found these gender differences do not extend to
the transition into drug use once opportunity has occurred (van
Etten et al., 1999). Similarly, weekly tobacco use was associated
with increased hazard of both cannabis use opportunity and pro-
gression to cannabis dependence, consistent with existing findings
relating to dependence (Wagner and Anthony, 2002). Conduct dis-
order was associated with faster progression to both opportunity
and dependence, echoing previous research showing disruptive or
aggressive behaviour in both males and females is associated with
earlier opportunity to use cannabis (Storr et al., 2011). Parental drug
problems were significantly associated with a more rapid tran-
sition to both opportunity and dependence, in line with existing
research relating to opportunity (Benjet et al., 2013). This fac-
tor most clearly demonstrated changes in the magnitude of effect
size between transitions, and given the especially strong associa-
tion with opportunity to use cannabis it is plausible that parental
drug problems facilitate an environment in which drug access is
increased, whether this is indirectly or directly through parents.
Alternatively, cannabis availability has previously been shown to
be influenced by genetic effects (Gillespie et al., 2009), and the
present finding may  represent a genetic liability to creating drug
use opportunities.
The pattern of results presented in this paper demonstrates that
the influence of factors differs throughout the stages of drug use
progression. Research relating to early onset of drug use often calls
for earlier detection and intervention (Chen et al., 2009), and the
current findings have two key implications for prevention. Firstly,
as factors play different roles across drug involvement, interven-
tions may  benefit from tailoring to stages of drug use. Secondly,
targeting of interventions may  improve by considering the consis-
tency and differences in associated factors across the stages of drug
use. Using the results of the present study may  facilitate identifi-
cation of populations who will benefit from targeted or indicated
prevention strategies (National Research Council (US) and Institute
of Medicine (US) Committee on the Prevention of Mental Disorders
and Substance Abuse Among Children, Youth, and Young Adults:
Research Advances and Promising Interventions, 2009).
There are certain considerations required in interpretation of
this work. Firstly, analyses were conducted on retrospective self-
report data, introducing the possibility of recall bias. This is a viable
method of data collection (Darke, 1998; Sartor et al., 2011), and
indeed recall of early experience with cannabis has been found to
be especially reliable (Johnson and Mott, 2001), but as the analyses
rely on accurate recall of age of onset of a number of behaviours
the work would benefit from replication in longitudinal cohorts.
Secondly, analyses of the progression from opportunity to
cannabis use initiation were not possible, as timing of transitions
was only available as time in years, and there was not enough varia-
tion in the speed of this transition to allow for analysis (the majority
of participants progressed to use within 1 year after having the
opportunity to use, data available on request). Thirdly, selected
covariates measured occurrence within an age range (6–13), and
consequently may  have occurred prior to the age of opportunity
to use cannabis for a small number of individuals. Fourthly, while
the prevalence of lifetime cannabis use in this sample was rela-
tively high at 68.2% (Lynskey et al., 2012) it is important to note
this estimate is consistent with previous estimates from the Aus-
tralian young adult population (Australian Institute of Health and
Welfare, 2014). Finally, interpretation of these analyses should be
in light of the twin and sibling sample used, as there is some residual
uncertainty about whether inferences from twin data have external
validity with respect to what might be found in general population
samples (Vitaro et al., 2009). Analyses were adjusted for clustering
effects using the Huber-White estimator, which was selected over
other potential analyses that can be conducted to explore within
twin/sibling frailties as the most parsimonious method.
Consideration of multiple stages of drug use from non-use to
dependence allows identification of factors uniquely associated
with specific transitions. The current results demonstrate that dif-
ferent factors are influential at different stages of the development
of cannabis dependence. Additionally, the differences and consis-
tencies in factors across the stages of drug use provide an insight
into which similarities and differences we may  expect to see occur-
ring through the transitions towards dependence. The findings
have implications for substance use prevention efforts, as both the
targeting of interventions as well as the interventions themselves
may  benefit from being tailored to stages of drug use.
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